Development of an Antisense Oligonucleotide Based Method to Manipulate RNA Editing of AMPAR Subunits by Chaytow, Helena
 
 
 
Development of an Antisense 
Oligonucleotide-Based Method to 
Manipulate RNA Editing of 
AMPAR Subunits 
 
 
Helena Anne Chaytow 
School of Biological Sciences 
Royal Holloway, University of London 
 
  
 
Research thesis submitted for the degree of Doctor of Philosophy  
  
2 
 
Declaration of Authorship  
I, Helena Anne Chaytow, hereby declare that this thesis and the work presented 
in it is entirely my own. Where I have consulted the work of others, this is always 
clearly stated. 
 
Signed: ______________________  
Date: ________________________  
3 
 
ABSTRACT 
 
AMPA receptors (AMPARs) are a subset of ionotropic glutamate receptor composed of 
one or more of four subunits (GluA1-4) and are essential for normal synaptic function. 
The GluA2 subunit undergoes RNA editing at a specific base, converting the amino acid 
from glutamine to arginine, which is critical for regulating calcium permeability. RNA 
editing is performed by Adenosine Deaminases Acting on RNAs (ADARs). ADAR2 exists 
as multiple alternatively-spliced variants within mammalian cells and some have been 
shown to reduce their editing efficiency. RNA editing in AMPARs is inefficient in patients 
with Amyotrophic Lateral Sclerosis and manipulating this process could be therapeutic 
against AMPAR-triggered neuronal cell death.  Antisense oligonucleotides (ASOs) are 
bases with chemically altered backbones used to manipulate DNA or RNA processing 
through complementary base pairing. ASOs were used to alter the GluA2 RNA editing 
event, either by disrupting the GluA2 double-stranded RNA structure essential for editing 
or by affecting the alternative splicing of ADAR2.  
The effects of specific ASOs on RNA editing were assessed by transfection into cell 
lines. Editing was quantified by an RT-PCR-based assay on RNA extracts then 
densitometric analysis of BbvI digestion products. ASOs targeting the secondary 
structure of the GluA2 subunit disrupted editing at this site to 50% of control in HeLa 
cells, and further disrupted editing to less than 10% in SH-SY5Y cells endogenously 
expressing the GluA2 subunit. ASOs targeting the ADAR2 transcript successfully 
inhibited the expression of a less efficient isoform, which led to increased editing of 30% 
compared to control HeLa cells.  Further work will include building on attempts to 
introduce the antisense transcripts into primary cortical cultures to analyse downstream 
effects of reduced editing. This is the first example of increasing RNA editing using ASOs 
and provides a number of potential tools to investigate associated cellular processes and 
implications of RNA editing. 
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snRNPs small nuclear ribonucleoproteins 
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TARPs transmembrane AMPA receptor regulatory proteins 
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1 LITERATURE REVIEW 
1.1 AMPA RECEPTORS 
1.1.1 AMPA Receptor Structure 
The glutamate system comprises three families of ionotropic glutamate receptors: AMPA 
(α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors, NMDA (N-methyl-
D-aspartate) receptors and kainate receptors, named after their high-affinity agonists. 
These receptors are formed from subunits which assemble as tetramers, where dimers 
pair up in the endoplasmic reticulum before being shuttled to the membrane 
(Traynelis et al., 2010). The subunits each have four domains: the extracellular 
amino-terminal domain, the extracellular ligand-binding domain (LBD), the 
transmembrane domain (TMD) and an intracellular carboxyl-terminal domain. Agonist 
binding to the ligand-binding domain leads to a conformational change in angle of the 
transmembrane domain (Willard & Koochekpour, 2013). This opens the pore running 
through the centre of the receptor, allowing for Na+, K+ and Ca2+ ions to flow through. 
The influx of Ca2+ ions is tightly controlled by the presence of the subunit GluA2 in AMPA 
receptors, which renders the receptor impermeable to calcium, whereas in contrast 
NMDA receptors are uniformly calcium-permeable. 
Glutamate receptor subunits fall into distinct classes, based upon their structure, 
homology and pharmacology, with each class comprising subunits that can form one of 
the three families of receptor (other classes reviewed in Traynelis et al., 2010). AMPA 
receptors function as ligand-activated cation channels and are formed from the subunits 
GluA1 to GluA4 (also known as GluR1-4 or GluRA-D, transcribed from human genes 
GRIA1-4), which are assembled as either homo- or heteromers. Determining the subunit 
composition of AMPA receptors in vivo is a challenge due to the presence of subunits 
within the cytoplasm, rather than at the membrane, and their dynamic regulation. Using 
single-cell genetic analysis, it was found that neurons in the CA1 region of the 
hippocampus predominantly contain GluA1/2 heteromers (around 80% of synaptic 
AMPA receptors) while the rest are GluA2/3 heteromers (Lu et al., 2009). A study looking 
into co-immunoprecipitation between subunits in different brain regions found the 
majority of GluA1 associating with GluA2, with some GluA1 not associating with any 
other subunit and so apparently remaining homomeric (Reimers et al., 2011). This study 
found that around 50% of AMPA receptors in the CA1 region were GluA2/3 heteromers, 
contradicting Lu et al., a discrepancy proposed to be due to partially assembled GluA2 
subunits in particular (Reimers et al., 2011). In general, it is believed that the majority of 
AMPA receptors in the brain are either of GluA1/2 or GluA2/3 composition, and are 
  
therefore impermeable to calcium due to the presence of the GluA2 subunit. Less is 
understood about the GluA4 subunit, although it is known to be expressed in the 
thalamus (Mineff & Weinberg, 2000) and cerebellum (Saab et al., 2012). The subunits 
are also differentially expressed during development, with expression of subunits 
generally increasing during synaptogenesis (Arai et al., 1997). 
1.1.2 AMPA Receptor Function 
Glutamate is the major fast excitatory neurotransmitter of the mammalian central 
nervous system (CNS), with diverse functions in fast synaptic transmission, long-term 
potentiation (LTP), long-term depression (LTD) and synaptic plasticity. Glutamate is 
involved with most areas of the nervous system, from corticospinal tracts controlling 
motion to nociceptive pathways to learning and memory (Kandel et al., 2000). Glutamate 
has also been found to play a role in disease states such as ischaemia, traumatic brain 
injury and hypoxia, as well as various cancers (Willard & Koochekpour, 2013). AMPA 
receptor gating, the binding of a ligand such as glutamate and the opening of the ion 
channel, involves three processes: activation, desensitisation and deactivation. 
Activation occurs when an agonist binding to the LBD of the AMPA receptor leads to a 
change in its conformation, with the clamshell-like structure of the LBD closing (Jin et al., 
2003). This change in conformation opens the ion pore formed of the TMDs, allowing 
ionic movement through the channel (Armstrong & Gouaux, 2000). Multiple possible 
conformations of the LBD in response to a variety of ligands allow different activation 
states of the AMPA receptor (reviewed in Sobolevsky, 2015). Desensitisation occurs 
when the pore closes, preventing movement of ions through the channel, while the 
agonist is still bound to the LBD thereby preventing over-stimulation. It is theorised that 
desensitisation causes further rearrangement of the LBD and reversal of the 
conformation change that occurred during activation (Sun et al., 2002). The receptor is 
deactivated when the agonist is unbound from the LBD.  
LTP, the strengthening of a synapse through repetitive usage, and LTD, the weakening 
of a synapse through usage, have been suggested as a molecular basis for at least some 
forms of learning. Indeed, LTP and LTD, particularly in the hippocampus, have been 
associated with different learning behaviours (Gruart et al., 2015). During LTP, calcium 
influx at the synapse in response to NMDA receptor activation leads to AMPA receptor 
insertion in the post-synaptic density. GluA1-containing AMPA receptors are recruited to 
the synapse either as a GluA1/2 heteromers (Adesnik & Nicoll, 2007) or initially as GluA1 
homomers, with GluA1/2 heteromers replacing these receptors shortly afterwards (Plant 
et al., 2006). Once these new AMPA receptors are in place, GluA2/3 heteromers replace 
the subunits to limit calcium influx (Shi et al., 2001). AMPA receptor trafficking to the 
post-synaptic density is therefore considered essential for synaptic plasticity (reviewed 
  
in Bassani et al., 2013). The process of trafficking AMPA receptors is dependent upon 
several elements, including the phosphorylation of the subunits themselves, the function 
of AMPA-receptor interacting proteins and transmembrane AMPA receptor regulatory 
proteins (TARPs), either in the case of movement to the post-synaptic density for LTP or 
endocytosing AMPA receptors for LTD (reviewed in Derkach et al., 2007).   
The influence of each AMPA receptor subunit can be examined in knockout mice of their 
respective genes. Gria1 knockout mice show learning deficits (Reisel et al., 2002) and 
synaptic dysfunction (Wiedholz et al., 2008), as well as changes in those genes 
regulating calcium dynamics and processing (Zhou et al., 2009). Knockout of the Gria2 
gene reduces the spine density in the dentate gyrus and alters the structure of the 
postsynaptic density (Medvedev et al., 2008). Gria2 knockout mice also show abnormal 
learning behaviour both in response to a stimulus and place preference conditioning 
(Mead & Stephens, 2003; Mead et al., 2005). Mice lacking the Gria3 gene show 
disturbed sleeping patterns and increased seizure generation (Steenland et al., 2008) as 
well as changes in behaviour such as increased aggression (Adamczyk et al., 2012). 
Mice lacking in both Gria2 and Gria3 show increased LTP in the hippocampus, possibly 
due to increased calcium currents (Meng et al., 2003). Low expression or knockout of 
Gria4 was associated with a phenotype that models absence seizures in mice (Beyer et 
al., 2008) and neurons showed reduced spontaneous excitation in thalamic circuitry (Paz 
et al., 2011). Knockout of both the Gria3 and Gria4 genes resulted in a loss of AMPA 
receptor response in the thalamic region (Wang et al., 2011). It therefore appears that 
AMPA receptors play a major role in learning and behaviour by influencing synaptic 
function. 
1.1.3 AMPA Receptor Regulation 
AMPA receptor subunits are expressed in both glial and neuronal cells but their 
expression is much higher in neuronal cells. Gria1 expression is regulated by acid 
sphingomyelinase and NFΚB sites in the promoter region, while little is known about the 
transcriptional regulation of Gria3 and Gria4. On the other hand, the transcriptional 
regulation of Gria2 is well studied due to its importance in calcium intake at the synapse. 
The Gria2 promoter was found to be thirty times more active in neuronal cells than in 
glial cells due to the RE1/NRSE promoter silencer element and the control of Sp1 and 
NRF-1 transcription factors (Myers et al., 1998). NRF-1 appears to specifically control 
the GluA2 promoter region but not the other AMPA receptor subunits (Dhar et al., 2009). 
Once transcribed, there are also controls over translation of the subunit mRNA. mRNA 
transcripts of AMPA receptor subunits can be transported along dendrites, suggesting 
that local translation can take place away from the cell soma (Grooms et al., 2006). As 
well as regulation through changes in subunit translation, AMPA receptors are regulated 
  
through altered shuttling to and from the membrane from intracellular reserve pools, 
which acts as the predominant form of AMPA receptor regulation (Petrini et al., 2009).  
1.1.4 Post-transcriptional Modifications 
AMPA receptor subunits undergo various degrees of co-transcriptional, 
post-transcriptional and post-translational modifications. The RNA transcripts of subunits 
have been shown to be altered in different processes such as alternative splicing or the 
deamination of adenosines. All AMPA receptor subunits undergo alternative splicing at 
the ligand binding domain, forming either the “flip” or “flop” isoform with the inclusion of 
either exon 14 or exon 15 respectively (Sommer et al., 1990). This process was found 
to influence desensitisation (Mosbacher et al., 1994). In Xenopus laevis oocyte 
preparations, it was found that homomers with flip variants of each of the subunits have 
an increased time constant for desensitisation, and conversely flop variants are more 
readily desensitised (Koike et al., 2000). While expression of the flip isoform appears to 
remain constant, the flop isoforms increase in expression during post-natal development, 
which suggests a role for them in more mature neurons (Monyer et al., 1991).  
Flip and flop isoforms are also differentially expressed and localised across the brain 
regions. The flop isoform, for example, is found uniformly across the neocortex of mice, 
whereas the flip isoforms are expressed in laminar patterns with higher expression in 
layers II, III and VI (Sommer et al., 1990). Within neurons, the flip isoform has been 
shown to be predominantly trafficked along dendrites, whereas the flop isoform remains 
in the soma (Coleman et al., 2006). The splicing pattern of subunits also appears to be 
dynamically regulated. For example, there was increased expression of the GluA2 flip 
isoform in the hippocampus of rats after seizures (Gitaí et al., 2010), while in cultured 
neurons there was an increase in expression of the flip isoforms for GluA2, GluA3 and 
GluA4 subunits following depolarisation (Orlandi et al., 2011).  
Alternative splicing of subunits GluA2, 3 and 4 is governed by the so-called “R/G” editing 
site located on exon 13 between transmembrane domains 3 and 4, as shown in Figure 
1.1A (Lomeli et al., 1994). RNA editing in the GluA2 subunit describes the deamination 
of adenosines in its mRNA transcript, and is discussed later. A positive correlation was 
found between the edited form of transcripts and the flip isoform, possibly due to the 
editing site residing near the splice site for exon 13 and therefore influencing the splicing 
machinery (Schoft et al., 2007). Other RNA editing sites, such as the Q/R site and 
hotspots within introns, are found within the GluA2 subunits and play important roles in 
the correct function of the AMPA receptors. Two hotspots are found within intron 11 of 
GluA2, hotspot 1 and hotspot 2 (Higuchi et al., 1993), and editing is required for efficient 
removal of intron 11 (Schoft et al., 2007). The Q/R editing site of the GluA2 subunit is 
critical for the subunit’s permeability to calcium and is discussed later. Although subunits 
  
GluA2, 3 and 4 are all edited at the R/G site, only the GluA2 subunit of AMPA receptors 
is edited at the Q/R site. 
Once translated, phosphorylation of the AMPA receptor subunits influences a number of 
intracellular events such as localisation and interactions with other proteins (Traynelis et 
al., 2010). Other post-translational modifications include palmitoylation and 
ubiquitination (reviewed in Lu & Roche, 2012). Palmitoylation, along with subsequent 
depalmitoylation, of all four AMPA receptor subunits has been implicated in correct 
trafficking and also serves as protection against degradation of the proteins (Hayashi et 
al., 2005). Ubiquitination of subunits has been linked to internalisation and occurs either 
before endocytosis with GluA1 (Schwarz et al., 2010) or after endocytosis with GluA2 
(Lussier et al., 2011).  
1.1.5 The GluA2 Subunit 
An AMPA receptor’s permeability to calcium is determined by the presence of the GluA2 
subunit, which makes the receptor impermeable to divalent ions such as calcium but still 
permeable to monovalent ions, and can therefore regulate calcium intake of the neuron 
(Burnashev et al., 1992). GluA2 subunits restrict calcium ion flow via a single amino acid 
(arginine) within the second transmembrane sequence (Figure 1.1C). The size and 
positive charge of arginine both contribute to the impermeability (Burnashev et al., 1992). 
Sequencing of the GRIA2 gene revealed that codon 586 was CAG, coding for arginine, 
whereas residue 607 in the amino acid sequence of GluA2, deduced by sequencing of 
the cDNA, was glutamine (Sommer et al., 1991; Higuchi et al., 1993). This change in 
base occurs in the RNA transcript and is the result of RNA editing at what has been 
termed the “Q/R site” due to the change in codon from glutamine (Q) to arginine (R). The 
Q/R site’s location in the second transmembrane domain is next to the pore, so can 
influence ion flow (Figure 1.1D). Homomers of edited GluA2 subunits show lower single 
channel conductance than unedited homomers (Swanson et al., 1997) and editing also 
appears to regulate tetramerisation of subunits, as edited GluA2 subunits remain in the 
endoplasmic reticulum while unedited subunits form tetramers before being trafficked to 
the cell membrane (Greger et al., 2003). This localisation to the endoplasmic reticulum 
may regulate the number of GluA2 subunits that are included in the dimer and therefore 
tetramer formation of the whole AMPA receptor (Greger et al., 2003). The GluA2 subunit 
therefore regulates ion conductance through AMPA channels at two levels: by regulating 
the assembly of the receptor and by changing the permeability to divalent ions. 
  
 
Figure 1.1 - Schematics of the GluA2 subunit in AMPA receptors. The presence of the GluA2 subunit in the AMPA receptor complex prevents calcium entry due to the arginine at the 
Q/R site. The Q/R site is located in the second transmembrane domain of the subunit, situating the amino acid directly next to the ion flow (modelling from Wright & Vissel, 2012). The 
R/G editing site is located between the third and fourth transmembrane domains and governs alternative splicing of the flip/flop exon. 
  
Calcium entry into a neuron can be controlled by dynamically altering expression of the 
GluA2 subunit compared to subunits GluA1, 3 and 4. Relative expression of the AMPA 
subunits are known to vary throughout development, with the expression of GluA2 
increasing postnatally in mouse along with other synaptic markers as synapses develop 
(Pandey et al., 2015). AMPA receptors are predominantly expressed by neuronal cells 
rather than glial cells in the CNS (Orlandi et al., 2011). Cultured rat cortical neurons show 
increasing expression of all four subunits as they undergo maturation in vitro (Orlandi et 
al., 2011). Orlandi et al. also showed that glutamate stimulation alters the relative 
expression of subunits, leading to downregulation of the GluA1 subunit and upregulation 
of the GluA2 subunit. The opposite change was shown in response to inhibited neuron 
stimulation by treatment with tetrodotoxin and APV (blocking sodium channels and 
NMDA channels respectively). This dynamic variation in subunit expression is still an 
area of investigation, particularly due to the regulatory elements for this system still being 
unknown. However, the importance of regulating GluA2 expression is becoming 
apparent, as switches between AMPA receptors containing GluA2 and lacking in GluA2 
have been found in the process of both long term potentiation and long term depression 
(Liu & Savtchouk, 2012). It also appears that expression of GluA2 is altered under 
pathological conditions. For example, sustained downregulation of the GluA2 subunit in 
the hippocampus was found following ischaemic insults in rats prior to the associated 
cell death (Noh et al., 2005). 
  
  
1.2 RNA EDITING  
1.2.1 Forms of RNA Editing 
RNA editing describes the modification of RNA transcripts so that the sequence differs 
from the original DNA. It was originally described in protozoans where uridylate residues 
are inserted into RNA sequences and is now thought to occur in most eukaryotes (Gray, 
2012). There are two major forms of RNA editing found in mammalian transcriptomes, 
caused by the deamination of a base thus changing the coding sequence. The first and 
most prevalent is A-to-I editing, where an adenosine is deaminated by the enzyme family 
adenosine deaminases acting on RNA (ADARs) to form the base inosine. In the 
deamination process, the amine group in adenosine is hydrolysed and released as 
ammonia, leaving a ketone group in the inosine molecule (Figure 1.2A). Inosine is read 
by the translational machinery as guanosine, thereby changing the coding sequence. 
This is due to the inosine molecule forming a stable base pair with cytosine (Figure 1.2B), 
whereas bonding with a thymine base forms a less stable base pair (Figure 1.2C), and 
so polymerases will preferentially pair inosines with cytosines (Yasui et al., 2008).  
 
Figure 1.2 – A) Chemical structures of adenosine and inosine. The site of hydrolytic deamination is shaded 
red in the adenosine and inosine structures. The similarity between inosine and guanosine leads to any 
inosine residues being mistaken for guanosine by the translation machinery (Kono & Akiyama, 2013). 
Watson-Crick base pairing between inosine and cytosine (B) is more stable than between inosine and 
thymine (C). 
  
The second form of RNA editing found in mammalian transcriptomes is C-to-U editing, 
where cytosine residues are deaminated to uracil bases. The most common and well-
studied example of this form of editing is in the apolipoprotein B transcript, where RNA 
editing changes a codon from CAA in the genomic sequence to UAA in the RNA 
transcript and therefore introducing a stop codon (Chen et al., 1990). This form of RNA 
editing is catalysed by the apolipoprotein B mRNA editing catalytic polypeptide-like 
(APOBEC) enzyme family, a diverse group of at least 10 enzymes that can recognise 
both DNA and RNA and therefore lead to many different modifications (reviewed in Salter 
et al., 2016). More than 50 mRNA transcripts in the mouse transcriptome have been 
shown to be a target for APOBEC1 (Rosenberg et al., 2011) whereas APOBEC3A has 
several hundred targets including roles in anti-viral and anti-retrotransposon defences 
(Sharma et al., 2015). There are also other, rarer, forms of RNA editing. For example, 
APOBEC3A has been associated with G-to-A editing in the Wilm’s tumour susceptibility 
gene through an unknown mechanism (Niavarani et al., 2015). Mitochondrial tRNAs in 
Physarum species have been shown to require RNA editing in the form of insertion of a 
base in their precursor transcript before maturation can take place (Gott et al., 2010) and 
U-to-C editing in tRNAs of marsupials have been shown to change their codon 
recognition sequences (Borner et al., 1996). RNA editing in rRNA transcripts is rarer still, 
but insertions of bases in rRNA transcripts has been observed in Physarum species 
(Mahendran et al., 1994).  
1.2.1.1 Mechanism of deamination 
In the context of AMPA receptor subunits, RNA editing describes the hydrolytic 
deamination of an adenosine to an inosine residue (Gray, 2012), or “A-to-I editing”, 
shown in Figure 1.2 and henceforth referred to simply as “RNA editing”. Deamination is 
catalysed by the enzyme family adenosine deaminases acting on RNA (ADARs) which 
recognise the double-stranded structure of RNA transcripts, rather than displaying 
sequence recognition. Unusually for RNA binding proteins, ADARs approach the RNA 
from the minor groove at the editing site, requiring a conformational change in the RNA 
to widen the major groove opposite the editing site (Matthews et al., 2016). Once the 
ADAR is bound to the duplex RNA structure, the targeted adenosine “flips” out of 
alignment of the duplex and into the hydrophobic active site of the catalytic domain of 
the ADAR (Yi-Brunozzi et al., 2001). In this state, the amine group can be hydrolysed 
and the adenosine is deaminated to form inosine, catalysed by a zinc ion found within 
the ADAR structure (Macbeth et al., 2005). Genes coding for ADAR enzymes are found 
in genomes throughout the animal kingdom (Jepson & Reenan, 2008), and comparative 
genetic analysis has suggested that the first ADAR-like gene originated just after the split 
of protozoa and metazoa (Jin et al., 2009). Three ADARs are coded for in the 
mammalian genome, although ADAR3 appears to be non-functional and may compete 
  
for binding sites with ADAR1 and ADAR2, possibly acting as a form of negative 
regulation (Hogg et al., 2011). ADAR1 is prevalent in the CNS and elsewhere in the 
body, whereas ADAR2 and ADAR3 appear to be more localised to the CNS (Gray, 
2012).  
1.2.1.2 Function of RNA editing 
Initially, the concept of altering bases after transcription could be considered at best 
unnecessarily laborious and at worst detrimental to the genes being expressed. Indeed, 
there are some sites in the human coding sequence at which A-to-I editing occurs at a 
high frequency and are deleterious to the protein, although in silico analysis of protein 
reactions indicate little change at the system level (Solomon et al., 2014). However, there 
are several advantages to the editing process. The majority of editing sites show variable 
levels of editing, with many showing an editing level of less than 50% (Ramaswami et 
al., 2013). Although there are instances where the edited base has been permanently 
changed to a guanosine in the genome across different species (Li et al., 2009), 
indicating that a mutation at the DNA level is a viable alternative in these cases, the 
flexibility of the editing process allows a single cell to transcribe both sequences, possibly 
safeguarding against deleterious mutations (Rieder & Reenan, 2012). In a study 
analysing 28 editing sites across four different developmental time points, two embryonic 
and two post-natal, it was found that almost all editing sites began with low levels of 
editing that increased through development, with the exception of the Q/R site in the 
GluA2 subunit which was edited at 100% at all time points (Wahlstedt et al., 2009). This 
regulation is apparently separate from expression levels of either ADAR1 or ADAR2, 
indicating other regulatory elements in the editing system that have yet to be identified. 
This flexibility in RNA editing levels therefore allows the embryonic cell to express a 
different isoform to the adult cell. Although RNA editing is prevalent across species, it 
has been suggested that the editing process has played a role in the evolution of higher 
organisms, as they show increased RNA editing activity (Gommans et al., 2010). In fact, 
the high levels of editing in the human transcriptome compared to other non-human 
primates, and their predominance in the CNS, suggests that this may be a factor in the 
development of higher brain function in humans (Paz-Yaacov et al., 2010). As well as 
the benefits in transcriptome diversity, RNA editing plays a role in the immune response. 
ADAR1 has an isoform that is inducible by interferon, and can edit the double-stranded 
RNA of invading viruses, preventing pathogenicity (Samuel, 2012), although some 
viruses such as HIV have evolved to take advantage of the RNA editing system in their 
propagation (Doria et al., 2009).  
The importance of editing is highlighted by Adar1-/- knockout mice, which have a 
phenotype that is lethal at embryonic day 11 due to defects in liver structure (Hartner et 
  
al., 2004). These mice also show that ADAR1 is essential for maintenance of 
haematopoietic stem cells, where it suppresses interferon signalling pathways (Hartner 
et al., 2009). Adar2-/- knockout mice survive until around post-natal day 21 after 
developing early-onset epilepsy (Brusa et al., 1995). This lethality is specifically due to 
the editing at the Q/R site of the GluA2 subunit, as crossing these knockout mice with a 
line containing the “edited” codon rescued the phenotype (Horsch et al., 2011). 
Therefore, although the editing process has been shown to be beneficial, both in terms 
of development and evolution, as well as normal functioning of organisms, the RNA 
editing of the Q/R site remains something of an enigma. The usual advantage of RNA 
editing, its flexibility, is lethal at the GluA2 Q/R site. In fact, in some fish species a 
mutation has changed the base to a guanosine in the genomic sequence so that the 
codon codes for an arginine without the need for RNA editing, thus removing the potential 
for error (Kung et al., 1996). Why the GluA2 Q/R site has remained dependent on the 
RNA editing process in the majority of species, despite the possibility of a lethal 
phenotype if the process is inefficient, remains unclear. 
1.2.2 ADAR Structure 
All ADARs in the mammalian genome have a similar modular structure, with a catalytic 
domain at their C-terminus and double-stranded RNA binding domains (dsRBMs), and 
Z-DNA binding domains in the case of ADAR1, at their N-terminus (Figure 1.3). The 
Z-DNA binding domains of ADAR1 make this ADAR unique across the adenosine 
deaminase enzyme family, although the function of this interaction is still unknown 
(Herbert et al., 1997). ADAR1p150 (1226 amino acids) is the interferon-inducible isoform 
of the enzyme, and contains the active Z-DNA binding domain (Patterson & Samuel, 
1995). ADAR1p110 is constitutively expressed and begins at exon 2 of the enzyme, 
making it a shorter protein of 931 amino acids in humans (George et al., 2011). ADAR2 
is a shorter enzyme still, with 701 amino acids and just two dsRBMs compared to 
ADAR1’s three (Figure 1.3). The catalytic domain is conserved across fish and 
mammals, whilst the dsRBMs vary (Slavov et al., 2000), although dsRBM1 appears to 
be better conserved than dsRBM2 (Slavov & Gardiner, 2002). The dsRBM is a 65-70 
amino acid domain that is conserved across eukaryotic proteins with a conserved αβββα 
structure (Masliah et al., 2013). It is common across RNA-binding proteins such as Dicer 
and Drosha, processing miRNAs, and TRBP in the RNAi pathway. Deletion or mutations 
introduced into either of the two dsRBMs in ADAR2 found that dsRBM1 appears to be 
more important for localisation of the enzyme, as the deletion of dsRBM1 led to diffuse 
fluorescence throughout the cell compared to localisation in the nucleolus, while 
dsRBM2 is more involved in the editing process as deletion reduced editing activity to 
50% of wild-type ADAR2 (Xu et al., 2006). Inositol hexakisphosphate bound to ADAR2 
  
stabilises the enzyme and is thought to contribute to its catalytic activity by slightly 
modifying the structure (Macbeth et al., 2005). 
 
Figure 1.3 - Structural features of mammalian ADARs. Both transcripts of ADAR1 contain three double-
stranded RNA binding motifs (dsRBMs), with ADAR1p150 containing two Z-DNA binding domains while 
ADAR1p110 only contains one. ADAR2 is shorter than the ADAR1 transcripts and only contains two 
dsRBMs. ADAR3 also contains two dsRBMs and an arginine-rich domain (noted as R). All four transcripts 
have the catalytic domain at their C-terminal.  
 
Both ADAR1 and ADAR2 form homodimers at certain editing sites around the RNA 
molecule, a process dependent upon the presence of RNA, and this quaternary structure 
is necessary for efficient editing (Jaikaran et al., 2002; Cho et al., 2003). There was no 
evidence of heterodimer formation between ADARs. ADAR3 on the other hand does not 
dimerise, which may explain why it is non-functional (Chen et al., 2000). ADAR3 is also 
shown to inhibit the actions of ADAR1 and ADAR2 on RNA, indicating a possible role as 
a negative regulator of RNA editing (Chen et al., 2000). 
Efficient deamination of adenosines is dependent upon the formation of double-stranded 
regions of RNA. There are two forms of A-to-I editing found in the genome: site-specific 
and promiscuous editing. Site-specific deamination is found amongst imperfect RNA 
duplexes. Complementary sequences in the RNA substrate that form the double-
stranded regions can be interspersed by large sections of single-stranded RNA, forming 
bulges and loops in the molecule’s secondary structure (Dawson et al., 2004). The 
imperfect duplex is important for RNA editing, as mutating the sequence so that base 
pairing was complete, apart from the binding partner of the edited adenosine, halved the 
editing efficiency (Ohman et al., 2000). This indicates that the bulges and loops formed 
from imperfect double-stranded RNA are a requirement for efficient editing, possibly 
reducing the number of ways that the ADAR can bind to the double-stranded RNA. Apart 
from loops within a duplex of RNA, editing is not dependent upon other secondary 
structure features and is not found to be particularly focussed in disordered regions of 
secondary structure (Solomon et al., 2014).  
It is difficult to determine the structure of the ADAR-RNA complex due to the lack of 
specific recognition sites, and so ADAR may bind in multiple conformations to the same 
double-stranded RNA transcript with equal affinities. Different groups have concluded 
  
that site selectivity is controlled by either the catalytic deaminase domain (Wong et al., 
2001) or by the dsRBMs (Stephens et al., 2004). More recently, it has been suggested 
through binding analysis that ADAR-RNA binding is controlled through the catalytic 
domain, but binding is dependent upon the presence of double-stranded RNA 5’ to the 
editing site dsRBMs (Phelps et al., 2015). Indeed, there are specific amino acids within 
the catalytic domain that have been shown to be involved in ADAR2 binding but are 
different from the ADAR1 sequence, possibly contributing to the differences in the two 
enzymes’ binding substrates (Matthews et al., 2016).  
An adenosine on its own is not enough to be recognised by an ADAR, its position on the 
duplex and the surrounding bases also play a role (Dawson et al., 2004). For example, 
at the R/G site of the GluA2 subunit, there are other adenosines within the duplex which 
are not deaminated (Stephens et al., 2000). ADAR1 and ADAR2 have distinct but 
overlapping rules when it comes to selection of an adenosine to be deaminated. ADAR1 
shows a preference for adenosine or uracil over cytidine or guanosine as the 5’ 
neighbouring base of the edited adenosine, but does not appear to have a similar rule 
for the 3’ neighbour (Polson & Bass, 1994). Similarly, ADAR2 shows a preference for 
adenosine and uracil for the 5’ neighbouring base, but it also shows a preference for the 
3’ base of guanosine or uracil over cytidine and adenosine (Lehmann & Bass, 2000). 
The base opposite the edited adenosine in the duplex cannot be uracil, as the adenosine 
must remain unpaired, and there is also a preference for cytidine over guanosine at this 
position (Wong et al., 2001). It appears that these preferences over neighbouring bases 
are not caused by the sequence itself, but are rather due to the effect of the neighbouring 
bases on the base flipping of adenosine (Kuttan & Bass, 2012). The point at which the 
targeted adenosine falls in the duplex structure also appears to be important, as ADAR1 
will not edit a base within three nucleotides of the 5’ end of the helix or 8 nucleotides 
from the 3’ end of the helix, and ADAR2 has a limit of two nucleotides from either end 
(Lehmann & Bass, 2000). However, these rules cannot fully describe why ADAR1 edits 
some sites and not others, likewise for ADAR2, nor can it explain why some adenosines 
fulfilling these preferences remain unedited.  
1.2.3 RNA Editing of Non-coding RNAs 
Promiscuous editing, or non-site specific editing, is found throughout intronic sequences 
of the genome and particularly in Alu sequences. In a perfect double-stranded section of 
RNA, up to 50% of adenosines may be edited (Savva et al., 2012). Alu sequences are 
short, interspersed elements; retrotransposons which duplicate themselves through 
reverse transcription of an RNA intermediate and spread through germline transmission. 
At present, Alu sequences are thought to make up 11% of the human genome (Ade et 
al., 2013). As long as the Alu element has another in the reverse orientation nearby to 
  
form the double-stranded structure, which is virtually always the case, it can be edited 
(Bazak et al., 2014). It was found that almost all adenosine bases within Alu sequences 
of non-coding regions had the capacity to be edited, although most showed very low 
levels of editing at less than 1% (Bazak et al., 2014). Despite this low level of editing at 
individual sites, the cumulative editing across the non-coding regions of the 
transcriptome dwarfs editing within coding regions, and so cannot be discounted (Bazak 
et al., 2014). Having large quantities of double-stranded RNA is detrimental to the cell, 
often activating anti-viral defences, however Alu elements appear to be the exception to 
this rule (Levanon & Eisenberg, 2015). Editing within Alu elements destabilises the 
double-stranded structures formed, and so may be a compensatory mechanism against 
the increase in double-stranded elements in the primate genome. It is also interesting to 
note that, as Alu elements invaded the primate genome, the editing rate at functional 
sites did not change, despite the increasing number of target sites for ADAR enzymes. 
This may be due to a division of labour as, whilst ADAR2 edits many of the functional 
editing sites such as the Q/R site in the GluA2 subunit, ADAR1 has been found to mainly 
edit the non-coding editing sites, although there is a great degree of overlap (Riedmann 
et al., 2008). One theory suggests that the editing of Alu sequences is used to promote 
sequence-specific editing sites, possibly through recruitment of ADARs, as site-specific 
editing is found closer to Alu sequences than would simply be predicted by chance 
(Daniel et al., 2014). Alu sequences are also commonly found as alternatively spliced 
exons, and editing of Alu elements can change the splicing patterns by removing stop 
codons (reviewed in Levanon & Eisenberg, 2015).  
Alu elements are known to contain microRNA (miRNA) target sites, and so editing Alu 
sequences may play a role in regulating the miRNA system (Liang & Landweber, 2007). 
As well as editing their target sites, miRNA sequences are also known to undergo editing 
themselves. Around 6% of primary miRNAs (pri-miRNAs) are edited at one or more 
bases, destabilising the hairpin structure essential for correct pri-miRNA processing 
(Gommans, 2012). By disrupting the cleavage of pri-miRNA into miRNAs, there will be 
fewer miRNAs available to perform their regulatory function. This editing may therefore 
lead to drastic changes in gene expression. Editing of non-coding RNAs has also been 
implicated in the RNA interference system, with roles both supporting and inhibiting the 
RISC complex (Nishikura, 2006). A decrease in editing is associated with several forms 
of cancer (Paz et al., 2007). For example, under-edited miRNA-376a* contributes to 
increased migration and invasiveness of human glioma cells (Choudhury et al., 2012), 
whereas under-editing of miRNA-455-5p has been linked to severity of melanomas, 
possibly through inhibited expression of tumour-suppressant genes (Shoshan et al., 
2015). When analysing RNA-seq samples from a variety of cancer patients, a positive 
correlation was found between dysregulation of RNA editing in the 3’ UTR of mRNAs, 
  
often containing miRNA target sites, and the progression of tumours (Zhang et al., 2016). 
On the other hand, increased levels of RNA editing of antizyme inhibitor 1 were found in 
samples of hepatocellular carcinoma (Chen et al., 2013).  
1.2.4 Identification of RNA Editing Sites 
A variety of methods have been used to determine RNA editing sites in the 
transcriptome. When RNA editing was first discovered, it was through identified 
mismatches between sequencing of DNA and RNA. It was therefore difficult to 
distinguish true RNA editing sites from mistakes in sequencing, with individual sites 
being characterised through laborious cloning and RNA isolation techniques (Sommer et 
al., 1991; Burns et al., 1997). The complete sequencing of various genomes allowed 
comparisons between known editing sites and the surrounding sequences across 
species. This led to proposed “signatures” at RNA editing sites that could be used to 
search for novel edited adenosines (Hoopengardner et al., 2003). However, these 
approaches overly constrained the search for editing sites, and novel adenosines were 
mostly located in coding sequences. The editing sites in coding sequences could be 
experimentally verified, and groups published results identifying handfuls of editing sites 
at a time (Hoopengardner et al., 2003; Levanon et al., 2005). The development of whole-
transcriptome sequencing (RNA-seq) technology revealed the complexity of the 
transcriptome (reviewed in Wang et al., 2009). Comparisons between DNA and RNA 
sequences showed that RNA editing was not just found in coding sequences, but was 
also prevalent in non-coding regions. Initial comparisons estimated 10,000 editing sites 
in human cell lines (Bahn et al., 2012), which has since expanded to predicting millions 
of A-to-I editing sites in the human transcriptome (Bazak et al., 2014). With such a large 
number of editing sites, there are now databases cataloguing editing sites and average 
editing levels at each site. Databases include RADAR (Ramaswami & Li, 2014), 
DARNED (Kiran & Baranov, 2010), RCARE (Lee et al., 2015) and RED (Sun et al., 
2016). However, these databases are only as strong as the data that support them, 
leading to discrepancies. For example, the number of editing sites found in coding 
sequences is dependent upon the detection method. The RADAR database identifies 
2411 editing sites in the human coding sequence, whereas the DARNED database 
records a more conservative 710 sites. When comparing these editing sites with the 
RefSeq gene sequences, Solomon et al. calculated a total of 708 non-synonomous 
editing sites in the human coding sequence (Solomon et al., 2014). Databases now also 
include tissue-specific editing frequencies at individual sites, and are constantly 
improving techniques to correct for detection errors, such as including “hyper edited” 
RNAs which are often missed in RNA-seq analysis (Porath et al., 2014; Picardi et al., 
2015).  
  
1.2.5 ADAR2 
ADAR2, first distinguished from ADAR1 in the 1990s, was the second enzyme in the 
mammalian ADAR family to be discovered, and has also been known as ADARB1, RED1 
or DRADA2 (Melcher et al., 1996; O’Connell et al., 1997). In the developing mouse at 
embryonic day 15 (E15), ADAR2 expression is not detected (Jacobs et al., 2009). In 
early development, expression of ADAR2 is limited to the thalamic nuclei of mice, but by 
postnatal day 7 (P7) is to be found in areas such as the hippocampus and cerebellum, 
while there is very low expression in the neocortex even at P21 (Paupard et al., 2000). 
In adult mice, ADAR2 has a relatively low expression in the cortex compared to other 
brain regions, with the highest expression in the thalamus. This coincides with high levels 
of editing in thalamic neurons compared to other neuronal populations (Jacobs et al., 
2009). The regulation of ADAR2 expression remains an area of active investigation. It is 
known that CREB can act as a transcription factor to activate ADAR2 expression (Peng 
et al., 2006), and that ADAR2 can regulate its own expression through a negative 
feedback loop which requires self-editing (Rueter et al., 1999). This self-editing alters the 
alternative splicing pattern of ADAR2, introducing a 47 nucleotide cassette (shown in 
Figure 1.4) which shifts the reading frame, forming a truncated protein which is non-
functional. ADAR2 is also regulated by tight control of localisation, specifically to the 
nucleolus (Sansam et al., 2003), as opposed to ADAR1 which is also found throughout 
the cytoplasm (Desterro et al., 2003). ADAR2 is shuttled into and out of the nucleolus 
from the nucleoplasm dynamically, which may be governed by the presence of editing 
substrates or small nucleolar RNAs (snoRNAs) (Desterro et al., 2003). Pin1 aids in the 
nuclear localisation of ADAR2, with WWP2 acting as a negative regulator (Marcucci et 
al., 2011) alongside the nuclear localisation signal found within ADAR2 itself (Maas & 
Gommans, 2009a). Another trans-factor implicated in ADAR2 regulation is a snoRNA, 
MBII-52. This snoRNA is brain-specific and has been shown to inhibit editing of the 5-
HT2C serotonin receptor through binding to the pre-mRNA itself thus preventing editing 
(Vitali et al., 2005). It is therefore possible that snoRNAs contribute to ADAR2 regulation 
by acting as site-specific inhibitors. Interestingly, there have been recent reports of 
altered editing events in response to neuronal activity in the hippocampus (Balik et al., 
2013), further supporting the idea that RNA editing is a mechanism for the fine-tuning of 
the nervous system. However, overstimulation of neurons by long-term exposure to 
glutamate at high concentrations (100 µM for an hour) leads to cleavage of ADAR2 and 
therefore a loss of editing (Mahajan et al., 2011). 
1.2.6 Alternative Splicing of ADAR2 
Alternative splicing refers to the inclusion or exclusion of sections of RNA in the final 
mRNA transcript, allowing the expression of different isoforms of the same protein. 
Intronic sections or whole exons, sometimes called cassette exons, can be introduced 
  
or removed from the transcript depending on the splicing machinery. ADAR2 has long 
been known to undergo alternative splicing (Lai et al., 1997; Rueter et al., 1999). Splicing 
events include an ‘AluJ cassette’ insertion after exon 5, early termination at the C-
terminus, a 47 nucleotide insertion in exon 2, and the inclusions of intron 9 and exons 
7a, 0 and 1a as summarised in Figure 1.4. Splicing of ADAR2 at any given site appears 
to be independent of the other splicing events, leading to a large number of splice 
variants in the human transcriptome (Kawahara et al., 2005). The splice variants also 
seem to be able to edit RNA substrates with different efficiencies, and the rates of 
splicing are variable between species. For example, the insertion of the 47 nucleotide 
cassette shows low inclusion in humans (15%) compared to mice (80%) (Slavov & 
Gardiner, 2002). The 47 nucleotide insertion causes a shift in the reading frame creating 
an editing site that forms an early stop sequence. This truncated protein is not functional, 
and is thought to be part of the regulation of ADAR2 expression, as mentioned above 
(Slavov & Gardiner, 2002). 
The inclusion of the 120 nucleotide AluJ cassette after exon 5 reduces the editing 
efficiency of the human ADAR2 enzyme by 50%, whereas the equivalent inclusion of a 
30 nucleotide AluJ cassette in the murine version improved its editing efficiency (Slavov 
& Gardiner, 2002). The C-terminus of ADAR2 can be spliced in a variety of ways. Splice 
variant “L-1” is the most prevalent in the human brain and contains the insertion of intron 
9. The second most prevalent isoform is the “S” variant in which exon 9 and intron 9 are 
not included and this splice variant shows no catalytic activity. It is debatable whether 
this variant is even translated into a protein (Kawahara et al., 2005). Variants “L-2” and 
“L-3” are relatively rare and contain longer or shorter versions of exon 9 respectively, 
without intron 9 (Kawahara et al., 2005). “Exon 0” is an insertion upstream of exon 1 and 
is thought to be controlled by a different promoter. ADAR2 transcripts containing exon 0 
have been found in both human and mouse brains although there is apparently no 
difference in catalytic activity (Maas & Gommans, 2009b). “Exon 7a” has been described 
as showing high levels of inclusion in ADAR2 transcripts in other tissues such as the 
heart and testes but low inclusion in the brain (around 3%), although its inclusion does 
appear to reduce ADAR2 catalytic activity significantly (Agranat et al., 2011). Although 
there are multiple possible alternatively spliced transcripts of ADAR2, the insertion of the 
AluJ cassette after exon 5 merits attention. The AluJ cassette is expressed in the 
mammalian nervous system and its inclusion decreases the efficiency of the ADAR2 
enzyme. Therefore manipulation of splicing to inhibit expression of this less efficient 
isoform could be a potential therapeutic target. 
 
  
 
Figure 1.4 – (A) Table describing each constitutive or alternatively spliced exon, their expression and impact 
on ADAR2 editing activity. “UTR” denotes untranslated region. (B) Schematic to represent possible 
alternative splicing events in the ADAR2 transcript. Adapted from Kawahara et al., 2005. “Ex” denotes an 
exon. “Intr” denotes an intron. Boxes shaded in grey indicate insertions from the intronic sequence. Two 
insertions can be made between exon -1 and exon 1, and these have been entitled exons 1a and 0. The 47 
nucleotide cassette is inserted at the start of exon 2. The AluJ sequence is inserted between exon 5 and 
exon 6, and there can be another insertion after exon 7. There are four variations of the C-terminal of ADAR2. 
“L-1” is the most common C-terminal which includes intron 9 between the full length exon 9 and exon 10. 
“S” is the second most common variant, with a splice site within exon 9 truncating this exon and splicing 
prematurely onto exon 10. “L-2” and “L-3” are both fairly rare. 
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1.2.7 RNA Editing in the Central Nervous System 
Within the millions of RNA editing events in the human transcriptome, a disproportionate 
number of site-specific editing sites are restricted to nervous tissue and associated with 
neuronal excitability (Holmgren & Rosenthal, 2013). Most site-specific editing events 
have been found in mRNA transcripts encoding receptor subunits, including GABAA α3; 
AMPA subunits GluA2, 3 and 4; kainate receptor subunits GluK1 and 2; and the 5-HT2C 
subunit, as summarised in Table 1.1.  
 
Table 1.1 - Summary of selected editing sites in coding sequences of genes in the central nervous system. 
 
ɣ-aminobutyric acid (GABA) receptors are the major inhibitory class of receptors in the 
mammalian CNS. It was found that the Gabra-3 transcript, which codes for the α3 subunit 
of GABAA receptors, is edited in exon 9 by both ADAR1 and ADAR2, leading to a change 
in amino acid sequence from isoleucine to methionine (Ohlson et al., 2007). This I/M 
editing site was found to be developmentally regulated in mice, with around 15% of 
transcripts edited at E15 increasing to more than 90% of transcripts being edited in the 
adult nervous system (Rula et al., 2008). This increase in editing has been shown to 
occur at the same time as reduced overall expression of the Gabra-3 transcript, as well 
as changing trafficking of the α3 subunit so that less was found at the cell surface (Daniel 
et al., 2011). This suggests that the increased editing at the I/M site is associated with 
the change in subunit composition of GABAA subunits, from predominantly α3 during 
development, to predominantly α1 in the adult CNS (Daniel et al., 2011). 
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Serotonin (5-hydroxytryptamine, or 5-HT) is one of the neurotransmitters involved in 
reward pathways, food intake and the regulation of mood (Kandel et al., 2000). There 
are multiple 5-HT receptor subtypes with associated subunits. One of which, the 5-HT2C 
subunit, has been shown to undergo RNA editing (Burns et al., 1997). This group found 
four A-to-I sites (A, B, C and D) within five consecutive codons, each resulting in a 
change in amino acid, and so multiple transcript variations were possible. The various 
transcripts were found to be expressed at different levels in different areas of the mouse 
CNS, with the most common transcript in whole brain RNA edited at sites A, B and D 
(Burns et al., 1997). Interestingly, they found the choroid plexus to have a distinct editing 
pattern, which was the first indication of a biological role for these editing sites. They also 
showed that 5-HT2C subunits edited at all four sites were 10-15 fold less responsive to 
agonists than subunits which remained unedited, possibly due to ineffective coupling to 
G proteins (Burns et al., 1997).  
Since this original research, the 5-HT2C subunit has become one of the most studied 
RNA editing sites in the mammalian genome, and as such is one of the best 
characterised.  The fact that editing reduces responsiveness to agonists, and that the 
editing is differentially regulated temporally and spatially, has led to RNA editing being 
linked to multiple conditions associated with serotonin. Reduced RNA editing at the 
5-HT2C subunit has been associated with mood disorders such as schizophrenia (Sodhi 
et al., 2001), depression (Gurevich et al., 2002) and bipolar disorder (Dracheva et al., 
2008), as well as other serotonin pathways such as neuropathic pain (Nakae et al., 
2008). In a mouse model with genetically determined lower serotonin levels in the 
forebrain (BALB/c mice) leading to increased spontaneous anxiety responses, stress led 
to increased editing at the 5-HT2C subunit and therefore decreasing the responsiveness 
to serotonin, while treatment with the anti-depressant fluoxetine abolished this change in 
editing (Englander et al., 2005). In a mouse model expressing a transgene of the fully 
edited 5-HT2C transcript, mice developed a phenotype similar to Prader-Willi syndrome, 
including hyperphagia and neonatal muscular hypotonia (Morabito et al., 2010). 
RNA transcripts encoding voltage-gated ion channel subunits have also been shown to 
undergo RNA editing. Potassium channels have been found to contain multiple editing 
sites across three different K+ channel genes (Hoopengardner et al., 2003). KV1.1 is 
particularly well characterised. As the editing site falls within the permeation pathway of 
the channel, changing an isoleucine to a valine, this change in amino acid alters the 
channel’s kinetics (Bhalla et al., 2004). The same study also found the site to be edited 
predominantly by ADAR2. The editing at this I/V site was shown to be variable spatially 
across the CNS, with highest editing levels in the spinal cord, thalamus and medulla 
(Hoopengardner et al., 2003). In the same comparative genomics study, several editing 
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sites were found in calcium channels. These editing sites have been characterised less 
comprehensively, although several have been localised to the calmodulin binding site of 
the CaV1.3 channel (Huang et al., 2012). ADAR2 knockout mice, crossed with mice 
expressing the fully edited version of the GluA2 subunit, show reduced editing in the 
CaV1.3 channel, particularly in neurons in the suprachiasmatic nucleus, which lead to 
reduced calcium channel inhibition and so increased firing (Huang et al., 2012). This, 
Huang et al. argue, implies an effect of RNA editing on the modulation of the rhythmicity 
of the suprachiasmatic nucleus and so may have broader implications in circadian 
rhythms.  
These studies into editing of receptors and channels have led to the hypothesis that 
editing may have evolved to fine-tune components of the nervous system, due to the 
differential regulation of editing throughout development and altered neuronal function 
(Penn et al., 2013). RNA editing would therefore have the same effect as alternative 
splicing, in which one gene can give multiple products with different activity profiles, and 
in some cases these two processes work in conjunction with each other.  
1.2.8 RNA Editing in Glutamate Receptors  
Within kainate receptors, subunits GluK1 and GluK2 both have an equivalent Q/R site in 
the same codon as the GluA2 subunit, and RNA editing reduces the kainate receptor’s 
conductance here (Swanson et al., 1996). Both GluK1 and GluK2 transcripts have also 
been shown to have sequences in the intron following the Q/R site that are 
complementary to the bases surrounding the edited adenosine, allowing the formation 
of double-stranded RNA for ADAR recognition (Herb et al., 1996). The Q/R site of GluK2 
is edited at a higher level than GluK1 in the brain, and is developmentally regulated with 
very low editing during embryogenesis that increases to around 80% efficiency in the 
adult CNS (Bernard et al., 1999). It appears that editing at the Q/R site of the GluK2 
subunit affects its trafficking from the endoplasmic reticulum to the membrane, and may 
also impact subunit assembly (Ball et al., 2010). As well as the Q/R site, GluK2 is edited 
at two other non-synonymous sites in its first transmembrane domain which can also 
affect the subunit’s permeability to calcium (Köhler et al., 1993).  
The deamination associated with AMPA receptors’ permeability to calcium takes place 
in codon 586 of the GRIA2 gene within exon 11 and is catalysed by ADAR2. The resulting 
inosine is read by translation machinery as a guanosine base, so the codon changes 
from CAG (glutamine) to CGG (arginine); hence this is called the Q/R site as shown in 
Figure 1.5 (Higuchi et al., 1993). This editing reaction produces the changes in calcium 
permeability previously mentioned. Other sites in the GluA2 subunit undergo RNA 
editing, including “hotspots” around exon 11 thought to aid splicing, and the “R/G site”, 
found in exon 13, which affects desensitisation of the AMPA receptor (Tariq & Jantsch, 
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2012). The R/G site is found at codon 764 and changes an arginine to a glycine in the 
extracellular loop between transmembrane domains 3 and 4 in subunits GluA2, 3 and 4 
but not GluA1 (Lomeli et al., 1994). Editing at this site has implications on the alternative 
splicing of the AMPA subunits as previously mentioned, and editing can be carried out 
by either ADAR1 or ADAR2 (Liu & Samuel, 1999). The R/G site also seems to have a 
wider range of editing levels when compared with the strict high editing efficiency of the 
Q/R site. R/G site editing ranges from around 10% in immature neurons to more than 
60% in mature neurons in vitro, which then decreased to around 30% editing after 
depolarisation with KCl (Orlandi et al., 2011). This correlates with findings that, following 
acute spinal cord injury, there is a reduction in R/G site editing in AMPA receptors in the 
spinal cord (Barbon et al., 2010).  
 
Figure 1.5 – Schematic of RNA editing reaction at the Q/R site of the GluA2 subunit. The Q/R site falls in 
codon 586 of the GluA2 transcript, part of exon 11. ADAR2 deaminates the adenosine within codon 586 
forming an inosine, which is read by the cell’s translation machinery as guanosine. This changes the coded 
amino acid from glutamine (Q) to arginine (R). 
1.3 RNA EDITING AT THE Q/R SITE OF GLUA2 
1.3.1 Discovery of the Exon Complementary Sequence and Imperfect Repeat 
Much of our knowledge on RNA editing at the Q/R site of the GluA2 subunit stems from 
work carried out by a German group in the early 1990’s (Higuchi et al., 1993). Transgene 
expression of a section of murine GluRB (previous nomenclature for Gria2) in PC12 cells 
was analysed using cDNA copies of RNA extracts. It was found that editing at the 
endogenous Q/R site was close to 100%. However, when plasmids containing small 
sections of GluRB were transfected into PC12 cells they showed lower editing of around 
43%. This was interpreted as evidence for additional elements needed for complete 
editing further up- or downstream of the Q/R site (Higuchi et al., 1993). Different plasmids 
were examined, each containing GluRB fragments with varying portions of exon 11 and 
the following intron. Through changing the length of the intron following the Q/R site, they 
discovered sequences within the non-coding bases that are essential for efficient editing, 
as summarised in Figure 1.6A. Using sequential deletions it was shown that there is a 
sequence of bases in intron 11 that are complementary to those surrounding the editing 
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site, and which were necessary for editing (Higuchi et al., 1993). This was termed the 
exon complementary sequence (ECS).  
 
Figure 1.6 – (A) Schematic showing the arrangement of the Q/R site, imperfect repeat and exon 
complementary sequence (ECS) on the GRIA2 gene as found by Higuchi et al. 1993. (B) Inverted 
complementarity of base sequences allow the formation of a double-stranded RNA structure. 
By substituting bases along this section of the gene, it was also shown that between the 
Q/R site and the ECS there were a series of bases that formed a so-called imperfect 
repeat, a series of inverted complementary bases that were able to form a predicted 
double-stranded section of RNA (Figure 1.6B). If the bases in the imperfect repeat were 
substituted but the complementary pairing (and therefore double-stranded structure) 
remained, then the Q/R site was still edited. This implied a reliance on secondary 
structure of the RNA molecule for the editing process. One of the plasmids used by this 
group contained a section of exon 11 and intron 11 including both the ECS and imperfect 
repeat from the murine sequence of GluRB. This they dubbed as the “B13 minigene” and 
is the transgene available in a plasmid for this project. 
1.3.2 Q/R Site Editing and Disease 
Editing at the Q/R site is unusual compared to most RNA editing events in that it is carried 
out to 100% efficiency in most mature neurons (Sommer et al., 1991). However, 
dysregulation of RNA editing has been studied in several degenerative diseases. 
Downregulation of the enzyme ADAR2 itself has been associated with the cell death of 
retinal ganglia cells in glaucoma (Wang et al., 2014). Lower ADAR2 expression was 
found in a mouse model of glaucoma and knockdown of ADAR2 using siRNA in retinal 
ganglion cells caused increased calcium currents and cell death in vitro (Wang et al., 
2014). Downregulation of ADAR2 was also found in a rat model of ischemia, in which it 
lead to reduced Q/R site editing (Peng et al., 2006). If ADAR2 expression was enhanced 
via transfection with the ADAR2 gene or through treatment with CREB, then Q/R site 
editing was restored and improved cell survival (Peng et al., 2006). A decrease in Q/R 
site editing has also been found in cells from human glioblastomas, which was 
associated with a change in ADAR2’s self-editing but no change in overall ADAR2 
expression (Maas et al., 2001).  
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Dysregulation of Q/R site editing has also previously been associated with 
neurodegenerative disorders. Through post-mortem analysis of neurons from the 
prefrontal cortex, patients with Alzheimer’s disease were shown to have a statistically 
significant decrease in Q/R site editing from more than 99.9% in control groups to 99% 
(Akbarian et al., 1995). The same study found 5% of GluA2 RNA was unedited at the 
Q/R site in neurons from the striatum of Huntington’s disease patients, again compared 
to the control group’s striatal neurons with 0.5% of RNA unedited (Akbarian et al., 1995). 
Another group looked at neurons from Alzheimer’s Disease patients and found that 
hippocampal neurons showed reduced Q/R site editing (down to 95% from more than 
99%) in those patients who carried the apolipoprotein E4 allele with no apparent change 
in ADAR2 expression (Gaisler-Salomon et al., 2014). RNA editing has also been shown 
to be inefficient in the lower motor neurons of patients with Amyotrophic Lateral Sclerosis 
(Kawahara et al., 2004). This group found that patients’ motor neurons had extremely 
variable editing efficiencies at the Q/R site (discussed later; Figure 1.9). It therefore 
appears that a decrease in Q/R site editing is common across a number of disease states 
where neuronal cell death is a factor.  
1.3.3 Transgenic Models Changing the Q/R Site 
Transgenic animal models have emphasised the importance of RNA editing in the GluA2 
subunit. A mouse model was created with the ECS from intron 11 removed, abolishing 
Q/R site editing (Brusa et al., 1995). Heterozygous mice of this model therefore had 
fewer edited subunits available, leading to higher calcium intake in neurons. By postnatal 
day 13, all carriers of the transgene developed seizures and had died by postnatal day 
20 (Brusa et al., 1995). On the other hand, when the genomic sequence is altered so 
that the “edited” form is coded in the DNA (i.e. the exon is originally transcribed as CGG 
rather than CAG), there appear to be no side effects (Kask et al., 1998). Mice expressing 
a transgenic inactive form of ADAR2 showed a similar phenotype to those without the 
ECS in intron 11 (Higuchi et al., 2000), which was rescued when the line was crossed 
with transgenic mice possessing a GRIA2 gene that was already the “edited” form 
(Horsch et al., 2011). This phenotypic rescue showed the importance of this particular 
editing event, and that although there were other lesser phenotypes such as reduced 
white blood cell count and altered lung function, they were not severe and the transgenic 
line was viable (Horsch et al., 2011).  
A conditional transgenic model was produced where ADAR2 is specifically targeted by 
the Cre/lox system in motor neurons under the VAChT promoter, titled AR2 mice 
(Hideyama et al., 2010). Exons 7 to 9 of the ADAR2 gene were flanked by loxP sites, 
targeted as they contain the majority of the catalytic domain, and then crossed with the 
VAChT-Cre.Fast line, which express Cre recombinase in cholinergic neurons including 
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motor neurons under the VAChT promoter (Misawa et al., 2003). Both homozygous and 
heterozygous mice for Cre recombinase displayed around 50% expression, and so AR2 
mice (ADAR2flox/flox/VAChT-Cre.fast) lack ADAR2 in roughly half of their motor neurons 
(Hideyama et al., 2010). When RNA from anterior horn neurons was obtained by laser-
dissection, it was found that editing at the Q/R site of GluA2 was variable, with less than 
half of the neurons showing 100% editing, and that those neurons that had less efficient 
editing also had evidence of removal of ADAR2. These mice were hypokinetic and had 
an abnormal posture, although there was no evidence of paralysis, and they showed 
lower rotarod performance and grip strength from 5 weeks onwards, correlating with the 
Cre expression profile (Hideyama et al., 2010). The mice also showed lower survival 
compared to controls of 81.5 ± 16.4 weeks compared to 105.1 ± weeks of control. The 
changes in motor behaviour corresponded with an observed reduction in anterior horn 
neurons from 2 months onwards, and AR2 mice’s muscles showed evidence of 
denervation. Again, rescue of the degenerative phenotype was possible when crossed 
with the transgenic line expressing the “edited” form of GluA2, producing the line AR2res 
(AR2/GluR-BR/R). These mice were phenotypically normal, with full motor function until 6 
months of age and the same number of anterior horn neurons as control at all time points 
(Hideyama et al., 2010). AR2 mice were shown to mislocalise the nuclear protein TDP-
43, mimicking a symptom of amyotrophic lateral sclerosis, and showed calpain-induced 
cleavage of TDP-43 which was not found in the AR2res line (Yamashita et al., 2012a). 
AR2 mice also show nuclear vacuoles in anterior horn neurons (Sasaki et al., 2014) and 
increased autophagy markers (Sasaki et al., 2015). These characteristics appear to be 
directly correlated with the decrease in functional ADAR2 expression, which is something 
that may occur naturally in aged mice (Hideyama et al., 2012a) and has also been found 
to a greater extent in motor neurons of ALS patients (Hideyama et al., 2012b).  
The same research group has created an AAV9 vector containing wild type ADAR2 
under a SYN1 promoter. This vector was injected into the tail vein of AR2 mice at 9 to 
13 weeks, the presymptomatic stage, or at 15 weeks after the mice start showing 
behavioural changes (Yamashita et al., 2013). Treatment at the presymptomatic stage 
showed a dramatic improvement, with little decline evident on the rotarod test, although 
less of an improvement was seen after treatment in the symptomatic stage. There was 
no improvement seen in grip strength, although there were an increased number of 
anterior horn neurons compared to AR2 mice injected with saline (Yamashita et al., 
2013). AAV9-ADAR2 injections lead to a 1.5 times increase in ADAR2 expression in 
spinal cord and brain homogenates, and Q/R site editing of the GluA2 subunit in laser-
captured anterior horn neurons showed an increase in editing to over 90%.  
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The importance of editing at the Q/R site in the GluA2 subunit is therefore clear, and has 
led to the proposed hypothesis for the aetiology of amyotrophic lateral sclerosis (ALS), 
whereby there is progressively lower ADAR2 activity in motor neurons, leading to higher 
incidence of unedited GluA2 subunits. When a majority of neurons contain the unedited 
form of GluA2, this causes the appearance of the clinical signs of ALS (Hideyama & 
Kwak, 2011). 
1.4 AMYOTROPHIC LATERAL SCLEROSIS 
1.4.1 Incidence and Symptoms 
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease with 
characteristic death of motor neurons. ALS is the third most common adult 
neurodegenerative disease after Alzheimer’s Disease and Parkinson’s Disease, with an 
incidence of 2 in every 100,000 (Chiò et al., 2013). Sometimes referred to as Lou 
Gehrig’s Disease after the famous American baseball player who suffered from ALS, this 
disease appears to be more prevalent in people who have a lower body mass index and 
who often take part in physical activity (Huisman et al., 2013). However, in a population-
based study there was no correlation found between ALS and physical activity (Veldink 
et al., 2005). There might still be the possibility of traits that lend towards an active 
lifestyle being significant in ALS development, but what these traits are and how they are 
linked to ALS have not been confirmed. A recent study looking at a population of 
American patients with ALS found no association with increased physical exercise, nor 
with other previously suggested environmental factors such as smoking or exposure to 
metal, dust or radiation (Yu et al., 2014). They did find an association with exposure to 
fertiliser. However, this study had a small sample size of n=66 and exposure levels were 
based on surveys, so associations need to be further investigated in a larger study. 
Several other environmental factors, such as smoking, vitamin E or antioxidants or 
exposure to metals or pesticides have also been suggested to be risk factors with varying 
degrees of association (reviewed in Ingre et al., 2015). 
The median survival for ALS patients is 2 years after confirmed diagnosis, or 3 years 
after symptom onset (Talbot, 2014). However, ALS can present in a variety of clinical 
manifestations, and 10% of patients will survive 10 years after diagnosis (Chiò et al., 
2013). The variation in clinical symptoms of ALS is not limited to life expectancy. In 30% 
of cases, onset of muscle weakness begins in an upper limb, whereas 35% of cases 
begin in a lower limb. 30% of cases begin with weakness in the muscles associated with 
speech or swallowing while the remainder of patients first show weakness in respiratory 
or axial muscles (Talbot, 2014). Muscle weakness then progresses through the voluntary 
neuromuscular system, although rate of progression can vary depending on genetic 
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background and possibly environmental factors. ALS is fatal through respiratory failure 
caused by paralysis of the diaphragm or intercostal muscles (Rothstein, 2009).  
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1.4.2 Genetic Mutations in ALS 
5-10% of ALS cases are familial (fALS) while the remaining 90% of cases appear to be 
sporadic (sALS). Within cases of fALS, mutations have been found in a variety of genes, 
as summarised in Figure 1.7. A database maintained by King’s College London, ALS 
Online Database or ALSoD, which tracks all known mutations found in ALS patients 
currently shows 659 mutations across 58 genes (Abel et al., 2012). 
 
Figure 1.7 - Pie charts indicating the proportion of familial ALS (fALS) to sporadic ALS (sALS) patients and 
the genes in which mutations are found. Data taken from (Robberecht & Philips, 2013; Lattante et al., 2015). 
The first identified mutation associated with fALS was in the superoxide dismutase 1 
(SOD1) gene (Rosen et al., 1993), and since then over 180 mutations in this gene have 
been identified. Mutations in SOD1 are found in around 20% of cases of fALS and around 
1% of sALS, with different mutations being associated with different presentations of 
ALS. For example, the A4V mutation is extremely aggressive leading to death within a 
year of symptom onset whereas the D90A mutation leads to much slower progression, 
with patients developing respiratory failure up to 10 years after onset (Renton et al., 
2014).  
Since the 1990s, improved sequencing techniques led to the discovery of mutations in 
genes such as TARDBP, FUS, VCP and ANG in fALS patients. Together with SOD1, 
these mutations can account for around 30% of those with familial ALS, as well as 
occurring in some cases previously designated sporadic (Ticozzi et al., 2011). For 
example, in a large cohort of more than 500 patients with ALS, mutations in the TARDBP 
gene were found in 5% of familial ALS cases and in 0.4% of sporadic ALS cases (Kirby 
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et al., 2010). Likewise, a study found FUS mutations in 5% of their cohort of fALS patients 
although only in a single sALS patient (Hewitt et al., 2010). Recently, linkage analysis of 
some familial ALS cases to chromosome 9 was shown to be due to a GGGGCC 
hexanucleotide repeat expansion within intron 1 of the C9ORF72 gene 
(Dejesus-hernandez et al., 2011; Renton et al., 2011). It has been reported that this 
expanded repeat may account for around 40% of cases with familial ALS (Cooper-Knock 
et al., 2012). Many of the less frequent genes are only found in specific populations of 
ALS patients. For example, mutations coding for OPTN (optineurin) were initially found 
in a Japanese family but are rarely found in European patients (Chiò et al., 2012). Despite 
these advances in understanding the genetics of ALS, how they relate to the specific 
death of motor neurons in the disease remain unknown. However, the genes affected 
and the proteins they code for are presumably involved in the pathological pathway. It is 
likely that several pathways may lead to the same outcome of motor neuron death and 
the symptoms of ALS. 
1.4.3 ALS and FTLD 
Frontotemporal lobe dementia (FTLD) is characterised by changes in behaviour, 
language and personality, with degeneration of neuronal populations in the frontal or 
temporal lobes detectable by MRI scans (Rosen et al., 2002). The discovery that TDP-43 
was a major component of the intracellular inclusions in both ALS and FTLD (Neumann 
et al., 2006) gave the first molecular evidence for the relationship between these two 
diseases. It is now a widely held view that ALS and FTLD are part of a continuum, with 
pure cases of each disease at either end but many patients showing aspects of both. For 
example, a large-scale study found 15% of ALS patients had signs of cognitive 
impairment (Ringholz et al., 2005), and those patients without dementia still showed a 
range of deficits in executive function (Massman et al., 1996). At a molecular level, FTLD 
is characterised by ubiquitin-positive plaques co-localising with either TDP-43 or FUS 
(Neumann et al., 2009). Around 40% of patients with FTLD were found to be familial, 
with mutations in MAPT and GRN found specifically in FTLD cases (Rohrer et al., 2009), 
while patients with SOD1 mutations are unlikely to show cognitive impairment (Wicks et 
al., 2009). Mutations in C9ORF72 on the other hand are found in patients throughout the 
FTLD-ALS spectrum (Benussi et al., 2014).  
1.4.4 Molecular Pathology of ALS  
Decades of research has discovered several intracellular processes that are 
dysregulated in ALS, although it is still unclear which, if any, of these events are the initial 
cause of disease. These mechanisms include aggregation of several different proteins 
including SOD1 and TDP-43, dysfunctional RNA processing, mitochondrial dysfunction 
and glutamate excitotoxicity (summarised in Figure 1.8).  
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Figure 1.8 - Summary of intracellular dysfunction found in ALS. Insoluble protein aggregates and RNA foci 
are characteristic markers of ALS patients. Cells also show impaired nucleocytoplasmic transport, 
mitochondrial dysfunction and increased oxidative stress, with changes in glutamate receptor composition 
also shown in both motor neurons and astrocytes. 
 
1.4.4.1 Motor Neuron Susceptibility 
As the progression of both familial and sporadic ALS is similar, it is reasonable to assume 
a common pathway in the degeneration of motor neurons. Why motor neurons are 
specifically targeted in ALS remains unclear, although it is true that they appear to be 
particularly vulnerable to cellular stresses associated with ALS, such as endoplasmic 
reticulum stress (Jara et al., 2015). They may also be more susceptible to excitotoxicity, 
as oculomotor neurons, which are spared in ALS, show a reduced inward calcium current 
after AMPA receptor stimulation compared to corticospinal neurons (Brockington et al., 
2013). Motor neurons also stretch a remarkably long distance with massive cytoskeletal 
networks, and microtubule defects are known to be part of ALS pathology (Bilsland et 
al., 2010). Neurons in general are particularly at risk of damage through misfolded 
proteins, as they are large and post-mitotic, so they cannot dilute any toxic waste through 
division and high rates of metabolism are needed to process the proteins produced over 
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their large surface area (Parakh & Atkin, 2016). It is possible that the small differences 
that set the motor neuron population apart sum up to the susceptibility seen in ALS.  
1.4.4.2 SOD1  
Superoxide dismutase 1, SOD1, is an important antioxidant enzyme converting 
superoxide (O2-) to H2O2 and O2. SOD1 is a homomeric Cu/Zn-binding enzyme (Rosen 
et al., 1993) found throughout motor neurons, associated with their mitochondria (Pardo 
et al., 1995). A large number of ALS-linked mutations are associated with this gene, and 
such mutations have been linked to a variety of downstream effects such as altered gene 
expression, dysfunctional mitochondria and activation of caspases (Liu et al., 2004). 
Mutations in SOD1 tend to be split into two groups, those that affect the β-barrel structure 
and those that affect the metal binding sites, both of which can affect the oligomerisation 
and formation of SOD1 aggregates (Kaur et al., 2016). Collection of mutant SOD1 into 
insoluble aggregates causes a build-up of reactive oxygen species in the cell, damaging 
other cellular components, due to a decrease in SOD1 activity (Graffmo et al., 2013). 
Mutated SOD1 has also been linked to dysfunction of the endoplasmic reticulum and 
Golgi apparatus (Soo et al., 2015). 
ALS is often considered a prion-like disease, due to its characteristic progression from 
an initial focal starting point then spread to neighbouring neuroanatomical structures, 
rather than from multiple but diverse locations (Ravits et al., 2013). In order for a protein 
to be classified as prion-like, it must have a prion-like binding domain and have the 
capacity to act as a “seed” protein, inducing other proteins to misfold. Although SOD1 
does not contain a prion-like domain, there is some evidence that it has prion-like 
properties. For example, spinal cord tissue homogenate from SOD1G93A mice can cause 
aggregates to form from wild-type SOD1 in vitro (Chia et al., 2010). In order for SOD1 to 
behave like a prion in the progression of ALS, it must be able to leave the motor neurons 
to travel to the neighbouring cells. Mutant SOD1 has been found in the media of primary 
neurons grown in culture from SOD1G93A mice, with evidence that the SOD1 has been 
secreted in exosomes (Basso et al., 2013). Spinal cord homogenates from SOD1G93A 
mice injected into another transgenic model (SOD1G85R mice) with low levels of 
aggregates induced motor neuron disease (Ayers et al., 2014). The second passage 
homogenates, taken from the induced strain into a second generation, also showed 
faster disease onset, as in prion disease. However, similar effects could be seen in a 
small proportion of mice who were injected with wild type SOD1, and seeding with two 
other mutant SOD1 strains failed to accelerate the disease (Ayers et al., 2016). 
Astrocytes have also been implicated in SOD1 pathology, as co-cultures with astrocytes 
expressing mutant SOD1 reduces the viability of motor neurons but not interneurons, 
GABAergic neurons or sensory neurons (Nagai et al., 2007). This could be due to 
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increase excitability of the motor neurons with increased sodium channel permeability 
(Fritz et al., 2013).  
Some now consider ALS with SOD1 mutations a separate pathology to the rest of ALS 
cases due to these patients often not presenting with the classic ALS hallmarks of 
ubiquitin-positive, TDP-43-positive cellular inclusions (Mackenzie et al., 2007; Arai et al., 
2006). Aggregates found in SOD1 fALS are SOD1 and ubiquitin positive, but in general 
do not recruit TDP-43 (Farrawell et al., 2015). Even though the mutated SOD1 protein 
has been shown to interact with endogenous TDP-43 in co-immunoprecipitation studies 
(Higashi et al., 2010), it has proven difficult to incorporate mutated SOD1 with the 
pathology associated with TDP-43 and C9ORF72. 
1.4.4.3 TDP-43 
TAR DNA-binding protein-43 (TDP-43) is generally localised to the nucleus but can be 
shuttled to and from the cytoplasm under normal conditions (Ayala et al., 2008). TDP-43 
has been associated with many roles, including acting as a transcription factor (Acharya 
et al., 2006), regulating splicing of exons (Mercado et al., 2005; Buratti et al., 2001) and 
stabilisation of mRNA transcripts (Strong et al., 2007). Knockdown of TDP-43 expression 
in the adult mouse brain led to changes in expression levels of over 600 genes and more 
than 900 changes in splicing (Polymenidou et al., 2011). TDP-43 binds to single stranded 
sequences, mainly to intronic repeat motifs (Xiao et al., 2011). It is therefore clear that 
TDP-43 plays a role in RNA processing.  
There are around 44 ALS-linked mutations in TARDBP (the gene coding for TDP-43), 
and the protein itself is abnormally cleaved and phosphorylated in ALS (Neumann et al., 
2006). Mutations in TARDBP appear to cause both loss of normal function of the protein 
TDP-43 and toxic gain-of-function (Kabashi et al., 2010). Altered splicing patterns are 
seen in mice carrying TDP-43 mutations, accompanied by increasing loss of motor 
neurons in the spinal cord, due to the loss of normal TDP-43 function (Arnold et al., 2013; 
Tsuiji et al., 2013). Gain of toxic function can be seen in the aggregates found in the cells 
of almost all ALS patients, both with sALS and fALS (Mackenzie et al., 2007), and 
increasing burden of deposits correlates with progression of ALS which can be tracked 
using diffusion tensor imaging (Kassubek et al., 2014). Unlike SOD1, TDP-43 fulfils both 
requirements for a prion-like protein, as it contains a predicted prion-like binding domain 
which is essential for its aggregation (Udan-Johns et al., 2014) and mutations in TDP-43 
at this domain can enhance aggregation properties (Lim et al., 2016). Extracts from 
diseased brains can also induce misfolding of TDP-43 in cell culture, showing the TDP-
43 aggregates have seeding properties (Nonaka et al., 2013). Misfolded TDP-43 has 
even been shown to act as a seed for incorrect folding of wild-type SOD1 in cell culture 
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(Pokrishevsky et al., 2016), hinting at a link between the tertiary structure of these two 
proteins and their influence on each other. 
1.4.4.4 FUS 
FUS (fused in sarcoma) protein shares both structural and functional similarities with 
TDP-43. FUS has been shown to bind to RNA polymerase II as well as RNAs from over 
5,000 genes, affecting both transcription and splicing patterns (Lagier-Tourenne et al., 
2012), particularly in cortical and motor neurons (Fujioka et al., 2013). FUS-positive 
inclusions are found in almost all ALS patients apart from those with SOD1-linked ALS 
(Deng et al., 2010). Those patients with mutations in the FUS gene show different forms 
of inclusions according to their mutation (Mackenzie et al., 2011), which then cause 
mislocalisation of the protein and the formation of stress granules (Gal et al., 2011). The 
original reports of FUS mutations in ALS also showed the change in localisation of the 
protein from the nucleus to the cytoplasm, indicating a loss of normal function 
(Kwiatkowski et al., 2009). The involvement of FUS supports the idea that the pathology 
of ALS at least involves dysregulated RNA processing. 
1.4.4.5 C9ORF72 
The major focus of the last few years of research into ALS pathology has been on the 
G4C2 repeat in C9ORF72. Before the expanded repeat mutation was linked to this gene, 
it was not known what the C9ORF72 protein did within the cell. Since the original 
discovery of the expanded repeat (Dejesus-hernandez et al., 2011; Renton et al., 2011), 
the normal function of the C9ORF72 protein has been linked to endosomal trafficking as 
it associates with Rab proteins (Farg et al., 2014), and high expression of the gene can 
be seen in the central nervous system (Rizzu et al., 2016). Normal function of C9ORF72 
may also aid stress granule formation, and so loss of expression could be linked to the 
increased number of stress granules seen in ALS neurons (Maharjan et al., 2016). How 
the expanded repeat could lead to neurodegeneration is still unclear, although there are 
three competing theories which are not necessarily mutually exclusive. The 
neurodegeneration may be through loss-of-function, where the expanded repeat causes 
reduced transcription of C9ORF72. There is conflicting evidence of this, as some groups 
have shown reduced expression of C9ORF72 in a zebrafish model, leading to changes 
in motor neuron pathology and reduced motion (Ciura et al., 2013), and there is evidence 
of reduced protein expression in the brains of ALS patients (Waite et al., 2014), possibly 
due to increased methylation of the C9orf72 gene itself (Belzil et al., 2013) although the 
methylation may also be a protective mechanism (Bauer, 2016). On the other hand, no 
change in expression was seen in ALS patient-derived induced pluripotent stem cell 
motor neurons (iPSC-MNs) (Sareen et al., 2013) and there are no identified loss-of-
function mutations found in this gene (Harms et al., 2013).  
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There are two possible mechanisms for toxic gain-of-function following the expanded 
repeat. Firstly, evidence that the repeat is transcribed into RNA and forms RNA foci in 
the cytoplasm of affected cells indicates that the RNA itself may be toxic (Dejesus-
hernandez et al., 2011). iPSC-MNs derived from patients with the C9ORF72 mutation 
maintain the expanded repeat, making them a useful model for analysis. These neurons 
show collection of RNA transcripts of the repeat into discrete RNA foci, which then allow 
the association of various RNA binding proteins (Cooper-Knock et al., 2014), and the 
toxic pathology associated with these foci can be diminished by treatment of antisense 
oligonucleotides with complementary sequences to C9ORF72 reducing RNA expression 
(Donnelly et al., 2013). One RNA-binding protein found to co-localise with the C9ORF72 
RNA foci was ADAR2, and when ADAR2 expression was knocked down with siRNA the 
RNA foci load was reduced by nearly 50% (Donnelly et al., 2013). Although this study 
did not find an association between C9ORF72 RNA foci and other ALS-linked RNA 
binding proteins, other groups have found co-localisation with Purα (Xu et al., 2013) and 
TDP-43 (Cooper-Knock et al., 2015). The repeat expansion appears to be transcribed 
without the means of a traditional promoter, with expression of sequences either up or 
downstream of the promoter not being detected in the RNA foci (Donnelly et al., 2013). 
This leads to both the sense and antisense sequence of the repeat being transcribed 
and forming foci (Mizielinska et al., 2013), and it appears that the antisense rather than 
the sense transcripts are associated with a nuclear loss of TDP-43 (Cooper-Knock et al., 
2015).  
As well as the RNA transcripts disrupting intracellular mechanisms, the RNA is translated 
into peptides which are the third proposed mechanism of pathology. Due to the sequence 
of the G4C2 repeat, translation from both the sense and antisense RNA strands form 
sections of di-peptide repeats (DPRs), either containing glycine-alanine (GA), glycine-
proline (GP), glycine-arginine (GR), alanine-proline (AP) or arginine-proline (RP). These 
DPRs form intracellular aggregates that are TDP-43-negative but ubiquitin- and p62-
positive (Mackenzie et al., 2014). It appears that DPR load does not correlate with degree 
of neurodegeneration in ALS patients (Mackenzie et al., 2013) as opposed to RNA foci 
(Mizielinska et al., 2013). It has recently been discovered that a major effect of the DPRs 
is on the nucleocytoplasmic transport of the cell. The DPRs of C9ORF72 interact with 
RanGAP, a major protein in nucleocytoplasmic transport, and Drosophila and iPSC-MNs 
expressing the repeat expansion show nuclear pore pathology (Zhang et al., 2015) and 
altered expression of over a dozen genes associated with nucleocytoplasmic transport 
(Freibaum et al., 2015).  
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1.4.4.6 Glutamate and Excitotoxicity  
Excitotoxicity describes over-stimulation from glutamate, which causes an increased 
influx in calcium leading to other downstream events such as oxidative stress (Sun et al., 
2010). Glutamate is a fundamental neurotransmitter in the CNS, and it is known to be 
abnormally regulated in ALS. Focus was originally targeted on the glutamate 
transmission system after there were significantly decreased levels of glutamate found 
in the spinal cord and brain homogenates of ALS patients (Plaitakis et al., 1988), 
although there were increased levels of glutamate found in the cerebrospinal fluid (CSF) 
in one study (Shaw et al., 1995) but reduced levels found in the CSF of ALS patients in 
a more recent study (Wuolikainen et al., 2011). Although in the spinal cord there was no 
reported change in overall AMPA or kainate receptor expression, NMDA receptors were 
expressed at lower levels in ALS patients (Allaoua et al., 1992) and a reduced expression 
of the GluA2 subunit has been seen (Takuma et al., 1999). Motor neurons were found to 
be particularly sensitive to AMPA or kainate receptor activation as opposed to NMDA 
receptor activity (Rothstein et al., 1993), and there was death specifically of motor 
neurons following injection with kainic acid, an agonist of both AMPA and kainate 
receptors, into the subarachnoid space of the spinal cord in rats (Sun et al., 2006). Motor 
neurons appear to be a particularly vulnerable neuronal population when it comes to 
excitotoxicity, possibly because of their low expression of the GluA2 subunit in their 
AMPA receptors leading to increased calcium currents (Van Damme et al., 2002). In 
organotypic spinal cord slices, it was found that non-NMDA receptor antagonists or 
blockade of glutamate synthesis and release prevented motor neuron death when 
exposed to high levels of glutamate (Rothstein et al., 1993).  
An important glutamate transporter expressed in astrocytes, EAAT2, was found to be 
downregulated in ALS patients compared to matched controls (Fray et al., 1998), 
possibly due to abnormally processed RNA transcripts as aberrant mRNAs were found 
in ALS patients (Lin et al., 1998). EAAT2 downregulation was found early in the 
pathology of rats carrying the SOD1G93A mutation (Howland et al., 2002), although not 
until late in the disease in mice carrying the same transgene (Warita et al., 2002). 
Additionally, synaptosomes from SOD1G93A mice showed an increase in glutamate 
release in response to depolarisation due to an increase in number of vesicles, indicating 
that it is not just the astrocytes that display dysregulation of glutamate (Milanese et al., 
2011). Double transgenic mice carrying the SOD1G93A mutation along with 
overexpression of EAAT2 delayed the degeneration of motor function, although there 
was no effect on the lifespan of the mice (Guo et al., 2003). It appears that mutant SOD1 
and dysregulation of glutamate can work synergistically to promote motor neuron death 
(Yin & Weiss, 2012) which corresponds with a more significant reduction in glutamate 
levels in the CSF of ALS patients with the familial disease compared to those with 
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sporadic ALS (Wuolikainen et al., 2011). There is also evidence that other 
neurotransmitter systems are dysfunctional in ALS, for example inhibitory currents are 
decreased in ALS patients (Zanette et al., 2002) correlating with a loss of interneurons 
in the spinal cord (Stephens et al., 2006), which could exaggerate the glutamate 
excitotoxicity. iPSC-MNs derived from ALS patients with SOD1, FUS and C9ORF72 
mutations also appear to be hyperexcitable (Wainger et al., 2014). Taken together, these 
studies suggest that dysregulation of glutamate transmission in motor neurons may at 
least be a contributing factor in ALS pathogenesis.  
Currently, the only therapy for ALS is the drug riluzole (Rattray & Bendotti, 2006). 
Riluzole, an inhibitor of glutamate release, showed great promise in extending the 
lifespan of the SOD1G93A mouse (Gurney, 1997), and was taken to clinical trials with 
results showing an increased life span of patients between 2 and 3 months (Bensimon 
et al., 1994; Lacomblez et al., 1996). Despite this reduced translation in effect between 
mouse model and human patient, riluzole remains the only treatment currently available 
for ALS as no other treatment has so far progressed beyond clinical trials. Riluzole’s 
effects, depending on dose, range from inhibition of Na+ currents and potentiation of 
calcium-dependent K+ currents to promotion of growth factors and modulation of ligand-
gated receptors (reviewed in Bellingham, 2011). More recently, Riluzole has been used 
in the treatment of other disorders associated with glutamate dysregulation such as 
spinal cord injury (Vasconcelos et al., 2016), glaucoma (Pirhan et al., 2016), major 
depressive disorder (Salardini et al., 2016) and even Alzheimer’s Disease (Pereira et al., 
2016).  
1.4.5 Mouse Models of ALS 
A great deal of effort has been put into creating a mouse model that properly recreates 
the clinical phenotype of ALS as well as the genetic component, with the models 
described here summarised in Table 1.2. The first transgenic mouse, and subsequently 
the most studied, is the SOD1G93A mouse with inserted transgenic copies of the G93A 
mutation in the mutant SOD1 gene. This mutation causes paralysis starting generally in 
one hind limb and ascends, caused by motor neuron death, and a higher copy number 
of the transgene causes a more severe phenotype (Gurney et al., 1994). Transferring 
the mutation onto a C57BL6/SLJ background reduced the mean survival by a month, 
indicating the presence of as yet unidentified genetic modifiers (Gurney, 1997; 
Heiman-Patterson et al., 2011), and changing the genetic background has allowed slow 
and quick progressive models to be established (Marino et al., 2015). Over the past 20 
years, the SOD1G93A mouse has shown a varied length of survival from 102 to 151 days 
(Benatar, 2007), which in some ways reflects the variability seen in ALS patients. Those 
patients who carry the G93A mutation in SOD1 have also shown varied survival spanning 
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from 62 to 243 months (Régal et al., 2006). Up to 20 different SOD1 mutations have now 
been modelled in mice with varying phenotypes, for example the G85R mutation gives a 
rapidly progressive paralysis with SOD1 inclusions (Bruijn et al., 1997). Knockout of the 
Sod1 gene in mice does not induce motor neuron cell death, and so mutations in SOD1 
appear to be more than simply loss-of-function (Reaume et al., 1996). Indeed, 
overexpression of wild-type human SOD1 in mice can also induce motor neuron 
degeneration (Graffmo et al., 2013). 
After the discovery of TDP-43 inclusions and mutations in TARDBP, several groups 
attempted to produce mouse models replicating these mutations. However, no mouse 
model with expression of mutated TDP-43 shows the ascending paralysis seen in ALS, 
although several lines show abnormal motor behaviour (reviewed in Philips & Rothstein, 
2015). Overexpression of wild type human TDP-43 does not appear to cause the 
formation of insoluble aggregates at lower expression levels (Arnold et al., 2013) 
although at higher expression levels human wild type TDP-43 induces similar pathology 
to mutated TDP-43A315T (Stallings et al., 2010). This group found that the TDP-43A315T 
mutation could cause an extremely aggressive set of symptoms, with formation of 
aggregates and later onset of paralysis (Stallings et al., 2010). Compared to the plethora 
of attempts at a mutant TDP-43 mouse model, only a handful of transgenic FUS models 
have been created. Overexpression of wild-type human FUS led to progressive hind-
limb paralysis and FUS-positive inclusions in motor neurons (Mitchell et al., 2013), while 
expression of FUS containing ALS-linked mutations led to a more aggressive pathology, 
with a higher number of aggregates in motor neurons (Verbeeck et al., 2012).  
Although the repeat expansion in C9ORF72 is known to be important in ALS due to its 
prevalence in fALS cases, it has proven difficult to model in mice. Knockout of the 
C9ORF72 gene did not induce motor neuron degeneration or a decrease in survival in 
mice (Koppers et al., 2015), despite motor deficits being observed in a C9ORF72 
knockdown model in zebrafish (Ciura et al., 2013). However, expression of the repeated 
sequence, G4C2, alone in an AAV vector in mice leads to motor deficits, although not 
actual paralysis, as well as a behavioural deficits, TDP-43-positive inclusions and loss of 
motor neurons (Chew et al., 2015). These mice only had 66 repeats of G4C2 due to size 
limitations in AAV vectors, which is not a pathological repeat size in humans. Another 
study introduced the entire human C9ORF72 gene including the expansion repeated up 
to 1,000 times in a bacterial artificial chromosome. Despite the presence of RNA foci and 
dipeptide repeats, these mice showed no neurodegeneration or changes in behaviour 
(O’Rourke et al., 2015). Comparison of these mouse models, summarised in Table 1.2, 
shows that there is still no mouse model that encapsulates the ALS phenotype 
completely. The SOD1G93A mouse model is still in use due to its phenotype of ascending 
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paralysis, but does not incorporate the molecular features of TDP-43 and C9ORF72 
dysfunction. On the other hand, those that do model these characteristics do not show 
the ascending paralysis that is the main clinical feature of ALS. 
 
Table 1.2 - Comparison of described mouse models of ALS. WT = wild type; (G4C2)N = number of 
hexanucleotide repeats in transgene; “-“ = not reported; DPRs = dipeptide repeats 
 
The disheartening lack of correlation to the clinical phenotype of ALS, as well as recent 
technological advances, has led to the focus being shifted more onto cell models, in 
particular iPSC-MNs. Fibroblasts can be taken from patients and “reprogrammed” into 
first stem cells and then motor neurons, forming neuronal cultures with any genetic 
mutation, as well as any undetected genetic modifiers, intact. This has been performed 
with TARDBP mutations as well as the C9ORF72 repeat expansion, which are both 
maintained after iPSC-MN induction (Devlin et al., 2015). 
1.4.6 ALS and the GluA2 Subunit 
In culture, motor neurons showed significantly more cell death in response to 
excitotoxicity induced by either kainate or an AMPA-specific agonist compared to dorsal 
horn neurons prepared in a similar manner (Van Den Bosch et al., 2000). This 
experiment was in the presence of inhibitors of NMDA receptors, and so the cell death 
appears to be mediated through the AMPA receptors themselves. By staining for Ca2+-
permeable AMPA receptors, it was shown that a significantly higher percentage of 
receptors were permeable to calcium in the motor neurons compared to the dorsal horn 
neurons (Van Den Bosch et al., 2000). It is possible that the increased selective cell 
death of motor neurons is due to decreased expression of the GluA2 subunit. However, 
Kawahara et al. investigated the distribution of GluA2 expression in neurons in the 
human CNS and found that, although there is a relatively low abundance of GluA2 
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subunits in spinal motor neurons, there was no difference in expression between ALS 
patients versus controls (Kawahara et al., 2003).  
Editing at the Q/R site of GluA2 was shown to be decreased in patients suffering from 
ALS (Kawahara et al., 2004). Laser dissection of spinal cords from patients with ALS 
versus control subjects after autopsy allowed editing efficiencies to be measured in 
individual motor neurons. In all control subjects’ neurons, editing was at 100% (see 
Figure 1.9) whereas in patients with ALS, editing efficiency varied between 0 and 100% 
(Kawahara et al., 2004). It has previously been found that editing at the Q/R site was 
complete in the motor cortex of patients with ALS (Takuma et al., 1999) and so it is 
possible that this editing deficiency is specific to spinal motor neurons. Associated with 
the decrease in editing efficiency, the same group analysed the expression of ADAR2. It 
was found that in ALS patients, some motor neurons do not express ADAR2 (Hideyama 
et al., 2012b). These neurons also showed TDP-43 pathology. When compared to 
expression of the GluA2 subunit, expression of ADAR2 was reduced by up to a third in 
ALS patients whereas there was normal ADAR1 and ADAR3 expression. Conversely, it 
has also been shown that editing is at 100% in transgenic rats expressing mutant human 
SOD1 (Kawahara et al., 2006). There are two possible conclusions from this, firstly 
SOD1 transgenic animals are only a model for ALS and so may not show all of the 
pathology associated with the disease. Alternatively, under-editing may only occur in the 
sporadic form of ALS rather than in the familial disease, or simply not in the SOD1-linked 
version of ALS. This may also support the theory that SOD1-associated ALS follows a 
different pathway to TDP-43-associated ALS. Downregulation of ADAR2 occurs naturally 
in ageing C57BL/6J mice, and was found to coincide with the mislocalisation of TDP-43 
(Hideyama et al., 2012a). Manipulation of TDP-43 in cell culture did not alter ADAR2 
expression (Yamashita et al., 2012b), and so it is possible that cytoplasmic TDP-43 
inclusions in ALS are a downstream event of altered ADAR2 expression and/or under-
editing of GluA2. 
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Figure 1.9 – Results from Kawahara et al. 2004, showing the range of editing efficiency from ALS patients 
in lower motor neurons compared to control subjects. A1-5 indicates successive patients with ALS. C1-5 are 
control subjects. N = number of motor neurons analysed per patient. The y-axis indicates editing efficiency. 
Each coloured circle represents a single neurons whose editing of the Q/R site of the GluA2 subunit was 
calculated. 
1.5 ANTISENSE OLIGONUCLEOTIDES 
For the past three decades, antisense oligonucleotides have been a promising area of 
research for a variety of diseases. The term “antisense oligonucleotide” (ASO) refers to 
complementary sequences of RNA or DNA, with or without modified backbones, that are 
directly targeted to a gene or RNA transcript. ASO technology was first published in 
1978, with an unmodified ASO targeting the 35S RNA of the Rous sarcoma virus 
(Stephenson & Zamecnik, 1978). This effectively inhibited translation of the virus’ RNA 
in chick embryo fibroblasts when the ASO bound to the RNA transcript via Watson-Crick 
base pairing (Zamecnik & Stephenson, 1978). Over the past four decades, this approach 
has been improved through altering the chemistry of the DNA or RNA backbone. There 
are multiple reasons for altering the backbone of the oligonucleotide, such as improving 
binding affinity, increasing resistance to degradation of the ASO by nucleases or 
increasing cellular penetration. 
1.5.1 Mechanisms of Action 
1.5.1.1 RNase H Degradation 
Antisense oligonucleotides can be used to knock down expression of genes through 
recruitment of RNase H, which cleaves the RNA strand of RNA/DNA hybrids. These 
ASOs are called gapmers, where flanking sequences complementary to the target RNA 
surround a central sequence that recruits endogenous RNase H to the complex, 
degrading the RNA. One example of this design of ASO is mipomersen, which targets 
apolipoprotein B100 in hypercholesterolemia. Mouse models showed a reduction in LDL 
cholesterol which was both dose-dependent and time-dependent (Crooke et al., 2005). 
These results were replicated in human trials with only mild reactions at the injection 
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sites (Kastelein et al., 2006; Raal et al., 2010) and this drug now has FDA approval for 
use in cases of hypercholesterolemia. Another example is the drug custirsen, targeting 
clusterin which is upregulated in some cancers. Clinical trials showed improved survival 
in patients with prostate cancer (Chi et al., 2010) although only a slight effect was seen 
in patients with metastatic breast cancer (Chia et al., 2009). Custirsen is currently in 
phase III clinical trials for prostate cancer and non-small cell lung cancer (OncoGeneX, 
2016).  
1.5.1.2 Disruption through Steric Hindrance 
Another approach to using antisense technology is through interfering with RNA 
processes through steric hindrance rather than recruiting enzymatic degradation. This 
was the approach used by Zamecnik and Stephenson (1978), and has been improved 
on over the years. Due to the dependence of many RNA processes on recognition sites 
or secondary structure of the RNA molecules, the simple addition of the short 
complementary sequences of modified nucleotides ought to be sufficient for disruption. 
The specificity of ASOs allow them to be directed to discrete regions of the RNA 
transcript, covering binding sequences and so preventing RNA binding proteins from 
carrying out their actions, or disrupting the secondary structure of transcripts and so 
preventing actions of the RNA transcript. By covering sequences associated with either 
splice enhancers or splice silencers, ASOs can promote exon skipping or exon inclusion 
respectively. 
This approach has successfully altered splicing in multiple models including those for 
Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (reviewed in Kole et 
al., 2012). Through targeting ASOs to sequences recruiting the spliceosome and 
preventing its action, therefore skipping exons containing mutations associated with 
DMD, a functional albeit shortened protein can be expressed and alleviate the DMD 
phenotype (Popplewell et al., 2009). Exon skipping using ASOs in DMD has reached the 
clinical trial phase, although drisapersen, an ASO that targets exon 51 of the DMD gene, 
did not show enough of a benefit over placebo in phase III trials for GSK to continue 
(Echigoya & Yokota, 2014). There are many possible reasons why the clinical trials 
failed. For example, exon 51 has been shown to contain mutations in 13% of DMD 
patients (Echigoya & Yokota, 2014), which is a relatively high percentage but clearly not 
broadly applicable. This highlights one downfall of ASO technology which needs 
consideration. When targeting diseases that have been associated with multiple genetic 
mutations, the specificity of an ASO means that one treatment will only be applicable to 
a small percentage of patients. One possible way to get around this would be to combine 
a cocktail of ASOs that target multiple exons, leading to a treatment that can be aimed 
at more patients (Echigoya & Yokota, 2014). Eteplirsen is another ASO targeting exon 
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skipping of exon 51 on the dystrophin gene with a different chemistry to drisapersen and 
produced by Sarepta, with good outcomes in clinical trials (Mendell et al., 2013) although 
it has recently been declined FDA approval. Exon skipping has also been used to 
improve specificity of ASO approaches, for example targeting exon 27 of apolipoprotein 
B reduces LDL cholesterol without influencing levels of the APOB48 transcript, unlike 
mipomersen (Disterer et al., 2013). 
1.5.2 Chemistries of Antisense Oligonucleotides 
Synthetic ASOs can have varied chemistries of phosphate backbone, the choice of which 
is important when considering stability, administration and biodistribution. Applying 
unmodified DNA bases to a cell would lead to nuclease degradation, and so altering the 
structure is important for the efficacy of any therapy. Chemical modifications of ASOs fall 
into two broad classes: altering the phosphate of the oligonucleotide to either a 
phosphorodiamidate or phosphorothioate backbone (blue in Figure 1.10) or modifying 
the ribose ring (green in Figure 1.10). All of these modifications maintain the 
oligonucleotide’s ability to form Watson-Crick base pairs with RNA transcripts, but 
stabilise the ASO as a single strand. Both the phosphorothioate backbone, with a sulphur 
atom instead of the non-bridging oxygen, and the phosphorodiamidate backbone are 
resistant to nuclease degradation (Hudziak et al., 1996; Noy et al., 2008).  
 
Figure 1.10 - Structures of DNA (A) compared to phosphorodiamidate morpholino oligonucleotides (B) and 
2'-O-methyl phosphorothioate oligonucleotides. Green indicates modifications to the ribose sugar; blue 
indicates modifications to the phosphate backbone. 
1.5.2.1 Ribose Ring Modifications 
The most common ASO with a 2’-O-methyl modification is 2’-O-methylphosphorothioate 
(OMe-PS), which has been used in several applications including familial 
hypercholesterolemia (Disterer et al., 2013) and Duchenne muscular dystrophy 
(Verhaart et al., 2014) where they have been shown to have a long half-life of around 35 
days in skeletal muscle and even longer in the heart. Drisaspersen is an OMe-PS 
currently in clinical trials for exon 51 skipping in DMD, apparently showing a good safetly 
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profile (Goemans et al., 2011). Another 2’ modified antisense chemistry is the 2’-O-
methyoxyethyl (2’-MOE) group of ASOs, which have been shown to be effective in exon 
skipping in spinal muscular atrophy (Hua et al., 2007) and have reached clinical trial 
stage with Nusinersen (Chiriboga et al., 2016). For use in Duchenne muscular dystrophy, 
it was determined that 2’-MOEs induced a higher percentage of exon skipping at exon 
23 of the DMD gene compared to 2’-OMe-PSs (Yang et al., 2013). RNase H degradation 
can also be induced using this chemistry through the use of gapmers, ASOs with 2’-MOE 
modified bases at 5’- and 3’- ends and a central region of unmodified bases to activate 
RNase H activity. This method has been shown for example in myotonic dystrophy to 
knock down CUG RNA repeats in skeletal muscle (Wheeler et al., 2012). Further 
modifying the ribose ring to a 2’-deoxy-2’-fluoro (2’-F) ASO, with the intention of 
improving exon skipping efficiencies, was found to recruit the interleukin enhancer-
binding factor 2 and 3 complex resulting in omission of the exon from the RNA transcript 
(Rigo et al., 2012).  
Through creation of a cyclic structure where a 2’-alkyl substitute is replaced at the 4’ 
position of the ribose ring, the sugar is “locked” into the conformation similar to RNA. 
These locked nucleic acids (LNAs) have greatly increased thermal stability, creating 
incredibly stable Watson-Crick base pairing even when mixed with other conformations 
within an ASO (Singh & Wengel, 1998). LNAs are capable of RNase H activation 
(Wahlestedt et al., 2000) as well as in exon skipping, particularly in a mixmer (Shimo et 
al., 2014). Other cyclic structures of ASOs include bicyclo-DNAs (bcDNAs) and tricyclo-
DNAs (tcDNAs). TcDNAs in particular show promising efficacies in terms of exon 
skipping in the DMD gene, with good biodistribution throughout tissues including the CNS 
and low toxicity (Goyenvalle et al., 2015). 
1.5.2.2 Neutrally Charged ASOs 
Charge-neutral ASOs are often used in exon-skipping studies due to their long half-life. 
Peptide nucleic acids (PNAs) are derivatives of 2-aminoethylglycine and positively 
charged lysine residues are often included to improve water solubility of the ASO (Hyrup 
& Nielsen, 1996). PNAs have particularly good cell-penetration when attached to DNA 
oligomers, for example conjugation to a nuclear localisation signal (Cutrona et al., 2000), 
or to cell penetrating peptides (Cordier et al., 2014).  The other neutrally-charged 
chemistry that is predominant in antisense studies is the phosphorodiamidate 
morpholino oligomer (PMO). PMOs are synthetic oligonucleotides that have a 
phosphorodiamidate backbone instead of the naturally occurring phosphodiester linkage 
between bases and a morpholine ring instead of the ribose ring (Figure 1.10B). As a 
result of this modified backbone, PMOs are extremely stable, with resistance to 
endogenous nucleases allowing the PMO to remain intact for longer (Eisen & Smith, 
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2008). The neutral charge of PMOs also reduces the chances of toxicity (Amantana & 
Iversen, 2005). Effective biodistribution of ASOs remains a challenge. Due to the neutral 
charge of PMOs, it is particularly difficult to get them into the target cells both in cell 
culture and in vivo as they require a charged carrier molecule to cross membranes. One 
method is to “leash” the PMO with a charged cDNA molecule to facilitate uptake into the 
cell (Morcos et al., 2008). Another method is to attach a charged cell-penetrating peptide 
to the PMO (Veltrop & Aartsma-Rus, 2014).  
The pharmacodynamics of the oligonucleotide are obviously important if they are to be 
therapeutic. ASOs with a phosphorothioate linkage, with their negative charge, bind to 
plasma proteins allowing infiltration to diverse tissues, whereas a phosphorodiamidate 
backbone is neutrally charged and so show a more rapid clearance from the blood at low 
concentrations (Geary et al., 2015). However, neutrally charged ASOs may be 
conjugated to a cell-penetrating peptide which would carry the ASO through the blood 
and into the cells (reviewed in Copolovici et al., 2014). Subcutaneous or intravenous 
injection will deliver ASOs to the periphery, however most will not cross the blood-brain 
barrier. Cell-penetrating peptides, nanoparticles or other kinds of carrier may be able to 
deliver ASOs into the CNS (Falzarano et al., 2014), alternatively direct administration to 
the CSF allows the ASO to target neurons with the potential to combat 
neurodegenerative diseases (Kordasiewicz et al., 2012). Intrathecal administration of 
ASOs have also reached phase I clinical trials with only relatively mild adverse effects 
experienced in both test and control groups (Miller et al., 2013).  
1.5.3 ASOs and Disease 
Diseases that are essentially monogenic are well-suited to treatment from ASOs. The 
specificity of the oligonucleotide reduces the potential for off-target effects, making this 
approach an attractive therapeutic option. Thanks to chemical modifications or differing 
routes of administration, ASOs can reach the CNS and so also target neurodegenerative 
disorders. Diseases such as Neurofibromatosis type 1 and 2, frontal-temporal dementia 
and Niemann-Pick Disease are all candidates for ASO therapy by targeting their 
associated genetic mutations (Siva et al., 2014).   
1.5.3.1 Exon Skipping in Duchenne Muscular Dystrophy 
Duchenne Muscular Dystrophy (DMD) is an X-linked neuromuscular disorder affecting 
boys, characterised by progressive weakness of muscles beginning early in childhood, 
eventually reaching the diaphragm and respiratory muscles leading to respiratory failure. 
The disorder is caused by mutations in the dystrophin gene, coding for the protein 
dystrophin which is integral for correct muscle contraction. These mutations often disrupt 
the reading frame leading to non-functional transcripts or premature stop codons 
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(Aartsma-Rus et al., 2003). ASOs can be targeted to the exons containing the mutation, 
preventing the spliceosome from reaching the RNA and so “splicing out” the affected 
exon (Popplewell et al., 2009). This approach has been shown to produce shortened but 
functional dystrophin protein in mouse models for DMD (Lu et al., 2003). These ASOs, 
having been promising in animal models, continued to clinical trials with drisapersen and 
eteplirsen as previously mentioned. Other approaches to DMD treatment using 
antisense technology include targeting multiple exons with a “cocktail” of ASOs, therefore 
making a more generic therapy for DMD patients with a broad range of mutations 
(Aartsma-Rus & van Ommen, 2007).  
1.5.3.2 Exon Skipping and Spinal Muscular Atrophy 
Spinal muscular atrophy (SMA) is a neurodegenerative disorder affecting motor neurons 
generally in infants, caused by a mutation in exon 7 of the SMN1 gene leading to loss of 
expression (Ahmad et al., 2016). This loss of function is partially compensated for by 
expression of SMN2, a duplication of SMN1 but with a nucleotide change in exon 7 
leading its exclusion in most transcripts. However, an ASO targeting an exon splice 
silencer in the preceding intron removes the inhibition and so promotes inclusion of exon 
7 in the SMN2 transcript. The function of these ASOs are therefore the opposite of those 
used in DMD, where the goal is promoting exon inclusion rather than exon skipping. This 
has been shown to ameliorate the SMA phenotype in a mouse model (Passini et al., 
2011). Further work has shown that so-called bi-functional ASOs can be used which both 
block the silencing sequence and recruit exon splice enhancers to the splice site, again 
showing amelioration of the SMA phenotype in mice (Osman et al., 2012). Nusinersen, 
the ASO that targets the intronic silencer element promoting exon 7 inclusion, was shown 
to have good distribution amongst neurons of the spinal cord after intrathecal injection in 
non-human primates (Rigo et al., 2014) and had good results following a phase I clinical 
trial (Chiriboga et al., 2016) 
1.5.3.3 ASOs and ALS 
Some research has been carried out into the prospect of ASO therapy in ALS, in three 
main areas. One target is the SOD1 gene, where targeting mutated SOD1 led to a 50% 
reduction in mutant SOD1 expression in rats, which did not delay symptom onset but did 
significantly delay symptom progression and increased mean survival (Smith et al., 
2006). In iPSC-MNs derived from patients with SOD1-linked fALS, treatment with a PMO 
targeting the mutant SOD1 lead to reduced cell death and lower levels of misfolded 
protein (Nizzardo et al., 2016). This ASO was well-tolerated in a preliminary in-human 
trial when delivered intrathecally, and is now in Phase I/II clinical trials (Miller et al., 2013).  
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Alternatively, the C9ORF72 expanded repeat proved to be an effective target, with 
several groups working in this area. The most popular approach has been to target the 
repeat with ASOs that recruit RNase H to degrade the RNA transcript (Sareen et al., 
2013; Donnelly et al., 2014; Lagier-Tourenne et al., 2013) although steric hindrance of 
the expansion preventing RNA-binding protein association has also been attempted 
(Donnelly et al., 2013). It was found that ASOs with RNase H binding targeting the 
intronic region downstream of the repeat had the greatest impact on expression, with a 
significant reduction in the number of cells containing RNA foci (Donnelly et al., 2014). A 
more specific ASO was designed to target the repeat expansion of C9ORF72 and 
therefore keep any expression of the normal length transcript, which reduced the 
behavioural deficits of increased anxiety and cognitive dysfunctions shown in a mouse 
model overexpressing 450 hexanucleotide repeats (Jiang et al., 2016). 
Acetylcholinesterase has also been a target for ASO therapy. Acetylcholinesterase has 
been shown to be increased in the serum of ALS patients and an ASO reducing 
acetylcholinesterase transcription in SOD1G93A mice showed a non-significant trend 
towards improved survival (Marc et al., 2013).  
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1.6 AIMS AND OBJECTIVES 
Editing at the Q/R site of the GluA2 subunit in AMPA receptor subunits is clearly crucial 
to the normal function of the neuron. Through its regulation of calcium permeability, 
dysregulation of the RNA editing process has been associated with several diseases, 
including ALS. However, the consequences of this dysregulation at an intracellular level 
remain unclear. This project will therefore have two sections: 
In the first section, ASOs will be designed to disrupt the Q/R editing site of the GluA2 
subunit. Specifically, PMOs will be used due to their previous success in manipulating 
splicing and RNA editing through steric hindrance, as well as their resistance to nuclease 
degradation. The following objectives will be met: 
1. An assay will be established to detect changes in Q/R site editing in cell lines 
2. Using this assay, the sequences of PMOs will be optimised to allow maximal 
disruption of the RNA editing process 
3. These PMOs will then be tested in increasingly neuronal-like cell models, finally 
attempting to test the effects of PMOs in primary cortical neuronal cultures 
Hypothesis 1: 
PMOs can be used to inhibit Q/R site editing through disruption of the secondary 
structure of the GluA2 transcript. 
Secondly, ASOs will be targeted to the ADAR2 transcript to change the alternative 
splicing pattern. Again, PMOs will be used. The following objectives will be met: 
1. An assay will be established to determine the inclusion of the AluJ cassette 
2. PMOs will be designed to prevent the AluJ cassette inclusion into the ADAR2 
transcript  
3. These PMOs will be tested in cell models to determine their efficiency at exon 
skipping and any effect that this has on Q/R site editing in the GluA2 subunit 
Hypothesis 2: 
PMOs can be used to “skip” the AluJ cassette in the ADAR2 transcript and therefore 
increase ADAR2’s ability to edit the Q/R site of the GluA2 subunit.
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2 MATERIALS AND METHODS 
2.1 BIOINFORMATICS ANALYSIS 
2.1.1 Online Resources 
 Ensembl (www.ensembl.org) 
 Genomic sequences 
 MFold (mfold.rna.albany.edu) 
 RNA folding  
 RNAstructure (rna.urmc.rochester.edu/RNAstructure) 
 RNA folding (software download) 
 SFold (sfold.wadsworth.org) 
 RNA folding and thermodynamics calculations 
 Human Splice Finder (www.umd.be/HSF/) 
 Detection of splicing elements 
 Sigma Aldrich “OligoEvaluator™” (www.oligoevaluator.com) 
 Thermodynamics of short sequences of nucleic acids 
 Clustal MUSCLE (www.ebi.ac.uk/Tools/msa/muscle/) 
 Sequence alignment and homology comparisons 
 
2.1.2 RNA Sequences 
The nucleotide sequences for the transcripts analysed were taken from the Ensembl 
database, the details of which are shown in Table 2.1. Sequences were exported from 
the Ensembl website in the FASTA format for input into subsequent web servers or 
software, or in some cases the Ensembl transcript code could be directly inputted into 
the online tool, such as with the Human Splice Finder. 
 
 
Table 2.1 - Details of Ensembl gene entries used. 
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2.1.3 RNA Secondary Structure 
To determine the secondary structure of the RNA molecules in both the GRIA2 and 
ADARB1 genes, the websites MFold, RNAstructure and SFold were used.  
2.1.3.1 MFold 
The MFold web server has previously been used to predict RNA structure for use in PMO 
design (Popplewell et al., 2009). Mfold calculated the Minimum Free Energy structure for 
a given sequence. The RNA Folding Form was used, with the default conditions 
maintained. Folding temperature was at 37°C, in 1M NaCl. Maximum loop sizes were 
kept at 30 bases and there was no limit on the distance between base pairs. The MFold 
RNA folding form has a limit of 9,000 bases to keep the processing times to a minimum. 
Fasta sequences of GRIA2 and ADARB1 were inputted into the entry form and output 
structures were saved as pdf files for later comparison. 
2.1.3.2 RNAstructure 
RNAstructure software was downloaded and the GRIA2 sequence opened in Fasta 
format within the RNAstructure program. First, a Partition Function file was created for 
the RNA sequence. From the RNA menu, the Partition Function RNA option was 
selected and the GRIA2 sequence in fasta format was inputted, and the file saved. The 
Partition Function calculates the base pair probabilities for a sequence. The Maximum 
Expected Accuracy (MaxExpect) structure could then be calculated based on 
probabilities from the partition function file. From the RNA menu, the MaxExpect: Predict 
RNA MEA Structure option was selected, and the partition function file inputted. Once 
the MaxExpect model had been calculated, the structures were drawn in the 
RNAstructure program and saved as pdf files for later comparison. 
2.1.3.3 SFold 
The SFold web server was used for further comparison of folding for the GRIA2 
sequence based on centroid structures. In the Srna application, the fasta sequence for 
GRIA2 was inputted with the default conditions kept. There was no limit for maximum 
distance between paired bases and folding was predicted at 37°C in 1M NaCl. Output 
structures were saved as pdf files for later comparison. 
2.1.4 Exon Splice Enhancer/Silencer Sequences 
Human Splice Finder gives information regarding consensus sequences, splice donor 
and acceptor sites, splice enhancer and splice silencer sequences in both the exon and 
the neighbouring introns. On the Human Splice Finder website, the Ensembl transcript 
number was inputted and the exon specified. The transcript number used for the 
ADARB1 gene was ENST00000360697, which is protein coding. Exon 6 of this transcript 
contains the AluJ cassette. 100 bases either side of the exon were included in analysis.  
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2.1.5 Oligonucleotide Binding Energy 
The website SFold was used to assess binding energies of potential oligonucleotide 
sequences. Within the SFold website, the SOligo tool was used (Ding & Lawrence, 2003; 
Ding et al., 2005). DNA sequences were inputted into the online form and the default 
parameters were used, with the exception of “preferred length of antisense oligos” which 
was increased to either 25 or 30 bases. Once the website had calculated the data, the 
output version “oligo_f.out” was chosen. This produced the data in a table format 
showing the binding energy for every oligonucleotide of the desired length that could bind 
to the inputted sequence (Column 5 in Figure 2.1). The binding energies for potential 
oligonucleotides were noted. 
 
Figure 2.1 - Example SFold SOligo output. Column 5 shows the binding energy between the target sequence 
and the designed antisense oligonucleotide. 
In order to calculate the internal binding energy of each oligonucleotide to itself, the 
Sigma Aldrich OligoEvaluator™ was used. Sequences of potential PMOs were inputted 
into their calculator. Default conditions were maintained and the option of “Display Primer 
Dimer and Hairpin Structures” was selected. For each PMO, if multiple outputs were 
calculated then the structure with the highest energy was selected. GC content for each 
morpholino was also taken using this online tool. The PMO-PMO (“primer-dimer”) and 
Hairpin structures with the highest energy were then subtracted from the binding energy 
calculated from the SOligo tool. Potential PMOs could then be ranked according to 
proposed binding energy to the RNA substrate. 
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2.2 PMOS 
2.2.1 Synthesis 
Phosphorothiodiamidate morpholino oligonucleotides (PMOs), once designed (see 
Bioinformatics section), were ordered from GeneTools (http://www.gene-tools.com/). 
25mer PMOs were ordered in the standard morpholino request form with no end 
modifications. 30mer PMOs were ordered with the first 25 bases (5’ to 3’) in the standard 
request form with the extra 5 bases requested in the Notes section. The fluorescent PMO 
was requested with a fluorescein modification at the 3’ end of the PMO9 (AluJ+93+117) 
sequence). Sequences are shown in Table 2.2.  
 
Table 2.2 - PMO names and sequences 
2.2.2 Suspension  
PMOs were shipped as sterile lyophilised solids. 300 µl of DEPC-treated sterile water 
(Ambion #AM9915G) was added per 300 nanomoles of PMO to make a 1 mM stock 
solution. Stock solutions were vortexed to ensure complete suspension of the PMO. 
2.2.3 Storage 
Stock solutions of PMO (1 mM) are stable at room temperature in sealed containers as 
recommended by GeneTools. 
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2.3 CELL CULTURE 
2.3.1 Media Recipes 
2.3.1.1 Media for HeLa and SH-SY5Y cell lines 
Growth media (500 ml total volume) 
- 440 ml Dulbecco’s Modified Eagle’s Medium (Sigma #D5796) 
- 50 ml foetal bovine serum (10%; Gibco #10500-064) 
- 5 ml L-Glutamine (2 mM final concentration; Gibco #A2916801) 
- 5 ml penicillin-streptomycin (100 units/ml penicillin final concentration; 100 µg/ml 
streptomycin final concentration; Gibco #15140122) 
Freezing media (50 ml total volume) 
- 35 ml Dulbecco’s Modified Eagle’s Medium (Sigma #D5796) 
- 10 ml foetal bovine serum (20%; Gibco #10500-064) 
- 5 ml DMSO (10%; Sigma #D8418) 
2.3.1.2 Media for primary cortical neurons 
Dissociation media (5 ml total volume) 
- 4.5 ml Dulbecco’s Modified Eagle’s Medium (Sigma #D5796) 
- 50 µl DNase (100 µg/ml final concentration) 
- 0.5 ml Trypsin (Thermo Fisher #12604021) 
Plating media (50 ml total volume) 
- 50 ml Dulbecco’s Modified Eagle’s Medium (Sigma #D5796) 
- 2.5 ml foetal bovine serum (10%; Gibco #10500-064) 
- 0.5 ml penicillin-streptomycin (100 units/ml penicillin final concentration; 
100 µg/ml streptomycin final concentration; Gibco #15140122) 
- 0.5 ml L-Glutamine (2 mM final concentration; Gibco #A2916801) 
Neurobasal media (50 ml total volume) 
- 48 ml Neurobasal media (Thermo Fisher #21103049) 
- 1 ml B27 supplement (Thermo Fisher #17504044) 
- 0.5 ml penicillin-streptomycin (100 units/ml penicillin final concentration; 
100 µg/ml streptomycin final concentration; Gibco #15140122) 
- 0.5 ml Glutamax (2 mM final concentration; Thermo Fisher #35050061) 
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2.3.2 Cell Lines and Storage 
HeLa cells and SH-SY5Y cells were kindly provided by Professor George Dickson and 
Professor Robin Williams respectively (both Centre of Biomedical Sciences, Royal 
Holloway University of London). All work was performed with sterile plasticware inside a 
class II laminar flow hood. For long term storage, cells were washed with 10 ml of 
1x phosphate buffered saline solution (PBS; Sigma-Aldrich #P4417) per T75 flask and 
detached from the plate via trypsinisation involving incubation for 1 minute with TrypLE 
(Thermo Fisher #12604021). Trypsin was inactivated by the addition of 9 ml of growth 
media and cells were counted using a haemocytometer. Cells were pelleted and 
resuspended at 1 x 105 cells per ml in freezing media. Suspended cells were aliquoted 
into cryovials (Thermo Fisher #377267) at 1 ml per vial and cooled slowly to -80°C before 
long-term storage in liquid nitrogen (gaseous phase).  
2.3.3 Thawing of frozen stocks and Maintenance 
Frozen HeLa and SH-SY5Y cells were quickly defrosted by placing the cryovial in a water 
bath at 37°C. Once defrosted, suspended cells were diluted with 9 ml of growth media 
then spun at 3,000 rpm for 5 minutes to pellet the cells. The media was removed and the 
cells resuspended in 1 ml of growth media before being seeded in a T75 flask 
(Corning #430372) with another 15 ml of growth media. Cells were then kept at 37°C 
with 5% CO2 and subcultured every 3 to 4 days or when 80% confluent. Immediately 
after defrosting, cells were allowed to recover for one week before being used in 
experiments. 
2.3.4 Sub-culturing 
When cells were 80% confluent, the media was aspirated and cells were washed with 
1x PBS. 1 ml of TrypLE was added to the cells and incubated for 1-2 minutes at 37°C to 
detach the cells from the flask. 9 ml of growth media was then added to the cells to a 
total volume of 10 ml, which was spun at 3,000 rpm for 5 minutes to pellet the cells. The 
media was removed and cells were resuspended in 1 ml of fresh growth media, 
pre-warmed to 37°C, followed by a further 9 ml. A portion of the suspended cells (1 ml 
of 10 ml for HeLa and 2 ml of 10 ml for SH-SY5Y) was placed in a fresh T75 flask with 
an additional 15 ml of growth media and allowed to grow in the incubator.  
2.3.5 Primary Cortical Neurons 
2.3.5.1 Plate Preparation 
6 well plates were coated with poly-D-lysine (100 µg/ml in PBS) and incubated at 37°C 
for 5 hours or at 4°C overnight. Plates were washed three times with sterile H2O and left 
to air dry. 
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2.3.5.2 Dissection 
Primary cortical rat neurons were prepared by Dr Ursu (Centre for Biomedical Sciences, 
Royal Holloway University of London) in accordance with Home Office regulations and 
the Animals Scientific Act 1986. A pregnant Sprague-Dawley rat at E18 was euthanised, 
the embryos removed and placed on ice. For each embryo, the head was severed and 
the top of the skull was carefully peeled off to expose the brain which was removed and 
placed in ice cold PBS. Under a dissection microscope, the meninges were removed and 
the two cortices separated and non-cortical tissue removed. Dissected cortices were cut 
into smaller sections before being transferred to a 15 ml tube containing 5 ml dissociation 
media. Sections were manually dissociated by pipetting before being incubated at 37°C 
for 10 minutes. Trypsin was then inactivated by the addition of 1.5 ml of FBS and 
incubated for 5 minutes at 37°C. Cells were spun at 1,500 rpm for 3 minutes and the 
media aspirated before the cells were resuspended in 1 ml of plating. Cells were counted 
using a haemocytometer and plated at 500,000 cells per well of a 6 well plate unless 
otherwise stated. Cells were incubated in plating media overnight at 37°C and 5% CO2. 
After 24 hours, plating media was aspirated and 2.5 ml of primary neuron growth media 
was added per well. Plates were then incubated at 37°C and 5% CO2 for 21 days, unless 
otherwise stated, with 500 µl of primary neuron growth media added to each well on top 
of existing media every 7 days.  
2.3.6 Plasmids 
2.3.6.1 Acquisition 
Both the plasmids containing the B13 minigene and the ADAR2 gene were kindly 
provided by the O’Connell group (University of Edinburgh).  
2.3.6.2 Transformation 
In order to grow sufficient plasmid for transfections, plasmids were transformed and then 
grown in E. coli competent cells. NEB 5α competent cells (New England Biolabs 
#C2987I), stored at -80°C, were thawed on ice and mixed gently. 50 µl were pipetted 
into an microcentrifuge tube on ice with 1 µg of plasmid and mixed by flicking before 
being placed on ice for 30 minutes. The bacteria were then heat shocked at 42°C for 30 
seconds and placed on ice for another 5 minutes. 950 µl of warm SOC media 
(Thermo Fisher #15544034) was added to the microcentrifuge tube which was then 
placed on a shaker (250 rpm) at 37°C for 60 minutes. Cells were then mixed by flicking 
and inverting before being streaked on an LB agar plate with 100 µg/ml of ampicillin. 
Plates were incubated at 37°C overnight.  
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2.3.6.3 Mini-Prep of Plasmid DNA 
Plasmid DNA was prepared in low quantities using the QIAprep spin Miniprep kit 
(Qiagen #27104) to check the plasmid composition. Single colonies from the agar plates 
were picked and grown up in a starter culture of 5 ml of Terrific Broth (Sigma #T0918) 
with 100 µg/ml of ampicillin at 37°C in a shaking incubator (250 rpm) overnight. 2 ml of 
each starter culture was then centrifuged at 6,800 x g for 3 minutes at room temperature. 
The supernatant was removed and the cells resuspended in 250 µl Buffer P1 before 
being transferred to a microcentrifuge tube. 250 µl of Buffer P2 was added and the tube 
mixed thoroughly through multiple inversions. 350 µl of Buffer N3 was then added and 
mixed immediately through inversions followed by centrifugation for 10 minutes at 13,000 
rpm. 800 µl of the supernatant was then added to a QIAprep spin column and centrifuged 
at 13,000 rpm for 30 seconds. The flow-through was discarded and the spin column 
washed by the addition of 500 µl of Buffer PB and centrifuged at 13,000 rpm for 30 
seconds. 750 µl of Buffer PE was then added to the column and centrifuged at 13,000 
rpm for 30 seconds. The flow-through was discarded and the column centrifuged at 
13,000 rpm for 1 minute to remove residual wash buffer. The QIAprep column was then 
placed in a sterile microcentrifuge tube and the DNA eluted in 50 µl of Buffer EB by 
incubation at room temperature for 1 minute followed by centrifugation at 13,000 rpm for 
1 minute. The plasmid DNA was quantified using NanoDrop (Thermo Scientific). 
2.3.6.4 Restriction Enzyme Digestion 
Plasmids containing the B13 minigene and ADAR2 transcript were confirmed through 
restriction enzyme digests according to previously published plasmid maps 
(O’Connell et al., 1998; Higuchi et al., 1993). For each digestion, 0.5 µg of plasmid DNA 
was mixed with 0.5 µl of enzyme, 1 µl of corresponding stock buffer solution and ddH2O 
water to a total volume of 10 µl. Diagnostic digestion reactions were incubated at 37°C 
for 1 hour and visualised under UV trans illumination after being run on a 1% agarose 
gel in 1x TAE buffer.  
2.3.6.5 Gel Electrophoresis 
A 50x stock solution of TAE was prepared for gel electrophoresis (40mM Tris, 20mM 
acetic acid, 1mM EDTA). Agarose gels were prepared using 1x TAE buffer. Restriction 
digest products were run on a 1% agarose gel. 0.6 g of agarose (Bioline #BIO-41025) 
was heated in 60 ml 1x TAE buffer until fully dissolved, then 0.5% SYBR Safe DNA gel 
stain (v/v) was added before the solution was poured into the gel cast and cooled. Gel 
electrophoresis tanks (Scie-Plas) were used to cast and run the agarose gels. Digest 
products were run at 90 volts for 45 minutes and visualised using the Ebox VX2 imaging 
system (PeqLab).  
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2.3.6.6 Maxi-Prep of Plasmid DNA 
Once the plasmid was confirmed through restriction digests, the EndoFree Plasmid Maxi 
Kit (Qiagen #12362) was used. From a starter culture, 250 µl of LB broth with the grown 
culture was placed in 250 ml of fresh, sterile LB broth and left on a shaker (250 rpm) 
overnight at 37°C. Bacterial cells were harvested by centrifugation at 5,000 rpm at 4°C 
for 15 minutes. The supernatant was discarded and the pellet resuspended in Buffer P1. 
10 ml of Buffer P2 was added and mixed thoroughly through multiple inversions. The 
solution was then centrifuged at 5,000 rpm for 60 minutes and the supernatant 
transferred to a fresh 50 ml tube. 2.5 ml of Buffer ER was added to the lysate and mixed 
through inversions before being incubated on ice for 30 minutes. The QIAGEN-tip 500 
was equilibrated by applying 10 ml of Buffer QBT and allowing the column to empty via 
gravity flow. The filtered lysate was added to the QIAGEN-tip 500, which was then 
washed with 30 ml of Buffer QC twice. DNA was eluted into 15 ml of Buffer QN in 
precipitated using 10.5 ml of isopropanol followed by centrifugation at 5,000 rpm for 60 
minutes at 4°C. The supernatant was carefully decanted and the pellet washed with 5 ml 
of 70% ethanol, before another centrifugation at 5,000 rpm for 60 minutes at 4°C. The 
supernatant was removed and the pellet allowed to air dry for 5 to 10 minutes before 
being redissolved in 200 µl Buffer TE. The plasmid DNA was the quantified using 
NanoDrop (Thermo Scientific).  
2.3.7 Transfection 
2.3.7.1 Preparing Cells for Transfection  
In preparation for transfection, cells were trypsinised and suspended in media before 
being seeded in 24 well plates at 200,000 cells per well. Cells were incubated at 37°C 
for 24 hours prior to transfection until at least 80% confluent. 
2.3.7.2 Lipofectamine 2000 
Plasmids containing the B13 minigene and ADAR2 transcript were transfected into HeLa 
cells using the transfection agent Lipofectamine® 2000 (Thermo Fisher #11668019). 
Following optimisation of transfection conditions for using these plasmids with the 
transfection reagent, a ratio of 1 μl Lipofectamine: 0.5 μg plasmid DNA per well in a 24 
well plate was found to give the best transfection efficiency with lowest cytotoxicity. For 
one 24 well plate, 1 µl of Lipofectamine and 0.5 µg of plasmid DNA were first each 
suspended separately in 600 μl of DMEM only (without serum or antibiotics) and 
incubated at room temperature for five minutes per manufacturer’s instructions. After 
incubation, the two suspensions were mixed together thoroughly through pipetting and 
incubated for a further 20 minutes (or up to six hours) at room temperature. 50 μl of the 
DMEM/Lipofectamine/DNA mix was then added to each well of the 24 well plate. 
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2.3.7.3 Endo-Porter 
PMOs were transfected at a range of concentrations, from 0.1-10 µM, as discussed in 
relevant results chapters. For HeLa and SH-SY5Y cells grown in a 24 well plate, prior to 
transfection the media was aspirated and 0.5 ml of fresh growth media was added to 
each well. Appropriate volumes from the stock solution of the required PMO were added 
directly to cells’ media followed by 3 μl of Endo-Porter (GeneTools; final concentration 
6 mM) and the plates swirled to mix. Following transfection, cells were incubated at 37°C 
for 24 hours (unless otherwise stated) before RNA extraction.  
For transfection of primary cortical neurons, media was removed, placed in a 15 ml tube 
and mixed, with 1 ml being returned to each well of the 6 well plate. 5 µl of PMO stock 
solution (final volume 5 µM) was then added to each well followed by 6 µl of aqueous 
Endo-Porter (GeneTools; final concentration 6 mM). Plates were swirled to mix and 
returned to the incubator. 
2.3.7.4 Leashing of PMOs 
For magnetofection to be effective, PMOs require a charged leash to be added for proper 
binding to the magnetic nanoparticles. Leashes were designed as the reverse-
complementary sequence of the 17 most 5’ bases of the PMO, with additional tail 
sequences of “gattg” (5’ to 3’) at the 5’ end and “gtgat” (5’ to 3’) at the 3’ end, ordered as 
DNA oligos from Sigma-Aldrich (sequences shown in Table 2.3). The leashes were 
suspended in DEPC-treated sterile water (Ambion #AM9915G) to form a 200 µM stock 
solution. 25 µl of leash stock solution was mixed with 5 µl of 1 mM PMO stock, 7.5 µl 
sterile H2O and 12.5 µl sterile 10x PBS. This leash mixture was then heated in the 
following heat cycle: 95°C for 5 min, 85°C for 1 min, 75°C for 1 min, 65°C for 5 min, 55°C 
for 1 min, 45°C for 1 min, 35°C for 5 min, 25°C for 1 min, and held at 15°C. Leashed 
PMOs were stable at 4°C for up to 6 weeks. To confirm leashing was successful, 1 µl of 
leashed PMO and 1 µl of leash only was added to 2 µl of 1x PBS and 1 µl ddH2O and 
incubated at 37°C for 30 minutes before being run on a 3% agarose gel in 1x TAE buffer. 
Successfully leashed PMOs will run at a higher molecular weight on the gel compared 
to leash only due to the larger size. 
 
Table 2.3 - Leash sequences for each 30mer PMO designed against the GRIA2 sequence for 
magnetofection. 
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2.3.7.5 Magnetofection 
10 µl of leashed PMO (1 µM final concentration) was added to 200 µl of DMEM only. 
PolyMag (Oz Biosciences #PN30100) or NeuroMag (Oz Biosciences # NM50200) were 
thoroughly vortexed before use, and 8 µl was added to the bottom of a 1.5 ml 
microcentrifuge tube (for a ratio of 1:1 unless otherwise stated). The leashed PMO in 
DMEM and reagent were then vigorously mixed together through pipetting and incubated 
at room temperature for 20 minutes. For transfection of primary cortical neurons, media 
was removed from each well, placed in a 15 ml tube and mixed, with 1 ml being returned 
to each well of the 6 well plate. 100 µl of the leashed PMO/reagent mix was then added 
to each well and the plate returned to the incubator on top of a magnetic plate 
(Oz Bioscience #MF10000). Neuronal plates were left on the magnetic plate for 1 hour 
unless otherwise stated before the magnetic plate was removed and neurons were kept 
at 37°C with 5% CO2 for 48 hours unless otherwise stated. 
2.3.8 Lentiviral Vector Transduction 
Lentiviral vectors were stored at -80°C. Immediately before transduction, aliquots of 
vectors were placed on ice and allowed to thaw. For transduction of primary cortical 
neurons, media was removed, placed in a 15 ml tube and mixed, with 1 ml being returned 
to each well of the 6 well plate. Volumes of virus based on required MOI were calculated 
by multiplying number of cells per well by the desired MOI to calculate the total 
transducing units needed, followed by dividing the total transducing units needed by the 
titre of the virus. The volume of virus was then added directly to the media in the wells 
and swirled to mix before the plate was returned to the incubator. 
2.3.9 Live Cell Imaging 
Cells were imaged without fixing due to the PMOs’ neutral charge not reacting with 
fixative reagents. PMOs would leach out of fixed cells as they would not be held by the 
fixative. Cells were therefore imaged whilst alive to maintain PMO localisation within the 
cell. Imaging was performed using an inverted Zeiss Vert.A1 microscope. Images were 
taken at x100 magnification with an Axiocam 503 mono camera combined with 
AxioVision software (Carl Zeiss, UK). For fluorescent images, the FITC channel was 
used in the same field for comparison between images. Images of cells transfected with 
F-PMO were taken at an exposure of 1500 ms, while cells transduced with the 
GFP-expressing lentiviral vector were taken at an exposure of 300 ms.  
2.3.10 Flow Cytometry 
HeLa and SH-SY5Y cells were plated at 350,000 cells per well of a 6 well plate and 
allowed to become 80% confluent. Cells were transfected with fluorescent PMO and 
EndoPorter as described (Section 2.3.7.3) for 24 hours before being trypsinised. Cells 
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were spun for 3 minutes at 3,000 rpm and resuspended in FACSFlow Solution 
(BD Biosciences #342003). The cytometer was standardised using CSPT standard 
beads (Thermo Scientific #C16509) in FACSFlow Solution. Cells were run through the 
cytometer at a medium flow rate. The FITC voltage was used to detect the green 
fluorescence tag of the fluorescent PMO. Samples were run until there were more than 
25,000 total counts. First, forward scatter vs side scatter was plotted for the cell 
population and those events with low forward scatter and high side scatter were excluded 
so that live cells remained (P1 gate; Figure 2.2). Next, events within the P1 gate were 
plotted with height versus area to gate for single cells and exclude clumps of cells or cell 
debris (P2 gate; Figure 2.2). The events within the P2 gate were then plotted on a 
histogram with FITC fluorescence. Control cells without transfection were used to gate 
background fluorescence (P3 gate), and percentage of events exceeding the P3 gate 
was taken as the transfection efficiency.  
 
Figure 2.2 - P1 and P2 gates for FACS analysis indicating live and single cell populations. P1 gates (inserts 
of each graph) show the polygons excluding low forward scatter and high side scatter to gate for live cells. 
P2 gate (main graph) shows the exclusion of low height versus high area to gate for single cells. Gating in 
transfected cells (A) was consistent with gating in control cells (B), showing no bias between control and test 
samples. 
2.3.11 Cell Toxicity Assay 
The MTT assay was used to calculate cell toxicity. 250 mg of MTT powder 
(Sigma #M2128) was dissolved in 250 ml PBS to form a stock solution of 5 mg/ml before 
being filter sterilised, aliquoted and stored at -20°C in the dark. 1/10th volume of total 
media (i.e. 100 µl of MTT in 1 ml of media) was added per well and swirled to evenly 
distribute the MTT/media mixture across the bottom of each well before being incubated 
for 4 hours in the incubator at 37°C with 5% CO2. Media was gently removed and the 
plates allowed to air dry at room temperature. 1 ml of DMSO was added per well of a 6 
well plate and placed on a shaker (200 rpm) to dissolve the crystals. 75 µl from each well 
was added to a 96 well plate and OD was read at 570 nm using the GloMax®-Microplate 
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Multimode Reader (Promega, USA). Readings were normalised against blank 
measurements (DMSO only, no MTT) and compared to control cells with no treatment. 
2.4 MOLECULAR BIOLOGY 
2.4.1 RNA extraction and DNase Treatment 
RNA extraction was performed using the ReliaPrep RNA Cell Miniprep System 
(Promega #Z6011). Cells were harvested by removal of media, washed with ice cold 
PBS and 250 µl of the “BL + TG” buffer was added. Wells were scraped using cell 
scrapers (USA Scientific #CC7600-0220) and the lysate removed and placed in 1.5 ml 
tubes. 85 µl of isopropanol was added per sample and the tubes vortexed for 30 seconds 
to shear genomic DNA. The lysate was then added to the minicolumns and centrifuged 
at 12,000 x g for 30 seconds at room temperature. The flow-through was discarded. 
500 µl of RNA wash solution was added to the minicolumns and centrifuged at 12,000 x g 
for 30 seconds at room temperature. The flow-through was discarded. The DNase 
incubation mix was prepared in a separate tube on ice, with 24 µl of yellow core buffer, 
3 µl MnCl2 0.09M and 3 µl of DNase I per sample, and mixed gently by pipetting. 30 µl 
of this mix was added to the membrane of each minicolumn and incubated at room 
temperature for 15 minutes. 200 µl of column wash solution was then added to the 
minicolumn and centrifuged at 12,000 x g for 15 seconds at room temperature. 500 µl of 
RNA wash solution was added to the column and centrifuged at 12,000 x g for 
30 seconds at room temperature. The minicolumn was then placed in a fresh collection 
tube, 300 µl of RNA wash solution was added and centrifuged at 12,000 x g for 2 minutes 
at room temperature to remove all traces of ethanol. The minicolumn was then 
transferred to an elution tube and 30 µl of nuclease-free water added to the column. This 
was incubated for 1 minute at room temperature before being centrifuged at 12,000 x g 
for 1 minute. The minicolumn was discarded and the RNA in the elution tube quantified 
using the NanoDrop (Thermo Scientific) before being stored at -80°C. 
2.4.2 One-step Reverse Transcription and First Round Polymerase Chain 
Reaction 
500 ng of DNase-treated RNA was used per reverse transcriptase-polymerase chain 
reaction (RT-PCR) reaction. The reverse transcriptase and PCR reactions were 
performed within one mix using the GeneScript RT-PCR system 
(GeneSys Ltd. #GS003). Each 25 μl reaction contained 1x GeneScript buffer (including 
MgSO4), 0.2 mM dNTP, 15 pM of each primer and 0.625 units of Taq polymerase made 
up to a final volume of 25 µl with RNase-free, DNase-free H2O provided. Samples were 
then put in an MJ Research PTC-200 Thermal Cycler (GMI #8252-30-0001) using a heat 
cycle of 45°C for 30 minutes, 92°C for 2 minutes, 10 cycles of 92°C for 30 seconds, 62°C 
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for 30 seconds and 68°C for 45 cycles, then 25 cycles of 92°C for 30 seconds, 60°C for 
30 seconds and 68°C for 45 seconds with an added 5 seconds per cycle, then a final 
anneal step at 68°C for 10 minutes. Primers are shown in Table 2.4. 
 
Table 2.4 - List of primers, sequences and product sizes of respective PCR fragments. 
2.4.3 Second Round Nested PCR 
Endogenously expressed GRIA2 required a nested PCR for proper analysis due to low 
levels of expression. Amplification of ADAR2 transcripts required a second amplification 
to remove some bias inherent in PCRs towards smaller fragments. For ADAR2 products, 
1 μl of product from the first round RT-PCR reaction was diluted 1:100 in ddH2O for the 
second round PCR. For GRIA2 products, 1 µl of first round product was added directly 
to the second round PCR. The GoTaq® DNA Polymerase kit (Promega #M3001) was 
used. The PCR master mix contained 1x GoTaq Reaction Buffer, 1 mM additional MgCl2, 
0.2mM of each dNTP, 1 μM of each primer (shown in Table 2.4) and 0.125 μl of GoTaq® 
DNA Polymerase (5u/μl) made up to 25 μl total volume with nuclease-free water. The 
PCR was performed in an MJ Research PTC-200 Thermal Cycler (GMI #8252-30-0001) 
with the following heat cycle: 95°C for 3 minutes, 18 cycles of 94°C for 30 seconds, 60°C 
for 30 seconds and 72°C for 45 seconds followed by a final annealing step of 72°C for 
10 minutes. Samples could then be stored at 4°C. 
2.4.4 Restriction digest 
RT-PCR cDNA products of the Q/R editing site were digested with the BbvI restriction 
endonuclease (New England Biolabs #R0173S). 10 μl of PCR product was incubated 
with 2 µl of 10x CutSmart® Buffer and 2 μl of BbvI (2U/μl) made up to total volume of 20 
μl with ddH2O. Digest samples were incubated at 37°C for 1 hour. The enzyme was then 
inactivated by the addition of 0.1% SDS to each sample before adding loading dye. 
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Samples were then run on a 3% agarose (w/v) gel as described at 80 V for one hour 
against HyperLadder® 25bp (Bioline # BIO-33057). 
2.4.5 Densitometry 
Images of gels were taken under ultraviolet light with 0.16 ms acquisition using the Ebox 
VX2 imaging system (PeqLab) and saved as Tiff files. Images could then be opened 
using ImageJ and the intensity of bands in each lane could be quantified (Figure 2.3; 
Figure 2.4). The lanes were drawn around and the “plot lanes” function used to 
graphically illustrate the intensity of each band. The peaks of intensity for each band 
were defined and the area measured (Figure 2.3B-D; Figure 2.4B-D). This area was then 
exported to excel for Q/R site editing or AluJ insertion analysis. 
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Figure 2.3 - Example analysis of Q/R site editing. Gel image (A) is opened in ImageJ and successive lanes 
are highlighted. The “Plot Lanes” function then charts the intensity of each band in a lane as peaks (B). 
These lanes are then closed to discount background (C) and the area of the peak calculated (D & E). 
 
 
Figure 2.4 - Example analysis of AluJ Cassette insertion. Gel image (A) is opened in ImageJ and successive 
lanes are highlighted. The “Plot Lanes” function then charts the intensity of each band in a lane as peaks 
(B). These lanes are then closed to discount background (C) and the area of the peak calculated (D & E). 
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2.5 Q/R SITE EDITING QUANTIFICATION 
Having determined the fluorescence of each band, the relative intensity of edited to 
unedited DNA was then compared. The BbvI enzyme has a recognition sequence that 
covers the Q/R editing site (shown in Figure 2.5).  
 
Figure 2.5 - Recognition site for BbvI enzyme taken from New England Bioloabs (neb.com) 
Primers were designed to span the edited adenosine and give distinct digest fragments 
following BbvI digest. The recognition site is the unedited sequence of DNA, so cDNA 
copies originating from RNA that had not undergone Q/R site editing would be cleaved 
into two fragments. Those copies that contained the edited sequence would not have a 
recognition site for the BbvI enzyme and so the cDNA product would remain undigested. 
Therefore, after the BbvI digest, three bands are visible on the agarose gels (as seen in 
Figure 2.3A): one relating to the undigested (edited) fragment and two for the digested 
fragments (unedited sequences). Fluorescence of each band was calculated as 
described above. The fluorescence of the edited fragment was divided by the total 
fluorescence of all three bands (total DNA) to give a percentage of edited DNA fragments 
for each sample. 
2.6 EXON SKIPPING OF THE ALUJ CASSETTE 
The same technique used for calculating editing percentages was applied to exon 
skipping of the AluJ cassette. Primers for both rounds of the nested PCR were targeted 
to exons 5 and 7, which surround the AluJ cassette. Therefore, if the AluJ cassette is 
included in the gene transcript the fragment will have a larger size than if the AluJ 
cassette has been skipped. The fluorescence of each band was calculated as previously 
described (Figure 2.4) and exon skipping percentages were determined by dividing the 
“skipped band” with total fluorescence (total DNA). 
  
 80 
 
2.7 CLONING AND PRODUCTION OF LENTIVIRAL VECTORS 
2.7.1 Annealed Oligo Insert Design and Hybridisation 
The lentiviral transfer plasmid containing the E4 sequence was created using the 
annealed oligo method. The E4 sequence was flanked by BsmBI overhangs (recognition 
site shown in Figure 2.6) according the method described by the Zhang lab, and the 
sequences shown in Figure 2.7 (Sanjana et al., 2014).  
 
 
Figure 2.6 - Recognition site for BsmBI enzyme taken from New England Biolabs (neb.com) 
 
 
Figure 2.7 - Annealed oligo sequences, forward and reverse complement with BsmBI overhangs highlighted 
in blue. Complement sequence shown to indicate bases that will anneal together. 
 
Sequences were ordered as DNA oligos from Sigma Aldrich and suspended as 100 µM 
stock solutions. Oligos were phosphorylated and hybridised in a single reaction. 1 µl 
each of the forward and reverse oligos were mixed with 1 µl of 10x T4 ligation buffer 
(also containing ATP) and 0.5 µl of T4 polynucleotide kinase made up to a final volume 
of 10 µl with sterile H2O. The mix was heated to 37°C for 30 minutes then 95°C for 5 
minutes with a temperature ramp down to 25°C at 5°C per minute.  
2.7.2 Production of LentiGuide Puro Plasmid 
The LentiGuide Puro plasmid (Addgene Plasmid #52963) was streaked on LB agar 
plates with ampicillin from glycerol stocks and incubated overnight at 37°C. Single 
colonies were picked and grown in a 5 ml starter culture with 100 µg/ml ampicillin on a 
shaker (250 rpm) overnight before a mini-prep was performed as described 
(Section 2.3.6.3) and the DNA quantified using NanoDrop. The plasmid was checked 
using a restriction endonuclease digest. 500 ng of LentiGuide Puro plasmid was digested 
with either BsmBI (Thermo Scientific #FD0454) in Buffer 3.1 at 55°C or XmaI 
(New England Biolabs #R0180) and SapI (New England Biolabs #R0569) enzymes in 
CutSmart buffer at 37°C for 3 hours. Digest products were run on a 1% agarose gel as 
previously described (Section 2.3.6.5) to confirm product sizes. Once the LentiGuide 
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Puro plasmid had been confirmed, a maxi-prep was performed as previously described 
(Section 2.3.6.6) and quantified using the NanoDrop. 
2.7.3 Digestion of LentiGuide Puro Backbone and Ligation 
Digestion of the LentiGuide Puro plasmid backbone and ligation of the annealed oligos 
was performed together in a single step as previously reported (Cong et al., 2013). The 
annealed oligo mix was diluted 1:250 in sterile water. 100 ng of the uncut LentiGuide 
Puro plasmid was added to 2 µl of the diluted annealed oligos, with 1 µl of BsmBI 
(Thermo Fisher #FD0454), 2 µl of FastDigest buffer, 0.5 µl of T4 Ligase (New England 
Biolabs #M0202S), 1 µl of DTT (100 mM stock; Sigma #DTT-RO), 1 µl of ATP (10 mM 
stock; New England Biolabs #P0756S) and sterile H2O made up to a final volume of 
20 µl. The mix was placed in a heat cycle of 37°C for 5 minutes then 23°C for 5 minutes 
for 6 cycles and stored at 4°C. The ligated plasmid was then transformed into competent 
cells as previously described (Section 2.3.6.2). Transformed cells were streaked on LB 
agar plates with ampicillin and incubated at 37°C for 24 hours. Single colonies were 
picked and grown in a 5 ml starter culture at 37°C overnight before a mini-prep was 
performed as previously described (Section 2.3.6.3).  
2.7.4 Diagnostic Digestions to Confirm Successful Ligation 
Two methods were used to check for successful ligation of the annealed oligos into the 
LentiGuide Puro backbone. Firstly, restriction endonuclease digests were performed as 
previously described with enzymes BsmBI (Thermo Fisher #FD0454), NcoI, XmaI and 
SapI (New England Biolabs #R0193; #R0180 and #R0569 respectively) and analysed 
using gel electrophoresis. Once the correct fragment sizes had been confirmed, a 
sample of the ligated plasmid (LG-E4) was sent for Sanger sequencing (MWG Eurofins). 
Chromatograms were compared and the presence of the E4 sequence following the 
promoter confirmed.  
2.7.5 Production of Complete Lentiviral Vector 
Production of lentiviral vectors was performed by Dr Ursu (Royal Holloway University of 
London). Briefly, HEK293T cells were seeded at 3 x 106 cells per 15 cm plates containing 
25 ml growth media and allowed to become 80% confluent. 2 hours prior to transfection, 
the media was replaced with fresh growth media. Plasmids were mixed in a 1:1:1:2 molar 
ratio (packaging:REV:envelope:transfer) to which 125 μl of 2.5 M CaCl2 was added and 
incubated at room temperature for 5 minutes. 1,250 μl of 2x HBS-buffered saline was 
added dropwise to the plasmid mix while it was being vortexed at high speed, and then 
this mix was added to the HEK293T media. Cells were incubated for 16 hours at 37°C 
with 5% CO2 then the media replaced with 18 ml of growth media. The cells were then 
incubated until the media was harvested 48 hours post-transfection, when another 18 ml 
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of growth media was added to the cells and harvested 72 hours post-transfection. Cell 
debris was removed from the harvested media (containing the virus) by being centrifuged 
at 1000 x g for 10 minutes at room temperature then filtered using a 0.22 µm pore size 
filter. The virus was then concentrated by ultracentrifugation at 50,000 x g for 2 hours at 
4°C. The supernatant was discarded and the virus resuspended in 50 µl of serum-free 
DMEM, before being spun again at 1,000 x g for 10 minutes at 4°C to further remove any 
debris. The virus was then incubated with 1 µl DNase at 37°C for 30 minutes to remove 
any residual DNA and the stored at -80°C. Lentiviral vectors were then titred using qPCR.  
2.8 SOFTWARE 
Densitometry was carried out using ImageJ (Schneider et al., 2012). Graphs were 
created using Igor Pro (WaveMetrics, Inc., Lake Oswego, OR, USA). Microscope images 
were captured and analysed using ZEN lite (Zeiss, Germany). Plasmid maps were drawn 
using SnapGene® software (from GSL Biotech; available at snapgene.com).  
2.9 STATISTICS 
Mean and standard deviation were calculated using Excel. Statistical analyses were 
carried out using IBM SPSS Statistics (Version 21). One-way or two-way ANOVAs were 
performed as appropriate followed by Bonferroni post hoc analysis. IC50s were 
calculated by fitting the Hill equation using Igor Pro 6.37 (WaveMetrics, Inc., Lake 
Oswego, OR, USA). Graphs were plotted using Igor Pro 6.37 and all error bars show 
standard error. All results are reported as mean ± standard error.
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3 OPTIMISATION OF A Q/R SITE EDITING ASSAY AND 
DESIGN OF PMOS 
3.1 INTRODUCTION 
It is known that ADAR enzymes require double-stranded RNA for the recognition of 
editing sites, and that disrupting this structure through nucleotide base substitution 
inhibits the editing of the Q/R site (Higuchi et al., 1993). It may therefore be possible to 
prevent this editing reaction from taking place by interfering with the folding of the RNA 
transcript using PMOs to competitively bind to the target sequences via Watson-Crick 
base pairing. In order to investigate the effect of PMOs on Q/R site editing, an assay was 
needed for the reliable quantification of editing. The ideal initial model should be simple 
to establish and reproducible, with specific and reliable quantification of Q/R site editing 
which is sensitive to manipulations causing either an increase or decrease in editing. It 
should also be easy to introduce the designed PMOs into the model in order to assess 
their effects. Cultured cell lines are often initially used as models for rapid assessment, 
even if this means sacrificing some components of the model such as neuronal 
characteristics or a human origin. Cell lines are a useful model for analysis of intracellular 
function, and have been frequently used for analysis of Q/R site editing.  
The research group who originally determined that the Q/R site was an RNA editing 
event used three different cell lines in their analysis, two originating from mouse (AtT20 
and Neuro2A) and one from rat (PC12) (Higuchi et al., 1993). AtT20 cells originated from 
a mouse pituitary tumour (Buonassisi et al., 1962) and have been shown to display 
neuronal-like characteristics such as neurite projections (Tooze et al., 1989). Neuro2A 
cells are from a mouse neuroblastoma and have also been differentiated into 
neuronal-like cells with dopaminergic characteristics (Tremblay et al., 2010). PC12 cells 
originated from a rat adrenal pheochromocytoma and can differentiate into sympathetic 
neuron-like cells (Greene & Tischler, 1976). RNA editing in coding sequences is well 
conserved within mammals (Pinto et al., 2014), but the different cell lines showed varying 
endogenous editing capacities. In the original Q/R site editing paper, the sequence 
spanning the Q/R site was amplified through PCR and cloned into M13 phages, then 
screened according to editing status (Higuchi et al,. 1993). Editing of small sections of 
the GluA2 subunit transfected into mouse cell lines was calculated at 87% (AtT20 cells) 
and 72% (Neuro2A cells), whereas PC12 cells were shown to endogenously express the 
GluA2 subunit and edited the Q/R site at 100% (Higuchi et al., 1993). Choice of cell line 
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is therefore important when studying Q/R site editing and may affect results. The group 
who originally discovered reduced editing efficiency in neurons of ALS patients have also 
examined the editing capacities of different cell lines (Yamashita et al., 2012c). Of the 
six cell lines used in this study, 3 showed an editing percentage at the Q/R site of close 
to 100%. This includes a HeLa cell line that stably expresses a section of the GRIA2 
gene controlled by the Tet-on system, which was used to study the interactions between 
TDP-43 and ADAR2 activity (Yamashita et al., 2012b). This HeLa cell line stably 
expressing the fragment of the GluA2 subunit was established when HeLa cells were 
found to be variable in their editing ability (Sawada et al., 2009), although other groups 
have found consistent HeLa Q/R site editing at around 25% (Penn et al., 2012). One 
human neuroblastoma cell line, SH-SY5Y cells, showed Q/R site editing of 50% 
(Yamashita et al., 2012c). This is contrary to another report of SH-SY5Y mRNA Q/R site 
editing at nearly 90% (Penn et al., 2012). Q/R site editing percentages appear to 
positively correlate with ADAR2 endogenous expression in the different cell lines 
(Yamashita et al., 2012c) which may explain the variability in reported Q/R site editing 
percentages. 
Cell lines have previously been used to analyse the effects of PMOs on Q/R site editing. 
Three cell lines were used: HeLa, SH-SY5Y and MIN-6 (Penn et al., 2012). HeLa and 
SH-SY5Y cells are of human origin, from a cervical cancer and neuroblastoma 
respectively, whereas MIN-6 originate from a rat β-pancreatic cell line. The HeLa cells 
were used as an exogenous reporter system with similar conditions used by Higuchi et 
al. (1993), where a plasmid containing the same sequence of the GluA2 gene (Figure 
3.1) was transfected into cells to analyse editing percentages. They found SH-SY5Y cells 
to have endogenous editing of around 85%, whereas MIN-6 cells were shown to have 
nearly 100% editing, similar to editing levels found in the brain (Penn et al., 2012). 
To measure the editing efficiency of the different cell lines, Penn et al. (2012) extracted 
RNA from cell samples and cDNA templates were made. These cDNA samples were 
then digested with the restriction endonuclease BbvI which has a recognition site that 
covers the unedited sequence of the Q/R editing site (GCAGC). Unedited cDNA copies 
were therefore digested by the enzyme and so showed two bands when separated on a 
gel, whereas edited DNA remained undigested. They also used Sanger sequencing 
methods to determine editing by comparing relative peaks of A versus G bases at the 
editing site within the RT-PCR product (Penn et al., 2012). These two methods for 
determining editing efficiency are the most commonly used throughout the literature 
(Pachernegg et al., 2015; Venø et al., 2012; Gaisler-Salomon et al., 2014). Other 
methods have also been developed to measure RNA editing, often in the 5-HT2C subunit, 
such as using real-time quantitative PCR, where different probes are designed to 
 85 
 
recognise the separate isoforms (Lanfranco et al., 2009) or using high-throughput 
sequencing techniques (Abbas et al., 2010). There have also been some creative 
alternative editing assays developed. For example, a yeast reporter system was 
developed where expression of the HIS3 gene, required for histidine auxotrophy, is 
linked to a shortened version of the R/G editing site on the GluA2 subunit (Garncarz et 
al., 2013). Editing at the R/G site was required for histidine expression and therefore for 
growth of the yeast culture in histidine-deficient medium (unedited transcripts coded for 
a stop codon). Potential enhancers for RNA editing were then transfected into this 
system and colonies that grew were identified and the enhancer further analysed 
(Garncarz et al., 2013). They also developed an editing assay in mammalian cells where 
the editing site was preceded by an RFP gene and followed by the gene for GFP. Editing 
was required for GFP expression, as again unedited R/G sites coded for a stop codon. 
Relative expression of GFP compared to RFP could then be assayed using FACS 
(Garncarz et al., 2013). However, this method is highly specific to the R/G site, which 
has a short sequence and little associated secondary structure, and it would probably 
not be possible to translate this system to the Q/R site. 
Bearing these previous studies in mind, a model was developed using HeLa cells 
transfected with the same plasmid originally used by Higuchi et al., (1993) and also used 
in the Penn et al. paper (2012). This plasmid contains the “B13 minigene”, a short 
sequence of the murine GluA2 gene, under the control of a CMV promoter (Figure 3.1). 
The B13 sequence contains the Q/R site, the exon complementary sequence and the 
imperfect repeat, features of the GluA2 transcript all known to be important in Q/R site 
editing (Figure 3.2). Transfection procedures were optimised to give strong B13 
expression in HeLa cells. It was also important that the endogenous editing efficiency of 
the cell models have the capacity to demonstrate both improved and reduced editing 
depending on the treatment added to give maximum flexibility to future experiments. 
HeLa cells had previously been shown to have an endogenous editing efficiency of 25% 
(Penn et al., 2012) and were therefore ideal. The editing assay was optimised for 
quantification of editing levels using BbvI restriction enzyme digestion followed by 
densitometric analysis of DNA digest fragment fluorescence. Having established the 
editing assay, a reliable model of secondary structure of the GluA2 RNA transcript was 
produced and used to design PMOs targeting the Q/R site, with an aim of sterically 
hindering RNA editing.  
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Figure 3.1 – A) Schematic of the B13 minigene, with locations of the Q/R site and exon complementary 
sequence (ECS), and the BbvI recognition sequence which covers the Q/R site. B) The pRK5 plasmid 
backbone with the SalI site indicated where the B13 minigene was inserted under the control of the CMV 
promoter. 
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Figure 3.2 - Sequence of B13 minigene. Exon 11 is shown in bold and the remaining sequence is the 
beginning of intron 11. The Q/R site is underlined in red. Bases surrounding the Q/R site highlighted in blue 
have their complementary bases found in the “exon complementary sequence” highlighted in blue in the 
intron. Highlighted in green are the bases in the “imperfect repeat”. 
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3.2 RESULTS 
3.2.1 Design of PCR-BbvI digest assay 
To quantify Q/R site editing in HeLa cells, a PCR-digest assay was designed. This was 
possible as the bases over the A-to-I editing site in this sequence are the recognition site 
of the BbvI restriction endonuclease in the unedited form (Figure 3.3). This means that 
cDNA copies of transcripts that are unedited will be cut by the enzyme whereas those 
that were edited will remain uncut. Due to the reliance of a complete enzymatic digest 
for reliable assessment of editing, high levels of BbvI were used (2 units per PCR reaction 
product) for an incubation time of 1 hour compared to the recommended 15 minutes 
using the Fast Digest conditions. During optimisation of the PCR-digest assay, it was 
discovered that SDS was needed in the loading dye of BbvI digest products, otherwise 
the enzyme interfered with the movement of DNA through the agarose gel (Figure 3.3B). 
Addition of 0.05% SDS denatured the enzyme sufficiently to allow the digest products to 
run as a distinct band. The intensity of these bands could then be quantified using 
densitometric analysis. Q/R site editing percentages could be calculated using the 
following equation: 
% 𝐸𝑑𝑖𝑡𝑖𝑛𝑔 =
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑈𝑛𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑 (𝐸𝑑𝑖𝑡𝑒𝑑)𝐵𝑎𝑛𝑑
(𝑇𝑜𝑡𝑎𝑙 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑢𝑛𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑 𝑎𝑛𝑑 𝑑𝑖𝑔𝑒𝑠𝑡𝑒𝑑 𝑏𝑎𝑛𝑑𝑠)
∗ 100  
This assay could now be used on cDNA copies of RNA transcripts from a mammalian 
cell model. 
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Figure 3.3 - PCR-Digest assay design. A) Schematic showing the B13 minigene and the BbvI recognition 
site. Forward and reverse primer placements are shown with blue arrows. If the transcript is edited then the 
adenosine is replaced by a guanosine and the recognition site is destroyed. B) Shows a 3% agarose gel run 
in 1x TAE buffer with the full PCR product only (314 base pairs) compared to the BbvI digest products (195 
and 113 base pairs). Samples were either treated with 0.05% SDS (+) or not (-). Product sizes compared 
against HyperLadder V (HL). “-ve” indicates water control PCR reaction with no DNA present. 
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3.2.2 Transfection of the B13 minigene in HeLa cells 
The pRK5 plasmid containing the B13 minigene was kindly donated from the O’Connell 
lab (Figure 3.1). HeLa cells were grown in 24 well plates at 200,000 cells per well over 
24 hours until 90% confluent. The transfection reagent Lipofectamine was tested at three 
different ratios, 0.5:1, 1:1 and 2:1 DNA to Lipofectamine. The results are shown in Figure 
3.4. Extracts from HeLa cells with no plasmid were shown to not amplify this section of 
the GluA2 transcript, which was expected. A plasmid containing the GFP transcript was 
used as a control transfection, and also showed no amplification of the GluA2 transcript. 
All three ratios of B13:Lipofectamine showed sufficient transfection to produce strong 
RT-PCR products (314 bp fragment in Figure 3.4). A ratio of 0.5 µg plasmid DNA to 1 µl 
of Lipofectamine per well was chosen to prevent cell toxicity.  
The RT-PCR reaction amplified only the RNA transcripts extracted and not any residual 
DNA from the plasmid. If RNA extracts, before DNase treatment, were used in a PCR 
reaction using the same B13 primers, a small amount of DNA was amplified (Figure 3.5). 
However, following DNase treatment there was no amplification of DNA. Following the 
reverse transcription reaction, a strong RT-PCR product was amplified (Figure 3.5). 
 
 
Figure 3.4 - Gel image of RT-PCR products run on a 2% agarose gel in 1x TAE buffer using HyperLadder V 
(HL) following different transfection conditions in HeLa cells. Extracts from HeLa cells only show no 
amplification of the GluA2 transcript. Control transfection of a plasmid with the GFP gene also showed no 
amplification. Transfections of 0.5 µg, 1 µg and 2 µg all showed good amplification of the GluA2 band at 314 
base pairs. “-ve” indicates water control PCR reaction with no DNA present. 
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Figure 3.5 - 2% agarose gel in 1x TAE buffer using HyperLadder V (HL) to show that a PCR reaction on 
DNase-treated RNA does not amplify any DNA, whereas reverse transcription followed by PCR reaction 
produces a strong product at 314 base pairs. “-ve” indicates water control PCR reaction with no DNA or RNA 
present. 
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3.2.3 Length of BbvI Digest on RT-PCR Product 
In order to establish the length of time the RT-PCR product needed to be incubated with 
the BbvI enzyme, the RT-PCR product was incubated for increasing lengths of time. The 
digest fragments were then run on a 3% agarose gel and the intensities quantified. 
Results, shown in figure Figure 3.6, indicate that the enzyme takes 10 minutes to 
complete digestion at this quantity of DNA, as indicated by the plateau in % digest (Figure 
3.6B). Subsequent digests were incubated for 1 hour at 37°C to ensure complete 
digestion. 
 
 
Figure 3.6 - (A) Gel images of 3% agarose gel run in 1% TAE buffer using HyperLadder V (HL) showing 
digest products of RT-PCR products following B13 plasmid transfection in HeLa cells. (B) Graph showing 
quantification of digestion at each time point. The graph plateaus after 10 minutes, indicating a complete 
digest. 
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3.2.4 Baseline Q/R site editing in the HeLa-B13 system 
Once the conditions for transfection of the B13 plasmid into HeLa cells had been 
optimised, a baseline measurement of the editing in the HeLa-B13 system could be 
determined. The B13 plasmid was transfected into HeLa cells, RNA was extracted and 
an RT-PCR was performed followed by a BbvI digest as described above (Figure 3.3). 
Digestion products were run on a 3% agarose gel in 1x TAE buffer (Figure 3.7A) and the 
Q/R site editing percentage determined through comparison of the intensity of each band 
measured through densitometric analysis; the results are shown in Figure 3.7B. Average 
editing in the HeLa-B13 system was calculated at 29.4 ± 1.04% (n=8), consistent with 
previous studies (Penn et al., 2012).  
There were two features necessary for the HeLa-B13 system if it was to be used as a 
model: reliability and scope for manipulation. The sensitivity of the HeLa-B13 system to 
change was demonstrated through co-transfection of the B13 plasmid with a plasmid 
containing another copy of ADAR2 (kindly donated by O’Connell lab). This increased 
pool of enzyme ought to increase the Q/R site editing. After co-transfection of the two 
plasmids into HeLa cells, RNA was extracted and analysed as before leading to an 
increase in Q/R site editing of 86.2 ± 6.14% (Figure 3.7B). The HeLa-B13 system 
therefore appears to be a suitable model to test treatments that may affect Q/R site 
editing. 
The endogenous editing at the Q/R site needed to be reliable and stable in a variety of 
conditions in order for any changes in Q/R site editing to be attributed to the PMO rather 
than B13 transfection. Editing was assessed after transfection over 24, 48 and 72 hours 
and remained consistent at 27.8 ± 1.06% with no significant difference between the time 
points (p=0.839, Figure 3.8) although there was some loss in cell viability at the 72 hour 
time point, likely due to over-confluency of cells and prolonged exposure to the 
transfection reagent. It therefore appears that the HeLa-B13 system is appropriate for 
testing any PMOs targeting the Q/R site, as it produces a reliable endogenous editing 
that is sensitive to changes made within the system.  
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Figure 3.7 – Q/R site editing in HeLa cells. A) Shows the gel image of the BbvI digest run on a 3% agarose 
gel in 1x TAE buffer with the B13 minigene only, and after a co-transfection with another plasmid containing 
ADAR2 cDNA. Product sizes compared against HyperLadder V (HL). “-ve” indicates water control PCR 
reaction with no DNA present. B) Shows quantification of the editing using densitometric analysis. Average 
editing of the B13 minigene in HeLa cells was 29.4 ± 1.04%, whereas after co-transfection with ADAR2 this 
increased to 86.2 ± 6.14% (p<0.05, n=8).  
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Figure 3.8 - A) Example of a 3% agarose gel of BbvI digest products from HeLa transfection with the B13 
minigene for 24, 48 or 72 hours. Product sizes compared against HyperLadder V (HL). “-ve” indicates water 
control PCR reaction with no DNA present. B) Quantification of Q/R site editing of the B13 minigene after 
24, 48 and 72 hours (28.6 ± 0.49%, 27.7 ± 2.23% and 26.9 ± 2.58% respectively) with no significant 
difference between groups (p=0.836; n=4).  
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3.2.5 Transfection of HeLa-B13 system with PMOs 
It is important that PMOs can be transfected into the HeLa-B13 system effectively, with 
a high transfection efficiency. The neutral charge of the PMO means that a specialised 
transfection reagent, EndoPorter (Gene Tools) was used for transfection. To assess the 
transfection efficiency, a 25mer PMO (F-PMO) was produced with a fluorescent tag of 
carboxyfluorescein attached to the 3’ end. Carboxyfluorescein emits light in the green 
wavelength with an excitation peak at 501.5 nm and an emission peak at 524.5 nm, and 
so can be viewed in the FITC channel. Two methods were used to assess transfection 
efficiency: cell imaging and flow cytometry, or FACS analysis. Due to the neutral charge 
of the F-PMO, the cells could not be fixed for staining as the F-PMO would not be 
immobilised, and so would leach out of the cells. Fixed cells would therefore not give an 
accurate transfection efficiency, and so images were taken with live cells, maintaining 
the compartmentalisation of the PMO (Figure 3.9A). Figure 3.9 shows HeLa cells 
transfected with 5 µM of F-PMO, the concentration chosen from the upper end of the 
range predicted to be used in the HeLa-B13 model. The first column of Figure 3.9A 
shows HeLa cells under phase-contrast. The third column shows the HeLa cells under 
the GFP channel, and the second column show these two channels merged. These 
merged images indicate that a high percentage of cells have taken up the F-PMO. From 
the images in GFP channel, it is not clear whether the fluorescence is background or a 
fluorescent cell due to the diffuse spread of the PMO. The two channels were therefore 
merged to show that the fluorescence pattern overlapped with the cells in the phase-
contrast images. Figure 3.9B shows a higher magnification of the HeLa cells. The white 
arrow indicates a cell with diffuse fluorescence, while the blue arrow indicates a cell 
which is showing higher fluorescence. A cell showing very high uptake of the F-PMO is 
unlikely to survive the transfection. On the other hand, a diffuse pattern within each cell 
is the indication that an effective transfection has taken place. Although the cell images 
give a good overall idea of the level of transfection in the HeLa cells, it does not give an 
exact percentage of cells transfected.  
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Figure 3.9 - Live microscope images of HeLa cells transfected with F-PMO. (A) scale bars indicate 100 µm. Left hand column show cells under phase-contrast, right hand column show 
cells in the GFP channel, centre column show the same field with merged channels. (B) shows a section at higher magnification, scale bar indicates 50 µm. White arrow indicates a cell 
showing diffuse fluorescence, yellow arrow indicates a cell showing intense fluorescence. 
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A more accurate method for quantifying transfection efficiency is FACS analysis, where 
transfected cells are sorted according to their fluorescence. The fluorescence of the PMO 
within cells will be at a higher intensity than the natural fluorescence of untransfected 
cells. A range of intensities were expected, correlating with the amount of PMO taken up 
into each cell. Here, the cells were not fixed. Instead, live cells were trypsinised and 
immediately placed in FACS buffer for flow cytometry in order to maintain 
compartmentalisation of the PMO in live cells.  
The output of the FACS analysis is shown in Figure 3.10. Live cells were selected based 
on avoiding those with low height (FSC-H) and low fluorescence (P1 gate) and single 
cells were selected based on avoiding those cells with a very low or very high FSC-H 
and FSC-A (P2 gate). The natural fluorescence of a HeLa cell was found using control 
samples, (Figure 3.10 top row) and any cells with a higher fluorescence than 102 of FITC-
A intensity were counted as transfected (P3 gate; Figure 3.10 bottom row). The number 
of cells found at each level of fluorescence could then be represented in a histogram 
(Figure 3.11). These results show that the transfected HeLa cells show a large shift in 
fluorescence compared to control, and that the majority of cells have been transfected.  
The peaks in the histograms for the positive sample (top three rows of Figure 3.11) are 
low and spread over a wide range of fluorescence intensities as expected. This mirrors 
the results from the live images of transfected HeLa cells, where fluorescence intensity 
can be low and diffuse or much brighter. This may indicate that within a population of 
HeLa cells, for example a well of a plate, the transfection of PMO is not uniform, which 
in turn may account for variation in the system. Table 3.1 shows the frequency of cells 
per sample that were positive for the fluorescent PMO, with a mean value of 99.5%. 
Subtracting the error of control cells captured in the P3 gate (2.41%), this gives a 
transfection efficiency of 97.09%. Table 3.1 also shows the median fluorescence in the 
FITC-A channel for each sample, highlighting the shift in fluorescence in transfected 
cells. This shows that, although the transfected cells show a range of fluorescence, over 
95% have taken up some of the PMO.  
These results indicate that the F-PMO was readily taken up by HeLa cells using the 
EndoPorter transfection reagent, and so the HeLa-B13 system was considered 
sufficiently optimised and appropriate for analysis of PMOs. 
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Table 3.1 - FACS analysis of HeLa cells transfected F-PMO. Table shows frequency of sample cells in the 
P3 (positive for green fluorescence) gate and the median fluorescence in the FITC-A channel per sample. 
 
 
Figure 3.10 - FACS analysis showing the overlaid gates for each sample. Top row are control HeLa cells, 
bottom row are HeLa cells transfected with F-PMO. Overlaid colours show: P1 gate selecting live cells (blue); 
P2 gate selecting single cells (orange) and P3 gate selecting fluorescent cells (green). Red cells are not 
included in any gates. 
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Figure 3.11 - Staggered histogram showing intensity of fluorescence for each sample. Top three rows show 
samples transfected with F-PMO, showing a shift to the right indicating green fluorescence compared to the 
bottom three rows of control HeLa cells. 
  
 101 
 
3.2.6 Comparison of human GRIA2 sequence against mouse and rat homologues 
Antisense oligonucleotides are specific to their target due to their exact reverse-
complement sequence. It was anticipated that multiple cell lines would be used to test 
the PMOs designed in this chapter, which would come from either human or murine 
origin. The B13 minigene (Figure 3.1) is a section of the murine GluA2 sequence. 
Therefore alignments were performed comparing the human GRIA2 sequence to the 
GluA2 of rat and mouse (Figure 3.12, Appendix 1). There is a high degree of homology 
between all three sequences. A percentage similarity was calculated as part of the 
Clustal MUSCLE package, and is shown in Table 3.2. The rat sequence shows 70.96% 
homology to the human sequence, which is slightly lower than the mouse homology of 
71.54%. The majority of the discrepancy between sequences is found in the intronic 
region, as shown in Table 3.3 where only exon 11 is compared between species. This is 
expected. It was found that homologous exons were conserved to around 85% identity 
overall between human and mouse, whereas in those intronic regions that could be 
aligned there was only 60% identity (Waterston et al., 2002). Both rat and mouse Gria2 
exon 11 show a 97.04% similarity to the human sequence, which when analysed in 
Figure 3.12 proves to be a difference of only 13 bases. It is not always the same base 
that differs between the mouse and rat sequences compared to human. The region 
surrounding the Q/R site (highlighted in row 3 of Figure 3.12) shows complete homology 
across the species, indicating that it is a conserved region due to its importance to the 
function of the AMPA receptor. Likewise, the exon complementary sequence (ECS) is 
conserved across the species. The imperfect repeat, also highlighted in Figure 3.12, 
shows 11 bases where there are substitutions across the species, indicating that it is 
less important than the ECS and Q/R site itself. 
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% Identity Matrix  
Exon 11 & Intron 11 
Human Rat Mouse 
Human 100.00 70.96 71.54 
Rat 70.96 100.00 87.84 
Mouse 71.54 87.84 100.00 
 
Table 3.2 - Percentage identity of human GRIA2 exon 11 and intron 11 compared to mouse and rat 
sequences. Comparison performed by MUSCLE. 
 
% Identity Matrix 
Exon 11 only 
Human Rat Mouse 
Human 100.00 97.04 97.04 
Rat 97.04 100.00 98.65 
Mouse 97.04 98.65 100.00 
 
Table 3.3 - Percentage identity of human GRIA2 exon 11 only compared to mouse and rat sequences. 
Comparison performed by MUSCLE. 
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Figure 3.12 - Alignment of Exon 11 and the beginning of Intron 11 of GRIA2 in the human sequence versus rat and mouse. Alignment was performed using MUSCLE with sequences 
from Ensembl. Full alignment of Exon 11 and Intron 11 is shown in Appendix 1. Exon 11 is shown in grey and the adenosine targeted by ADAR2 is highlighted by the blue box in row 3. 
Stars beneath the sequences indicate a perfect consensus at that base between the three species. Regions indicated as important for Q/R site editing (Higuchi et al 1993) are highlighted 
in blue. Imperfect repeat highlighted in intron 11, rows 4 and 5, while ECS is highlighted in row 5.   
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3.2.7 Prediction of the secondary structure surrounding the Q/R site 
The secondary structure of the GluA2 transcript is essential for normal Q/R site editing 
(Higuchi et al., 1993), and one aim of this project is to design antisense oligonucleotides 
to inhibit editing through disruption of surrounding double-stranded regions. Therefore, 
to accurately target these double-stranded sequences, a reliable model of the secondary 
structure surrounding the Q/R site was needed. Prediction of folding in RNA transcripts 
has progressed over the last few decades, but is still reliant on several assumptions and 
simplifications. Modelling secondary structures based on thermodynamic parameters 
(for example the MFold web serve; Zuker, 2003) is a common method and has been 
previously used to design antisense oligonucleotides (Penn et al., 2012). Other methods 
include comparative analysis and prediction through cluster analysis.  
To generate the most reliable structure possible, multiple models were produced initially 
using the MFold program to find the minimum free energy model, and the resulting 
structures were qualitatively compared, specifically around the Q/R site. The structure 
was compared across human and murine sequences for consistency across the different 
models used in future experiments. Variations in sequence length were tested, looking 
at either the complete exon 11 and intron 11 of GRIA2 or just the short section of GRIA2 
found in the B13 minigene. Finally, three methods for RNA structure prediction, based 
on production of a minimum free energy model, base-pair probabilities or Boltzmann 
weight coefficients, were compared on the B13 minigene sequence to see if the predicted 
structure was influenced by the different approaches. If the predicted structure remained 
the same despite changing these factors, then it can be assumed that the model is as 
accurate as possible and can be used as the basis for antisense oligonucleotide design. 
3.2.7.1 Comparison of predicted human and murine secondary structures of 
GRIA2 
A major limitation with most structure prediction software is that the number of bases 
allowed in the input is limited to improve computing speed; for example MFold has a limit 
of 9,000 bases. This means that, in most cases, a complete premRNA transcript cannot 
be modelled due to the presence of large introns. However, Higuchi et al. (1993) showed 
the importance of intron 11 in A-to-I editing at the Q/R site as it contains the exon 
complementary sequence as well as the imperfect repeat (Figure 3.2). It is also possible 
that bases several hundred nucleotides up or downstream may influence the secondary 
structure of a transcript. A balance is therefore needed between using enough bases in 
the model for a meaningful prediction but that are still be able to be inputted into the 
software.  
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The Q/R editing site, exon complementary sequence and the imperfect repeat are all 
found at the end of exon 11 and at the beginning of intron 11 of the GRIA2 gene. 
Therefore, the complete sequence of exon 11 and intron 11 was used, at a total of 4,887 
bases in human GRIA2, to predict a detailed model of the GluA2 transcript. Although the 
human sequence was used, any antisense oligonucleotides will initially be tested in the 
HeLa-B13 system, and the B13 minigene was derived from mouse DNA (Higuchi et al. 
1993). At later stages, if any oligonucleotides were to be tested in primary neuronal 
cultures, these would be of rat origin. Therefore, it was important to compare the 
predicted secondary structure of mouse and rat GluA2 to that of human so that any 
targeted secondary structure was present in all three species, especially as the intronic 
regions of these genes varied (Figure 3.12). The same section of mouse and rat GluA2 
sequence (exon 11 and intron 11; 4,602 bases and 4,960 bases respectively) were 
inputted into the MFold secondary structure prediction software.  
MFold is often used for designing small molecules (Zuker, 2003; Penn et al., 2012). 
Sequences were inputted into the online form and simulations were performed under 
default settings. MFold calculates the secondary structure of RNA transcripts through 
nearest neighbour energy parameters, predicting structures with the minimum free 
energy (MFE structure). The MFE models for the human, rat and mouse sequences are 
shown in Figure 3.13 (complete output for each sequence shown in Appendix 2). Overall, 
the whole structures appear similar but not identical. This is unsurprising due to the 
variation in intronic sequences between the species. A qualitative comparison of the 
region surrounding the Q/R site however shows that the structure here appears to be 
preserved (inserts of Figure 3.13). The edited adenosine (highlighted in each insert) is 
consistently six bases into the beginning of a section of double-stranded RNA, just 
downstream from a large loop. This double-stranded region extends to a small internal 
loop of a couple of bases then a large loop of 16 bases on each strand, followed by 
another region of double-stranded structure. The exon complementary sequence is 
paired to the Q/R site, and is 5’ to a second section of double-stranded structure. This 
analysis indicates that the structure of the RNA surrounding the Q/R site has been 
conserved across these three species, probably due to the reliance of ADAR2 on 
secondary structure of the RNA transcript to perform the A-to-I editing reaction. This 
same structure around the Q/R site is found in 38 out of 47 predicted models in the 
human sequence. 
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Figure 3.13 - Secondary structures of Exon 11 and Intron 11 of the GRIA2 gene in human (dG = -1025.11), rat (dG = -1055.22) and mouse (-999.57) as predicted by MFold. Each model 
is the predicted structure with the lowest free energy for each sequence. All predicted structures for each sequence can be found in Appendix 2. Inserts in each structure indicate the 
location of the Q/R site, shown by a red arrow. 
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3.2.7.2 Predicted secondary structure of the B13 minigene 
The B13 minigene (Figure 3.1), a small section of the end of exon 11 and the beginning 
of intron 11 of Gria2, will be initially expressed within HeLa cells in order to test the 
antisense oligonucleotides. Therefore, the secondary structure of the B13 transcript (741 
bases) itself was predicted for the PMO design. The MFE model is shown in Figure 3.14, 
and all predicted models from the MFold output can be found in Appendix 3. This 
structure shows the same pattern as was found in the complete exon 11 – intron 11 MFE 
model (Figure 3.13). The edited adenosine is found six bases into a double-stranded 
region, followed by a small and then larger internal loop which leads to a further double-
stranded region. This pattern can be seen in 11 out of the 15 predicted secondary 
structure models for the B13 minigene given in the MFold output (Appendix 3). 
Repeatedly finding the same secondary structure surrounding the editing site supports 
its reliability as a basis for PMO design. The free energy for each model is shown on the 
structures in Appendix 3, and the free energy for the MFE structure is shown in Figure 
3.14. The free energies for all 15 structures are within 10.3 kcal/mol, indicating that any 
may occur within the cell. The different predicted structures are important to consider as 
the RNA transcript may not remain in one conformation, and so any ASO should apply 
to as many structures as possible. 
The MFE approach to predicting nucleotide secondary structure was the first to be used 
widely in molecular biology, and is based on the assumption that the structure with the 
MFE is the most likely to occur. However, comparing the equilibrium constants across 
all predicted structures for a given sequence, Mathews et al showed that the probability 
of the complete MFE structure of an RNA transcript existing is extremely small (Mathews 
et al., 2010), which is supported by the fact that the difference in binding energy between 
the MFE and all other predicted structures is within -10.3 kcal/mol. The probability of a 
base pair occurring can be calculated by comparing the free energy within each predicted 
structure and how often that base pair occurs; base pairs with a higher probability have 
been shown to be more likely to be incorporated in the actual structure (Mathews, 2004). 
This probability can then be added to the MFE model, and the areas of secondary 
structure that have a higher base pair probability can be considered more reliable. 
Furthermore, a composite structure showing only those base pairs with the highest 
probabilities can be produced, giving a structure of the maximum expected accuracy (Lu 
et al., 2009). A maximum expected accuracy model for the B13 minigene was produced 
using the MaxExpect function within the RNA Structure software (Reuter & Mathews, 
2010). The output is shown in Figure 3.15. If compared to the MFE model (Figure 3.14), 
it can be seen that the structure surrounding the Q/R site is preserved. The edited 
adenosine is six bases from a large loop, within a section of double-stranded RNA, 
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followed be a small then larger internal loop then another region of double-stranded RNA. 
The MaxExpect program has calculated the probability of the bases surrounding the 
edited adenosine to be paired at 90-95%, whereas the bases leading to the small and 
large internal loops have a low probability of base pairing, indicating that they are more 
likely to remain single-stranded. The probability of the imperfect repeat forming the 
double-stranded structure was calculated as >99%, probably due to the complete 
complementary sequences. 
A third approach to secondary structure prediction is the production of a centroid 
structure using the web server SFold (sfold.wadsworth.org/cgi-bin/index.pl; Ding et al., 
2005). This assumes that the base pairing of RNA follows a Boltzmann distribution (i.e. 
the structure is dependent on the temperature and free energy of the system). Structures 
can then be assigned Boltzmann probabilities and clustered according to base-pair 
distances. A centroid is a single structure that best represents a group of structures within 
the cluster, based on the lowest base-pair distance for each individual structure. SFold 
also determines an ensemble centroid, where the entire set of structures is included in 
the production of the structure. A particular sequence may therefore produce several 
centroid structures with one overall ensemble centroid. The ensemble centroid for the 
B13 minigene is shown in Figure 3.16, and shows a comparable free energy of -216.54 
kcal/mol compared to the MFE structure which had -237 kcal/mol. As can be seen by 
comparison to the MFE model and the MaxExpect output (Figure 3.14; Figure 3.15), the 
structure surrounding the Q/R editing site is again conserved according to this method 
of prediction. The edited adenosine is still six bases into a region of double-stranded 
sequence, which extends further and ends at a small then larger internal loop which is 
followed by more double-stranded RNA. This structure is consistent across all methods 
of secondary structure prediction, whether the sequence is extended, between species 
tested here and using different prediction software. 
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Figure 3.14 – MFE model of predicted secondary structure of B13 minigene. The total predicted RNA 
transcript is shown in the top right hand corner, with the areas of secondary structure surrounding the Q/R 
site expanded. The edited adenosine is highlighted by the red arrow and the free energy (ΔG) indicated. 
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Figure 3.15 - MaxExpect output from the RNA Structure software. Probabilities of each base pair are 
indicated according to colour, with a key in the top left hand corner. Complete structure is shown on the left 
hand side, with the area surrounding the Q/R editing site enlarged. The base pairs surrounding the Q/R site 
have a 90-95% probability of binding. The edited adenosine is highlighted with a red arrow and the free 
energy (ΔG) indicated. 
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Figure 3.16 - Ensemble centroid structure for the B13 minigene as predicted by SFold. Complete structure 
shown in the top corner with the Q/R editing site expanded. The edited adenosine is highlighted with a red 
arrow and the free energy (ΔG) indicated. 
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3.2.8 Design of antisense oligonucleotide 
Through changing the length of inputted sequence, species of origin and using different 
software, a consensus secondary structure has been formed that appears to be 
conserved in the majority of predicted models. This structure was then used for the 
design of PMOs to disrupt Q/R site editing. The double-stranded region of RNA 
surrounding the edited adenosine is essential for the editing reaction to take place, and 
so targeting PMOs to this region should lead to competition between the PMO and the 
RNA transcript itself for binding. This steric interference should disrupt the secondary 
structure sufficiently for ADAR2 to not bind to the Q/R editing site. A second area of 
secondary structure that is important for editing is the imperfect repeat, found 
downstream of the edited adenosine after a loop of single stranded structure. This 
imperfect repeat was also shown to be essential for Q/R site editing (Higuchi et al., 1993) 
and so disruption of the double-stranded structure through PMOs binding may also inhibit 
the editing reaction. 
The PMOs designed here were given a sequential number (PMO 1-6) as well as an 
indication of the target sequence. This set of PMOs were titled with the target gene, 
GRIA2, followed by numbers according to the bases that they bind to up or downstream 
from the exon 11/intron 11 boundary, which was designated “0” (Figure 3.17A). For 
example, PMO1 (GRIA2+284+308) is a previously published antisense oligonucleotide 
that has been shown to disrupt Q/R site editing (Penn et al., 2012), and binds to bases 
284 to 308 downstream of the exon 11/intron 11 boundary (Figure 3.17A). The remaining 
five PMOs were designed to target specific areas of secondary structure based on the 
model predicted to be most reliable. All six PMOs shown here (Figure 3.17) are 25 bases 
long, the longest standard PMO length possible from GeneTools. Increased length of 
PMO is thought to correlate to improved PMO binding (Popplewell et al., 2009).  
PMO1 (GRIA2+284+308) binds to the complementary strand of RNA to the edited 
adenosine, including the exon complementary sequence. PMO2 (GRIA2-30-6) was 
designed to bind to the same strand as the edited adenosine and so directly covers the 
Q/R editing site, with the most 5’ base targeting a small area of single-stranded structure 
for improved binding. This PMO will test whether targeting the strand containing the 
edited adenosine itself, rather than the exon complementary sequence, influences the 
potential for editing inhibition. The double-stranded structure that includes the edited 
adenosine extends further than the reach of PMO1 (GRIA2+284+308) and PMO2 
(GRIA2-30-6). Therefore two more PMOs were designed, targeting each strand, to 
completely cover this section. PMO3 (GRIA2-14+10) binds downstream to PMO2 
(GRIA2-30-6), not directly covering the edited adenosine but still extending into the 
double-stranded structure. It also has the advantage of binding to bases in the large 
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internal loop, and therefore might be able to better penetrate the double-stranded 
structure. PMO4 (GRIA2+262+286) binds to the complementary strand opposite PMO3 
(GRIA2-14+10), and again has target bases in the single-stranded region. PMO5 
(GRIA2+19+43) and PMO6 (GRIA2+50+74) target the imperfect repeat, which forms a 
region of double-stranded RNA the other side of the large internal loop from the region 
targeted by the other PMOs. The target bases for PMO5 (GRIA2+19+43) begin in the 
internal loop and extend into the imperfect repeat, ending one base into a bulge of single 
stranded RNA. PMO6 (GRIA2+50+74) begins in this bulge and extends further into the 
imperfect repeat. The newly designed PMOs are summarised in Figure 3.17, with a 
schematic of where the PMOs bind in relation to the exon 11/intron 11 boundary (A) as 
well as in terms of the secondary structure (B). PMO sequences and targets are 
summarised in Figure 3.17C.  
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Figure 3.17 - PMOs designed around the secondary structure predicted by MFold. A) Placement of PMOs 
along the exon 11/intron 11 boundary of the mouse GRIA2 sequence. Numbers refer to bases up (-) or 
downstream (+) of the exon 11/intron 11 boundary (designated 0) where the PMO begins and ends. B) 
Placement of PMOs targeting areas of secondary structure and the edited adenosine, shown as the red 
circle. C) Table of PMO names and sequences and their target regions. The edited adenosine is indicated 
by the red circle. PMO1 (GRIA2+284+308) has been previously published (Penn et al 2012). 
 
  
 115 
 
The main purpose of this set of PMOs was to target the desired secondary structure 
elements around the Q/R site. However, other components of PMO design have been 
shown to improve binding, such as the percentage of G or C bases in the PMO (GC 
content) or the energy involved in the binding of PMO to RNA transcript (Popplewell et 
al., 2009) and these calculations are shown in Table 3.4. PMO1 (GRIA2+284+308) has 
been previously shown to inhibit Q/R site editing (Penn et al., 2012) and so presumably 
binds to the RNA transcript. However, the GC content is lower than the 40-60% ideal 
(Aartsma-Rus et al., 2009). For the 5 new PMOs designed here, three have a GC content 
that falls within this range, whereas PMO5 (GRIA2+19+43) and PMO6 (GRIA2+50+74) 
have GC contents that also fall lower than the suggested range (Table 3.4). Higher GC 
content should increase PMO binding as base pair bonds between G and C are stronger 
than between A and T, and so those three PMOs with lower GC contents may show 
decreased binding.  
The intermolecular binding energy was calculated using the SFold webserver 
(sfold.wadsworth.org; Table 3.4). A more negative binding energy was shown to be 
correlated with effective PMOs (Aartsma-Rus et al., 2009). Again, the published PMO1 
(GRIA2+284+308) shows a high intermolecular dimer energy, which is in fact positive. 
When calculated for each newly designed PMO, there was a range of binding energies, 
with the lowest intermolecular dimer for PMO4 (GRIA2+262+286) at -4.9 kcal/mol and 
all are lower than 2.2 kcal/mol for PMO1 (GRIA2+284+308), except PMO6 
(GRIA2+50+74) with a binding energy of 2.3 kcal/mol. From this energy required to form 
the intermolecular dimer, the energy needed to overcome secondary structure within the 
PMO is subtracted, both any hairpin structures and inter-PMO binding. Once these 
values had been taken into account, all PMOs were calculated to have a positive binding 
energy (Table 3.4). PMO3 (GRIA2-14+10), PMO4 (GRIA2+262+286) and PMO5 
(GRIA2+19+43) all have a total binding energy of less than that for PMO1 
(GRIA2+284+308), which was calculated to have a binding energy of 5.7 kcal/mol. PMO2 
(GRIA2-30-6) has a total binding energy of 7.1 kcal/mol, while PMO6 (GRIA2+50+74) 
has an even more positive total binding energy of 13.8 kcal/mol.  
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Table 3.4 - GC content and binding energies of designed PMOs. Intermolecular energies calculated using 
SFold (sfold.wadsworth.org). Hairpin and PMO-PMO energies calculated using OligoAnalyzer 3.1 (IDT). All 
ΔG are in kcal/mol. 
  
 117 
 
3.3 DISCUSSION 
This chapter has established the HeLa-B13 system for analysing the effect of antisense 
oligonucleotides on Q/R site editing. Transfection, RT-PCR and restriction digest 
procedures were adjusted for reliable assessment of the RNA editing reaction. The 
HeLa-B13 system was shown to be appropriate for Q/R site analysis as it reliably 
reproduced endogenous editing of 30%, which would allow treatments to both increase 
and decrease editing, and proved to be sensitive to manipulations in editing after 
co-transfection with an extra copy of ADAR2, which increased the editing percentage. 
HeLa cells were also shown to have a high transfection efficiency using the EndoPorter 
transfection reagent when tested with a fluorescent PMO. The B13 minigene, of mouse 
origin, was compared to human and rat sequences and shown to share a high identity, 
and the sequence surrounding the Q/R site and the ECS was conserved as shown by 
aligning the three sequences. Any antisense oligonucleotides targeted to the B13 
minigene would therefore be able to be tested in cell models from any of these species 
in future experiments. In order to design antisense oligonucleotides that disrupted 
secondary structure of the transcript, a reliable model of the secondary structure was 
needed. It was found that the secondary structure surrounding the Q/R site remained the 
same regardless of changes to sequence length, species of origin or program used. This 
model was therefore considered sufficiently reliable for antisense oligonucleotide design. 
Finally, PMOs were designed to target bases covering all of the predicted 
double-stranded structure surrounding the edited adenosine.  
The HeLa-B13 system was chosen to be the original model for testing the effect of 
antisense oligonucleotides on Q/R site editing as HeLa cells are easily manipulated and 
the overexpression of a small section of GRIA2 simplifies the system by removing any 
variables associated with expression levels. The PCR-digest was based on previously 
reported methods, where the sequence surrounding the Q/R site is amplified and then 
digested with the BbvI restriction enzyme if unedited (Peng et al., 2006; Sawada et al., 
2009; Penn et al., 2012). The digest fragments can then be separated on an agarose 
gel, and any edited (undigested) fragments can be compared in intensity to the unedited 
(digested) fragments to achieve a Q/R site editing percentage. Once this assay was set 
up, transfection conditions for the plasmid containing the B13 minigene into HeLa cells 
were optimised. This allowed an endogenous editing capacity of 30% in HeLa cells to be 
calculated. This was shown to be consistent across three different time points of 24, 48 
and 72 hours, indicating that this is the maximum possible editing efficiency for HeLa 
cells under these conditions. One limiting factor is the endogenous ADAR2 expression 
within the cell line, as shown by the increase in editing found after co-transfection with 
an additional copy of the ADAR2 gene. 
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An endogenous editing capacity of around 30% at the Q/R site of transfected HeLa cells 
is similar to previous work (Penn et al., 2012). However, editing in HeLa cells has been 
reported to be variable by different groups. In a study into the regulation of RNA editing 
at the Q/R site, one group found endogenous editing of HeLa cells transfected with the 
B13 minigene to be 60% (Marcucci et al., 2011). In this paper, the Q/R site editing was 
measured through PCR amplification of the sequence which was then cloned into a 
vector and sequenced. The relative heights of the peak at the edited adenosine between 
adenosine and guanosine were measured and a percentage of editing calculated. 
Another lab has analysed the endogenous editing capacity of a variety of cell lines 
(Yamashita et al., 2012c). This group had previously found wide variation in HeLa Q/R 
site editing, with some cells showing no editing and some showing 100% editing, 
although the average was around 25% (Sawada et al., 2009). They therefore developed 
a HeLa cell line that stably expressed a section of GluA2, and found Q/R site editing in 
this cell line to be at 100% (Yamashita et al., 2012c). This study calculated the Q/R site 
editing using the BbvI digest method, and comparing the intensities of edited to unedited 
bands using a Bioanalyzer. It therefore appears that the endogenous editing capacity of 
HeLa cells is variable between research groups.  
This variability may be attributed to the changes in method for calculated Q/R site editing. 
Indeed, Wong et al compared the BbvI restriction digest analysis to the method of clone 
sequencing (Wong et al., 2009). Using the clone sequencing technique is labour-
intensive and takes a significantly longer time than the restriction analysis, making it less 
appropriate for studies looking at changes in Q/R site analysis. On the other hand, Wong 
et al. discuss the major bias within the restriction analysis, which is dependent on the 
strands hybridising to form either wholly edited or wholly unedited hybrid strands. 
However, an edited and unedited strand may hybridise. This would then not be cut by 
the BbvI enzyme as the recognition site is not complete despite half of the DNA remaining 
unedited, and so the amount of undigested (edited) transcripts would be overestimated. 
This group suggest an alternative method for calculated Q/R site editing through qPCR 
analysis, where probes are targeted to the edited adenosine (Wong et al., 2009). This 
method is dependent on the probes being sensitive enough to distinguish between 
transcripts with one base pair different, but would remove the bias in the hybridisation. 
qPCR analysis was used in detecting the presence of edited isoforms in the 5-HT2C, 
some of which are expressed at very low levels (Lanfranco et al., 2009). This approach 
was advantageous in the context of the serotonin subunit as the different probes could 
distinguish between the many possible isoforms. However, there is only one edited 
adenosine at the Q/R site, and so only two isoforms to account for: edited and unedited. 
Therefore, for this study the BbvI restriction analysis was chosen due to its high 
reproducibility and cost- and time-effectiveness. However, it may be interesting to use 
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the qPCR editing analysis to try and detect subtler changes in response to PMO 
transfection.  
It was also established that PMOs were able to be transfected efficiently into the HeLa 
cell line. Two methods were used for this analysis, first a visual confirmation that cells 
were being transfected with the F-PMO by live imaging and then a quantitative analysis 
using flow cytometry. Both methods showed that F-PMO using the EndoPorter 
transfection reagent displayed a good transfection efficiency in HeLa cells, with the 
FACS analysis calculating a transfection efficiency of 97.04%. This efficiency is 
extremely high, and so supports the HeLa-B13 system as an appropriate model for this 
project. The FACS analysis indicates that the cells had a varied uptake of the F-PMO, 
and that although the majority were transfected, there were some cells that took up much 
more than others as shown by a shallow and broad peak in the fluorescence histogram. 
This difference in transfection between cells could contribute to variation in the HeLa-
B13 system, as there would be mixed populations of cells with high and low 
concentrations of intracellular PMO within one sample. It is possible that the F-PMO has 
not actually entered the cell and is instead bound at the membrane, despite the cells 
being washed with PBS before imaging or with FACS buffer before flow cytometry 
analysis. However, the neutral charge of the PMO makes this explanation for 
fluorescence unlikely, and so the transfection efficiency for HeLa cells was considered 
high.  
Having optimised the HeLa-B13 system, the next step was to design the PMOs to disrupt 
editing. A reliable model for secondary structure was needed in order to target the PMOs 
to regions of double-stranded RNA within the secondary structure. The most common 
method for finding the secondary structure of an RNA transcript is using nearest-
neighbour parameters to find the structure with the minimum free energy (MFE), 
indicating that it would be most stable. MFold is a web server where RNA and DNA 
sequences can be inputted and MFE models predicted (Zuker, 2003). This program has 
been used for over a decade in multiple areas of molecular biology from using the 
CRISPR-Cas system (Hwang et al., 2013) to microRNA target prediction (Rajewsky, 
2006). Although this method of structure calculation determines the nearest 
neighbouring base a given nucleotide is likely to pair to, it is possible that sequences 
several hundred bases up- or downstream would influence the structure. Therefore, 
working within the sequence length limits in MFold, the total sequence of exon 11 and 
intron 11 from Gria2 was compared to that of the short section found in the B13 minigene. 
It appears that the B13 minigene contains enough of the intronic and exonic sequence 
to maintain the secondary structure surrounding the Q/R site, as these comparisons 
showed a conserved structure across the models. This almost certainly contributes to 
 120 
 
the ability of the B13 transcript to be recognised by ADAR2, which recognises editing 
sites through double-stranded RNA regions (Savva et al., 2012).  
As well as using a shorter sequence of Gria2 in the HeLa-B13 system than would be 
found endogenously in neurons, the B13 minigene is of mouse origin whereas future 
experiments with these PMOs could be conducted in cell lines of rat or even human 
origin. It was therefore important that any targeted secondary structure was conserved 
across the three species. Through comparison of the MFE models for mouse, rat and 
human for exon 11 and intron 11 of Gria2, it was demonstrated that the double-stranded 
RNA regions surrounding the edited adenosine appeared to be conserved between 
these species. This is perhaps understandable due to the importance of the Q/R site in 
terms of normal neuronal function, as abolishing editing leads to severe seizures in a 
mouse model (Brusa et al., 1995) and reduced editing specifically in motor neurons leads 
to progressive paralysis (Hideyama et al., 2010).  
Despite being used intensively in the literature, the model with the minimum free energy 
is not always accurate. It does not account for any tertiary interactions, and has been 
shown to not always be accurate in identifying the most probable structure (Ding & 
Lawrence, 2003). This is likely due to RNA transcripts being actively folded rather than 
passively folding into minimum free energy states, as well as other factors altering 
secondary structure such as alterations in pH, ionic composition or interactions with other 
RNAs or RNA-binding proteins. Attempts have been made to make the prediction more 
accurate. MaxExpect is part of the RNA Structure program that, while still calculating the 
MFE model, builds on this prediction by calculating base pairing probabilities and giving 
the structure with the highest overall probability. SFold is another web server that collects 
predicted structures into clusters based on their similarities according to their Boltzmann 
weights and base pairing probabilities, and uses these clusters to generate an overall 
prediction based on the most probable clusters (Ding et al., 2005). Each of these 
programs was used to predict the secondary structure of the B13 minigene. Although 
some intronic sections varied, the region surrounding the edited adenosine is conserved. 
It therefore appears that the structure surrounding the Q/R editing site is predicted to be 
the same despite different approaches to the prediction. RNA structure prediction still 
has a place in molecular biology due to the time-intensive assays needed for in vivo (or 
even in vitro) study of RNA secondary structure, which involves targeting the RNA with 
different probes that cut at specific double- or single-stranded regions and then running 
the results on capillary electrophoresis (Wan et al., 2013). 
Due to the similarities across the different secondary structure predictions, the MFE 
model was taken as the basis for PMO design. The main aim of this set of PMOs was to 
target specific regions of double-stranded structure, either around the edited adenosine 
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itself or at the imperfect repeat. Taken as a set, these PMOs cover this whole region. 
When taking the calculated binding energies into account, it is perhaps surprising that 
PMO1 (GRIA2+284+308) has been reported to disrupt Q/R site editing (Penn et al., 
2012) due to its positive binding energy of 5.7 kcal/mol and low GC content of 36%. 
However, if this PMO is used as a benchmark, the more negative total binding energies 
for PMO3 (GRIA2-14+10), PMO4 (GRIA2+262+286) and PMO5 (GRIA2+19+43) at 4, 
2.7 and 4.9 kcal/mol respectively indicate that these PMOs show strong potential for 
binding to the RNA transcript. PMO2 (GRIA2-30-6) on the other hand shows a higher 
total binding energy of 7.1 kcal/mol. This positive binding energy means that this PMO 
might not be strong enough to penetrate the RNA transcript’s secondary structure. 
However, PMO2 (GRIA2-30-6) targets the edited adenosine itself and its surrounding 
sequence. Therefore, if the PMO can bind to the target RNA, this one has the potential 
to prevent ADAR2 editing to the greatest extent. PMO6 (GRIA2+50+74) targets the 
section of the imperfect repeat furthest from the edited adenosine in the model of 
secondary structure, and the total binding energy for this PMO was calculated as 13.8 
kcal/mol, the highest in the set. Both of these aspects indicate that PMO6 
(GRIA2+50+74) is least likely to have an effect on Q/R site editing. 
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4 USING ANTISENSE OLIGONUCLEOTIDES TO DISRUPT 
EDITING AT THE Q/R SITE THROUGH STERIC 
HINDRANCE 
4.1 INTRODUCTION 
The formation of RNA duplex structures and how they influence RNA secondary 
structure is known to be crucial for efficient RNA editing, as discussed (Higuchi et al., 
1993). In the previous chapter, models for the secondary structure of the GluA2 RNA 
transcript were produced using minimum free energy and base pair probability 
predictions. Using these models, PMOs were designed to target the secondary structure 
that surrounds the Q/R site. Through complementary base pairing, these PMOs will bind 
to the RNA sequence and therefore disrupt the internal secondary structure. By 
designing sequences that are completely complementary to the RNA molecule, binding 
to the PMOs should be preferable compared to the imperfect complementary sequences 
within the RNA sequence itself. Disruption of the RNA secondary structure, and therefore 
inhibition of editing at the Q/R site, would mimic the decline in Q/R site editing found in 
patients with ALS (Kawahara et al., 2004). This could produce a model for any cellular 
events found downstream of Q/R site editing disruption, for example increased 
susceptibility to excitotoxicity from overstimulation by glutamate. 
In this chapter, PMOs were tested in cell models. The first aim was to replicate the results 
published by Gregor’s lab in 2012. This group found that a PMO designed to be 
complementary to the Exon Complementary Sequence (PMO1 (GRIA2+284+308) from 
the previous chapter) of the Q/R site could inhibit RNA editing, with an IC50 of 1.9 μM in 
the HeLa-B13 system (Penn et al., 2012). This PMO, along with 5 other PMOs designed 
in the previous chapter, were transfected into the HeLa-B13 system and the Q/R site 
editing was analysed. PMOs were then redesigned and again tested in the HeLa-B13 
system followed by a cell line that endogenously expresses GluA2, SH-SY5Y cells. Using 
these two cellular models, the efficiency of each PMO could be compared for its ability 
to disrupt Q/R site editing. 
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4.2 RESULTS 
4.2.1 Transfection of 25mer PMOs into the HeLa-B13 system 
The PMOs designed in the previous chapter and summarised in Figure 3.15 were 
transfected into HeLa-B13 system (HeLa cells transfected with a plasmid containing the 
B13 minigene). After 24 hours, RNA was extracted and the editing at the Q/R site was 
quantified using the BbvI assay established in the previous chapter. All editing 
percentages were normalised to control samples transfected with the B13 plasmid only. 
An initial transfection at 1 µM per PMO did not show any significant effect of the 25mers 
on Q/R site editing compared to control (Figure 4.1A), although there appears to be a 
non-significant effect with treatment of PMO1 (GRIA2+284+308) and PMO4 
(GRIA2+262+286). The results may not have reached significance due to the variation 
seen between samples as shown by the large error bars (Figure 4.1A).  
PMO concentration was then increased to 10 µM, and Q/R site editing was measured 
using the same method. This concentration is recommended by GeneTools as a test 
concentration. PMO2 (GRIA2-30-6) and PMO4 (GRIA2+262+286) significantly 
decreased editing (86.9 ± 6.36% and 71.1 ± 2.4% of control respectively, p<0.05; Figure 
4.1B). Interestingly, PMO1 (GRIA2+284+308) showed no effect on Q/R site editing (103 
± 1.28% of control), despite being previously reported to inhibit editing by more than 50% 
at this concentration (Penn et al., 2012). In fact, PMO1 (GRIA2+284+308) shows more 
of an effect at 1 µM, with a non-significant decrease to 69.64 ± 10.0 % of control, than at 
10 µM which showed no change in editing percentage. This lack of reproducibility is a 
concern, and may be due to variation in individual transfected cells as seen with the 
fluorescently tagged PMO in the previous chapter.  
When considering the targeted secondary structure for each PMO, it was hoped that 
PMO2 (GRIA2-30-6) would have a strong inhibitory effect on Q/R site editing as it covers 
the edited adenosine itself (Figure 3.15) and so when placed over the target sequence 
would completely prevent ADAR2 binding. However, at both 1 µM and 10 µM there was 
only a reduction in editing percentage to around 85% of control. There was no significant 
change in efficacy between the concentrations of 1 µM and 10 µM for this PMO despite 
a ten-fold increase in concentration (p=0.953), although there is less variation in the 
samples at 10 µM of PMO, which reaches significance when compared to control 
(p<0.05). The same can be said for PMO4 (GRIA2+262+286), where there is no 
significant change in editing inhibition between treatments at 1 µM and 10 µM (73.10 ± 
9.57% compared to 71.18 ± 2.43; p=0.856), although samples treated with 10 µM of 
PMO4 (GRIA2+262+286) were significantly different from control samples (p<0.05).  
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PMO3 (GRIA2-14+10) targets the same strand as the Q/R site but slightly downstream 
from the edited adenosine, extending into the loop of RNA in an attempt to improve PMO-
RNA binding. Despite the strong potential for disruption in terms of target sequence, 
PMO3 (GRIA2-14+10) follows a similar pattern to PMO1 (GRIA2+284+308). At 1 µM 
there was a non-significant reduction in Q/R site editing (82.39 ± 7.77%) while at 10 µM 
there was no change in editing at all (108.4 ± 4.14%). PMO5 (GRIA2+19+43) and PMO6 
(GRIA2+50+74) target consecutive sections of the imperfect repeat, separated from the 
double-stranded structure around the Q/R site by an internal loop of RNA. These two 
PMOs appear to have the least impact on editing inhibition. At 1 µM, each of these PMOs 
led to a non-significant decrease in editing at 90.46 ± 6.79% and 85.90 ± 6.58% 
respectively. At 10 µM, these PMOs did not cause any decrease in Q/R site editing. In 
fact, they appear to increase editing to 119.55 ± 0.87% and 135.2 ± 4.24% respectively. 
The reason for this increase in editing is unknown.  
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Figure 4.1 - Changes in editing after treatment with PMOs 1-6 at 1 µM (A) or 10 µM (B). All editing 
percentages are normalised to levels of editing in control transfections of the B13 plasmid only. Treatment 
with 1 µM of each PMO did not significantly change the Q/R site editing in the HeLa-B13 system (A). 
Treatment with PMO2 (GRIA2-30-6) and PMO4 (GRIA2+262+286) at 10 µM significantly reduced Q/R site 
editing to 86.9 ± 6.36% and 71.1 ± 2.4% of control, respectively (n=3, *** = p<0.05). Interestingly, PMO1 
(GRIA2+284+308) shows no effect even at high concentrations. 
 
  
 126 
 
4.2.2 Redesigned 30mer PMOs 
Although PMO2 (GRIA2-30-6) and PMO4 (GRIA2+262+286) showed a significant 
reduction in editing, this effect could not be improved through adjusting the transfection 
conditions, either by extending the time of transfection or applying the PMO first then 
transfecting in the B13 plasmid and vice versa. Therefore new PMOs were redesigned 
based on PMO4 (GRIA2+262+286), which showed the greatest effect at 10 µM, and 
PMO1 (GRIA2+284+308), which has been previously published. The aim of the 
redesigned PMOs was to improve potential binding through analysing the binding 
energies of the PMOs based on predicted intermolecular and intramolecular energies, 
as well as using predicted secondary structure models to further improve targeted disrupt 
the secondary structure. 
4.2.2.1 Targeting the Double-Stranded RNA with 30mer PMOs 
The length of PMOs were extended to 30 bases, as longer PMO length has been 
reported to increase binding (Pramono et al., 2012), and extending the targeted bases 
further into the double-stranded region should increase the disruption to the secondary 
structure. To assess the best placement for the extra five bases, the secondary structure 
of the GluA2 RNA transcript predicted in the previous chapter was used as a guide 
(Figure 4.2). PMOs could also be targeted to regions of single-stranded RNA, such as 
the open loop (Figure 4.2) for improved binding, as targeting accessible RNA has been 
shown to be an important factor for PMO design (Popplewell et al., 2009). Using the 
placement of PMO1 (GRIA2+284+308) and PMO4 (GRIA2+262+286) as starting points, 
the best placements for 30mers could then be calculated. 
 
Figure 4.2 - Targeted regions of secondary structure. 30mer PMOs were extended further into the double-
stranded region to disrupt the secondary structure, but also with an aim of beginning in the open loop region 
for enhanced binding. Edited adenosine is indicated by the red arrow.  
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4.2.2.2 Calculating Intermolecular Binding Energies for Prospective 30mers 
Alongside the secondary structure, predicted binding energies between the RNA 
molecule and potential new PMOs were also used to develop the 30mers. SFold predicts 
the energy of every oligonucleotide of a given length along the target RNA sequence, 
and so regions with a more negative binding energy can be targeted (example in Figure 
4.3), as a more negative binding energy should allow the PMO to bind more strongly to 
the RNA. The final PMOs were taken as a balance between the desired target sequence 
and the sequence with the most favourable binding energy. 
The target sequence of the B13 minigene was used and intermolecular binding energies 
for 30mers were calculated. The original 25mers were found within the suggested 
outputs; any 30mer containing PMO4 (GRIA2+262+286) or PMO1 (GRIA2+284+308) 
was considered. Figure 4.3 shows the potential antisense sequences around the original 
PMO4 (GRIA2+262+286) sequence. Sequences shifted downstream along the target 
sequence (down the rows in the output) reach further into the double-stranded region of 
the structure (Figure 4.2). Of the 6 30mers shown that contain PMO4 (GRIA2+262+286) 
(highlighted in yellow), although the last sequence binds to the most bases within the 
double-stranded structure, there is a relatively large difference in binding energies 
between this sequence (-5.7 kcal/mol) and the sequence shifted one base 5’ (-7.1 
kcal/mol). The sequence for PMOE4 (GRIA2+261+290) was therefore chosen by 
including the most penetration of the double-stranded structure while also accounting for 
predicted binding energies (Figure 4.6; Table 4.1).  
 
Figure 4.3 - Sample output from SFold webserver for the design of PMOE4 (GRIA2+261+290). Left hand 
RNA sequence is the target GluA2 sequence. Right hand sequence is the complementary sequence for 
PMO design, shifting one base along the target sequence per row. PMO4 (GRIA2+262+286) is highlighted 
in orange and yellow in progressive oligonucleotide designs. “GC content” gives a percentage of GC bases 
in the suggested antisense design. ΔG gives the intermolecular energy between target sequence and 
antisense sequence.  
A second 30mer based on PMO4 (GRIA2+262+286) was designed using 
recommendations from the SFold web server (sfold.wadsworth.org) as guidance, which 
suggests avoiding a “GGGG” sequence, keeping the intermolecular binding energy to 
less than -8 kcal/mol and with a GC content of between 40 and 60%. PMOE4B 
(GRIA2+250+279) is the only 30mer that fulfils all of these criteria (Figure 4.4), although 
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this led to its target being further away from the Q/R site than the other two 30mer PMOs 
(Figure 4.6).  
 
Figure 4.4 - SFold output indicating binding for PMOE4B (GRIA2+250+279). Left hand RNA sequence is the 
target GluA2 sequence. Right hand sequence is the complementary sequence for PMO design, shifting one 
base along the target sequence per row. PMO4 (GRIA2+262+286) is highlighted in orange and yellow in 
progressive oligonucleotide designs. “GC content” gives a percentage of GC bases in the suggested 
antisense design. ΔG gives the intermolecular energy between target sequence and antisense sequence. 
PMO1 (GRIA2+284+308) and the 30mers binding to the surrounding bases have a 
positive ΔG. However, as PMO1 (GRIA2+284+308) has been previously reported to be 
functional even with the positive binding energy, PMOE1 (GRIA2+279+308) was 
designed based simply on the secondary structure (Figure 4.6). 
 
Figure 4.5 - SFold output indicating binding for PMOE1 (GRIA2+279+308). Left hand RNA sequence is the 
target GluA2 sequence. Right hand sequence is the complementary sequence for PMO design, shifting one 
base along the target sequence per row. PMO1 (GRIA2+284+308) is highlighted in orange and yellow shows 
progressive oligonucleotide designs. “GC content” gives a percentage of GC bases in the suggested 
antisense design. ΔG gives the intermolecular energy between target sequence and antisense sequence. 
4.2.2.3 Calculating Total Binding Energy 
Hairpin ΔG and ΔG of PMO-PMO interactions were calculated using Oligo Analyzer 
(IDT). These are possible internal structures formed with the PMO to itself or to another 
PMO molecule. ΔG of PMO-PMO interactions of -9.78 kcal/mol indicates a sequence of 
6 bases (4 G/C and 2 A/T) that bind somewhere else in the PMO, while -7.05 kcal/mol 
and -6.6 kcal/mol both indicate a 4 base sequence (2 G/C and 2 A/T). The total binding 
energy of a PMO was then calculated by taking the energy of intermolecular bonds and 
subtracting the internal binding energies (PMO-PMO interactions or hairpin structures). 
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Total binding energies are shown in Table 4.1. Theoretically, only a negative binding 
energy is energetically favourable for a PMO to bind to an RNA molecule. However, 
PMO4 (GRIA2+262+286) has already shown to have an effect on Q/R site editing, 
presumably through binding to the RNA molecule itself, and has a calculated binding 
energy of 5.24 kcal/mol. This probably indicates that the modelled calculations used in 
the binding energy calculations are not taking all factors into account. Of the 30mer 
PMOs, PMOE1 (GRIA2+279+308) and PMOE4 (GRIA2+261+290) have the highest 
potential for PMO-PMO interactions, with a ΔG of -9.78 kcal/mol, indicating that they may 
be less effective as they form dimers with themselves rather than binding to RNA. 
PMOE4B (GRIA2+250+279) is the only 30mer here with a negative total binding energy, 
and so in this context shows the strongest potential for binding.  
 
Table 4.1 - Binding energies of 30mer PMOs. Intermolecular energies calculated using SFold 
(sfold.wadsworth.org). Hairpin and PMO-PMO interaction energies calculated using OligoAnalyzer 3.1 (IDT). 
All ΔG are in kcal/mol. 
 
4.2.2.4 Final 30mer PMO Design 
Newly designed PMOs are shown in Figure 4.6 as well as their overlap with the original 
25mer on which they were based. PMOE1 (GRIA2+279+308) has 5 bases extended 5’ 
to cover more of the double-stranded region around the Q/R site (Figure 4.6). PMOE4 
(GRIA2+261+290) has 4 bases further 3’, reaching into the double-stranded region, with 
one more base 5’ extending into the internal loop which would improve initial binding 
between the PMO and the RNA. PMOE4B (GRIA2+250+279) fulfils SFold’s suggested 
criteria and as a result is shifted further away from the Q/R site. Based on the energy 
calculations, PMOE4B (GRIA2+250+279) is predicted to bind most effectively to the RNA 
whereas based on the secondary structure model and previous work with the 25mers, 
PMOE4 (GRIA2+261+290) is predicted to be the most effective. 
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Figure 4.6 – A) Placement of 30mer PMOs in relation to the original 25mers and the exon 11/intron 11 
boundary. B) Regions of binding for new 30mer PMOs extending further into the double-stranded region. 
Overlap with the original 25mers indicated on the MFE model of the B13 minigene. PMOE1 
(GRIA2+279+308) is extended 5 bases further 5’ than PMO1 (GRIA2+284+308). PMOE4 (GRIA2+261+290) 
is extended 4 bases 3’ and one base 5’ to PMO4 (GRIA2+262+286). PMOE4B (GRIA2+250+279) is shifted 
and extended 12 bases 5’ to PMO4 (GRIA2+262+286), avoiding the GGGG sequence and targeting the 
open loop region, as recommended by SFold. C) Table of 30mer PMOs, their sequence and their target.
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4.2.3 Transfection of 30mer PMOs 
The newly designed 30mer PMOs were transfected into the HeLa-B13 system at 10 µM 
as previously described. Q/R site editing was quantified as before; the results are shown 
in Figure 4.7. PMO1 (GRIA2+284+308) achieved a small effect that reached significance 
(78.0 ± 5.39% of control, p<0.01), which was a similar inhibition to that found in the 
previous transfection at 1 µM and is a larger effect than the transfection at 10 µM under 
the same conditions (Figure 4.1). However, the 30mer PMOE1 (GRIA2+279+308), which 
is an extension of PMO1 (GRIA2+284+308), was significantly more effective than PMO1 
(54.3 ± 3.66%, p<0.01). PMO4 (GRIA2+262+286) showed a strong ability to inhibit Q/R 
site editing, which was measured as 26.4 ± 3.57% of control (p<0.01) and is significantly 
greater than the inhibition shown under the same conditions previously (Figure 4.1). 
PMOE4 (GRIA2+261+290), which is PMO4 (GRIA2+262+286) but extended into the 
double-stranded structure, also showed a strong effect at Q/R site editing inhibition (40.0 
± 4.72%, p<0.01) which was not significantly different to the effect of PMO4 
(GRIA2+262+286). PMOE4B (GRIA2+250+279), which was shifted away from the 
“GGGG” sequence and into the open loop region, showed significantly less inhibition 
compared to PMOE4 (GRIA2+261+290) (52.4 ± 2.88%, p<0.05) which was similar in 
effect to PMOE1 (GRIA2+279+308). 
 
Figure 4.7 - Q/R site editing with 30mer PMOs. N=3 per group, *** = p<0.01 compared to control. The 
strongest inhibition of Q/R site editing is seen with PMO4 (GRIA2+262+286) and PMOE4 (GRIA2+261+290) 
(26.4 ± 3.57% and 40.0 ± 4.72%). PMOE4B (GRIA2+250+279) and PMOE1 (GRIA2+279+308) showed 
similar effects (52.4 ± 2.88% and 54.3 ± 3.66%) while PMO1 (GRIA2+284+308) showed a small effect (78.0 
± 5.39%). 
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4.2.4 Concentration-inhibition curves for RNA editing elicited by the 30mer PMOs 
For a better comparison of efficacy of the different PMOs, a range of concentrations for 
each 30mer was tested in the HeLa-B13 system. Due to the variability seen across 
transfections of the same conditions, each concentration was repeated in six biological 
repeats. The concentration-inhibition curves are shown in Figure 4.8. These results show 
that all three 30mer PMOs are effective at inhibiting Q/R site editing at lower doses, with 
IC50s of 1.78 ± 0.11 µM, 1.93 ± 0.13 µM and 2.42 ± 0.42 µM for PMOE4 
(GRIA2+261+290), PMOE4B (GRIA2+250+279) and PMOE1 (GRIA2+279+308) 
respectively. Based on these data, PMOE4 (GRIA2+261+290) is the most effective at 
Q/R site inhibition. This correlates with the initial transfection at 10 µM where PMOE4 
(GRIA2+261+290) was most effective of the 30mer PMOs (Figure 4.7). Compared to the 
published IC50 for PMO1 (GRIA2+284+308), PMOE4 (GRIA2+261+290), PMOE4B 
(GRIA2+250+279) and the published PMO have similar effects while PMOE1 
(GRIA2+279+308) is slightly less effective (Table 4.2).  
 133 
 
 
Figure 4.8 – Concentration curves for PMOE4 (GRIA2+261+290), PMOE4B (GRIA2+250+279) and PMOE1 (GRIA2+279+308). N=6 per concentration. IC50 values were calculated 
using the Hill equation. 
PMO IC50 (µM) 
Residual Q/R Site Editing 
(% of Control) 
PMOE4 (GRIA2+261+290) 1.78 ± 0.11 40.00 ± 4.72 
PMOE4B (GRIA2+250+279) 1.93 ± 0.13 52.44 ± 2.88 
PMOE1 (GRIA2+279+308) 2.42 ± 0.42 54.31 ± 3.66 
PMO1 (GRIA2+284+308) (Penn et al. 2012) 1.9 Not reported 
Table 4.2 - Comparison of IC50s for each 30mer PMO in the HeLa-B13 system and their maximum inhibition percentages of control.  
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4.2.5 Testing PMOs in a Cell Line Endogenously Expressing GluA2  
Although the HeLa-B13 system was useful as a primary test due to its easy manipulation, 
a system which endogenously expresses the GluA2 subunit would be a better model to 
test the PMOs. The SH-SY5Y cell line, derived from a human neuroblastoma, is often 
used as a neuronal model (Lopes et al., 2010; Agholme et al., 2010), and has previously 
been shown to express AMPA receptor subunits (Sun et al., 2010), including GluA2 
(Kritis et al., 2015). SH-SY5Y cells are from a human origin (Biedler et al., 1978). Of the 
three 30mer PMOs designed in this chapter, only PMOE1 (GRIA2+279+308) is 
completely complementary to the human sequence of GRIA2, and so this was tested in 
SH-SY5Y cells.  
One advantage of an endogenously expressing cell line is that both mRNA and 
premRNA can be analysed through alternative primer design. Figure 4.9 describes the 
primers designed for this system. Both forward primers are placed in exon 11. The 
reverse primer for premRNA transcripts is placed in intron 11 to target RNA transcripts 
before splicing has occurred. The reverse primer for detecting mRNA transcripts is 
placed in exon 12, so that premRNA transcripts will not be amplified as the intron is too 
large for the polymerase enzyme. Both of these primer sets cover the Q/R site and 
therefore contain the BbvI recognition site, and so the restriction digest analysis could 
be used to determine the Q/R editing state of SH-SY5Y cells with and without PMOE1 
(GRIA2+279+308).  
 
Figure 4.9 - Primer design for premRNA and mRNA transcripts targeting the area of GRIA2 surrounding the 
edited adenosine. Exon 11 contains the edited adenosine. Primers for premRNA transcripts are indicated 
with blue arrows, targeting intron 11, while primers for mRNA transcripts are indicated in purple targeting 
exon 12, both sets covering the Q/R site and therefore the BbvI recognition site, allowing editing percentage 
quantification.  
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4.2.6 Transfecting SH-SY5Y cells with PMOE1 (GRIA2+279+308) and the effect on 
GluA2 Q/R site RNA editing 
SH-SY5Y cells showed endogenous editing at the Q/R site in mRNA of 90.89 ± 1.10% 
in control samples at 24 hours and 97.20 ± 1.72% at 48 hours (Figure 4.10). Editing in 
premRNA transcripts appears to be more variable, with samples measured after 48 
hours showing high levels of editing (88.6 ± 1.41%) while samples measured at 24 hours 
showed a large variation with editing at 58.5 ± 14.0% (Figure 4.11).  SH-SY5Y cells were 
transfected with 10 µM of PMOE1 (GRIA2+279+308) for 24 or 48 hours. The effects of 
transfection and length of time of transfection were compared using a two-way ANOVA. 
PMOE1 (GRIA2+279+308) showed a strong inhibition of Q/R site editing in premRNA 
transcripts after only 24 hours (9.63 ± 3.67% editing) compared to control at this time 
point (58.5 ± 14.0%; p<0.05) and editing remained inhibited at the 48 hour time point 
(8.25 ± 1.5%; p<0.05 compared to control). Transcripts of mRNA from cells transfected 
with PMOE1 (GRIA2+279+308) showed a significant decrease in Q/R site editing after 
24 hours (Figure 4.10: 46.6 ± 1.84%, p<0.01), although at 48 hours following transfection 
the Q/R site editing was almost completely inhibited (15.4 ± 1.22%, p<0.01 compared to 
both 24 hour transfection and control). The two-way ANOVA showed a statistically 
significant interaction between transfection and length of time of transfection in mRNA 
transcripts (p<0.025), highlighting the fact that longer transfection times improved the 
inhibitory effect of PMOE1 (GRIA2+279+308).   
Editing in mRNA was used to analyse the effect of PMOE1 (GRIA2+279+308) 
transfection. GluA2 premRNA appears to have variable editing as shown by the large 
error bars in control samples (Figure 4.11), and so calculating editing of the mRNA 
transcript was considered to be a more reliable method. Transcripts were analysed after 
24 hours or 48 hours of transfection with a range of concentrations (Figure 4.12). After 
24 hours of transfection, low concentrations of PMOE1 (GRIA2+279+308) had little effect 
on Q/R site editing, shown in blue in Figure 4.12. PMOE1 (GRIA2+279+308) sharply 
increases in effectiveness between 0.5 and 2.5 µM then reaches steady state inhibition 
at the higher concentrations with around 60% inhibition of editing compared to control 
levels. When the curve was fit with the Hill Function, an IC50 of 0.92 ± 0.11 µM was 
calculated, indicating that 920 nM of PMOE1 (GRIA2+279+308) is sufficient to cause 
half of the total inhibition possible under these conditions. When incubated for 48 hours, 
lower concentrations of PMOE1 (GRIA2+279+308) have a greater effect on Q/R site 
editing. For example 250 nM of PMOE1 (GRIA2+279+308) will only reduce editing to 
97.6 ± 0.51% after 24 hours whereas after a 48 hour incubation the same concentration 
reduces Q/R site editing to 89.7 ± 2.02% of control. As the lower concentrations have a 
larger effect on Q/R site editing at 48 hours, the slope of the Hill Function fit is less steep, 
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with an IC50 of 1.48 ± 0.17 µM. Overall there is the potential for greater steady state 
inhibition with 48 hour incubation periods, with a maximum inhibition leading to just 15.4 
± 1.22% editing (Table 4.3). These IC50 values show that PMOE1 (GRIA2+279+308) is 
more effective than data previously published on PMO1 (GRIA2+284+308) (Penn et al., 
2012), which had an IC50 value of 2.8 µM in SH-SY5Y cells after 24 hours of transfection 
(Table 4.3) and which did not show any effect on Q/R site editing at 10 µM in this work 
(Figure 4.1).  
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Figure 4.10 - Q/R site editing in mRNA of SH-SY5Y cells after treatment with 10 µM PMOE1 
(GRIA2+279+308) compared to control cells of EndoPorter only; n=3 per condition. Q/R site editing was 
measured after either 24 or 48 hours. Two-way ANOVA was used to determine significance between length 
of time and transfection conditions on Q/R site editing, *** = p<0.05 compared to control at 48 hours.  
 
Figure 4.11 - Q/R site editing in premRNA of SH-SY5Y cells after treatment with 10 µM PMOE1 
(GRIA2+279+308) compared to control cells of EndoPorter only; n=3 per condition. Q/R site editing was 
measured after either 24 or 48 hours. Two-way ANOVA was used to determine significance between length 
of time and transfection conditions on Q/R site editing, *** = p<0.05 compared to control at 48 hours. 
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Figure 4.12 - SH-SY5Y mRNA after transfection with PMOE1 (GRIA2+279+308) for 24 vs 48 hours at 
increasing concentrations. N=6 per concentration. IC50 of PMOE1 (GRIA2+279+308) in SH-SY5Y cells for 
24 hours and 48 hours shown in the bottom left hand corner, calculated using the Hill Function.  
 
Transfection Conditions IC50 (µM) Maximum Inhibition 
PMOE1 (GRIA2+279+308) – 24 hours 0.92 ± 0.11 46.61 ± 1.83% 
PMOE1 (GRIA2+279+308) – 48 hours 1.48 ± 0.17 15.4 ± 1.22% 
PMO1 (GRIA2+284+308) (Penn et al. 2012) 2.8 Not Reported 
Table 4.3 - IC50 for PMOE1 (GRIA2+279+308) after 24 or 48 hours transfection compared to PMO1 
(GRIA2+284+308) IC50 previously reported in SH-SY5Y cells, and the maximum inhibition found at these 
time points. 
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4.3 DISCUSSION 
This chapter looks at the effect of 25mer and 30mer PMOs on the disruption of Q/R site 
RNA editing in both the HeLa-B13 system and an endogenously expressing GluA2 
system, SH-SY5Y cells. In the previous chapter, 25mer PMOs were designed to span 
the region of double-stranded structure surrounding the Q/R site. These 25mers were 
transfected into the HeLa-B13 system and the Q/R site editing analysed using the BbvI 
assay. Two PMOs, PMO2 (GRIA2-30-6) and PMO4 (GRIA2+262+286), show a 
moderate effect at disrupting Q/R site editing at 10 μM, although there was no significant 
effect at 1 μM for any PMO. PMO1 (GRIA2+284+308) was previously reported to disrupt 
editing to 60% of control samples (Penn et al., 2012). However in this analysis under the 
same conditions, PMO1 (GRIA2+284+308) only showed a limited effect in the HeLa-B13 
system. The same plasmid backbone with the B13 minigene was used to transfect the 
HeLa cells, and PMOs were transfected with EndoPorter in both the previous study and 
this assay. Various other transfection conditions were tested to try and improve the 
efficiency of PMO1 (GRIA2+284+308) as well as the other 25mers such as adjusting 
transfection conditions of the B13 plasmid or transfecting plasmid before the PMO. None 
of these adjustments improved the impact of the 25mers on Q/R site editing. There are 
several variables that may affect the impact of PMOs in the HeLa-B13 system, including 
transfection reagents, efficiency of expression of the B13 plasmid as well as how 
functional the PMO is itself. 
Due to the limited effect of the 25mers in the HeLa-B13 system, new PMOs were 
designed in an effort to improve their impact on Q/R site editing. It has previously been 
suggested that longer PMOs are more effective due to their increased binding energies, 
and so are more likely to bind to the target bases and have an effect (Pramono et al., 
2012). Therefore, the length of the PMO was extended from 25 bases to 30. For these 
30mers, binding energies were predicted using online tools to calculate the inter- and 
intramolecular energies. Total binding energy was calculated by taking the energy 
needed to overcome any internal structure of the PMO (hairpin structures and PMO-
PMO interactions) and subtracting this from the energy given by the PMO binding to the 
RNA molecule. A more negative overall binding energy should mean that the most 
favourable condition would be for the PMO to bind to the GluA2 RNA transcript, 
disrupting the secondary structure through steric hindrance. Total binding energies have 
previously been suggested to be one of the factors considered for ideal PMO design 
(Pramono et al., 2012). The only PMO to be predicted to have a negative total binding 
energy was PMOE4B (GRIA2+250+279) with -6.18 kcal/mol; the total binding energies 
of the other extended PMOs and the 25mers PMO1 (GRIA2+284+308) and PMO4 
(GRIA2+262+286) were all positive. Considering these energy calculations, PMOE4B 
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(GRIA2+250+279) should bind more effectively than PMOE4 (GRIA2+261+290) and 
PMO4 (GRIA2+262+286). Indeed, PMOE4B (GRIA2+250+279) could be the only PMO 
to have an effect as a positive total binding energy would mean that it would take an 
input of energy for the PMO to bind to RNA, which is unlikely to happen under normal 
cellular conditions. However, when transfected into the HeLa-B13 system, all 30mers 
showed a strong ability to disrupt Q/R site editing despite their predicted energies. 
Although there is no evidence that these PMOs are directly binding to the RNA transcript, 
this is the simplest explanation for the change in Q/R site editing. It therefore appears 
that this method of calculating binding energies is too simplistic for the complex 
conditions of the cell nucleus, and cannot accurately predict how well a PMO will bind to 
RNA. 
The most accurate method for determining effectiveness of a PMO is still in vitro testing. 
The HeLa-B13 system was used to study each of the 30mer PMOs at decreasing 
concentrations. The results from these experiments produced a graph with a plateau at 
the lower concentrations where the PMO did not have any effect, and a plateau at the 
higher concentrations where the maximum effect had been reached. These graphs could 
then be treated as dose-response curves for each PMO. These dose responses were 
then fit with the Hill Function allowing an IC50 to be calculated. IC50s for PMOE4 
(GRIA2+261+290), PMOE4B (GRIA2+250+279) and PMOE1 (GRIA2+279+308) were 
1.78 ± 0.11 µM, 1.93 ± 0.13 µM and 2.42 ± 0.42 µM respectively. These are similar to the 
IC50 calculated by Penn et al. for PMO1 (GRIA2+284+308), which they found to be 1.9 
µM when fit with a sigmoidal curve (Penn et al., 2012). An IC50 in this context represents 
the concentration of PMO needed to produce half of the maximum inhibition under these 
conditions. However, the value is dependent on the model, and the concentrations 
needed for an inhibition of 50% of Q/R site editing may vary in any other system. There 
are multiple variables that might affect this outcome, for example the transfection 
efficiency of EndoPorter and so concentration of PMO per cell, expression of ADAR2 in 
HeLa cells and therefore efficiency of Q/R site editing itself, as well as the ability of the 
PMO to prevent Q/R site editing. The plateau at the higher concentrations of PMO shows 
where the inhibition of Q/R site editing is limited by another variable in the system. This 
is likely to be the high expression of the B13 minigene in the plasmid and therefore 
increased production of GluA2 RNA, meaning that there is not sufficient PMO within the 
cell to interfere with every transcript.  
Due to these limitations of the system, the IC50s do not give biologically relevant 
concentrations of the PMO’s inhibitory effect. However, they are a useful means for 
comparison across the PMO designs. It is evident that the 30mers based on PMO4 
(GRIA2+262+286) are more efficient at Q/R site editing disruption than the 30mer based 
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on PMO1 (GRIA2+284+308). PMOE4 (GRIA2+261+290) also appears to be slightly 
more effective than PMOE4B (GRIA2+250+279) as their maximum effect is significantly 
different. Comparing the IC50s shows that PMOE4 (GRIA2+261+290) is fairly similar to 
PMOE4B (GRIA2+250+279), with an IC50 of 1.78 ± 0.11 µM versus 1.93 ± 0.13 µM. 
PMOE4B (GRIA2+250+279) accommodates the suggestions for antisense 
oligonucleotide design from the SFold website, namely to avoid “GGGG” sequences, to 
keep the GC content between 40 and 60% and to keep the intermolecular binding energy 
below -8 kcal/mol. Both PMOE4 (GRIA2+261+290) and PMOE4B (GRIA2+250+279) 
have a GC content within these boundaries, however avoidance of the “GGGG” 
sequence does not appear to have been necessary. Of the three 30mers tested in the 
HeLa-B13 editing system, PMOE4 (GRIA2+261+290) appears to be the most effective. 
Having compared the 30mers in the HeLa-B13 system, the next step was to test the 
PMOs in a cell line that endogenously expressed the GluA2 subunit, and so co-
transfection with the B13 plasmid was not necessary. As the B13 minigene was 
comprised of the sequence from the murine Gria2 gene, the ideal cell line would be 
derived from a mouse neuronal lineage. Neuro2A cells are derived from a mouse 
neuroblastoma and can be differentiated to develop neuronal-like features (Klebe & 
Ruddle, 1969). However, in the proliferative form these cells do not appear to express 
the GluA2 subunit. SH-SY5Y cells are derived from a human neuroblastoma patient 
(Biedler et al., 1973). These cells show expression of the GluA2 subunit in both their 
proliferating and differentiated forms (Yamashita et al., 2012; Voss et al., 2007), and Q/R 
site editing was shown to be up to 100% in mRNA transcripts. Due to the differences in 
sequence between the human GRIA2 and mouse Gria2 genes, only PMOE1 
(GRIA2+279+308) is completely complementary to the human sequence. Therefore, 
although this model is not ideal, it provides a useful proof-of-principle that these PMOs 
work in an endogenous cellular system for GluA2 Q/R site editing, and so PMOE1 
(GRIA2+279+308) was tested in SH-SY5Y cells.  
With an initial high concentration of 10 µM, it was clear that PMOE1 (GRIA2+279+308) 
would have a strong effect on this endogenous cell line, as it was able to inhibit Q/R site 
editing to around 10% in premRNA samples after just 24 hours, and similar inhibition in 
mRNA after 48 hours. A-to-I editing occurs in the nucleus, probably at the same time as 
splicing events (Bentley, 2014). PMOE1 (GRIA2+279+308) therefore needs to interfere 
with the secondary structure of the transcript within the nucleus at the time of 
transcription. PMOs have been shown to localise to both the cytoplasm and the nucleus 
(Summerton, 2005), and should therefore be able to disrupt Q/R site editing efficiently, 
as shown in Figure 4.10. After 24 hours, mRNA samples only showed a 50% inhibition 
in editing. This could be accounted for by transportation of RNA transcripts from the 
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nucleus. At the time of transfection there will already be some GluA2 transcripts present 
in the cytoplasm with complete Q/R site editing. 24 hours post-transfection, the mRNA 
transcript population will be mixed between those influenced by PMOE1 
(GRIA2+279+308) and those transcripts that were already in the cytoplasm, whereas 
after 48 hours the turnover of transcripts could mean that they have all been affected by 
PMOE1 (GRIA2+279+308), accounting for the improved inhibition after longer 
transfection time.  
Lower concentrations of PMOE1 (GRIA2+279+308) were then tested to compare dose 
response curves to those found in the HeLa-B13 assay. The IC50 for PMOE1 
(GRIA2+279+308) was 0.92 ± 0.11 µM after 24 hours and 1.48 ± 0.17 µM after 48 hours. 
Although the concentration of PMOE1 (GRIA2+279+308) needed for half of the inhibitory 
effect was less after 24 hours, the maximum inhibition possible is much greater after 48 
hours. At every concentration of PMOE1 (GRIA2+279+308) the effect is equal or greater 
after 48 hours of incubation compared to 24 hours, indicating that the PMO is remaining 
in the nucleus and continuing to affect RNA editing throughout this incubation time. Penn 
et al. also investigated the effect of PMO1 (GRIA2+284+308) in SH-SY5Y mRNA after 
24 hours, where they found an IC50 of 2.8 µM using a logarithmic regression. Direct 
comparison of these IC50s indicate that PMOE1 (GRIA2+279+308) is around three times 
more potent, although the IC50 for PMOE1 (GRIA2+279+308) was calculated using the 
Hill Function. When comparing between the two systems studied in this chapter, the IC50 
for PMOE1 (GRIA2+279+308) falls from 2.42 ± 0.42 µM in the HeLa-B13 system to 0.92 
± 0.11 µM in SH-SY5Y cells. This shows the beneficial effect of removing variables from 
a model system. The major variable of the B13 plasmid, and therefore the unknown 
efficiency of both its transfection and expression, is not part of the SH-SY5Y model and 
so the IC50 is closer to a value representing the efficiency of the PMO at steric hindrance 
of Q/R site editing alone.
 143 
 
5 THE DELIVERY OF ANTISENSE OLIGONUCLEOTIDES 
INTO PRIMARY NEURONAL CULTURES 
5.1 INTRODUCTION 
Neurons taken from the neocortex of embryonic or early postnatal mice or rats can be 
used in primary cultures to study neuronal development and function in vitro. The cortex 
is dissected and the meninges removed to reduce contamination with other cell types 
before the neurons are dissociated by trypsinisation and plated (Hilgenberg & Smith, 
2007). Neurons are then kept generally for three to four weeks in vitro, although they can 
be kept longer (Lesuisse & Martin, 2002). Culturing the neurons in neurobasal (low-
serum) media supplemented with B27 selects against dividing cells, such as glial cells 
contaminating the cultures, and selects for the post-mitotic neurons. Neurons cultured in 
neurobasal media showed staining for astrocytic markers can be as low as less than 1% 
of the total cell count (Brewer et al., 1993). Cortical neurons cultured in this manner 
develop large, pyramidal-like cell bodies and begin extending neurite-like projections 
after a few days in vitro, with synaptic markers such as GAP-43 showing expression after 
just 4 days in vitro (DIV). After 5 DIV, neurons show low level expression of synaptic 
markers such as synaptophysin and α- and β-synuclein, with expression increasing over 
successive weeks in culture both for excitatory and inhibitory synapses (Harrill et al., 
2015). These cultures can be depolarised with potassium chloride which leads to an 
influx of Ca2+ into the neurons, an effect also seen through stimulation by glutamate, 
kainate or AMPA (Glaum et al., 1990). After 14 DIV, neurons exposed to 500 nM of 
glutamate for 5 minutes showed around 80% cell death after 24 hours (Choi, 1988). More 
dense neuronal cultures showed a higher sensitivity to glutamate excitotoxicity, largely 
mediated by NMDA receptors (Ha et al., 2009). Mature synapses have been observed 
in neuronal cultures from 10 DIV, with synaptogenesis increasing throughout the second 
and third week in vitro (Grabrucker et al., 2009).  
AMPA receptor subunits GluA1, 2 and 3 are all found at both the RNA and protein level 
in primary cortical cultures after 6-10 DIV, with GluA4 only showing low expression 
(Janssens & Lesage, 2001). GluA1 and GluA2 are more highly expressed than GluA3, 
showing relatively stable expression from 12 DIV onwards (Orlandi et al., 2011). Q/R site 
editing of the GluA2 subunit is efficient to 100%, and is not affected by activity unlike the 
R/G editing site which shows reduced editing levels after depolarisation (Sanjana et al., 
2012). Although the editing at the Q/R site remains constant, ADAR2 expression is 
shown to decrease after acute or chronic glutamate stimulation (Bonini et al., 2015). The 
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endogenous expression of AMPA receptor subunits and high endogenous editing of the 
Q/R site, as well as other neuronal characteristics, make primary cortical neurons a more 
realistic model than the HeLa-B13 system and SH-SY5Y cells used in the previous 
chapter. This chapter therefore focuses on examining methods for introducing our PMOs 
into primary cortical neurons. These PMOs could then reduce the RNA editing as seen 
in models in previous chapters, and the effect of inhibited RNA editing on neuronal 
viability as well as other downstream processes could be assessed.  
Primary neuronal cultures are notoriously challenging to transfect due to their sensitivity 
to changes in pH and temperature as well as being post-mitotic, and so all transfection 
techniques have costs and benefits that need to be taken into account (reviewed in Karra 
& Dahm, 2010). Nucleofection, for example, has shown high efficiency in transfection of 
primary neurons but can only be performed on cells on the day of isolation, and therefore 
before the extension of neurites or synaptogenesis (Zeitelhofer et al., 2007). Calcium-
phosphate transfection is a classic technique with high efficiency in other cell types, but 
only around 1-5% transfection efficiency in primary neuronal cultures (Watanabe et al., 
1999). Although this may be sufficient for single-cell techniques such as microscopy or 
electrophysiology, a higher transfection efficiency would be needed to demonstrate any 
effects of inhibited RNA editing. Electroporation or biolistic delivery again show relatively 
low efficiency of between 5 and 20% as well as only being possible before the neurons 
have differentiated in vitro (Dib-Hajj et al., 2009). Lipid-based transfection reagents such 
as Lipofectamine 2000 traditionally show a very low transfection efficiency of between 1-
5% in primary neurons with high levels of toxicity, although transfection can be as high 
as 20% in some reports (Ohki et al., 2001).  
Considering the low transfection efficiencies of these classic techniques, alternative 
methods were investigated. The 30mer PMOs from the previous chapter showed the 
highest efficacy in the HeLa-B13 system (Figure 4.4), and so these PMOs were tested 
in primary cortical neurons. Three methods were used in this chapter with varying levels 
of success: transfection with Endo-Porter; magnetofection and transduction using a 
lentiviral vector (summarised in Figure 5.1). Endo-Porter is the transfection reagent 
developed specifically for use with the neutrally-charged PMOs by GeneTools, and is 
reported by the manufacturer to be successful in primary neuronal culture (Summerton, 
2005). Magnetofection involves binding the molecule that needs to be carried to a 
magnetic nanoparticle, and has been shown to be effective with DNA and shRNA 
sequences in primary neuronal cultures to a transfection efficiency of more than 20% 
(Buerli et al., 2007). However, in order to carry the neutrally-charged PMO into the 
neurons, the PMO must first be bound to a negatively charged “leash”, a short section of 
DNA which is partly complementary to the PMO leaving a charged overhang to bind to 
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the magnetic nanoparticle (Popplewell et al., 2012). Finally, lentiviral vectors are known 
to transduce primary neuronal cultures with as high as 90% efficiency (Ding & Kilpatrick, 
2013). Although the virus cannot produce the PMO chemistry backbone, lentiviral vectors 
have previously been used to express small nuclear RNA for steric hindrance purposes 
such as exon skipping (Goyenvalle et al., 2009) as well as to produce guide RNAs for 
the CRISPR-Cas9 system (Vidigal & Ventura, 2015). Therefore the sequence of the 
PMO can be cloned into the lentiviral system with the appropriate promoter, leading to 
overexpression of the RNA which can then target the GluA2 transcript. These three 
techniques were optimised in order to enhance RNA editing inhibition in primary neuronal 
cultures.  
 
Figure 5.1 - Schematic of transfection and transduction techniques tested in this chapter. Three methods 
were tested: transfection of the PMO with Endo-Porter (purple); magnetofection of the PMO (green) and 
transduction of the PMO sequence with a lentiviral vector (blue). 
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5.2 RESULTS 
5.2.1 Transfections using Endo-Porter 
Endo-Porter is the transfection reagent produced specifically for the neutral charge of 
PMOs, and successfully transfected PMOs into the HeLa-B13 system and SH-SY5Y 
cells in the previous chapter. This was therefore the first transfection method tested in 
primary cortical neurons. 
5.2.1.1 Cell Viability Assay 
The standard Endo-Porter reagent is in DMSO solution. However, even very low 
concentrations of DMSO have been shown to be toxic to primary neuronal cultures 
(Hanslick et al., 2009). GeneTools also produces a version of Endo-Porter that is instead 
in aqueous solution, and would therefore be less toxic to sensitive cell cultures. This 
Endo-Porter variant was compared to Endo-Porter in DMSO in terms of viability of the 
primary neurons at 21 DIV. Both the standard concentration of Endo-Porter (6 mM) and 
half of that concentration were tested, and cell viability was measured using the MTT 
assay after 24 hours compared to the viability shown in untreated neurons (control). 
Endo-Porter in DMSO was shown to decrease cell viability to 48.8 ± 1.8% and 52.5 ± 
2.28% of control at 6 mM and 3 mM respectively (p<0.05), whereas Endo-Porter in 
aqueous solution showed no effect on cell viability at either concentration (6 mM, p=1.00; 
3 mM, p = 0.610; Figure 5.2).  
Aqueous Endo-Porter was then tested over 24, 48 and 72 hours for any effect on viability 
after prolonged exposure. At 24 and 48 hours there was no difference in cell viability 
compared to control, although after 72 hours of exposure there was a slight decrease in 
cell viability at both concentrations tested, to 86.8 ± 2.38% (p<0.01) and 82.3 ± 4.62% 
(p<0.05) for 6 mM and 3 mM respectively (Figure 5.3). Aqueous Endo-Porter could 
therefore be used for short-term experiments in primary cortical neurons.  
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Figure 5.2 - Cell viability assay testing for toxicity of different concentrations of Endo-Porter in DMSO 
compared to aqueous solution in primary neurons at 21 DIV (n=6). Endo-Porter in DMSO showed a 
significant decrease in cell viability after 24 hours (*** = p<0.05) whereas there was no toxicity after 
incubation with Endo-Porter in aqueous solution. Treatments compared to control neurons with no 
EndoPorter added. 
 
 
 
Figure 5.3 - Cell viability assay testing the toxicity of Endo-Porter in aqueous solution over 24, 48 and 72 
hours at 6 mM and 3 mM concentrations in primary neurons at 21 DIV (n=6). Aqueous Endo-Porter showed 
no change in cell viability until 72 hours. * = p<0.1; *** = p<0.05. Treatments compared to control neurons 
with no EndoPorter added. 
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5.2.1.2 F-PMO Transfection 
The PMO tagged with a carboxyfluorescein 5’ modification (F-PMO) used in a previous 
chapter to test transfection efficiency could also be used to test the transfection of 
primary cortical neurons. Primary cultures were transfected with 5 µM of F-PMO with 6 
µM of aqueous Endo-Porter and fluorescence was visualised after 24, 48 and 72 hours. 
Media was changed to clear (without phenol red), PMO-free media immediately before 
visualisation to remove background fluorescence. After 24 hours, there was a strong 
fluorescent signature in the FITC channel (Figure 5.4A) with F-PMO collecting in discrete 
areas rather than the general background fluorescence of F-PMO in the media. When 
viewed in bright field, the cell bodies of the neurons remained intact and there was good 
neurite extension without any obvious cell debris in the media (Figure 5.4B). The 
collections of F-PMO seen in the FITC channel coincided with the cell bodies of the 
neurons when the two channels were merged (Figure 5.4C). This pattern is still seen 
after 48 hours, where images from the FITC channel show a strong fluorescent signature 
of the F-PMO (Figure 5.4D), the cells appeared healthy when viewed in bright field 
(Figure 5.4E) and the merged channels images show that most if not all cell bodies show 
some uptake of the F-PMO (Figure 5.4F). The transfection then appears to remain stable 
after 72 hours (Figure 5.4G-I).  
When qualitatively comparing the fluorescence in the FITC channel over the different 
time points, there was a general trend of increasing levels of F-PMO fluorescence, and 
the strongest fluorescence was judged to be at the 72 hour time point (Figure 5.4G). It 
was not possible to perform FACS analysis with neurons at this stage in vitro, as 
detachment from the plate would destroy the neurite projections and not give an accurate 
transfection efficiency. As before with the live cell imaging of the F-PMO, staining for 
other markers was not possible as the PMO would leach out of a fixed cell and not 
maintain its normal localisation, therefore qualitative image analysis was relied upon. 
Images from each of these time points show a strong co-localisation of the F-PMO to the 
cell bodies of the neuron when compared to the bright field image (yellow arrows), but 
the F-PMO does not appear to localise to the whole neuron, particularly the neurite 
projections seen in the bright field images (red arrows). This is clearer under the FITC 
channel (Figure 5.4A, D, G) which shows the collection of the F-PMO into puncta rather 
than diffusely spreading throughout the cytoplasm. Although the Q/R site editing is 
thought to occur in the nucleus, and so localisation to the cell body is ideal, these puncta 
indicate that the PMO may be collected in endosomes and so may prove detrimental to 
the PMOs’ ability to disrupt Q/R site editing. 
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Figure 5.4 - Transfection of primary cortical neurons with fluorescent PMO and aqueous Endo-Porter after 24 hours (A-C), 48 hours (D-F) and 72 hours (G-I). Images taken under the 
FITC channel (A, D, G) and bright field (B, E, H) were merged (C, F, I). Yellow arrows show F-PMO in puncta, coinciding with cell bodies of neurons in the bright field image. Red arrows 
show neurite projections with no coinciding fluorescence.  
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5.2.1.3 Changes in Q/R Site Editing 
Experiments with the fluorescent PMO suggest that aqueous Endo-Porter can localise 
the PMO to the primary neurons (Figure 5.4), and so the 30mer PMOs targeting the Q/R 
site designed in the previous chapter (Figure 4.4) were tested in this model. PMOE4 
(GRIA2+261+290), PMOE4B (GRIA2+250+279) and PMOE1 (GRIA2+279+308) were 
transfected at 5 µM into primary cortical neurons for 24, 48 or 72 hours. The F-PMO was 
used as a scrambled PMO control, as well as cells treated with Endo-Porter only and 
cells left without treatment. At each time point, RNA was extracted from which cDNA 
created and digested with the BbvI enzyme. The results of the digest are shown in Figure 
5.5, where the edited (uncut) DNA was compared to unedited (digested) DNA.  
cDNA run on an agarose gel showed that there is no change in editing in any of the 
samples treated with a PMO (Figure 5.5A, B or C at each time point) compared to the 
100% editing efficiency of control samples (Figure 5.5D, E and F at each time point). 
This experiment was repeated twice with the same results. It therefore appears that, 
although the fluorescent PMO seemed to show localisation to the neuronal cell bodies, 
the transfection did not cause the PMOs to interfere with RNA editing. Due to the success 
of the PMOs in previous cell models, this is likely due to inefficient transfection into the 
neurons themselves or into the nucleus, or collection of the PMO into endosomes within 
the cell. Alternative transfection methods were therefore considered. 
 
 
Figure 5.5 - A sample gel image of a 3% agarose gel run in 1X TAE buffer, with 5 µl of Hyperladder V (“HL”; 
25 bp, Bioline) visualised using the Ebox VX2 imaging system and quantified using ImageJ analysis.”-ve” 
indicates negative (water) control. Results are of PMO transfections into primary cortical neurons at 21 DIV 
with Endo-Porter in aqueous solution. Primary cortical neurons were transfected for 72, 48 or 24 hours with 
5 µM PMOE4 (GRIA2+261+290) (A), 5 µM PMOE4B (GRIA2+250+279) (B), 5 µM PMOE1 
(GRIA2+279+308) (C), 5 µM F-PMO (D), Endo-Porter only (E) or left as cells only (F). DNA bands show that 
all samples have remained completely edited. 
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5.2.2 Transfections using Magnetofection 
5.2.2.1 Initial Magnetofection 
An alternative method for transfection of primary neuronal cultures that has previously 
been shown to be successful is magnetofection (Oz Biosciences; Buerli et al., 2007). 
Magnetofection relies on the binding of DNA, in this case the PMOs, to magnetic 
nanoparticles which are then concentrated onto the surfaces of cell membranes by a 
magnet underneath the cell’s plate. As PMOs have a neutral charge, in order for the 
PMOs to bind to the magnetic nanoparticles they first have to be leashed to a short 
sequence of charged DNA (Amantana & Iversen, 2005). The leashed PMOs (L-PMO) 
PMOE4 (GRIA2+261+290) and PMOE4B (GRIA2+250+279) were incubated with the 
standard magnetofection reagent, PolyMag; added to the neuron media and placed on 
the magnetic plate for half an hour. Media was changed after either 20 minutes (lanes 
“A” in Figure 5.6) as previously described (Buerli et al., 2007) or 24 hours (lanes “B” in 
Figure 5.6) according to manufacturer’s instructions. PMOE4 (GRIA2+261+290) showed 
a slight inhibition with 7.4% of the sample remaining unedited, while PMOE4B 
(GRIA2+250+279) did not show any impact on editing. This is a small effect compared 
to that seen in the HeLa-B13 system, and so the magnetofection conditions were 
adjusted in an attempt to optimise editing inhibition.  
The PMOE4 (GRIA2+261+290) samples showing a slight inhibition in editing did not 
show any difference at the cDNA level between the media change 20 minutes or 24 
hours after magnetofection (lanes A versus B in Figure 5.6). However, visual inspection 
of the neurons confirmed that the toxicity of the PolyMag reagent was reduced after the 
shorter exposure to the magnetofection reagent (A), whereas there was pronounced cell 
death after leaving the reagents on the neurons for 24 hours (B). This media change was 
therefore incorporated into the magnetofection protocol.  
 
Figure 5.6 - A sample gel image of a 3% agarose gel run in 1X TAE buffer, with 5 µl of Hyperladder V (“HL”; 
25 bp, Bioline) visualised using the Ebox VX2 imaging system and quantified using ImageJ analysis.”-ve” 
indicates negative (water) control. Gel shows the initial magnetofection conditions of a 1:1 ratio of 
PolyMag:L-PMO, changing the media after either 20 minutes (A) or 24 hours (B). Cells were incubated for 
48 hours post-magnetofection. Percentages show average Q/R site editing inhibition in each condition, n=2. 
PMOE4 (GRIA2+261+290) shows 7.4% reduction in Q/R site editing compared to controls. 
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5.2.2.2 PolyMag versus NeuroMag 
As well as the generic magnetofection reagent, other versions are available that have 
been optimised for specific cell culture systems. PolyMag, although moderately effective, 
caused a considerable amount of cell death, as seen when the neurons were observed 
under a microscope. Alternatively, NeuroMag has been developed specifically for 
primary neuronal cultures, shows low toxicity in primary neuronal cultures and has been 
shown to transfect primary neurons with an efficiency of around 30% (Wang et al., 
2014a). NeuroMag was therefore compared to PolyMag with leashed PMOE4 
(GRIA2+261+290) under the same transfection conditions (Figure 5.7). A 1:1 ratio was 
used for both transfection reagents, and neurons were left for 48 hours post-
magnetofection. PolyMag again caused 10% of the sample to remain unedited, whereas 
there was no effect seen in the samples treated with NeuroMag. Without knowing the 
exact difference between the two magnetofection reagents, it is difficult to determine the 
reason for this loss in transfection efficiency. It is possible that, in order to reduce the 
toxicity in the sensitive primary culture, NeuroMag was made to be a weaker reagent 
than PolyMag, which would explain the reduced efficacy. We therefore focused on the 
slight inhibition found using PolyMag with PMOE4 (GRIA2+261+290) and adjusted these 
conditions, both attempting to improve the inhibition and reduce the cell death. Once the 
magnetofection conditions had been improved using PMOE4 (GRIA2+261+290), they 
could then be applied to the other 30mer PMOs.  
 
 
Figure 5.7 - A sample gel image of a 3% agarose gel run in 1X TAE buffer, with 5 µl of Hyperladder V (“HL”; 
25 bp, Bioline) visualised using the Ebox VX2 imaging system and quantified using ImageJ analysis.”-ve” 
indicates negative (water) control. Comparison between PolyMag and the primary neuron-specific 
NeuroMag transfection of PMOE4 (GRIA2+261+290), each at a 1:1 ratio. RNA was extracted after 48 hours 
and editing quantified. Percentages show average Q/R site editing inhibition in each condition, n=2. 
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5.2.2.3 Increasing PMO Concentration and Length of Magnetofection 
One condition that could be optimised is the ratio of PolyMag reagent to L-PMO. Initial 
conditions used a 1:1 ratio, which had a final concentration of 1 µM of PMO. This is a 
low concentration which achieved only a 10% reduction in editing in the HeLa-B13 
system. However, keeping a 1:1 ratio of PolyMag to L-PMO at higher PMO 
concentrations leads to large volumes of PolyMag being added to the primary neuronal 
cultures which would certainly cause cell death. The concentration of L-PMO was 
therefore increased to 2 µM while keeping the same volume of PolyMag, using a ratio of 
1:2. Figure 5.8A shows the results of primary cortical cultures magnetofected at a 1:1 or 
1:2 ratio.  
As well as increasing the concentration of L-PMO, in an attempt to improve the inhibitory 
effect of PMOE4 (GRIA2+261+290), the incubation time post-magnetofection was 
increased from 48 hours to 96 hours (Figure 5.8B). It was hoped that a prolonged 
exposure of the neurons to the PMOs would lead to more interactions with the GluA2 
transcripts and so an increase in RNA editing inhibition. However, as can be seen in 
Figure 5.8B, the editing inhibition remained marginal. In fact, the samples with a 1:2 ratio 
of PolyMag to L-PMO after 96 hours show no change in editing at all compared to control 
samples. Samples with a 1:1 ratio of PolyMag to L-PMO show an improvement 
compared to those incubated for 48 hours, but inhibition remains marginal at 5%.  
 
Figure 5.8 - A sample gel image of a 3% agarose gel run in 1X TAE buffer, with 5 µl of Hyperladder V (“HL”; 
25 bp, Bioline) visualised using the Ebox VX2 imaging system and quantified using ImageJ analysis.”-ve” 
indicates negative (water) control. Transfection of primary cortical neurons using magnetofection changing 
the ratio of PolyMag:L-PMO of PMOE4 (GRIA2+261+290) from 1:1 to 1:2 with incubation of either 48 or 96 
hours. Percentages show average Q/R site editing inhibition in each condition, n=2.  
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5.2.2.4 Reducing Concentration of PolyMag and Length of Magnetofection 
One possible reason for the low levels of inhibition could be due to the cell death in the 
cultures following magnetofection. If a large majority of the cells are dying, then any of 
these neurons where the editing has been affected by the PMO will not be included in 
the Q/R site editing analysis. Conditions were therefore tested in an attempt to improve 
cell viability, either by reducing the concentration of PolyMag by half (leading to a 0.5:1 
ratio of PolyMag to L-PMO; lanes A in Figure 5.9) or reducing the incubation time post-
magnetofection (Figure 5.9). Reducing the time post-magnetofection to 24 hours 
eliminated any RNA editing inhibition from PMOE4 (GRIA2+261+290), either at 0.5:1 (24 
hours lane A; Figure 5.9) or 1:1 ratios (24 hours lane B; Figure 5.9). However, by 
reducing the ratio of PolyMag to L-PMO to 0.5:1, there was a large increase in editing 
inhibition after 48 hours with 60% of cDNA remaining unedited (48 hours lane A; Figure 
5.9), whereas no change in editing was seen at the 1:1 ratio (48 hours lane B; Figure 
5.9). This was accompanied by an increase in cell viability, which appears to be a crucial 
limiting factor in this model. 
 
Figure 5.9 – A sample gel image of a 3% agarose gel run in 1X TAE buffer, with 5 µl of Hyperladder V (“HL”; 
25 bp, Bioline) visualised using the Ebox VX2 imaging system and quantified using ImageJ analysis.”-ve” 
indicates negative (water) control. Transfection of primary cortical neurons using magnetofection changing 
the ratio of PolyMag:L-PMO of PMOE4 (GRIA2+261+290) from 0.5:1 (A) to 1:1 (B) with incubation of either 
24 or 48 hours. Percentages show average Q/R site editing inhibition in each condition.  
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5.2.2.5 Increasing Cell Density 
In a further attempt to increase cell viability after magnetofection, the density of primary 
cortical neurons in the plate was increased. Cultures used up to this point had a seeding 
density of 500,000 cells per well. An increase to 1 million cells per well could improve 
cell viability as more dense neuronal cultures tend to be more tolerant to harmful 
reagents. The previously effective conditions of a 0.5:1 ratio of PolyMag to L-PMO, with 
media changed 20 minutes post-magnetofection and incubated for 48 hours, were used. 
The results, shown in Figure 5.10, indicate that increasing the neuronal density to 1 
million cells per well does improve the editing inhibition, calculated at 14%, compared to 
500,000 cells per well with an inhibition of 10% (n=2 per condition). However, these 
results show a smaller effect on RNA editing compared to the previous magnetofection 
(Figure 5.9) which showed a 60% reduction in editing, despite using the same conditions 
here.  
 
 
Figure 5.10 – A sample gel image of a 3% agarose gel run in 1X TAE buffer, with 5 µl of Hyperladder V 
(“HL”; 25 bp, Bioline) visualised using the Ebox VX2 imaging system and quantified using ImageJ analysis.”-
ve” indicates negative (water) control. Transfection of primary cortical neurons using magnetofection 
comparing seeding densities between 500,000 and 1,000,000 neurons per well of a 6 well plate (n=2 per 
condition). Ratio of PolyMag:L-PMO of PMOE4 (GRIA2+261+290) was 0.5:1 with incubation of 48 hours, 
after which RNA was extracted and editing quantified. Percentages show average Q/R site editing inhibition 
in each condition. 
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5.2.2.6 Changing the Magnetofection Time Point 
Previous magnetofections were performed on primary cortical neurons that had been in 
culture for 21 DIV. This is a standard time point for experiments involving receptors, as 
after three weeks neuronal cultures show robust expression of synaptic markers (Harrill 
et al., 2015) and respond to stimulation indicating mature synapse formation (Glaum et 
al., 1990). However, neurons at 21 DIV are also known to be less responsive to 
transfection than neurons at early time points in culture, and the efficiency of 
magnetofection decreases by 50% at this time point compared to 7 DIV (Buerli et al., 
2007). However, neurons can be transfected at an earlier time point and then allowed to 
mature further (Wang et al., 2014a). As primary cortical neurons have been shown to be 
responsive to glutamate after 14 DIV, this time point was also tested in an attempt to 
improve transfection efficiency. Results in Figure 5.11 show that none of the conditions 
tested had any effect on editing. Comparisons were made between 500,000 (A) and 1 
million (B) cells per well at 14 DIV and 21 DIV, with a 0.5:1 ratio of PolyMag to L-PMO 
and an incubation of 48 hours. These conditions, which had previously shown 
transfection leading to an inhibition of Q/R site editing (Figure 5.9; Figure 5.10), now 
showed no change in editing despite using the same conditions and reagents.  
 
 
Figure 5.11 – A sample gel image of a 3% agarose gel run in 1X TAE buffer, with 5 µl of Hyperladder V 
(“HL”; 25 bp, Bioline) visualised using the Ebox VX2 imaging system and quantified using ImageJ analysis.”-
ve” indicates negative (water) control. Transfection of primary cortical neurons using magnetofection 
comparing seeding densities between 500,000 (A) and 1,000,000 (B) neurons per well of a 6 well plate (n=2 
per condition) at 14 DIV or 21 DIV. Ratio of PolyMag:L-PMO of PMOE4 (GRIA2+261+290) was 0.5:1 with 
incubation of 48 hours, after which RNA was extracted and editing quantified. Percentages show average 
Q/R site editing inhibition in each condition. 
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5.2.2.7 Summary of Magnetofection Conditions 
Magnetofection appears to have a better transfection efficiency than Endo-Porter, the 
transfection reagent produced specifically for PMOs, which didn’t show any effect in 
primary neuronal cultures (Figure 5.6). Several conditions were varied in an attempt to 
optimise a robust and reliable magnetofection protocol including the ratio of 
magnetofection reagent to leashed PMO, the length of transfection, the time point of 
transfection for the neurons in vitro and number of seeded neurons. These conditions 
and the resulting percentage inhibition of Q/R site editing are summarised in Table 5.1.  
Although the magnetofection technique did at one point reduce editing by 60%, this result 
was not reproducible, and often repetition of identical conditions did not result in a 
change of editing at all. The conditions resulting in an inhibition of editing to 60% were a 
0.5:1 ratio of PolyMag to leashed PMOE4 (GRIA2+261+290) magnetofected into 
neurons seeded at 1,000,000 cells per well at 21 DIV and incubated for 48 hours (Figure 
5.9). However, when these conditions were repeated in successive magnetofections, 
Q/R site editing was inhibited by 14% (Figure 5.10) and <1% (Figure 5.11). Several 
conditions showed a decrease in editing by around 10%, but were not replicable in 
successive biological repeats. Magnetofection therefore appears to have the potential to 
introduce PMOs into neurons, but this system for delivery is not reliable enough to allow 
for the analysis of downstream intracellular effects of reduced Q/R site editing.  
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Table 5.1 - Summary of magnetofection conditions tested and calculated inhibition of Q/R site editing in primary cortical neuron cultures. 
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5.2.3 Transductions using Lentiviral Vectors 
Lentiviral vectors are an efficient transduction system that harness the properties of the 
HIV-1 virus to transfer genetic material into cells, and have been shown to efficiently 
transfer genes into post-mitotic neurons with low cytotoxicity and high efficiency 
(reviewed in Hutson et al., 2014). Lentiviral vectors can also be adapted with mutations 
in their integrase enzyme, forming integration-deficient vectors able to stably transduce 
neurons in vitro and in vivo without introducing genetic material into the host’s genome 
(Yáñez-Muñoz et al., 2006). Here, a third generation integration-deficient lentiviral vector 
system was used, with the HIV-derived genome split into three vectors to improve safety 
(Dull et al., 1998). The sequence of PMOE4 (GRIA2+261+290) was taken and inserted 
into a transfer plasmid under a U6 promoter, which when co-transfected with the 
packaging and envelope vectors in HEK293T cells combined and produced a lentivirus 
containing the PMOE4 (GRIA2+261+290) sequence to be expressed under a U6 
promoter.  
5.2.3.1 Cloning Strategy 
The LentiGuide-Puro plasmid was purchased from AddGene (Plasmid #52963) and was 
originally designed to produce guide RNAs for the CRISPR-Cas9 system (Sanjana et al., 
2014). The plasmid contains a filler region flanked by BsmBI cut sites which can be 
removed and replaced with the desired oligo sequence. Figure 5.12A shows the plasmid 
map for LentiGuide-Puro plasmid. The plasmid backbone was checked using restriction 
endonucleases with a known number of cut sites within the sequence (Figure 5.12B). 
Digestion using the BsmBI restriction endonuclease removed the filler sequence, leaving 
the two digest fragments of the backbone with 8,309 base pairs and the filler sequence 
of 1,873 base pairs. The XmaI endonuclease only has one cut site within the plasmid 
and so digestion with this enzyme linearised the plasmid. The SapI enzyme has three 
cut sites on the plasmid creating digest fragments of 6,183, 2,828 and 1,171 base pairs 
(Figure 5.12B).  
Once the plasmid backbone had been confirmed, the PMOE4 (GRIA2+261+290) 
sequence could be cloned into the plasmid using the annealed oligo cloning technique, 
summarised in Figure 5.13. PMOE4 (GRIA2+261+290) was chosen for this stage as it 
gave the highest inhibition in primary neurons using the magnetofection technique and 
in the HeLa-B13 system. The base sequence from PMOE4 (GRIA2+261+290) and its 
complementary sequence were taken and the overhangs from a BsmBI digest were 
added. These oligos could then be hybridised. The plasmid backbone was digested with 
BsmBI and run on an agarose gel. The plasmid backbone without the filler sequence 
was extracted and the DNA ligated with the annealed oligos. The complete plasmid could 
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be checked for complete insertion using specific restriction endonucleases. By removing 
the filler sequence from the plasmid, both of the BsmBI sites and one SapI site were 
destroyed. Correct ligation of the E4 (GRIA2+261+290) sequence introduced one NcoI 
recognition site, along with one already found in the plasmid backbone. An NcoI digest 
would therefore give digest fragments of 4,938 and 3,388 base pairs. These digest 
checks were performed on the ligated plasmid and the resulting gel image is shown in 
Figure 5.14.  
 
Figure 5.12 – (A) Plasmid map for lentiGuide-Puro plasmid. Filler sequence flanked by BsmBI cut sites 
shown in light blue. Sequences inserted between BsmBI cut sites are preceded by a human U6 promoter. 
(B) A sample gel image of a 1% agarose gel run in 1X TAE buffer visualised using the Ebox VX2 imaging 
system. The gel shows the results of a restriction digest of LentiGuide-Puro confirming that the BsmbI cut 
sites are intact (two cut sites, predicted bands of 8,309 + 1,873 bp) and that the plasmid backbone is as 
expected with XmaI (one cut site, plasmid is linearised) and SapI (three cut sites, predicted bands of 6,183 
+ 2,828 + 1,171 bp). Phage Lambda DNA StyI size markers shown on the right of each gel. 
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Figure 5.13 - Cloning strategy for the development of a vector containing the PMOE4 (GRIA2+261+290) 
sequence. Sequence from PMOE4 (GRIA2+261+290) was synthesised as an oligo, along with its 
complementary sequence, BsmBI overhangs were added and the two oligos hybridised. LentiGuide-Puro 
plasmid was digested using the BsmBI enzyme, and the linearised plasmid was ligated to the annealed 
oligos. 
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Figure 5.14 – A sample gel image of a 1% agarose gel run in 1X TAE buffer visualised using the Ebox VX2 
imaging system. Diagnostic digest of two plasmid vectors obtained from two mini prep cultures. BsmBI sites 
and one SapI have been destroyed. One NcoI site introduced in the PMOE4 (GRIA2+261+290) sequence, 
with one in the backbone, gives two digest fragments (4,938 + 3,388 bp) indicating that both plasmids contain 
the correct inserts. Phage Lambda DNA StyI size markers shown on the left. 
 
Following the positive checks on the plasmid using restriction endonuclease digests, the 
transfer plasmid was sequenced to confirm the insertion of the PMOE4 
(GRIA2+261+290) sequence in the correct site. Figure 5.15 shows the sequencing 
results, confirming that the LG-E4 plasmid contains the E4 (GRIA2+261+290) oligo. 
Once the ligation was confirmed to be successful, the integration-deficient lentiviral 
vector was synthesised by co-transfecting feeder cells with all plasmids and harvesting 
the virus from the supernatant. The virus was then purified and titred. An integration-
deficient lentiviral vector was used as integration of the E4 sequence was not necessary, 
and instead the sequence could be transcribed into short sequences of RNA. 
 
Figure 5.15 - Sequencing chromatograms from LG-E4 ligation using forward primers in the U6 promoter 
sequence. E4 (GRIA2+261+290) sequence was confirmed to be within the plasmid, following the U6 
promoter. 
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5.2.3.2 GFP Transductions 
To test for the appropriate multiplicity of infection (MOI) for efficient transduction of 
primary cortical neurons, a range of MOIs were tested in primary cortical neurons at 21 
DIV. Transduction of lentiviral vectors into primary neuronal cultures are usually 
performed either at the time of plating or at 1 DIV (Bender et al., 2007; Cisterni et al., 
2000). However, at this stage the neurons are undifferentiated, and expression of the 
GluA2 subunit is not stable until 12 DIV (Orlandi et al., 2011). Therefore at 21 DIV, 
relatively high MOIs were tested using a lentiviral vector expressing the green fluorescent 
protein (GFP). GFP is often used as a reporter gene for expression (Kain et al., 1995) 
due to its easy visual readout of transfection efficiency, as successfully transduced 
neurons will overexpress GFP and the fluorescence can be detected under the 
microscope in the 488 nm channel. The plasmid map for the GFP-expressing transfer 
vector is shown in Figure 5.16. The GFP gene is under the CMV promoter, which has 
been previously reported to show moderate expression in primary neuronal cultures 
(Boulos et al., 2006).  
Primary cortical neurons at 21 DIV were transduced using the GFP-expressing lentiviral 
vector and incubated for 48 hours. A range of MOIs from 5 to 25 were tested to determine 
the optimum conditions for this system. At an MOI of 5, neurons showed a low level of 
transduction (Figure 5.17A-C). Qualitative comparison of the merge of GFP and bright 
field and images indicate a transduction efficiency of roughly 50% in the 10 and 25 MOI 
conditions (Figure 5.17F, I), whereas there was a much lower transduction efficiency at 
5 MOI (Figure 5.17C).  
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Figure 5.16 - Plasmid map for the GFP-expressing transfer vector. The GFP gene is under the CMV 
promoter. 
 
 
Figure 5.17 - Comparing MOIs of lentiviral vector expressing GFP in primary neuronal culture. Primary 
neurons were transduced with 5 MOI (A, B, C), 10 MOI (D, E, F) and 25 MOI (G, H, I). Images taken in FITC 
channel (A, D, G) and bright field (B, E, H) were merged to compare transduced neurons to those that have 
not taken up the GFP-expressing viral vector. 
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5.2.3.3 LG-E4 and Q/R Site Editing 
Based on the GFP expression from the neurons transduced with a GFP-expressing 
lentiviral vector, neurons were transduced at 21 DIV across the same range of MOIs. 
Neurons transduced with the LG-E4 vector were compared to those transduced with the 
GFP vector as a control and neurons only. RNA was extracted and Q/R site editing was 
measured as before. Figure 5.18 shows the results of the Q/R site editing analysis. There 
was apparently no change in Q/R site editing after transduction with the LG-E4 vector at 
any of the MOI ranges, as seen by the absence of bands at the unedited position. This 
was repeated twice with the same results found.  
 
Figure 5.18 - A sample gel image of a 3% agarose gel run in 1X TAE buffer, with 5 µl of Hyperladder V (“HL”; 
25 bp, Bioline) visualised using the Ebox VX2 imaging system and quantified using ImageJ analysis.”-ve” 
indicates negative (water) control. Transduction of primary cortical neurons at 21 DIV using MOIs of 5, 10 
and 25 of the LG-E4 lentiviral vector. RNA was extracted after 48 hours and Q/R site editing quantified, with 
no observed change in editing status. 
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5.3 DISCUSSION 
In this chapter, attempts were made to introduce the PMOs, or the equivalent sequence 
in to be transcribed in RNA form, into primary neuronal cultures. Three methods were 
tested: using the Endo-Porter transfection reagent which had success in previous cell 
models, an alternative transfection method called magnetofection and designing a 
lentiviral vector to overexpress the sequence as RNA. Test transfections using Endo-
Porter with the fluorescent PMO appeared to successfully localise the PMO to the 
neurons, in particular to the cell body. However, subsequent transfections using this 
method with the PMOs targeting the double-stranded region of the GluA2 transcript had 
no effect on editing at the Q/R site. The alternative transfection method, magnetofection, 
showed some change to Q/R site editing, but this was unreliable as transfections using 
identical conditions gave variable resulting inhibition of Q/R site editing. The final strategy 
was to create a lentiviral vector containing the antisense sequence of PMOE4 
(GRIA2+261+290) under the human U6 promoter. This would then be overexpressed as 
RNA transcripts which would perform the same function as the PMOs. However, despite 
the neurons showing good transduction of a vector expressing GFP, again there was no 
change in Q/R site editing after transduction with the LG-E4 vector. 
These results are disappointing but perhaps not unexpected. As previously mentioned, 
primary neuronal cultures are notoriously difficult to transfect, despite multiple methods 
being available (Karra & Dahm, 2010). Although Endo-Porter was specifically designed 
for use with PMOs, these results show it is not effective in primary neuronal cultures. 
Endo-Porter was developed based on a number of peptides previously shown to cross 
animal cell membranes due to basic and amphiphilic sections of amino acids such as 
the HIV protein tat (Mann & Frankel, 1991). Synthetic versions of these peptides were 
made containing a lipophilic face of leucines and lysines, which were even more efficient 
at penetrating cell membranes (Summerton, 2005). However, these peptides showed 
high cell toxicity, possibly due to alterations to the permeability of the cell membrane. 
Focus then changed to indirect delivery into the cell through endosomes, thereby not 
compromising the permeability of the cell membrane. The PMO would be leashed to a 
complementary section of anionic DNA, which would then form a stable complex with 
polyethyleneimine (PEI). PEI could then bind to the plasma membrane and be 
endocytosed, along with the bound PMO, after which the PEI would be ionised causing 
permeabilisation of the endosome membrane and movement of the PMO from the 
endosome into the cytosol (Morcos, 2001). However, PEI has reduced activity in the 
presence of serum and shows some cell toxicity. Therefore Endo-Porter was developed, 
with the aim to make a transfection reagent with high efficiency in the presence of serum, 
simplifying cell culture practice, and with reduced cell toxicity. Endo-Porter is a short 
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peptide based on the indirect, endocytosis-based delivery system with a lipophilic face 
and a weak-base face with a lysines in the sequence to improve solubility, and was 
shown to permeabilise membranes at the lower pH associated with endosomes but 
showed no permeabilisation at the neutral pH found at the cell membrane therefore 
reducing cell toxicity (Summerton, 2005). However, it is unclear how Endo-Porter recruits 
the neutrally-charged PMOs to the membrane, as most transfection reagents rely on the 
charged nature of the DNA particles. It is possible that the transfection is reliant on the 
increased endocytosis caused by Endo-Porter and the PMO being in a high enough 
concentration in the media to have collected near the cell membrane. Images taken after 
transfection with the fluorescently-tagged PMO showed the PMO collecting near the cell 
body of the neurons (Figure 5.4). However, there is no evidence that the PMO has 
actually entered the neuron, as similar images would be seen if the PMO were simply 
bound to the membrane. If the PMO were collecting at the membrane rather than being 
endocytosed, this could account for the lack of inhibition of Q/R site editing. Equally, 
assuming the PMO has entered the cell, it is unclear from the images whether it reaches 
the nucleus of the neuron. The PMO may be collected in endosomes rather than being 
free in the cytosol. Ideally, counter-staining for nuclear markers would give more 
indication as to the location of the PMO. However, the neutral charge of the PMO means 
that it is not held by fixing agents and so fixed cells will not retain the PMO in the correct 
cellular compartment for analysis.  
A different version of Endo-Porter, suspended in aqueous solution rather than DMSO, 
was used compared to previous chapters in an attempt to reduce cell toxicity. This 
change in transfection reagent may have had an effect on the efficiency of the reagent 
itself. There are very few reported studies using Endo-Porter in aqueous solution as 
opposed to in DMSO, mainly in vivo experiments in sheep (Wang et al., 2014b). This 
may be due to the low toxicity of Endo-Porter in DMSO for most cell types, so researchers 
do not need to use a less-toxic version. However, this means that it is difficult to 
determine whether aqueous Endo-Porter is equally effective at the same concentrations. 
Here, the same concentration was used as previously in the HeLa-B13 system and in 
SH-SY5Y cells. However, the lack of effect may have been due to reduced efficiency, 
and so higher concentrations of aqueous Endo-Porter could be explored.  
Magnetofection of the PMOs was partially successful, in that a reduction in editing was 
achieved under some conditions. The method of magnetofection has previously been 
reported by two separate groups to successfully transfect DNA and shRNAs into 
neurons. The first group transfected primary hippocampal neurons (Buerli et al., 2007) 
while the second used primary motor neurons from the spinal cord (Fallini et al., 2010). 
Although both are using the same magnetofection technique, their protocols vary 
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significantly. Buerli et al. use the CombiMag reagent with additional Lipofectamine 2000 
while Fallini et al. use NeuroMag, the magnetofection reagent specifically designed for 
use with primary neurons. In the experiments conducted in this chapter, magnetofection 
using NeuroMag was not found to have any effect on the RNA editing while 
Lipofectamine in combination with magnetofection was not tested due to the known 
toxicity of Lipofectamine and its low transfection efficiency (Ohki et al., 2001). These two 
papers also varied in age of neurons transfected, with the hippocampal neurons being 
transfected between 10 and 21 DIV and the motor neurons being transfected at 2 DIV. 
Buerli et al. used a ratio of 1 µg plasmid DNA to 2 µl of 1:10 diluted CombiMag to 2 µl 
Lipofectamine, while Fallini et al. used a ratio of 0.5 µg DNA to 1.75 µl NeuroMag. Results 
in this chapter show varied results in response to changing the L-PMO to PolyMag ratio, 
with a 0.5:1 ratio giving the largest change in RNA editing (Figure 5.9). Buerli et al. left 
the neurons on the magnet for 25 minutes following no change in media while Fallini et 
al. left the neurons on the magnet for only 15 minutes with a change of media after one 
hour. The results in this chapter also support a change of media after incubation on the 
magnet, as this reduced cell toxicity. The largest change in Q/R site editing seen in this 
chapter was under the conditions of 21 DIV, a 0.5:1 ratio of L-PMO to PolyMag, with a 
media change 20 minutes post-transfection and then incubation of 48 hours (Figure 5.9). 
These conditions are within the range set by the two previous studies on magnetofection. 
The differences between methods from these two papers and those reported in this 
chapter may be due to the different populations of neurons, as this chapter looks at the 
transfection of cortical neurons rather than hippocampal or motor neurons. However, the 
results from this chapter found that the method of magnetofection does not produce 
reliable results. The same conditions on successive experiments would alternatively 
show a change in editing and then show no change at all. This unreliability indicates that 
this method would not be useful to study the downstream effects of inhibited Q/R site 
editing, as it is not reproducible over successive biological repeats. 
One limitation in the magnetofection protocol is that the PMOs need to be leashed to 
charged DNA fragments so that they can properly interact with the magnetic 
nanoparticles. Once the magnetic nanoparticles have bound to the leashed PMO, they 
are then pulled onto the neuron and endocytosed. However, although this is an additional 
step compared to transfection using Endo-Porter, leashing of PMOs has previously been 
reported to transfect muscle cells using Lipofectamine (Gebski et al., 2003). Another 
factor in this magnetofection reaction is that there is no additional transfection reagent 
increasing the permeability of the neuronal membrane, instead the method is reliant on 
the collection of the L-PMO-magnetic nanoparticle complex on the cell membrane in the 
cell’s natural endocytosis mechanisms. This is the reason for the combination approach 
of magnetofection reagent CombiMag with Lipofectamine 2000, as seen in Buerli et al. 
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However, as mentioned previously, transfection reagents such as Lipofectamine 2000 
are known to be toxic to primary neurons, and so although they can be used in 
combination with PolyMag for increased transfection efficiency, they could not be used 
in this context. Due to the lack of additional transfection reagent, this then leads to the 
question of how the leashed PMO enters the cell at all, as the magnetic nanoparticles 
will only concentrate them onto the membrane. Clearly some PMOs have entered the 
primary neurons, as a small change in Q/R site editing was achieved. However, the 
variability seen in the results may be a reflection on this reliance of endogenous 
endocytosis mechanisms.  
It was hoped that lentiviral vectors would solve the issue of introducing the antisense 
sequence into the primary neuronal cultures. Lentiviral vectors are an excellent tool for 
the transfer of genetic material and have been shown to transduce post-mitotic primary 
cortical neurons at high efficiency (Zhang et al., 2006), with promising use as therapies 
for neurodegenerative diseases (reviewed in Hutson et al., 2014). The vectors used in 
this chapter were third generation lentiviral vectors, with the necessary genes for 
production of the virus split over three plasmids: the packaging plasmid, envelope 
plasmid and the transfer plasmid containing the desired sequence. Lentiviral vectors 
have previously been used to express shRNAs under the same human U6 promoter for 
the purposes of knockdown of gene expression (Van den Haute et al., 2003). The vector 
backbone used in this chapter was previously created for use in the CRISPR-Cas9 
system to express guide RNAs in target cells, and has since been used effectively 
(Sanjana et al., 2014). The major change in this strategy was that the sequence is no 
longer in the form of a PMO, but would now be single-stranded RNA transcripts binding 
to the GluA2 transcript. The positive control for successful transduction used a lentiviral 
vector that expressed GFP, which showed good expression at 10 and 25 MOI at 21 DIV. 
GFP expression was driven by the CMV promoter, which has previously been reported 
to give transduction efficiencies of more than 50% (Bender et al., 2007). However, the 
LG-E4 RNA was under the human U6 promoter, which is commonly used for siRNA 
expression in lentiviral systems and has shown high expression in neurons (Mäkinen et 
al., 2006). This change in promoter between the two vectors may mean that the good 
transduction seen with GFP was not replicated with the human U6 promoter in the LG-
E4 vector. An alternative positive control would be to tag the E4 (GRIA2+261+290) 
sequence itself with the GFP construct. However, this would inhibit binding of the RNA 
to the GluA2 subunit, so a vector without the GFP insert would still need to be used. Due 
to these limitations in a GFP-tagged RNA sequence, the output of a positively transduced 
sample was a change in Q/R site editing.  
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From the conditions used here, there was no impact on Q/R site editing following LG-E4 
transduction. It may be possible to induce inhibition of RNA editing through changing the 
transduction conditions. Polybrene is often used to improve lentiviral transduction, but is 
known to be toxic to neurons so cannot be used in this case (Peluffo et al., 2012). To 
improve transduction, higher MOIs may be used. The highest MOI used in this study was 
25. As no cell death was seen at this MOI, this range could be increased first in a toxicity 
assay to check that the neurons can tolerate this high MOI followed by the Q/R site 
editing assay. Ultimately, following this pilot study, a log range of MOIs will be tested to 
ascertain the efficient transduction conditions for primary cortical neurons. Caffeine may 
also be used during production of the lentiviral vector, which has been reported to 
increase the titre of viral production up to 8 fold (Ellis et al., 2011). Through increasing 
the titre, higher MOIs may be used in transduction allowing an increased expression of 
the E4 sequence. 
Alternatively, transductions at different time points could be investigated. The neurons in 
this study were transduced at 21 DIV, whereas transductions at much earlier time points 
such as 4 DIV have been reported (Zhang et al., 2006). Earlier transductions with the 
LG-E4 vector could be investigated, although at this stage the neuronal cultures are more 
vulnerable as they have not yet formed networks. A range of MOIs would again need to 
be investigated at this early time point to assess the correct level for minimal toxicity. 
Once the lentiviral vector is within the neurons, the cultures could be maintained for 
several weeks to observe changes in Q/R site editing at a later stage. Alternatively, it 
may be that the human U6 promoter is not working in this system and there is no 
expression of E4 (GRIA2+261+290) RNA. The human U6 promoter has been found to 
be more effective at expressing shRNA than the murine equivalent, even in murine cells, 
and so changing species of the U6 promoter would be unlikely to change the outcome 
(Roelz et al., 2010). Other promoters that are used to express short RNA sequences 
such as siRNAs and shRNAs in lentiviral vectors include the U1 promoter (Denti et al., 
2004) or the U7 promoter (Goyenvalle et al., 2009). Use of either of these promoters may 
increase the effect of E4 (GRIA2+261+290) RNA in the neurons, although there are 
some reports that these promoters have similar expression patterns (ter Brake et al., 
2008). 
Attempts at transfection and transduction of primary neurons in this chapter were made 
once the neurons had already been plated and networks had begun to be established. 
This was so that the PMO could interact with the GluA2 subunit once it had been 
expressed stably at around 12 DIV (Orlandi et al., 2011). Methods such as nucleofection, 
which must be carried out before the neurons are plated, were discounted for this reason. 
However, the backbone chemistry of the PMO renders it resistant to nuclease activity, 
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and as such can remain in cells for long periods of time without being degraded. 
Additionally, neurons are post-mitotic, and so any transfection performed on the day of 
plating should not be diluted by successive cell divisions. Considering these points, 
nucleofection of primary neurons with a leashed PMO at 0 DIV, then plating them and 
allowing them to mature, may be an alternative method worthy of investigation. 
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6 EXON SKIPPING OF THE ALUJ CASSETTE 
6.1 INTRODUCTION 
Splicing of the introns in an RNA transcript is a process carried out by the spliceosome, 
a ribonucleoprotein megaparticle formed from multiple small nuclear ribonucleoproteins 
(snRNPs) and associated splicing factors that bind to the RNA and carry out the intron 
excision (reviewed in Lee & Rio, 2015). The way that the spliceosome recognises the 
difference between exons and introns is still not completely understood. There are two 
possibilities: the spliceosome either recognises the introns to be spliced out (“intron 
definition”) or the exons to be ligated together (“exon definition”). If the splicing factors 
recognise the intron, and the basal machinery is placed across the intronic regions, then 
this would put a limit on the length of introns. Evidence suggests that intron definition is 
the more ancient mechanism, as single-celled organisms such as yeast have introns in 
general no longer than 350 nucleotides (Ram & Ast, 2007). In exon definition, the basal 
splice machinery is placed over the exon. This limits the length of exons and frees introns 
to extend for several kilobases as is seen in multicellular organisms (Ram & Ast, 2007). 
It may be that the extension of introns through evolution forced the spliceosome to 
instead recognise the exon, shifting the definition away from intronic definition 
(Robberson et al., 1990). The average length of the vertebrate exon is 170 bases, and if 
the exon is extended beyond 300 bases then cryptic splice sites may be activated within 
the exon or the exon may be skipped altogether as the splice machinery cannot span 
the exon, further supporting the idea of exon definition (Robberson et al., 1990).  
The splicing reaction begins with the assembly of the spliceosome around the premRNA 
transcript. U1 snRNP is initially recruited to the 5’ splice site due to its recognition of the 
consensus sequence. Other splice factors become involved, such as BBP (Branch point 
Binding Protein) interacting with the branch point within the intron and U2AF65/U2AF35 
interacting with the 3’ splice site, forming the E complex (Figure 6.1 part 2). The U2 
snRNP then stably interacts with the branch point, displacing the BBP/U2AF splice 
factors and forming the A complex (Figure 6.1 part 3). The U4.U5.U6 tri-snRNPs 
recognise and bind to the 5’ splice site, forming the pre-catalytic B complex (Figure 6.1 
part 4), before U1 and U4 snRNPs destabilise and the activated B complex is formed 
(Figure 6.1 part 5) which catalyses the first transesterification reaction. Complex C is 
then reached (Figure 6.1 part 6) which completes the final esterification reaction of 
splicing. 
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Figure 6.1 - Summary of the recruitment and action of the spliceosome. 5’ ss = 5’ splice site. 3’ ss = 3’ splice 
site. BP = branch point. BBP = Branch point Binding Protein. Small nuclear ribonucleoproteins (snRNPs) 
U1, U2, U4, U5 and U6 as well as auxiliary factors U2AF64 and U2AF35 form the spliceosome. Diagram 
adapted from (Kornblihtt et al., 2013; De Conti et al., 2013). 
The spliceosome itself, containing the necessary snRNPs and associated splicing 
factors, has been isolated from mammalian cells with other splice regulatory elements in 
a huge complex called the supraspliceosome which also contains other RNA processing 
components such as those for 3’-end processing (Raitskin et al., 2002) and RNA editing 
(Raitskin et al., 2001). Structural analysis shows four active spliceosomes within the 
supraspliceosome connected to the same premRNA transcript and therefore able to 
process four introns simultaneously (Azubel et al., 2006), and may play a part in 
regulation of alternative splicing by recruiting the appropriate splice regulatory elements 
(Sebbag-Sznajder et al., 2012). 
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Splicing at a given junction may be constitutive, i.e. present in all transcripts, or 
alternative, i.e. only present in some transcripts, allowing different RNA sequences and 
therefore variation in proteins (Siva et al., 2014). There are several events that can be 
classified as alternative splicing: an exon may be “skipped” or an intron retained in the 
mRNA sequence; there may be mutually exclusive exons of which only one or the other 
is found within a transcript; there may be alternative 3’ splice sites, 5’ splice sites or 3’ 
untranslated regions as well as alternative first and last exons. 
Splice sites can be defined as either “strong” or “weak”, depending on their similarity to 
the consensus sequence, which is a sequence of 9 bases at the 5’ splice site and 15 
bases at the 3’ splice site that are sufficient to ensure splicing takes place (Roca et al., 
2005). The consensus sequence for the 5’ splice site is the exact complementary 
sequence for the U1 snRNP, which is required for the assembly of the splicing machinery 
(Figure 6.1), while the 3’ splice site and branch point consensus sequences are more 
loosely defined (De Conti et al., 2013). Each splice site can be ranked according to its 
similarity to the consensus sequence, and the more similar the sequence is, the more 
likely the site is to be spliced. However, a splice site does not necessarily need to 
completely match the consensus sequence to be functional. Indeed, out of 5,000 
constitutively expressed exons examined, less than 5% matched the consensus 
perfectly (Chasin, 2007). The presence of pseudo-splice sites (sequences that are 
similar to or match the consensus but are not spliced) or cryptic splice sites (sequences 
that become spliced when the natural splice site is inactivated) further support the idea 
that there are factors governing the use of a splice site other than its similarity to the 
consensus sequence. For example, an exon in the human genome is more likely to be 
included in the mRNA transcript if it is flanked by shorter introns (Fox-Walsh et al., 2005). 
Other factors that can help determine whether a splice site is used or not are called splice 
regulatory elements and can take the form of either cis-acting or trans-acting. Cis-acting 
elements are regulatory sequences in the RNA that recruit RNA-binding factors to either 
aid or repress splicing. These include hexamer recognition sites that act as Exon Splice 
Enhancers (ESEs) or Exon Splice Silencers (ESSs), or Intronic Splice Enhancers (ISEs) 
and Intronic Splice Silencers (ISSs), depending on their location and the factors they 
recruit (Gamazon & Stranger, 2014). ESEs tend to be found close to splice sites and can 
compensate if the splice site is “weak”, promoting exon inclusion in the mRNA transcript. 
If the splice site is mutated to be closer to the consensus sequence then the reliance on 
the ESE for exon inclusion is removed (Graveley, 2000). A study of human gene 
sequences found hexamer recognition sites at both 5’ and 3’ splice sites that could be 
grouped to form five 5’ ESE hexamer motifs and eight 3’ ESE motifs (Fairbrother et al., 
2002). ESS sites are abundant and highly conserved, and in general fall into two classes: 
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those than resemble the hnRNPA1 recognition site and those that recruit other silencing 
factors (Wang et al., 2006). ISEs cluster into 6 motifs according to sequence, with similar 
patterns to ESSs, and each group likely recruits specific trans-acting factors leading to 
intron splicing (Wang et al., 2012).  
Trans-acting factors are the RNA-binding elements that bind to the cis-regulatory 
sequences and include several heterogeneous ribonucleoprotein families (Kornblihtt et 
al., 2013). There are two large families of trans-acting regulators that can determine 
splicing. Serine-arginine (SR) proteins in general enhance splicing, binding to ESEs and 
ISEs as well as recruiting the U1 snRNP, while heterogeneous nuclear 
ribonucleoproteins (hnRNPs) appear to be antagonistic to SR proteins and in general 
are negative regulators of splicing (reviewed in Fu & Ares, 2014). Although several cis-
acting elements resemble the recognition sites for individual trans-acting elements, there 
is not always a one-to-one relationship between a cis-acting splice factor and an RNA 
binding protein. For example, the action of some regulatory elements may depend upon 
the proximity of the element to the splice site itself or whether or not it is located in the 
exon (Goren et al., 2006). The balance between the splice enhancer and splice silencer 
regulatory elements, both in cis and trans, help determine whether or not a splice site is 
used.  
More than 90% of human genes are capable of undergoing alternative splicing, and most 
have alternative isoforms present in more than 15% of their transcripts (Wang et al., 
2008). Alternative splicing has an important role in both normal physiology and disease. 
Genes that are alternatively spliced are found to be differentially regulated throughout 
the nervous system, governing various processes such as development, pre-synaptic 
function and post-synaptic responses (as reviewed in Li et al., 2007). Defects in 
alternative splicing, such as mutations disrupting splice sites, have been linked to several 
disorders including cystic fibrosis and schizophrenia (Gamazon & Stranger, 2014). The 
most common method of endogenous alternative splicing in the human transcriptome is 
“exon skipping” or “cassette exon inclusion” (Wang et al., 2008). An exon that is not 
present in one or more transcripts of a gene, either due to a “weak” splice site or silencer 
elements, can be defined as a cassette exon and the method of alternatively splicing this 
exon is termed exon skipping. This is the method of alternative splicing that can include 
the AluJ cassette within the ADAR2 transcript (Gerber et al., 1997). The AluJ cassette is 
so called due to its similarity to Alu transposon sequences. It was found that its inclusion 
in the ADAR2 transcript led to a reduced editing efficiency in vitro (Gerber et al., 1997). 
In this study, synthetic double-stranded RNA was used to assess the editing of ADAR2 
containing the AluJ cassette or without the AluJ cassette at the Q/R site, hotspot 1 and 
R/G editing sites of the GluA2 transcript. In all cases, purified ADAR2 without the AluJ 
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cassette exon was around twice as efficient at editing as purified ADAR2 containing the 
AluJ cassette (Gerber et al., 1997).  
ASO technologies have been used to alter natural splicing patterns in several areas. 
These previous studies have utilised bioinformatic design tools to predict the optimal 
sequence to manipulate splicing. By targeting the ASO to sequences around the splice 
site, the ASOs can compete with the splice machinery and so interfere with the splicing 
process. This method can be used to promote either exon inclusion or exon skipping 
depending on the sequence targeted. In spinal muscular atrophy, ASOs have been used 
to include exon 7 in the SMN2 gene, thereby increasing SMN protein production, by 
targeting the ASO to an ISS in intron 7 (Zhou et al., 2013). The ASO blocks the silencer 
site, therefore promoting exon inclusion in the mRNA transcript. Alternatively, ASOs can 
block enhancer sites where the same principle is applied and the removal of the 
enhancer reduces exon inclusion, for example to restore the reading frame in mutated 
genes (Aartsma-Rus et al., 2003).  
In order to design effective ASOs, guidelines have been suggested which identify 
important parameters to consider, and these parameters have been compared to 
observed efficacy of the designed ASOs (Aartsma-Rus et al., 2009; Popplewell et al., 
2009). Both of these studies looked at the application of ASOs in exon skipping. It 
appears that targeting exonic sequences show improved results compared to targeting 
intronic sequences, possibly due to greater GC content and so stronger binding. A strong 
determinant was reported to be the difference in free energy between the oligonucleotide 
sequence and the exonic sequence (Aartsma-Rus et al., 2009). The number of predicted 
ESE sites, either by the RESCUE-ESE database (Fairbrother et al., 2002) or by the 
Human Splice Finder database (Desmet et al., 2009) covered by the ASO also correlated 
with efficacy, particularly the strength of binding for SC35 and Tra2β splice factors 
(Aartsma-Rus et al., 2009). The length of the ASO, the folding of the premRNA transcript 
and so the accessibility of the target site, as well as the proximity of the target sequence 
to the exon acceptor site are also factors to be considered (Popplewell et al., 2009). 
ASO-induced exon skipping has been applied to several degenerative disorders, 
including Duchenne muscular dystrophy (Popplewell et al., 2009) which has progressed 
to clinical trials (Sarepta, 2015) and spinal muscular atrophy (Porensky et al., 2012), also 
in Phase III clinical trials with IONIS Pharmaceuticals. 
The aim of this chapter was to use ASOs to promote exclusion of the AluJ cassette from 
the ADAR2 mRNA transcript, which has the potential to improve the enzyme’s editing 
efficiency. The PMO chemistry was again used due to the success of this ASO backbone 
in exon skipping in other contexts such as the DMD gene (Wu et al., 2014). Bioinformatic 
resources were used analyse the sequence of the AluJ cassette as well as its flanking 
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intronic regions. Entropies of the AluJ cassette splice sites were calculated and 
compared to neighbouring splice sites in order to assess their strength. Secondary 
structure models of ADAR2 pre-mRNA were generated to analyse target sequence 
accessibility and the AluJ cassette sequence was scanned for cis-acting splice regulatory 
elements. Binding energies for potential ASO sequences were calculated to maximise 
binding to the premRNA transcript. PMOs were then designed that fulfilled each of these 
requirements: they covered regions containing enhancer sequences and avoided 
silencer elements, targeted open loop regions of secondary structure and had a negative 
binding energy. Once the PMOs were designed, they could then be tested for their ability 
to exclude the AluJ cassette by transfection into HeLa cells. HeLa cells co-transfected 
with the B13 minigene were used to detect any changes in A-to-I editing at the Q/R site 
of the GluA2 transcript. The HeLa-B13 system edits the Q/R site at around 30% and so 
any increase in editing efficiency could be detected. Increasing the Q/R site editing in 
the GluA2 transcript has the potential to be a therapeutic target for ALS, as editing has 
been shown to be variable in ALS patients compared to 100% efficiency in healthy 
controls (Kawahara et al., 2004). The PMOs designed in this chapter were therefore 
developed to exclude the AluJ cassette from the ADAR2 transcript with an aim to 
increase its editing efficiency, and therefore indirectly increase Q/R site editing. 
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6.2 RESULTS 
6.2.1 Targeting PMOs against Inclusion of the AluJ Cassette 
6.2.1.1 Targeting Splice Sites 
There are several factors to consider in the process of designing a PMO for exon 
skipping. The first areas to target are the splice sites themselves, as a PMO binding to 
these sequences may prevent the spliceosome from incorporating the exon into the final 
transcript. MaxEntScan is a web server that calculates the maximum entropy for each 
splice site (Yeo & Burge, 2004), and the higher the entropy score the more likely a splice 
site will be used (Ye et al., 2014). Figure 6.2 shows the consensus sequence for U2-
dependent introns, the most common form of intron and the form that surrounds the AluJ 
cassette. Below are the corresponding sequences for the AluJ cassette and its 
surrounding introns, with the MaxEntScan scores for each splice site. The splice sites at 
either end of the AluJ cassette are much weaker (4.19 and 2.05 for 3’ splice site and 5’ 
splice site respectively) than the splice sites up- and downstream with which they are in 
competition (9.83 and 9.11 for the 3’ splice site and 5’ splice site respectively). 
Mismatched bases are shown in red in Figure 6.2. As can be seen, although the AluJ 3’ 
splice site matches the consensus sequence, there are mismatches in the 5’ splice site 
and in the branch point. This indicates that the spliceosome will not be efficiently 
recruited and may explain why this exon is alternatively spliced, supported by the lower 
MaxEntScan entropy scores at each splice site. As this is considered a “weak” splice 
site, the AluJ cassette may be more reliant on splice enhancers (De Conti et al., 2013). 
It may also mean that ASOs targeted at the splice sites have a good chance of preventing 
inclusion of the AluJ cassette. 
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Figure 6.2 - Schematic of consensus splice sites at either end of an exon and the branch point within the intron, compared to the AluJ sequence and its upstream and downstream exon. 
Bases in red indicate a mismatch with the consensus sequence. Below shows the MaxEntScan scores for each splice site (arbitrary units), with a higher maximum entropy score 
indicating a stronger splice site. Splice sites are labelled 5’ or 3’ in relation to the intron being excised. 
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6.2.1.2 Exon Splice Enhancers and Silencers  
Other sequences to target in ASO design would be the exon splice enhancers, which 
facilitate the inclusion of an exon, while sequences to avoid would be the exon splice 
silencers as they encourage the exclusion of an exon, which is our aim. Online resources 
were therefore utilised to determine where the enhancers and silencers were in the AluJ 
cassette itself and surrounding intronic sequences. The website Human Splicing Finder 
(HSF) was preferred for this task as this tool incorporates a number of sources of motifs 
including ESE Finder (Cartegni et al., 2003) and RESCUE-ESE (Fairbrother et al., 2002) 
databases, and as the title suggests this is specifically for human sequences. In the input 
form, “Analyse sequence” was selected and the sequence was chosen by the Ensembl 
transcript number – ENST00000360697 – and exon 6 (the AluJ cassette). HSF 
automatically analyses the 100 bases of intronic sequence either side of the chosen exon 
as well as the exonic sequence itself.  
The graphical output of splice enhancer and silencer motifs is shown in Figure 6.3. Along 
the 𝑥-axis runs the RNA sequence (5’-3’) and the grey box represents the AluJ cassette. 
Coloured lines represent predicted cis-regulatory elements for different factors: above 
the 𝑥-axis indicates ESE motifs in shades of red and pink and below indicates ESS motifs 
in shades of blue and green. This graph shows that there are multiple predicted binding 
sites throughout the AluJ sequence for both ESE and ESS elements. ESS motifs should 
be avoided in ASO design for exon skipping, as they help to exclude the exon. However, 
this analysis shows that the ESS binding sites (blue) are evenly spaced throughout the 
sequence and so there is not an obvious area to avoid. On the other hand, there is a 
cluster of binding sites for ESEs at the 3’ end of the sequence, indicating a potential 
target for PMO design as covering the enhancer sequences may prevent exon inclusion. 
Specifically targeting SC35 hexamers has previously been reported to be beneficial in 
ASO design for exon skipping (Aartsma-Rus et al., 2009) although elsewhere it did not 
show an effect on ASO design (Echigoya et al., 2015). SC35 hexamers (shown in bright 
red; Figure 6.3) appear to be spaced fairly evenly throughout the sequence, although 
there are three spaced within 30 bases in the centre of the exon, as well as two at the 3’ 
end. 
The Human Splice Finder analysis also searches for putative exon splice enhancer 
(PESE) and putative exon splice silencer (PESS) octamers (Zhang & Chasin, 2004). 
These octamers were determined through a different set of criteria, where sequences 
overrepresented in noncoding exons were classed as PESEs whereas octamers 
underrepresented in noncoding exons were classed as PESSs when compared to their 
prevalence in intronic sequences (Zhang & Chasin, 2004). Octamers were chosen to 
include potential binding sites that exceeded six bases. PESSs are shown in green 
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(Figure 6.3), and indicate that intronic regions immediately flanking the AluJ cassette are 
rich in silencer elements, and so ought to be avoided. PESEs are indicated in pink, and 
show a small cluster of enhancer elements in the centre of the AluJ cassette and a larger 
cluster of enhancer elements at the 3’ end of the exon. 0 
Targeting the 3’ end of the exon would also cover the splice consensus sequence, which 
should also prevent exon inclusion. The yellow line running through the graph indicates 
overall balance of the ESEs to ESSs, and so peaks in the yellow line indicate an overall 
enhanced area while a trough below the 𝑥 axis indicates an overall silenced area. This 
again supports the idea of covering the 3’ end of the AluJ cassette as there is a “peak” 
of ESE strength in this region. 
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Figure 6.3 - Results from Human Splicing Finder analysing exon splice enhancers and silencers surrounding the AluJ cassette. Sequence runs 5’ to 3’ along the 𝑥 axis with the grey box 
indicating the 120 bases of the AluJ cassette. Boxes above the 𝑥 axis (in red and pink) indicate sequences associated with splice enhancers while boxes below (in blue and green) 
represent motifs for exon silencers. 
 184 
 
6.2.1.3 Secondary Structure of the AluJ Cassette 
In order to bind to RNA, an ASO must be able to access its complementary target bases. 
The secondary structure of the RNA transcript can be complex, and RNA naturally folds 
due to Watson-Crick base pairing to form double-stranded regions within the transcript 
interspersed with loops and bulges of single-stranded regions. If the target sequence for 
an ASO is within a region of double-stranded RNA, the ASO will need to compete for 
binding with the RNA transcript and so may have less of an effect. It would therefore be 
ideal to target the PMO to bases found in single-stranded regions of RNA so that it can 
access the complementary bases. Targeting ASOs to open regions of RNA secondary 
structure as predicted by MFold has previously been shown to correlate with efficacy of 
the ASO (Aartsma-Rus et al., 2009; Popplewell et al., 2009). 
The AluJ cassette and its surrounding upstream and downstream intronic sequence was 
submitted to the RNA folding form of the MFold website, a total of 1,412 bases. This 
produced 23 predicted secondary structures within the default constraints and the 
structure with the lowest free energy is shown in Figure 6.4. Using this diagram it was 
possible to target potential ASO sequences towards single-stranded regions, which 
theoretically would allow the ASO to bind more easily to the RNA. At the 3’ end of the 
exon (3’ss in Figure 6.4), the splice site is within a double-stranded region. However, 
there is an open region starting four bases in from the splice site, and so this is a potential 
target for ASO design. At the 5’ end of the exon, the predicted structure shows a mixture 
of double-stranded regions and bulges of single-stranded RNA, therefore this is also a 
good target for ASO design, especially if the ASO begins within one of the single-
stranded sections (Figure 6.4). 
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Figure 6.4 - Secondary structure of the AluJ cassette and surrounding intronic region. On the right is the 
complete secondary structure, with the AluJ cassette itself highlighted in blue (and with capital letters) and 
shown in the left hand image. Also indicated are the 5’ and 3’ splice sites (5’ss and 3’ss respectively).  
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6.2.1.4 Binding Energies  
The information from predicted RNA secondary structure and splice regulatory element 
location narrowed down the area for ASO design to the 5’ and 3’ end of the AluJ exon, 
while avoiding the flanking intronic sequences due to their ESS sequences. The next 
step for ASO design was to calculate the binding energies of different possible 
sequences, and therefore choose the ASO that will have the highest binding efficiency 
to the RNA transcript. To do this, the sequence of the AluJ cassette was assessed using 
the RNA dimer prediction tools available on the SFold website. This website analyses 
every possible complementary oligonucleotide of a pre-chosen length (in this case 25 
bases) along the selected gene sequence and calculates the intermolecular dimer 
energy between the RNA sequence provided and its exact complementary sequence. 
The output for SFold oligo is shown in Figure 6.5. At the 5’ and 3’ end of the exon, 
oligonucleotides 25 bases long complementary to the very end of the exon had 
intermolecular dimer energies of -3.4 kcal/mol and -11.6 kcal/mol respectively. If the 
binding energy is more negative then the ASO is more likely to bind to the RNA. 
Therefore, the 25 bases at either end of the AluJ exon make promising candidates for 
ASOs. Shifting the sequences slightly along the exon did not improve the potential 
binding energy, as they did not become more negative. Choosing the sequence needs 
to be based on a balance between covering the splice sites and enhancer sequences of 
the exon and finding the most efficient binding, and these two considerations appear to 
be fulfilled with the 25-base sequences at either end of the AluJ exon. 
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Figure 6.5 - SFold oligo output for the AluJ cassette. Highlighted columns indicate the binding energy between an antisense oligonucleotide and the RNA transcript at that location. 
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Taking the two sequences at each end of the exon, it was then possible to calculate the 
energy needed for these two ASOs to overcome any internal secondary structure. This 
was done using the OligoEvaluator program, which gives the PMO-PMO interaction and 
hairpin binding energies for a given sequence. For the sequence at the 5’ splice site, the 
energy needed to overcome PMO-PMO interactions and hairpins structures were -3.2 
and -1.6 kcal/mol respectively. For the sequence at the 3’ splice site, the energy needed 
to overcome PMO-PMO interactions and hairpins structures were -3.1 and -1.6 kcal/mol 
respectively. These energies were then subtracted from the intermolecular binding 
energy given by the SFold website to produce a total binding energy for the ASO. This 
correction provides a more accurate prediction for the energy involved in binding 
between ASO and RNA transcript (Popplewell et al., 2009). The more negative the 
binding energy, the stronger the bonds between ASO and RNA molecule, and each of 
these sequences had total binding energies of 1.4 and -6.9 kcal/mol respectively. These 
results are summarised in Table 6.1. Although the PMO at the 5’ splice site has been 
calculated to have a positive binding energy of 1.4 kcal/mol, previous studies on the 
effective design of ASOs for exon skipping purposes have indicated that targeting the 
acceptor splice site, i.e. at the 5’ end of an exon, will improve the potential for exon 
skipping (Aartsma-Rus et al., 2009). Therefore this sequence was included despite the 
positive predicted binding energy. 
Drawing on the information from both the predicted secondary sequences and the 
predicted splice enhancer elements, a third ASO was designed. The 3’ splice site has 
the most ESE binding sites as predicted by HSF (Figure 6.3), and so could be considered 
the prime target. However, secondary structure analysis of the sequence indicates that 
the splice site is within a region of double-stranded structure (Figure 6.4). Therefore, a 
third sequence was designed which targets the open loop structure found 3 bases 
upstream of the 3’ splice site, hopefully improving binding to the target RNA. The same 
binding energy analysis was performed with this sequence. The results from the SFold 
website calculated an intermolecular binding energy of -9.5 kcal/mol, while 
OligoEvaluator calculated energies for hairpin structures and PMO-PMO interactions to 
be -1.6 and -3.1 kcal/mol respectively, giving a total binding energy of -4.8 kcal/mol 
(Table 6.1).  
The GC content of each PMO was also calculated as a higher GC content improves 
binding due to the strength of a GC bond. Each sequence showed a GC content of more 
than 50% (Table 6.1). The SFold oligo output also show that all sequences avoid runs of 
four or more G bases, as the presence of this motif has been associated with weaker 
ASO activity (Chan et al., 2006).  
 189 
 
 
Table 6.1 - Binding energies for potential PMO sequences 
 
6.2.1.5 Final PMO Designs 
The final PMOs are shown in Figure 6.6, and are based on the combination of predicted 
ESEs and ESSs, the predicted secondary structure of the AluJ cassette and surrounding 
introns and the predicted binding energies of each of the sequences. At the 5’ end, PMO8 
(AluJ+1+25) targets the first 25 nucleotides in the AluJ cassette. At the 3’ end, PMO10 
(AluJ+96+120) targets the 25 nucleotides at the 3’ splice site. PMO9 (AluJ+93+117) is 
shifted 3 bases upstream of PMO10 (AluJ+96+120), targeting the predicted single-
stranded region. The binding sites of each PMO on the secondary structure model are 
shown in Figure 6.6A and summarised in the schematic in Figure 6.6B. Figure 6.6C 
shows a table with the sequences of each PMO. These three PMOs were produced by 
GeneTools and tested for their ability to skip the AluJ cassette in HeLa cells.  
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Figure 6.6 – A) Schematic diagram showing complementary binding sites of each ASO to the AluJ cassette. 
B) Secondary structure of AluJ cassette and surrounding intronic sequence. AluJ cassette is highlighted in 
blue, and each ASO’s binding site is indicated. C) Table of sequences of each ASO. 
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6.2.2 Exclusion of the AluJ Cassette 
Once the PMOs were designed (Figure 6.6) they were transfected into HeLa cells using 
EndoPorter and the inclusion of the AluJ cassette was quantified by comparing 
intensities of PCR fragments including the AluJ cassette to those that did not. HeLa cells 
endogenously express the ADAR2 enzyme, and there was found to be an endogenous 
inclusion of the AluJ cassette of 62.7 ± 0.97% in transcripts (Figure 6.7). The PMO 
designed to target the 5’ splice site, PMO8 (AluJ+1+25), was compared to those PMOs 
targeting the 3’ end of the AluJ cassette, PMO9 (AluJ+93+117) and PMO10 
(AluJ+96+120). Figure 6.7 shows the effect on exon skipping of all three of these PMOs 
at 2 µM. PMO8 (AluJ+1+25) shows a moderate effect on exon skipping, reducing the 
inclusion of AluJ to 44.1 ± 0.96% compared to control HeLa cells. However, PMO9 
(AluJ+93+117) appears to have a much stronger exon skipping effect, with 2 μM inducing 
near-complete exon skipping (0.62 ± 0.41% AluJ inclusion; Figure 6.7). Interestingly, 
PMO10 (AluJ+96+120) does not have any significant effect on inclusion of the AluJ 
cassette (58.6 ± 1.45%), even though it is simply shifted three bases from PMO9 
(AluJ+93+117). 
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Figure 6.7 – The effect of 2 µM of each PMO on AluJ insertion in HeLa cells 24 hours after transfection. A) 
PMO9 (AluJ+93+117) shows the strongest exon skipping ability with AluJ cassette insertion reduced to 0.63 
± 0.41%. PMO8 (AluJ+1+25) shows a moderate ability to exclude the AluJ cassette (44.1 ± 0.96%) whereas 
PMO10 (AluJ+96+120) shows no significant change in editing (58.6 ± 1.45%) compared to endogenous 
HeLa AluJ inclusion (62.7 ± 0.97%). N=3, *** = p<0.05 compared to control. B) A sample gel image of a 3% 
agarose gel run in TAE buffer, with 5 µl of Hyperladder V (25 bp, Bioline) visualised using the Ebox VX2 
imaging system and quantified using ImageJ analysis.”-ve” indicates negative (water) control. Gel shows the 
change in AluJ inclusion after different PMO treatments at 2 µM. The larger band (247 base pairs) includes 
the AluJ cassette. Inclusion is almost completely inhibited with 2 µM of PMO9 (AluJ+93+117).  
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To further compare the effect of each PMO, a range of concentrations were transfected 
into HeLa cells; the results are shown in Figure 6.8. These results support the initial 
comparison performed at 2 µM. A dose-response curve shifted to the left indicates 
increased potency against AluJ cassette inclusion, and is supported by a lower IC50. 
PMO10 (AluJ+96+120) shows little effect on AluJ inclusion, and only shows a significant 
reduction in percent inclusion at the highest concentration of 5 µM (50.9 ± 1.25%, 
p<0.05). Due to this marginal effect on AluJ inclusion, it was not possible to calculate an 
IC50 for this PMO from this concentration range. The dose-response curve of PMO8 
(AluJ+1+25) is to the left of PMO10 (AluJ+96+120), and shows a moderate potency, 
while PMO9 (AluJ+93+117) in comparison shows a stronger effect on AluJ inclusion and 
so the curve is shifted even further to the left.  
PMO8 (AluJ+1+25) showed a maximum effect at 2 µM (15.87 ± 5.22% AluJ inclusion) 
and at 500 nM of PMO8 (AluJ+1+25) there was no significant difference to control (52.94 
± 1.95% AluJ inclusion; p=0.292). PMO9 (AluJ+93+117) on the other hand showed 
excellent exon skipping of the AluJ cassette. This is evident by the lower IC50 of PMO9 
(AluJ+93+117) (0.18 ± 0.015 µM) compared to PMO8 (AluJ+1+25) (IC50 = 1.19 ± 0.24 
µM). PMO9 (AluJ+93+117) has a greater maximum inhibition of AluJ inclusion compared 
to PMO8 (AluJ+1+25), with higher concentrations (>3 µM) showing less than 5% 
inclusion of the AluJ cassette. These data show that PMO9 (AluJ+93+117) is the most 
efficient PMO at preventing inclusion of the AluJ cassette in the ADAR2 transcript of 
these original three PMOs. Interestingly, PMO10 (AluJ+96+120) has no effect on exon 
skipping compared to PMO9 (AluJ+93+117) which has a very strong effect, even though 
there are only 3 bases difference between them.  
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Figure 6.8 - Dose response curves showing exon skipping abilities of PMOs 8 and 9. N=3 per concentration. 
PMO9 (AluJ+93+117) is more effective at excluding the AluJ cassette as can be seen by the shift of the 
dose-response curve to the left and the lower IC50 (0.18 ± 0.015 µM) compared to PMO8 (AluJ+1+25) (IC50 
= 1.19 ± 0.24 µM).  
 
6.2.3 Targeting the 3’ end of the AluJ Cassette 
The difference between PMO9 (AluJ+93+117) and PMO10 (AluJ+96+120) in their ability 
to prevent AluJ cassette inclusion is striking despite having a difference in nucleotide 
sequence of only 3 bases. A possible reason for this change in efficacy is an inability for 
PMO10 (AluJ+96+120) to bind to the RNA transcript. The 5’ end of the PMO will bind to 
the 3’ end of the target sequence, and in this instance the 3’ end of PMO10 
(AluJ+96+120)’s target sequence is within a predicted region of double-stranded 
secondary structure (Figure 6.9A). This could be preventing the PMO from accessing the 
bases. If this were the case, then PMOs designed to bind successively further into the 
double-stranded region would become less effective. Therefore, two more PMOs 
(PMO9A (AluJ+94+118) and PMO9B (AluJ+95+119)) were designed to shift one base in 
the 3’ direction between PMO9 (AluJ+93+117) and PMO10 (AluJ+96+120), shifting one 
base at a time (Figure 6.9B). These four PMOs now cover the 3’ end of the AluJ cassette 
moving along the sequence towards the 3’ end.  
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Figure 6.9 – Schematic to show the newly designed PMO9A (AluJ+94+118) and PMO9B (AluJ+95+119) on the 3’ end of the AluJ cassette. A) 3’ sp lice site of the AluJ exon and 
associated secondary structure. Double-stranded and single-stranded regions of RNA are also indicated B) Sequences of each PMO targeting the 3’ splice site C) target site for PMO9 
(AluJ+93+117) D) target site for PMO9A (AluJ+94+118) E) target site for PMO9B (AluJ+95+119) F) target site for PMO10 (AluJ+96+120) 
 196 
 
HeLa cells were transfected with the new PMOs and the AluJ inclusion was determined. 
The resultant dose-response graphs are shown in Figure 6.10. At 2 µM, PMO9 
(AluJ+93+117), PMO9A (AluJ+94+118) and PMO9B (AluJ+95+119) all show excellent 
skipping of the AluJ cassette, with less than 5% inclusion after treatment with each PMO. 
At 100 nM none of the PMOs showed any effect on AluJ inclusion. However, PMO9 
(AluJ+93+117) is more effective at the lower concentrations, as shown by the lower IC50 
of 0.18 ± 0.02 µM, compared to PMO9A (AluJ+94+118) which had an IC50 of 0.36 ± 0.03 
µM. PMO9B (AluJ+95+119) had a slightly increased IC50 compared to PMO9A 
(AluJ+94+118) at 0.47 ± 0.03 µM, although this may be difficult to assess accurately 
given the poor curve fits to the data. It does appear that these PMOs do follow the trend 
of becoming less effective as they move further towards the 3’ splice site, as predicted. 
However, the difference between each PMO is only seen at lower concentrations, and 
the differences between PMO9A (AluJ+94+118) and PMO9B (AluJ+95+119) are 
marginal. At 2 µM they produce near-complete AluJ exclusion whereas PMO10 
(AluJ+96+120), targeting one base downstream, is completely ineffective.  
 
 
Figure 6.10 – Comparison of newly designed PMOs targeting the 3’ splice site and their efficacy on AluJ 
cassette exclusion (n=3). IC50s of each PMO shown in the top right hand corner. 
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6.2.4 Effect of Exon Skipping on Q/R Site Editing 
ADAR2 transcripts without the AluJ cassette have previously been reported to exhibit a 
higher rate of RNA editing at the Q/R site (Gerber et al., 1997). Therefore, removal of 
the AluJ cassette from the transcript using the PMOs designed in this chapter could affect 
the Q/R site editing of the GluA2 transcript. This was tested in the HeLa-B13 system 
used previously, where HeLa cells were co-transfected with a plasmid containing a short 
section of the GluA2 subunit, covering the Q/R editing site, as well as a PMO. 2 µM of 
each PMO was transfected into the HeLa-B13 system and the Q/R site editing was 
quantified. 2 µM was chosen as an initial concentration as this produced near-complete 
AluJ exclusion for PMO9 (AluJ+93+117), PMO9A (AluJ+94+118) and PMO9B 
(AluJ+95+119) (Figure 6.10). Q/R site editing percentages were calculated as in previous 
experiments and normalised to control, the results of which are shown in Figure 6.11. 
PMO9 (AluJ+93+117) was the only PMO to have a significant effect on Q/R site editing 
(p<0.05), with an increase to 124 ± 1.62% of control. PMO9A (AluJ+94+118) and PMO9B 
(AluJ+95+119), although they do cause the AluJ cassette to be excluded, do not appear 
to have any significant effect on Q/R site editing (105 ± 0.79% and 110 ± 2.5% 
respectively), nor do PMO8 (AluJ+1+25) with a moderate effect on AluJ exclusion (107 
± 1.00% of control) or PMO10 (AluJ+96+120) with no effect on AluJ exclusion (113 ± 
3.93%).  
As PMO9 (AluJ+93+117) showed an ability to alter Q/R site editing, transfection 
conditions were manipulated in an attempt to increase the Q/R site editing percentage 
further. PMO9 (AluJ+93+117) concentrations were increased from 2 µM to 5 µM, 
ensuring high levels of exon skipping, and the transfection was carried out across 24 
hours and 48 hours. A longer transfection time would allow for more of the transcripts 
without the AluJ cassette to be translated into functional protein, and so within the pool 
of ADAR2 enzyme available for RNA editing, successively more would be without the 
AluJ cassette. It could therefore be hypothesised that an increase in transfection time 
would increase the change in Q/R site editing. 
Results from this experiment are shown in Figure 6.12. Under the original transfection 
conditions (2 µM for 24 hours), PMO9 (AluJ+93+117) increased Q/R site editing to 
127.72 ± 4.25% of control. If the concentration of PMO9 (AluJ+93+117) was increased 
to 5 µM, Q/R site editing was not further increased to a significant extent (134.04 ± 
1.02%). An increase in concentration of PMO9 (AluJ+93+117) may not have had an 
effect as 2 µM was likely already sufficient for almost complete exclusion of the AluJ 
cassette. Prolonging the time of transfection from 24 hours to 48 hours also did not 
significantly change the increase in Q/R site editing (136.31 ± 1.71% at 2 µM and 128.67 
 198 
 
± 2.47% at 5 µM). It therefore appears that this increase of roughly 30% compared to 
control is the highest increase in Q/R site editing possible within the HeLa-B13 system.  
 
Figure 6.11 - Changes in Q/R site editing after transfection with 2 µM of each PMO. N=3 per condition, *** 
= p<0.05 compared to control. All Q/R site editing percentages are normalised to control HeLa-B13 system 
samples.  
 
 
Figure 6.12 - Changes in Q/R site editing after increasing concentrations of PMO9 (AluJ+93+117) and after 
increased transfection time as % change of control. N=3 per condition, *** = p<0.05 compared to control. All 
Q/R site editing percentages are normalised to control HeLa-B13 system samples. 
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6.3 DISCUSSION 
This chapter has looked at the design of antisense oligonucleotides to force the exclusion 
of the AluJ cassette from the ADAR2 transcript through a technique commonly referred 
to as exon skipping and the subsequent impact on Q/R site editing. The success of the 
majority of these PMOs for inducing exon skipping supports the idea of relying on 
bioinformatic resources for antisense oligonucleotide design. A major guidance in the 
design of the PMOs was the prediction of binding sites for exon splice enhancers (ESEs) 
and exon splice silencers (ESSs). These were predicted using the Human Splice Finder 
web server, the results of which showed a high abundance of ESEs at the 3’ splice site. 
Although there was a cluster of ESE sites near the 5’ splice site of the AluJ cassette, 
these appeared to be balanced out by a cluster of ESS sites, and so the output of this 
analysis favoured targeting the 3’ splice site, which is unusual as ESEs are generally 
found at the 5’ end of an exon (Wang et al., 2006). The bioinformatic analysis was then 
supported by the in vitro testing of the PMOs in the HeLa cell line, as PMO9 
(AluJ+93+117) (targeting the 3’ splice site) showed an improved efficiency over PMO8 
(AluJ+1+25) (targeting the 5’ splice site).  
Another guide to PMO design was the prediction of the binding energy of each PMO. To 
calculate the binding energy for each sequence, the intermolecular energy between the 
PMO and the RNA transcript was calculated using the SFold web server, and the energy 
needed to overcome any internal structure of hairpins or PMO-PMO interactions was 
subtracted. These calculations showed that PMO9 (AluJ+93+117) had a negative total 
binding energy of -4.8 kcal/mol. PMO8 (AluJ+1+25) has a calculated total binding energy 
of 1.4 kcal/mol. This could be considered detrimental to the ability of PMO8 (AluJ+1+25) 
to promote exon skipping, as energy would have to be put into the system to enable 
binding between PMO8 (AluJ+1+25) and the ADAR2 transcript. PMO10 (AluJ+96+120) 
on the other hand had a calculated binding energy of -6.9 kcal/mol and so, based purely 
on these parameters, ought to bind most effectively and so induce the greatest exon 
skipping, with PMO9 (AluJ+93+117) being slightly less effective (with a total binding 
energy of -4.8 kcal/mol) and PMO8 (AluJ+1+25) not having any effect at all. This was 
not the case when tested in vitro, as PMO10 (AluJ+96+120) turned out to be ineffective 
at inducing exon skipping whereas PMO8 (AluJ+1+25) had a moderate effect despite 
having a positive calculated binding energy. This could indicate that the prediction of 
binding energies is not accurate enough to properly determine the required energy for 
PMO binding. There are clearly other parameters not included in these calculations that 
affect whether or not the PMOs bind to the RNA. It has previously been reported that a 
PMO with a more negative binding energy correlates with improved exon skipping 
(Popplewell et al., 2009). However, in this paper the total binding energies for the PMOs 
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were more negative than those tested here, with binding energies in the region of -30 
kcal/mol to -40 kcal/mol, and also the PMOs ranged in length up to 30 bases. It could 
therefore be the case that binding energies may influence the PMO design process but 
only when the binding energy is calculated to be within this range, and that longer PMOs 
have the potential for a more negative binding energy. Nevertheless, if the binding 
energy is calculated to be higher, it does not necessarily mean that the PMO will not 
bind.  
The secondary structure of the ADAR2 transcript surrounding the AluJ cassette was also 
predicted using the MFold web server, and used to guide PMO design towards single-
stranded regions of RNA. Based on this prediction, PMO9 (AluJ+93+117) was designed 
to target an open region of RNA found 3 bases upstream of the 3’ splice site compared 
to PMO10 (AluJ+96+120) which targeted a region of double-stranded RNA at the 3’ 
splice site itself. This proved to be an important adjustment, as PMO9 (AluJ+93+117) 
showed excellent exon skipping efficiency while PMO10 (AluJ+96+120) did not have any 
effect. This large difference in efficacy when there was just a 3 base shift in the sequence 
was unexpected, and so PMO9A (AluJ+94+118) and PMO9B (AluJ+95+119) were 
designed to be intermediate steps, moving a single base towards the 3’ splice site each 
time. PMO9A (AluJ+94+118), one base shifted to downstream of PMO9 (AluJ+93+117), 
proved to be marginally more effective than PMO9B (AluJ+95+119) in vitro at lower 
concentrations as shown by changes in the IC50 for each PMO. PMO9 (AluJ+93+117) 
was the most effective at AluJ cassette exclusion, with an IC50 of 0.18 ± 0.02 µM, then 
PMO9A (AluJ+94+118) with an IC50 of 0.36 ± 0.03 µM followed by PMO9B 
(AluJ+95+119) with an IC50 of 0.47 ± 0.03 µM. The IC50s for PMO9A (AluJ+94+118) and 
PMO9B (AluJ+95+119) are very similar, and analysis of the dose-response curves 
indicate PMO9B (AluJ+95+119) in particular does not produce a good fit. PMO9A 
(AluJ+94+118) and PMO9B (AluJ+95+119) could therefore be considered to have the 
same effect on AluJ exclusion. PMO10 (AluJ+96+120) only showed a minimal effect on 
exon skipping within the concentration range tested here. When comparing the 
sequences to the secondary structure of the RNA target, it can be seen that PMO9A 
(AluJ+94+118), PMO9B (AluJ+95+119) and PMO10 (AluJ+96+120) are entering 
progressively further into the double-stranded region around the 3’ splice site. The PMOs 
may therefore be prevented from accessing these bases and so are unable to form 
strong enough bonds with the RNA, leading to inefficient exon skipping. These IC50 
values follow the predicted trend of decreasing efficacy as the PMO moves further into 
the double-stranded structure. However, PMO9A (AluJ+94+118) and PMO9B 
(AluJ+95+118) were still effective at exon skipping at the higher concentrations, whereas 
PMO10 (AluJ+96+120) only showed a slight effect at 5 µM. This large difference in 
potency between PMO9B (AluJ+95+119) and PMO10 (AluJ+96+120) is still 
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unexplained. To further investigate the reasons for PMO10 (AluJ+96+120) not showing 
any effect, it might be interesting to design PMOs that target bases further into the 
double-stranded region, beyond the splice site, to assess whether they too are prevented 
from binding. Alternatively, other splice sites located within double-stranded regions of 
RNA could be targeted to see whether these aspects of secondary structure should be 
avoided in all designs for exon skipping ASOs.  
Looking at which PMOs of the five designed were successful at preventing the inclusion 
of the AluJ cassette, it could be considered that targeting the predicted ESE binding sites 
and single-stranded RNA, while avoiding ESS binding sites and double-stranded RNA 
regions, are the more important considerations in antisense oligonucleotide design, while 
prediction of intermolecular binding energies is not accurate enough to be an effective 
guide. While this was true of the five PMOs tested in this chapter, splice sites in other 
transcripts would need to be tested in order to rule out using binding energies to predict 
PMO targets and instead focus on secondary structure and ESE binding sites. Aartsma-
Rus et al. have performed analyses on previously published ASOs using exon skipping 
in the dystrophin gene, both effectively and ineffectively, to determine whether guidelines 
can be extrapolated from these studies (Aartsma-Rus et al., 2009). The conclusions from 
their work are partly contradictory to those reported in this experiment, as they concluded 
that of the 156 ASOs analysed (104 that showed good exon skipping, 52 that were 
ineffective) the best parameters for guiding design were the GC content of the sequence 
and its predicted binding energy, which were found to not be of significance to these five 
PMOs. To truly determine whether these parameters aid ASO design, much higher 
numbers of PMOs would need to be tested, ideally across a large number of exons 
spliced at different rates, although this scale of analysis is prohibitively expensive. 
Aartsma-Rus et al. also determined that the majority of effective PMOs covered ESE 
binding sites, which supports the findings from this chapter (Aartsma-Rus et al., 2009). 
It appears that the most reliable parameter for PMO design in exon skipping from those 
evaluated here would be targeting the predicted binding sites of ESEs. Predicted 
secondary structure, and therefore targeting accessible bases in the RNA transcript, was 
an important aspect of the in silico PMO design. However, previous work has shown that 
a more accurate and reliable method for finding accessible bases is to use hybridisation 
array analysis (Popplewell et al., 2009). Here, the target RNA sequence is amplified and 
exposed to all possible hexamers. Binding, detected through biotinylated bases and 
fluorescent labelling, indicates an accessible sequence of hexamers and so could be 
targets for ASOs. This technique could aid further ASO design to the AluJ cassette 
sequence, as the results are experimentally verified rather than relying on the 
assumptions that are part of predictive software. 
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PMO9 (AluJ+93+117) was not only extremely efficient at excluding the AluJ cassette, 
but this also led to an indirect increase in RNA editing at the Q/R site of the GluA2 
subunit. When the ADAR2 transcript does not include the AluJ cassette, it is more 
efficient at A-to-I editing (Gerber et al., 1997), and so PMO9 (AluJ+93+117), through 
exon skipping technology, can influence the efficiency of the ADAR2 enzyme. What is 
curious is that PMO9A (AluJ+94+118) and PMO9B (AluJ+95+119) also prevented the 
inclusion of the AluJ cassette, but did not show any change in Q/R site editing in the 
HeLa-B13 system. It is possible that these PMOs did have an effect on RNA editing but 
it was not large enough to achieve significance, although the reasons why they would 
have a smaller effect than PMO9 (AluJ+93+117) are unclear. In order to have an impact 
on RNA editing at the Q/R site, the PMO needs to bind efficiently to the ADAR2 RNA 
transcript in the nucleus to prevent AluJ cassette inclusion. This process must be carried 
out on the majority of transcripts, so that the translated ADAR2 protein does not include 
this sequence. Once the majority of ADAR2 does not contain the AluJ cassette sequence 
then the enzyme’s editing efficiency has the potential to be affected. Since PMO9 
(AluJ+93+117) was shown to be more efficient at exon skipping than PMO9A 
(AluJ+94+118) and PMO9B (AluJ+95+119) at lower concentrations, it is possible that 
this difference in exon skipping ability was magnified across the pathway. There are 
several steps between the exon skipping effect of the PMO and the Q/R site editing 
efficiency, with multiple opportunities for other variables to influence the result. These 
external variables could be related to the PMOs themselves, for example PMO9A 
(AluJ+94+118) and PMO9B (AluJ+95+119) may not enter the nucleus as efficiently or 
may not bind to the RNA transcript as strongly, or it could be related to how the ADAR2 
transcript is processed or transported after splicing takes place. Furthermore we have 
not examined the protein levels of ADAR2 in our HeLa cell lines and we do not know 
whether the PMOs used in this study have significantly altered the expression levels of 
ADAR2 protein within the cell. 
PMO9 (AluJ+93+117) increased Q/R site editing to 130% of control at 2 µM after 24 
hours of transfection, although this percentage increase could not be improved by 
increasing the concentration of PMO9 (AluJ+93+117) nor increasing the transfection 
time. It therefore appears that this 30% increase in RNA editing is limited by some factor 
other than the efficiency of ADAR2. This is likely to be an inherent limitation within the 
HeLa-B13 system. One possible constraint could be ADAR2 expression levels within 
HeLa cells, particularly as it was shown in a previous chapter that Q/R site editing could 
be increased through simply overexpressing ADAR2. It has also been previously shown 
that increasing ADAR2 mRNA concentrations can increase the extent of Q/R site editing 
in HeLa cells modified to stably express the GluA2 transcript (Sawada et al., 2009, 
Yamashita et al., 2012c). It is therefore possible that manipulation of endogenous levels 
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of ADAR2 can only increase editing by 30%, particularly as the B13 minigene is under 
the control of a CMV promoter and is expected to be expressed at very high levels and 
so possibly overwhelming the ADAR2 enzyme available. Due to the transfection 
conditions of the HeLa-B13 system, the cells cannot be incubated for longer than 48 
hours without significant cell death. It is therefore possible that even at this longer 
incubation time there remains a pool of ADAR2 enzyme that include the AluJ cassette 
as they were translated before PMO treatment and so were not subject to exon skipping.  
In the original paper describing the difference in editing between the two ADAR2 
isoforms, with and without the AluJ cassette, ADAR2 containing AluJ was 50% more 
active than the transcript without AluJ on synthetic double-stranded DNA (Gerber et al., 
1997). However, at higher concentrations of ADAR2, both isoforms performed equally 
well. This indicates that the difference in editing efficiency between the two isoforms of 
ADAR2 is subtle, and so perhaps the editing assay used in our study is not sensitive 
enough to detect any smaller differences in editing. The previous study was also 
performed over one hour, whereas this study looked at Q/R site editing after 24 or 48 
hours. It is therefore possible that any difference in editing was evident at a shorter time 
period and had been corrected by the time the analysis took place.  
On the other hand, an increase of 30% could be sufficient protection against 
excitotoxicity for motor neurons. The Q/R site editing in motor neurons of ALS patients 
was extremely variable, with some motor neurons showing no editing at the Q/R site at 
all (Kawahara et al., 2004). This lack of Q/R site editing has been attributed to low 
expression of ADAR2 in motor neurons of ALS patients (Hideyama et al., 2012). 
Therefore, in cells with this low expression level, the subtle difference between 
transcripts containing the AluJ cassette and those without could make a large impact on 
the editing efficiency. However, it is difficult to find a model in which to test this 
hypothesis. The AluJ cassette is only found in human (and possibly other primate) 
ADAR2 transcripts, and so basic primary neuronal models from mouse or rat cortices 
could not be used. A possibility would be to use human induced pluripotent stem cell-
derived motor neurons. The expression levels of alternatively spliced ADAR2 transcripts 
in these cells have not yet been determined, and it is not known whether Q/R site editing 
is variable in motor neurons derived from stem cells of ALS patients as was seen in the 
original study with laser-captured motor neurons from the spinal cord. However, using 
the PMOs designed here to manipulate Q/R site editing in motor neurons would allow for 
functional assessments to be performed. The Ca2+ influx through AMPA receptors 
following treatment with the PMOs could be determined, and the effect of overstimulation 
by glutamate on cell viability could be analysed. 
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7 DISCUSSION 
In this work, antisense oligonucleotide technology was utilised to both disrupt and 
enhance RNA editing at the Q/R site of the GluA2 subunit in AMPA receptors. Editing at 
the Q/R site, with its known importance in normal neurological function 
(Brusa et al., 1995; Hideyama et al., 2010), was targeted due to the variability in editing 
levels seen in patients with ALS (Kawahara et al., 2004). Antisense oligonucleotides are 
a useful tool in molecular biology due to their specificity, limited off-target effects, and 
their resistance to degradation allowing for prolonged interactions. Antisense technology 
is commonly used in exon skipping, where the oligonucleotide influences splicing 
machinery to alter patterns of exons (Osman & Miller, 2014; Wu et al., 2014). This work 
aimed to use antisense technology to manipulate another intracellular process, RNA 
editing, through disruption of RNA secondary structure as well as to use exon skipping 
to change alternative splicing patterns of the ADAR2 enzyme and increase its efficiency. 
Manipulating Q/R site editing could have consequences for ALS research, both providing 
a model for disrupted editing in cells and a potential therapy by increasing the editing 
efficiency. 
7.1 USING PMOS TO INHIBIT Q/R SITE EDITING 
In the first part of this thesis, PMOs were designed to inhibit Q/R site editing. Building on 
the design published by Penn et al (2012), 30mer PMOs were designed to target the 
double-stranded structure around the Q/R editing site of the GluA2 transcript. These 
PMOs were shown to inhibit editing in the HeLa-B13 system, and the effect of PMOE1 
(GRIA2+279+313) was shown to successfully translate to the SH-SY5Y cell line which 
endogenously express the GluA2 subunit. Q/R site editing in the mRNA of SH-SY5Y 
cells was inhibited from 100% edited transcripts to less than 20% after 48 hours of 
treatment. For the first time, PMOs were shown to inhibit Q/R site editing in primary 
cortical neurons, although the method for transfection was unreliable and continues to 
require further optimisation before the downstream consequences of inhibited Q/R site 
editing can be fully analysed. Lentiviral vectors have the potential to introduce the 
antisense sequence easily into primary cortical neurons, and this avenue also continues 
to be explored. Integration-deficient lentiviral vectors (IDLVs), with mutations in the 
integrase enzyme preventing insertion of the transgene into the genome, have been 
shown to efficiently transduce neurons both in vivo and in vitro 
(Yáñez-Muñoz et al., 2006). Following an intracortical injection, IDLVs have been shown 
to effectively transduce corticospinal neurons in vivo (Hutson et al., 2012), and so are a 
promising potential vector to introduce antisense sequences into neurons both in culture 
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and in future in vivo models. Lentiviral vectors containing the human U6 small nuclear 
promoter (U6) have been show to express shRNA sequences in mouse models 
(Mäkinen et al., 2006) and are now commonly used to express guide RNA sequences in 
the CRIPSR/Cas9 system (Koike-Yusa et al., 2014). Expression of the equivalent RNA 
sequences used in the PMOs for this chapter by IDLVs could therefore provide a system 
to test the effect of Q/R site editing inhibition in a variety of models.  
This model of disrupted Q/R site editing in vitro would contribute to the knowledge gained 
from AR2 mice, which have a conditional knockdown of ADAR2 in motor neurons 
(Hideyama et al., 2010). In these mice, reduced Q/R site editing was associated with 
behavioural phenotypes of loss of motor function and a reduced life expectancy. 
Application of the GRIA2 PMOs to primary cortical neurons could elucidate intracellular 
events downstream of a loss of editing that may contribute to these behavioural changes. 
Here we show the first evidence for antisense technology targeting the Q/R site editing 
in primary neurons, with slight, albeit unreliable, inhibition of editing. PMO-mediated 
inhibition of Q/R site editing could be improved through conjugation of the PMOs to a 
cell-penetrating peptide, which have the ability to both cross the blood-brain barrier and 
enter neuronal populations (Stalmans et al., 2015). This modification would also allow 
the PMOs to be used in mouse models of ALS as well as in primary cell cultures.  
With strong disruption of Q/R site editing in cell lines, it is hoped that further adjustment 
of the methods for introducing the PMOs into primary cortical neurons would establish a 
consistent neuronal model to investigate these proposed molecular events, which could 
be key in understanding the molecular pathogenesis of ALS. Disruption of Q/R site 
editing is not only found in ALS patients, but in other neurological pathologies such as 
Alzheimer’s disease (Gaisler-Salomon et al., 2014) and ischaemia (Peng et al., 2006). It 
is possible that disruption of Q/R site editing, with or without downregulation of ADAR2, 
is part of a general pathway for neuronal damage and so this model could have more 
far-reaching applications. 
A model has been proposed by Yamashita and Kwak explaining the role of disrupted 
RNA editing at the Q/R site in the pathology of ALS (Yamashita & Kwak, 2014). TDP-43 
aggregation is a hallmark of ALS (Neumann et al., 2006) and in laser-captured motor 
neurons from sporadic ALS patients, all those that showed downregulation of ADAR2 
also showed TDP-43 pathology (Aizawa et al., 2010). However, overexpression of full 
length or fragments of TDP-43 and knockdown of TARDBP expression failed to induce 
downregulation of ADAR2 in cell lines, indicating that TDP-43 pathology is not upstream 
of ADAR2 dysregulation (Yamashita et al., 2012b). Loss of ADAR2 expression may 
therefore be upstream of TDP-43 pathology, as loss of the RNA binding protein is only 
found in neurons with downregulated editing enzyme. This hypothesised cascade is 
 206 
 
shown in Figure 7.1A. PMOs designed to disrupt the secondary structure of GluA2 have 
the same effect on Q/R site editing as downregulation of ADAR2. The model developed 
here could therefore mimic the hypothesised cascade from this stage (shown in red in 
Figure 7.1B), and it would be interesting to determine whether loss of Q/R site editing 
was sufficient to cause mislocalisation and aggregation of TDP-43. If so, this would be 
further evidence that TDP-43 pathology is a downstream event from ADAR2 
dysregulation, supporting the hypothesised cascade.  
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Figure 7.1 - A) proposed ALS cascade hypothesis by Yamashita and Kwak (2014) where inhibited Q/R site editing in motor neurons leads to TDP-43 aggregation and cell death. 
B) Incorporating the PMOs designed in this thesis into the cascade. 
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7.2 USING PMOS TO CHANGE THE ALTERNATIVE SPLICING PATTERN OF 
ADAR2 
This work also shows the first time that antisense technology has targeted the ADAR2 
enzyme in order to change its alternative splicing patterns. PMOs were designed based 
on information from a variety of bioinformatic resources such as prediction of splice 
regulatory elements, secondary structure of the RNA transcript and binding energies. 
Using these data, a total of 5 PMOs were designed targeting the AluJ cassette with 
varying degrees of exon skipping ability. PMO9 (AluJ+93+117) was then also shown to 
indirectly promote the RNA editing reaction at the Q/R site through increasing the 
availability of the more active form of ADAR2, the transcript without the AluJ cassette. 
This is the first preliminary evidence that changing the alternative splicing pattern of 
ADAR2 can change the percentage of editing at the Q/R site. This could have important 
implications. As previously discussed, variability of Q/R site editing percentage is found 
in motor neurons of ALS patients (Kawahara et al., 2004). Therefore if improving 
ADAR2’s editing efficiency could increase Q/R site editing in those neurons with 
underedited sites, associated increases in calcium influx and neuronal cell death could 
be prevented. It would be interesting to investigate whether ADAR2 expression or Q/R 
site editing of the GluA2 transcript is impacted in any other model for ALS, such as the 
SOD1G93A mouse model, and if so whether our PMO can have an effect on these 
processes.  
Work with AR2 mouse model of ALS showed that increasing ADAR2 expression could 
rescue their degenerative phenotype by preventing the loss of motor function, reducing 
motor neuron cell death and increasing Q/R site editing to over 95% 
(Yamashita et al., 2013). In this study, the ADAR2 sequence was inserted into AAV9 
vectors which could then be injected intravenously in the mouse tail vein. The ADAR2 
sequence was taken from the cDNA amplicons of “ADAR2a”, without the AluJ cassette. 
The ADAR2 gene, under the SYN1 promoter, was specifically expressed in neurons with 
no observable expression in the periphery. Total ADAR2 mRNA expression increased 
by 1.5-fold, with no change in expression of endogenous mouse ADAR2 
(Yamashita et al., 2013). This paper focussed on the effect of ADAR2 overexpression on 
the Q/R editing site, but did not discuss any side effects of this treatment. It would be 
interesting to determine whether expression of the “ADAR2b” isoform in an AAV vector, 
including the AluJ cassette, would have the same effect on Q/R site editing.  
ADAR2 edits adenosines at thousands of sites across the genome, and so a 1.5-fold 
increase in expression could have broader consequences. Mice with a knockout of 
ADAR2, when crossed with the mouse line expressing the “edited” version of Gria2, 
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show changes in expression across a range of genes, many of which are expressed in 
neurons, as well as specific phenotypic changes such as altered startle reflexes which 
may be associated with a loss of editing in the 5-HT2C gene (Horsch et al., 2011). 
Therefore, although the overexpression of ADAR2 using the AAV9 vector was limited to 
neuronal cells, general overexpression of the ADAR2 enzyme may cause nonspecific 
effects. In this thesis, we have described a more subtle approach to increase 
endogenous ADAR2 activity, which if applied successfully in vivo could potentially limit 
the side-effects seen with ADAR2 overexpression.  
Overexpressing ADAR2 is an efficient treatment in the AR2 mouse model for ALS, but 
currently this method would not be a viable therapeutic approach for humans. Although 
gene therapy has reached clinical trials for many applications including cancers, immune 
disorders and neurological disorders (summarised in Figure 7.2), only two therapies have 
so far received European approval: Glybera (uniQure), which uses an AAV vector to 
deliver additional lipoprotein lipase in patients with pancreatitis (Ylä-Herttuala, 2012), 
and Strimvelis, an ex vivo therapy correcting expression of adenosine deaminase in 
SCID patients (Schimmer & Breazzano, 2016). Fears over patients developing 
leukaemia due to random insertion of transgenes into the genome, which has occurred 
in several clinical trials, form a large part of the argument against approval for gene 
therapies (Ginn et al., 2013).  
 
Figure 7.2 - Indications addressed by gene therapy clinical trials, figure taken from (Ginn et al., 2013) 
Use of antisense technology, on the other hand, does not carry the same risk for 
oncogenesis. Mipomersen, targeting apolipoprotein B expression in patients with familial 
hypercholesterolaemia (Raal et al., 2010), was approved by the FDA for use in 2013 
(Toth, 2013). Alicaforsen is an antisense oligonucleotide targeting ICAM-1 in cases of 
ulcerative colitis and inflammatory bowel disease (van Deventer et al., 2004; Greuter et 
al., 2016) and has been given orphan drug status by both the US and the EU, allowing 
its fast track through the regulatory processes. For patients with Duchenne Muscular 
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Dystrophy, the battle to get Eteplirsen approved by the FDA continues. Eteplirsen targets 
the DMD gene, employing exon skipping technology to skip exon 51 and produce a 
functional truncated dystrophin protein which delays the progression of Duchenne 
Muscular Dystrophy symptoms (Mendell et al., 2016). If approved, these successful 
antisense therapies could pave the way for the dozens of other drug candidates showing 
success in clinical trials, such as Nusinersen in the treatment of spinal muscular atrophy 
(Haché et al., 2016). Antisense oligonucleotides have a good safety profile in clinical 
trials, in general showing only mild adverse effects such as flu-like symptoms or reactions 
around the site of administration such as post-lumbar puncture syndrome or back pain 
(Miller et al., 2013). Elevated transaminases, a possible indication of liver damage, have 
also been reported in some clinical trials with mipomersen (Raal et al., 2010) but not in 
other cases (Haché et al., 2016). Therefore, while gene therapy to increase expression 
of the ADAR2 enzyme might show good results in mouse models, the safety profile of 
this kind of therapy is prohibitive. On the other hand, antisense therapies have been 
shown to be well-tolerated by humans, and so increasing the efficacy of the ADAR2 
enzyme through PMO-mediated exon skipping as a therapy for ALS could be more likely 
to pass regulatory standards in a potentially rapid line of clinical development. 
7.3 STUDY LIMITATIONS 
There are, of course, limitations to any scientific experiment which will affect the quality 
of results given and the ability to comprehensively answer a given hypothesis. If broader 
conclusions are to be drawn then these limitations must be acknowledged and 
addressed. Firstly, this work was limited by the restriction to cell culture models. 
Secondly, the method for quantification of Q/R site editing, using quantification of 
restriction endonuclease digest products, may have impacted the quality of results found. 
Also, a limit on the number of PMOs available to test in this body of work prevented 
broader conclusions from being drawn on ideal PMO target sequences. Finally, the 
method of delivery of PMOs prevented the assessment of the effects of Q/R site editing 
inhibition in primary neuronal cultures. 
Use of cell culture models in this work was necessary, but limiting. There is no 
replacement for working with cell lines in molecular biology that is comparable in terms 
of ease of manipulation, cost and replicability. The main limitation of working with cell 
lines is the basic nature of the model. Only one cell type exists in the system, which is 
not neuronal, and the cells do not necessarily behave in the same way as in vivo. For 
example, SH-SY5Y cells were used to test the effect of PMOs on endogenously 
expressed GluA2 transcripts. However, there is little evidence that these transcripts 
develop into a mature AMPA receptor, and so this model may be more closely related to 
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an immature neuron (Kovalevich & Langford, 2013). Despite these drawbacks, cell 
culture work will likely remain the preliminary model for many areas of molecular biology. 
However, alternative options will continue to develop into more physiologically 
comparable models. For example, the ease with which fibroblasts form induced 
pluripotent stem cells, which can then differentiate into a multitude of cell types including 
motor neurons, opens new possibilities for physiologically comparable in vitro work. Use 
of these models could overcome the limiting basic nature of working with cell lines, and 
possibly make the results more predictive of in vivo effects.  
The method chosen for measurement of percentage editing at the Q/R site was based 
on previous reports (Sawada et al., 2009; Yamashita et al., 2012a; Whitney et al., 2008) 
and ease of replication. However, densitometric analysis of restriction endonuclease 
products contains some inherent bias. This method relies on detection of DNA bands on 
visualisation of agarose gels, and so may not be accurate enough to pick up small 
changes in editing. For this work, this limitation was accepted as unavoidable but as a 
point which may affect the quality of results. For example, the effect of PMO9A 
(AluJ+94+118) or PMO9B (AluJ+95+119) on Q/R site editing may have been too small 
for detection using this method despite these PMOs showing strong exon skipping of the 
AluJ cassette. Therefore in future work, alternative methods of quantification of editing 
may be compared.  
In this project, a number of PMOs targeted at specific sites were examined. This required 
the usage of a number of bioinformatic prediction tools to assess the target sequence 
before PMO production and involved an important part of this thesis. However, it also 
meant that the ideal scenario of “walking” the PMOs along the gene, shifting the target 
sequence by a few bases each time, was not possible. Therefore, conclusions made on 
the success of the PMOs in vitro compared to the predicted success in silico cannot be 
definitively made without analysis of further sequences. Despite this restriction, the 
in silico predictions were sufficiently successful to produce PMO sequences that both 
inhibited Q/R site editing when targeting GluA2 secondary structure and increasing Q/R 
site editing when targeting skipping of the AluJ cassette in the ADAR2 transcript. 
The main limitation in this project was the method of delivery of the PMOs. Use of 
peptide-based transfection reagents are common practice in cell lines, but have limited 
efficiencies in more complex systems as shown with the primary cortical neurons here. 
Transfection reagents also do not allow the PMOs to be taken into in vivo models. In 
order to further the work done here, a more efficient method of delivery ought to be 
utilised such as peptide conjugation.   
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7.4 FURTHER WORK 
Following the work discussed in this thesis, work in the immediate future would be 
characterising the effects of both of these sets of PMOs in more relevant cell models, 
either inhibiting the Q/R site editing in primary cortical neurons or testing PMOs targeting 
either the GluA2 subunit or the ADAR2 transcript in induced pluripotent stem cell-derived 
motor neurons. This would be the most accurate cell culture model possible and, as 
fibroblasts could be sourced from ALS patients, may test the PMOs in an ALS model of 
motor neurons. The results shown in this thesis confirm that the PMOs can target the 
first steps of the cascade proposed in Figure 7.1A, however the effect of PMOs on later 
steps would need to be characterised. Therefore, analysis of PMOs in neuronal models 
could assess the effect of inhibited Q/R site editing on TDP-43 aggregation, and whether 
altering ADAR2 splicing patterns can improve cell viability (Figure 7.1B). Ultimately, with 
appropriate peptide conjugations for administration, these PMOs would need to be tested 
in vivo to assess the true effect of altered editing on cell viability.  
Beyond validating these PMOs in a more applicable model, an interesting avenue for 
exploration would be whether other editing sites in the genome could be disrupted using 
PMOs. This thesis has shown that PMOs targeting regions of double-stranded secondary 
structure can effectively disrupt Q/R site editing. Other editing sites in coding regions are 
known to have important physiological functions, for example editing of the 5-HT2C 
transcript occurs within a predicted double-stranded loop, with reduced editing being 
associated with schizophrenia (Sodhi et al., 2001), depression (Gurevich et al., 2002) 
and neuropathic pain (Nakae et al., 2008). Using PMOs to disrupt the secondary 
structure of this editing site could therefore give indications towards molecular 
mechanisms affected in these disorders. This thesis has also shown that skipping of the 
AluJ cassette exon in the ADAR2 transcript leads to an increase in Q/R site editing. 
Further work should determine whether any other editing sites, both in coding and 
noncoding sequences, are affected by this shift in ADAR2 isoform. Additionally, there 
are several other ADAR2 isoforms expressed in mammalian tissue 
(Kawahara et al., 2005). Directing exon skipping to these other alternatively spliced 
exons may also impact RNA editing either at the Q/R site of the GluA2 transcript or others 
throughout the genome
 213 
 
8 BIBLIOGRAPHY 
AARTSMA-RUS, A., JANSON, A.A.M., KAMAN, W.E., BREMMER-BOUT, M., DEN DUNNEN, J.T., BAAS, 
F., VAN OMMEN, G.-J.B. & VAN DEUTEKOM, J.C.T. (2003) Therapeutic antisense-induced exon skipping 
in cultured muscle cells from six different DMD patients. Human molecular genetics. 12 (8), 907–914. 
AARTSMA-RUS, A. & VAN OMMEN, G.-J.B. (2007) Antisense-mediated exon skipping: a versatile tool with 
therapeutic and research applications. RNA. 13 (10), 1609–1624.  
AARTSMA-RUS, A., VAN VLIET, L., HIRSCHI, M., JANSON, A. A M., HEEMSKERK, H., DE WINTER, C.L., 
DE KIMPE, S., VAN DEUTEKOM, J.C.T., ’T HOEN, P. A C. & VAN OMMEN, G.-J.B. (2009) Guidelines for 
antisense oligonucleotide design and insight into splice-modulating mechanisms. Molecular Therapy. 17 (3), 
548–553.  
ABBAS, A.I., URBAN, D.J., JENSEN, N.H., FARRELL, M.S., KROEZE, W.K., MIECZKOWSKI, P., WANG, 
Z. & ROTH, B.L. (2010) Assessing serotonin receptor mRNA editing frequency by a novel ultra high-
throughput sequencing method. Nucleic acids research. 38 (10), e118 
ABEL, O., POWELL, J.F., ANDERSEN, P.M. & AL-CHALABI, A. (2012) ALSoD: A user-friendly online 
bioinformatics tool for amyotrophic lateral sclerosis genetics. Human mutation. 33 (9), 1345–1351.  
ACHARYA, K.K., GOVIND, C.K., SHORE, A.N., STOLER, M.H. & REDDI, P.P. (2006) cis-requirement for 
the maintenance of round spermatid-specific transcription. Developmental biology. 295 (2), 781–790.  
ADAMCZYK, A., MEJIAS, R., TAKAMIYA, K., YOCUM, J., KRASNOVA, I., CALDERON, J., CADET, J.L., 
HUGANIR, R., PLETNIKOV, M. & WANG, T. (2012) GluA3-deficiency in Mice is Associated with Increased 
Social and Aggressive Behaviour and Elevated Dopamine in Striatum. Behavioral Brain Research. 229 (1), 
265–272.  
ADE, C., ROY-ENGEL, A.M. & DEININGER, P.L. (2013) Alu elements: an intrinsic source of human genome 
instability. Current opinion in virology. 3 (6), 639–645.  
ADESNIK, H. & NICOLL, R.A. (2007) Conservation of Glutamate Receptor 2-Containing AMPA Receptors 
during Long-Term Potentiation. Journal of Neuroscience. 27 (17), 4598–4602.  
AGHOLME, L., LINDSTRÖM, T., KÅGEDAL, K., MARCUSSON, J. & HALLBECK, M. (2010) An in vitro 
model for neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical 
characteristics of mature neurons. Journal of Alzheimer’s disease. 20 (4), 1069–1082.  
AGRANAT, L., SPERLING, J. & SPERLING, R. (2011) A novel tissue-specific alternatively spliced form of 
the A-to-I RNA editing enzyme ADAR2. RNA biology. 7 (2), 253–262. 
AHMAD, S., BHATIA, K., KANNAN, A. & GANGWANI, L. (2016) Molecular Mechanisms of 
Neurodegeneration in Spinal Muscular Atrophy. Journal of experimental neuroscience. 10, 39–49.  
AIZAWA, H., SAWADA, J., HIDEYAMA, T., YAMASHITA, T., KATAYAMA, T., HASEBE, N., KIMURA, T., 
YAHARA, O. & KWAK, S. (2010) TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the 
RNA editing enzyme ADAR2. Acta neuropathologica. 120 (1), 75–84.  
AKBARIAN, S., SMITH, M.A. & JONES, E.G. (1995) Editing for an AMPA receptor subunit RNA in prefrontal 
cortex and striatum in Alzheimer’s disease, Huntington's disease and schizophrenia. Brain research. 699 
(2), 297–304. 
 214 
 
ALLAOUA, H., CHAUDIEU, I., KRIEGER, C., BOKSA, P., PRIVAT, A. & QUIRION, R. (1992) Alterations in 
spinal cord excitatory amino acid receptors in amyotrophic lateral sclerosis patients. Brain Research. 579 
(1), 169–172.  
AMANTANA, A. & IVERSEN, P.L. (2005) Pharmacokinetics and biodistribution of phosphorodiamidate 
morpholino antisense oligomers. Current opinion in pharmacology. 5 (5), 550–555.  
ARAI, T., HASEGAWA, M., AKIYAMA, H., IKEDA, K., NONAKA, T., MORI, H., MANN, D., TSUCHIYA, K., 
YOSHIDA, M., HASHIZUME, Y. & ODA, T. (2006) TDP-43 is a component of ubiquitin-positive tau-negative 
inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and 
biophysical research communications. 351 (3), 602–611.  
ARAI, Y., MIZUGUCHI, M. & TAKASHIMA, S. (1997) Developmental changes of glutamate receptors in the 
rat cerebral cortex and hippocampus. Anatomy and embryology. 195 (1), 65–70. 
ARMSTRONG, N. & GOUAUX, E. (2000) Mechanisms for activation and antagonism of an AMPA-sensitive 
glutamate receptor: crystal structures of the GluR2 ligand binding core. Neuron. 28 (1), 165–181.  
ARNOLD, E.S., LING, S.-C., HUELGA, S.C., LAGIER-TOURENNE, C., POLYMENIDOU, M., DITSWORTH, 
D., KORDASIEWICZ, H.B., MCALONIS-DOWNES, M., PLATOSHYN, O., PARONE, P.A., DA CRUZ, S., 
CLUTARIO, K.M., SWING, D., TESSAROLLO, L., MARSALA, M., SHAW, C.E., YEO, G.W. & CLEVELAND, 
D.W. (2013) ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron 
disease without aggregation or loss of nuclear TDP-43. PNAS 110 (8), E736–E745. 
AYALA, Y.M., ZAGO, P., D’AMBROGIO, A., XU, Y.-F., PETRUCELLI, L., BURATTI, E. & BARALLE, F.E. 
(2008) Structural determinants of the cellular localization and shuttling of TDP-43. Journal of cell science. 
121 (Pt 22), 3778–3785.  
AYERS, J.I., FROMHOLT, S., KOCH, M., DEBOSIER, A., MCMAHON, B., XU, G. & BORCHELT, D.R. 
(2014) Experimental transmissibility of mutant SOD1 motor neuron disease. Acta neuropathologica. 128 (6), 
791–803.  
AYERS, J.I., FROMHOLT, S.E., O’NEAL, V.M., DIAMOND, J.H. & BORCHELT, D.R. (2016) Prion-like 
propagation of mutant SOD1 misfolding and motor neuron disease spread along neuroanatomical pathways. 
Acta Neuropathologica. 131 (1), 103–114 
AZUBEL, M., HABIB, N., SPERLING, R. & SPERLING, J. (2006) Native spliceosomes assemble with pre-
mRNA to form supraspliceosomes. Journal of Molecular Biology. 356 (4), 955–966.  
BAHN, J.H., LEE, J.-H., LI, G., GREER, C., PENG, G. & XIAO, X. (2012) Accurate identification of A-to-I 
RNA editing in human by transcriptome sequencing. Genome research. 22 (1), 142–150. 
BALIK, A., PENN, A.C., NEMODA, Z. & GREGER, I.H. (2013) Activity-regulated RNA editing in select 
neuronal subfields in hippocampus. Nucleic acids research. 41 (2), 1124–1134. 
BALL, S.M., ATLASON, P.T., SHITTU-BALOGUN, O.O. & MOLNÁR, E. (2010) Assembly and intracellular 
distribution of kainate receptors is determined by RNA editing and subunit composition. Journal of 
neurochemistry. 114 (6), 1805–1818.  
BARBON, A., FUMAGALLI, F., CARACCIOLO, L., MADASCHI, L., LESMA, E., MORA, C., CARELLI, S., 
SLOTKIN, T.A., RACAGNI, G., DI GIULIO, A.M., GORIO, A. & BARLATI, S. (2010) Acute spinal cord injury 
persistently reduces R/G RNA editing of AMPA receptors. Journal of neurochemistry. 114 (2), 397–407.  
 215 
 
BASSANI, S., FOLCI, A., ZAPATA, J. & PASSAFARO, M. (2013) AMPAR trafficking in synapse maturation 
and plasticity. Cellular and Molecular Life Sciences. 70 (23), 4411–4430 
BASSO, M., POZZI, S., TORTAROLO, M., FIORDALISO, F., BISIGHINI, C., PASETTO, L., SPALTRO, G., 
LIDONNICI, D., GENSANO, F., BATTAGLIA, E., BENDOTTI, C. & BONETTO, V. (2013) Mutant copper-
zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in 
astrocytes: implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis. 
The Journal of biological chemistry. 288 (22), 15699–15711.  
BAUER, P.O. (2016) Methylation of C9orf72 expansion reduces RNA foci formation and dipeptide-repeat 
proteins expression in cells. Neuroscience letters. 612, 204–209.  
BAZAK, L., HAVIV, A., BARAK, M., JACOB-HIRSCH, J., DENG, P., ZHANG, R., ISAACS, F.J., RECHAVI, 
G., LI, J.B., EISENBERG, E. & LEVANON, E.Y. (2014) A-to-I RNA editing occurs at over a hundred million 
genomic sites, located in a majority of human genes. Genome research. 24 (3), 365–376.  
BELLINGHAM, M.C. (2011) A Review of the Neural Mechanisms of Action and Clinical Efficiency of Riluzole 
in Treating Amyotrophic Lateral Sclerosis: What have we Learned in the Last Decade? CNS Neuroscience 
and Therapeutics. 17 (1), 4–31.  
BELZIL, V. V., BAUER, P.O., PRUDENCIO, M., GENDRON, T.F., STETLER, C.T., YAN, I.K., PREGENT, 
L., DAUGHRITY, L., BAKER, M.C., RADEMAKERS, R., BOYLAN, K., PATEL, T.C., DICKSON, D.W. & 
PETRUCELLI, L. (2013) Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone 
trimethylation, an epigenetic event detectable in blood. Acta Neuropathologica. 126 (6), 895–905.  
BENATAR, M. (2007) Lost in translation: treatment trials in the SOD1 mouse and in human ALS. 
Neurobiology of disease. 26 (1), 1–13.  
BENDER, F.L.P., FISCHER, M., FUNK, N., OREL, N., RETHWILM, A. & SENDTNER, M. (2007) High-
efficiency gene transfer into cultured embryonic motoneurons using recombinant lentiviruses. Histochemistry 
and Cell Biology. 127 (4), 439–448.  
BENSIMON, G., LACOMBLEZ, L. & MEININGER, V. (1994) A controlled trial of riluzole in amyotrophic 
lateral sclerosis. ALS/Riluzole Study Group. The New England journal of medicine. 330 (9), 585–591.  
BENTLEY, D.L. (2014) Coupling mRNA processing with transcription in time and space. Nature Reviews 
Genetics. 15 (3), 163–175.  
BENUSSI, L., ROSSI, G., GLIONNA, M., TONOLI, E., PICCOLI, E., FOSTINELLI, S., PATERLINI, A., 
FLOCCO, R., ALBANI, D., PANTIERI, R., CEREDA, C., FORLONI, G., TAGLIAVINI, F., BINETTI, G. & 
GHIDONI, R. (2014) C9ORF72 hexanucleotide repeat number in frontotemporal lobar degeneration: a 
genotype-phenotype correlation study. Journal of Alzheimer’s disease 38 (4), 799–808.  
BERNARD, A., FERHAT, L., DESSI, F., CHARTON, G., REPRESA, A., BEN-ARI, Y. & KHRESTCHATISKY, 
M. (1999) Q/R editing of the rat GluR5 and GluR6 kainate receptors in vivo and in vitro: evidence for 
independent developmental, pathological and cellular regulation. The European Journal of Neuroscience. 
11 (2), 604–616. 
BETTS, C., SALEH, A.F., ARZUMANOV, A. A, HAMMOND, S.M., GODFREY, C., COURSINDEL, T., GAIT, 
M.J. & WOOD, M.J. (2012) Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With 
Improved Cardiac Exon Skipping Activity for DMD Treatment. Molecular Therapy — Nucleic Acids. 1 (8), 
e38.  
 216 
 
BEYER, B., DELEUZE, C., LETTS, V.A., MAHAFFEY, C.L., BOUMIL, R.M., LEW, T.A., HUGUENARD, J.R. 
& FRANKEL, W.N. (2008) Absence seizures in C3H/HeJ and knockout mice caused by mutation of the 
AMPA receptor subunit Gria4. Human Molecular Genetics. 17 (12), 1738–1749. 
BHALLA, T., ROSENTHAL, J.J.C., HOLMGREN, M. & REENAN, R. (2004) Control of human potassium 
channel inactivation by editing of a small mRNA hairpin. Nature structural & molecular biology. 11 (10), 950–
956.  
BIEDLER, J.L., HELSON, L. & SPENGLER, B.A. (1973) Morphology and Growth , Tumorigenicity , and 
Cytogenetics of Human Neuroblastoma Cells in Continuous Culture Morphology and Growth , 
Tumorigenicity , and Cytogenetics of Human Neuroblastoma Cells in Continuous Culture. Cancer Research. 
33, 2643–2652. 
BIEDLER, J.L., ROFFLER-TARLOV, S., SCHACHNER, M. & FREEDMAN, L.S. (1978) Multiple 
Neurotransmitter Synthesis by Human Neuroblastoma Cell Lines and Clones Multiple Neurotransmitter 
Synthesis by Human Neuroblastoma Cell Lines and Clones. Cancer Research. 38, 3751–3757. 
BILSLAND, L.G., SAHAI, E., KELLY, G., GOLDING, M., GREENSMITH, L. & SCHIAVO, G. (2010) Deficits 
in axonal transport precede ALS symptoms in vivo. PNAS. 107 (47), 20523–20528. 
BONINI, D., FILIPPINI, A., VIA, L. LA, FIORENTINI, C., FUMAGALLI, F., COLOMBI, M. & BARBON, A. 
(2015) Chronic glutamate treatment selectively modulates AMPA RNA editing and ADAR expression and 
activity in primary cortical neurons. RNA Biology. 12 (1), 1–11. 
BORNER, G.V., MORL, M., JANKE, A. & PAABO, S. (1996) RNA editing changes the identity of a 
mitochondrial tRNA in marsupials. EMBO Journal. 15 (21), 5949–5957. 
BOULOS, S., MELONI, B.P., ARTHUR, P.G., BOJARSKI, C. & KNUCKEY, N.W. (2006) Assessment of 
CMV, RSV and SYN1 promoters and the woodchuck post-transcriptional regulatory element in adenovirus 
vectors for transgene expression in cortical neuronal cultures. Brain research. 1102 (1), 27–38.  
BREWER, G.J., TORRICELLI, J.R., EVEGE, E.K. & PRICE, P.J. (1993) Optimized survival of hippocampal 
neurons in B27-supplemented Neurobasal, a new serum-free medium combination. Journal of neuroscience 
research. 35 (5), 567–576. 
BROCKINGTON, A., NING, K., HEATH, P.R., WOOD, E., KIRBY, J., FUSI, N., LAWRENCE, N., 
WHARTON, S.B., INCE, P.G. & SHAW, P.J. (2013) Unravelling the enigma of selective vulnerability in 
neurodegeneration: motor neurons resistant to degeneration in ALS show distinct gene expression 
characteristics and decreased susceptibility to excitotoxicity. Acta neuropathologica. 125 (1), 95–109.  
BRUIJN, L.I., BECHER, M.W., LEE, M.K., ANDERSON, K.L., JENKINS, N.A., COPELAND, N.G., SISODIA, 
S.S., ROTHSTEIN, J.D., BORCHELT, D.R., PRICE, D.L. & CLEVELAND, D.W. (1997) ALS-linked SOD1 
mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-
containing inclusions. Neuron. 18 (2), 327–338. 
BRUSA, R., ZIMMERMANN, F., KOH, D., FELDMEYER, D., GASS, P., SEEBURG, P.H. & SPRENGEL, R. 
(1995) Early-Onset Epilepsy and Postnatal Lethality Associated with an Editing-Deficient GluR-B Allele in 
Mice. Science. 270, 1677–1680. 
BUERLI, T., PELLEGRINO, C., BAER, K., LARDI-STUDLER, B., CHUDOTVOROVA, I., FRITSCHY, J.-M., 
MEDINA, I. & FUHRER, C. (2007) Efficient transfection of DNA or shRNA vectors into neurons using 
magnetofection. Nature protocols. 2 (12), 3090–3101.  
 217 
 
BUONASSISI, V., SATO, G. & COHEN, A. (1962) Hormone-producing cultures of adrenal and pituitary tumor 
origin. PNAS. 1184–1190. 
BURATTI, E., DÖRK, T., ZUCCATO, E., PAGANI, F., ROMANO, M. & BARALLE, F.E. (2001) Nuclear factor 
TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. The EMBO journal. 20 (7), 
1774–1784.  
BURNASHEV, N., MONYER, H., SEEBURG, P.H. & SAKMANN, B. (1992) Divalent ion permeability of 
AMPA receptor channels is dominated by the edited form of a single subunit. Neuron. 8 (1), 189–198. 
BURNS, C.M., CHU, H., RUETER, S.M., HUTCHINSON, L.K., CANTON, H., SANDERS-BUSH, E. & 
EMESON, R.B. (1997) Regulation of serotonin-2C receptor G-protein coupling in RNA editing. Nature. 
387303–308.  
CAO, G., PEI, W., GE, H., LIANG, Q., LUO, Y., SHARP, F.R., LU, A., RAN, R., GRAHAM, S.H. & CHEN, J. 
(2002) In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects 
against Ischemic Brain Injury and Neuronal Apoptosis. The Journal of neuroscience 22 (13), 5423–5431.  
CARTEGNI, L., WANG, J., ZHU, Z., ZHANG, M.Q. & KRAINER, A.R. (2003) ESEfinder: A web resource to 
identify exonic splicing enhancers. Nucleic acids research. 31 (13), 3568–3571. 
CHAN, J.H.P., LIM, S. & WONG, W.S.F. (2006) Antisense Oligonucleotides: From Design to Therapeutic 
Application. Clinical and Experimental Pharmacology and Physiology. 33 (February), 533–540. 
CHASIN, L.A. (2007) Searching for splicing motifs. Advances in experimental medicine and biology. 623, 
85–106. 
CHEN, C.X., CHO, D.S., WANG, Q., LAI, F., CARTER, K.C. & NISHIKURA, K. (2000) A third member of the 
RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA 
binding domains. RNA. 6 (5), 755–767. 
CHEN, L., LI, Y., LIN, C.H., CHAN, T.H.M., CHOW, R.K.K., SONG, Y., LIU, M., YUAN, Y.-F., FU, L., KONG, 
K.L., QI, L., ZHANG, N., TONG, A.H.Y., KWONG, D.L., MAN, K., LO, C.M., LOK, S., TENEN, D.G. & GUAN, 
X.-Y. (2013) Recoding RNA editing antizyme inhibitor 1 predisposes to hepatocellular carcinoma. Nature. 
19 (2), 209–216. 
CHEN, S.H., LI, X.L., LIAO, W.S.L., WU, J.H. & CHAN, L. (1990) RNA editing of apoliopoprotein B mRNA. 
J. Biol. Chem. 265 (12), 6811–6816. 
CHEW, J., GENDRON, T.F., PRUDENCIO, M., SASAGURI, H., ZHANG, Y.-J., CASTANEDES-CASEY, M., 
LEE, C.W., JANSEN-WEST, K., KURTI, A., MURRAY, M.E., BIENIEK, K.F., BAUER, P.O., WHITELAW, 
E.C., ROUSSEAU, L., STANKOWSKI, J.N., STETLER, C., DAUGHRITY, L.M., PERKERSON, E.A., 
DESARO, P., ET AL. (2015) C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, 
and behavioral deficits. Science. 348 (6239), 1151–1154. 
CHI, K.N., HOTTE, S.J., YU, E.Y., TU, D., EIGL, B.J., TANNOCK, I., SAAD, F., NORTH, S., POWERS, J., 
GLEAVE, M.E. & EISENHAUER, E.A. (2010) Randomized phase II study of docetaxel and prednisone with 
or without OGX-011 in patients with metastatic castration-resistant prostate cancer. Journal of clinical 
oncology. 28 (27), 4247–4254. 
CHIA, R., TATTUM, M.H., JONES, S., COLLINGE, J., FISHER, E.M.C. & JACKSON, G.S. (2010) 
Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death 
mechanism in amyotrophic lateral sclerosis. PloS one. 5 (5), e10627. 
 218 
 
CHIA, S., DENT, S., ELLARD, S., ELLIS, P.M., VANDENBERG, T., GELMON, K., POWERS, J., WALSH, 
W., SEYMOUR, L. & EISENHAUER, E.A. (2009) Phase II trial of OGX-011 in combination with docetaxel in 
metastatic breast cancer. Clinical cancer research 15 (2), 708–713.  
CHIÒ, A., CALVO, A., MAZZINI, L., CANTELLO, R., MORA, G., MOGLIA, C., CORRADO, L., D’ALFONSO, 
S., MAJOUNIE, E., RENTON, A., PISANO, F., OSSOLA, I., BRUNETTI, M., TRAYNOR, B.J. & RESTAGNO, 
G. (2012) Extensive genetics of ALS: a population-based study in Italy. Neurology. 79 (19), 1983–1989.  
CHIÒ, A., LOGROSCINO, G., TRAYNOR, B., COLLINS, J., SIMEONE, J., GOLDSTEIN, L. & WHITE, L. 
(2013) Global Epidemiology of Amyotrophic Lateral Sclerosis: a Systematic Review of the Published 
Literature. Neuroepidemiology. 41 (2), 118–130.  
CHIRIBOGA, C.A., SWOBODA, K.J., DARRAS, B.T., IANNACCONE, S.T., MONTES, J., DE VIVO, D.C., 
NORRIS, D.A., BENNETT, C.F. & BISHOP, K.M. (2016) Results from a phase 1 study of nusinersen (ISIS-
SMNRx) in children with spinal muscular atrophy. Neurology. 86 (10), 890–897.  
CHO, D.S.C., YANG, W., LEE, J.T., SHIEKHATTAR, R., MURRAY, J.M. & NISHIKURA, K. (2003) 
Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. Journal of 
Biological Chemistry. 278 (19), 17093–17102. 
CHOI, D.W. (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1 (8), 623–634. 
CHOUDHURY, Y., TAY, F.C., LAM, D.H., SANDANARAJ, E., TANG, C., ANG, B.-T. & WANG, S. (2012) 
Attenuated adenosine-to-inosine editing of microRNA-376a * promotes invasiveness of glioblastoma cells. 
Journal of Clinical Investigation. 122 (11), 4059–4076. 
CISTERNI, C., HENDERSON, C.E., AEBISCHER, P., PETTMANN, B. & DEGLON, N. (2000) Efficient gene 
transfer and expression of biologically active glial cell line-derived neurotrophic factor in rat motoneurons 
transduced wit lentiviral vectors. J Neurochem. 74 (5), 1820–1828. 
CIURA, S., LATTANTE, S., LE BER, I., LATOUCHE, M., TOSTIVINT, H., BRICE, A. & KABASHI, E. (2013) 
Loss of function of C9orf72 causes motor deficits in a zebrafish model of Amyotrophic Lateral Sclerosis. 
Annals of neurology 74 (2), 180-7 
COLEMAN, S.K., MÖYKKYNEN, T., CAI, C., VON OSSOWSKI, L., KUISMANEN, E., KORPI, E.R. & 
KEINÄNEN, K. (2006) Isoform-specific early trafficking of AMPA receptor flip and flop variants. The Journal 
of neuroscience 26 (43), 11220–11229. 
CONG, L., RAN, F.A., COX, D., LIN, S., BARRETTO, R., HABIB, N., HSU, P.D., WU, X., JIANG, W., 
MARRAFFINI, L.A. & ZHANG, F. (2013) Multiplex genome engineering using CRISPR/Cas systems. 
Science. 339 (6121), 819–823 
COOPER-KNOCK, J., HEWITT, C., HIGHLEY, J.R., BROCKINGTON, A., MILANO, A., MAN, S., 
MARTINDALE, J., HARTLEY, J., WALSH, T., GELSTHORPE, C., BAXTER, L., FORSTER, G., FOX, M., 
BURY, J., MOK, K., MCDERMOTT, C.J., TRAYNOR, B.J., KIRBY, J., WHARTON, S.B., ET AL. (2012) 
Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain. 135 (Pt 
3), 751–764. 
COOPER-KNOCK, J., WALSH, M.J., HIGGINBOTTOM, A., HIGHLEY, J.R., DICKMAN, M.J., EDBAUER, 
D., INCE, P.G., WHARTON, S.B., WILSON, S. A., KIRBY, J., HAUTBERGUE, G.M. & SHAW, P.J. (2014) 
Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain. 
137 (7), 2040–2051.  
 219 
 
COOPER-KNOCK, J., HIGGINBOTTOM, A., STOPFORD, M.J., HIGHLEY, J.R., INCE, P.G., WHARTON, 
S.B., PICKERING-BROWN, S., KIRBY, J., HAUTBERGUE, G.M. & SHAW, P.J. (2015) Antisense RNA foci 
in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy. Acta 
Neuropathologica 130 (7), 63-75 
COPOLOVICI, D.M., LANGEL, K., ERISTE, E. & LANGEL, Ü. (2014) Cell-penetrating peptides: design, 
synthesis, and applications. ACS nano. 8 (3), 1972–1994 
CORDIER, C., BOUTIMAH, F., BOURDELOUX, M., DUPUY, F., MET, E., ALBERTI, P., LOLL, F., 
CHASSAING, G., BURLINA, F. & SAISON-BEHMOARAS, T.E. (2014) Delivery of Antisense Peptide Nucleic 
Acids to Cells by Conjugation with Small Arginine-Rich Cell-Penetrating Peptide (R/W)9. PLoS ONE. 9 (8), 
e104999. 
CROOKE, R.M., GRAHAM, M.J., LEMONIDIS, K.M., WHIPPLE, C.P., KOO, S. & PERERA, R.J. (2005) An 
apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing 
hepatic steatosis. Journal of lipid research. 46 (5), 872–884.  
CUTRONA, G., CARPANETO, E.M., ULIVI, M., RONCELLA, S., LANDT, O., FERRARINI, M. & BOFFA, 
L.C. (2000) Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nature 
biotechnology. 18 (3), 300–303 
DANIEL, C., WAHLSTEDT, H., OHLSON, J., BJÖRK, P. & OHMAN, M. (2011) Adenosine-to-inosine RNA 
editing affects trafficking of the gamma-aminobutyric acid type A (GABA(A)) receptor. The Journal of 
biological chemistry. 286 (3), 2031–2040.  
DANIEL, C., SILBERBERG, G., BEHM, M., OHMAN, M. & ÖHMAN, M. (2014) Alu elements shape the 
primate transcriptome by cis-regulation of RNA editing. Genome Biology. 15 (2), R28.  
DAWSON, T.R., SANSAM, C.L. & EMESON, R.B. (2004) Structure and sequence determinants required for 
the RNA editing of ADAR2 substrates. The Journal of biological chemistry. 279 (6), 4941–4951.  
DE CONTI, L., BARALLE, M. & BURATTI, E. (2013) Exon and intron definition in pre-mRNA splicing. RNA. 
4 (1), 49–60.  
DEJESUS-HERNANDEZ, M., MACKENZIE, I.R., BOEVE, B.F., BOXER, A.L., BAKER, M., RUTHERFORD, 
N.J., NICHOLSON, A.M., FINCH, N.A., GILMER, F., ADAMSON, J., KOURI, N., WOJTAS, A., SENGDY, 
P., HSIUNG, G.R., KARYDAS, A., SEELEY, W.W., JOSEPHS, K.A., GESCHWIND, D.H., WSZOLEK, Z.K., 
ET AL. (2011) Expanded GGGGCC hexanucleotide repeat in non-coding region of C9ORF72 causes 
chromosome 9p-linked frontotemporal dementia and amyotrophic lateral sclerosis. Neuron. 72 (2), 245–256.  
DENG, H.-X., ZHAI, H., BIGIO, E.H., YAN, J., FECTO, F., AJROUD, K., MISHRA, M., AJROUD-DRISS, S., 
HELLER, S., SUFIT, R., SIDDIQUE, N., MUGNAINI, E. & SIDDIQUE, T. (2010) FUS-immunoreactive 
inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Annals of 
neurology. 67 (6), 739–748.  
DENTI, M.A., ROSA, A., STHANDIER, O., DE ANGELIS, F.G. & BOZZONI, I. (2004) A new vector, based 
on the PolII promoter of the U1 snRNA gene, for the expression of siRNAs in mammalian cells. Molecular 
therapy 10 (1), 191–199. 
DERKACH, V. A, OH, M.C., GUIRE, E.S. & SODERLING, T.R. (2007) Regulatory mechanisms of AMPA 
receptors in synaptic plasticity. Nature reviews. Neuroscience. 8 (2), 101–113. 
 220 
 
DESMET, F.-O., HAMROUN, D., LALANDE, M., COLLOD-BÉROUD, G., CLAUSTRES, M. & BÉROUD, C. 
(2009) Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic acids 
research. 37 (9), e67.  
DESTERRO, J.M.P., KEEGAN, L.P., LAFARGA, M., BERCIANO, M.T., O’CONNELL, M.A. & CARMO-
FONSECA, M. (2003) Dynamic association of RNA-editing enzymes with the nucleolus. Journal of Cell 
Science. 116 (9), 1805–1818.  
DEVLIN, A., BURR, K., BOROOAH, S., FOSTER, J.D., CLEARY, E.M., GETI, I., VALLIER, L., SHAW, C.E., 
CHANDRAN, S. & MILES, G.B. (2015) Human iPSC-derived motoneurons harbouring TARDBP or 
C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nature Communications. 12 (6), 
5999  
DHAR, S.S., LIANG, H.L. & WONG-RILEY, M.T.T. (2009) Nuclear respiratory factor 1 co-regulates AMPA 
glutamate receptor subunit 2 and cytochrome c oxidase: tight coupling of glutamatergic transmission and 
energy metabolism in neurons. Journal of neurochemistry. 108 (6), 1595–1606.  
DIB-HAJJ, S.D., CHOI, J.S., MACALA, L.J., TYRRELL, L., BLACK, J.A., CUMMINS, T.R. & WAXMAN, S.G. 
(2009) Transfection of rat or mouse neurons by biolistics or electroporation. Nature protocols. 4 (8), 1118–
1126.  
DING, B. & KILPATRICK, D.L. (2013) Lentiviral vector production, titration, and transduction of primary 
neurons. Methods in molecular biology 1018, 119–131.  
DING, Y. & LAWRENCE, C.E. (2003) A statistical sampling algorithm for RNA secondary structure 
prediction. Nucleic Acids Research. 31 (24), 7280–7301. 
DING, Y.E., CHAN, C.H.I.Y.U. & LAWRENCE, C.E. (2005) RNA secondary structure prediction by centroids 
in a Boltzmann weighted ensemble. RNA. 11, 1157–1166.  
DISTERER, P., AL-SHAWI, R., ELLMERICH, S., WADDINGTON, S.N., OWEN, J.S., SIMONS, J.P. & 
KHOO, B. (2013) Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces 
LDL cholesterol in vivo. Molecular therapy 21 (3), 602–609 
DONNELLY, C.J., ZHANG, P.-W., PHAM, J.T., HEUSLER, A.R., MISTRY, N. A, VIDENSKY, S., DALEY, 
E.L., POTH, E.M., HOOVER, B., FINES, D.M., MARAGAKIS, N., TIENARI, P.J., PETRUCELLI, L., 
TRAYNOR, B.J., WANG, J., RIGO, F., BENNETT, C.F., BLACKSHAW, S., SATTLER, R., ET AL. (2013) 
RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 80 (2), 
415–428.  
DONNELLY, C.J., ZHANG, P., PHAM, J.T., HEUSLER, A.R., MISTRY, N.A., VIDENSKY, S., DALEY, E.L., 
POTH, E.M., FINES, D.M., MARAGAKIS, N., TIENARI, P.J., PETRUCELLI, L., TRAYNOR, B.J., WANG, J., 
RIGO, F., BENNETT, C.F. & BLACKSHAW, S. (2014) RNA Toxicity from the ALS/FTD C9ORF72 Expansion 
Is Mitigated by Antisense Intervention. Neuron. 80 (2), 415–428.  
DORIA, M., NERI, F., GALLO, A., FARACE, M.G. & MICHIENZI, A. (2009) Editing of HIV-1 RNA by the 
double-stranded RNA deaminase ADAR1 stimulates viral infection. Nucleic acids research. 37 (17), 5848–
5858.  
DRACHEVA, S., PATEL, N., WOO, D. A, MARCUS, S.M., SIEVER, L.J. & HAROUTUNIAN, V. (2008) 
Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide. Molecular psychiatry. 13 
(11), 1001–1010.  
 221 
 
DULL, T., ZUFFEREY, R., KELLY, M., MANDEL, R.J., NGUYEN, M., TRONO, D. & NALDINI, L. (1998) A 
third-generation lentivirus vector with a conditional packaging system. Journal of virology. 72 (11), 8463–
8471.  
ECHIGOYA, Y. & YOKOTA, T. (2014) Skipping multiple exons of dystrophin transcripts using cocktail 
antisense oligonucleotides. Nucleic acid therapeutics. 24 (1), 57–68.. 
ECHIGOYA, Y., MOULY, V., GARCIA, L., YOKOTA, T. & DUDDY, W. (2015) In Silico Screening Based on 
Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular 
Dystrophy. Plos One. 10 (3), e0120058.  
EISEN, J.S. & SMITH, J.C. (2008) Controlling morpholino experiments: don’t stop making antisense. 
Development 135 (10), 1735–1743.  
ELLIS, B.L., POTTS, P.R. & PORTEUS, M.H. (2011) Creating higher titer lentivirus with caffeine. Human 
gene therapy. 22 (1), 93–100.  
ENGLANDER, M.T., DULAWA, S.C., BHANSALI, P. & SCHMAUSS, C. (2005) How stress and fluoxetine 
modulate serotonin 2C receptor pre-mRNA editing. The Journal of neuroscience 25 (3), 648–651.  
FAIRBROTHER, W.G., YEH, R.-F., SHARP, P.A. & BURGE, C.B. (2002) Predictive identification of exonic 
splicing enhancers in human genes. Science. 297 (5583), 1007–1013.  
FALLINI, C., BASSELL, G.J. & ROSSOLL, W. (2010) High-efficiency transfection of cultured primary motor 
neurons to study protein localization, trafficking, and function. Molecular neurodegeneration. 21 (5), 17.  
FALZARANO, M.S., PASSARELLI, C. & FERLINI, A. (2014) Nanoparticle delivery of antisense 
oligonucleotides and their application in the exon skipping strategy for duchenne muscular dystrophy. 
Nucleic acid therapeutics. 24 (1), 87–100.  
FARG, M.A., SUNDARAMOORTHY, V., SULTANA, J.M., YANG, S., ATKINSON, R.A.K., LEVINA, V., 
HALLORAN, M.A., GLEESON, P.A., BLAIR, I.P., SOO, K.Y., KING, A.E. & ATKIN, J.D. (2014) C9ORF72, 
implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. 
Human Molecular Genetics. 23 (13), 3579–3595 
FARRAWELL, N.E., LAMBERT-SMITH, I.A., WARRAICH, S.T., BLAIR, I.P., SAUNDERS, D.N., HATTERS, 
D.M. & YERBURY, J.J. (2015) Distinct partitioning of ALS associated TDP-43, FUS and SOD1 mutants into 
cellular inclusions. Scientific reports. 5, 13416.  
FOX-WALSH, K.L., DOU, Y., LAM, B.J., HUNG, S.-P., BALDI, P.F. & HERTEL, K.J. (2005) The architecture 
of pre-mRNAs affects mechanisms of splice-site pairing. PNAS 102 (45), 16176–16181. 
FRAY, A.E., INCE, P.G., BANNER, S.J., MILTON, I.D., USHER, P.A., COOKSON, M.R. & SHAW, P.J. 
(1998) The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an 
immunohistochemical study. European Journal of Neuroscience. 10 (8), 2481–2489.  
FREIBAUM, B.D., LU, Y., LOPEZ-GONZALEZ, R., KIM, N.C., ALMEIDA, S., LEE, K., BADDERS, N., 
VALENTINE, M., MILLER, B.L., WONG, P.C., PETRUCELLI, L., KIM, H.J., GAO, F. & TAYLOR, J.P. (2015) 
GGGGCC Repeat Expansion in C9ORF72 Compromises Nucleocytoplasmic Transport. Nature. 525129–
133. FRITZ, E., IZAURIETA, P., WEISS, A., MIR, F.R., ROJAS, P., GONZALEZ, D., ROJAS, F., BROWN, 
R.H., MADRID, R. & VAN ZUNDERT, B. (2013) Mutant SOD1-expressing astrocytes release toxic factors 
that trigger motoneuron death by inducing hyperexcitability. Journal of neurophysiology. 109 (11), 2803–
2814.  
 222 
 
FU, X.-D. & ARES, M. (2014) Context-dependent control of alternative splicing by RNA-binding proteins. 
Nature Reviews Genetics. 15 (10), 689–701.  
FUJIOKA, Y., ISHIGAKI, S., MASUDA, A., IGUCHI, Y., UDAGAWA, T., WATANABE, H., KATSUNO, M., 
OHNO, K. & SOBUE, G. (2013) FUS-regulated region- and cell-type-specific transcriptome is associated 
with cell selectivity in ALS/FTLD. Scientific reports. 3, 2388. 
GAISLER-SALOMON, I., KRAVITZ, E., FEILER, Y., SAFRAN, M., BIEGON, A., AMARIGLIO, N. & 
RECHAVI, G. (2014) Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer’s disease. 
Neurobiology of aging. 35 (8), 1785-91  
GAL, J., ZHANG, J., KWINTER, D.M., ZHAI, J., JIA, H., JIA, J. & ZHU, H. (2011) Nuclear localization 
sequence of FUS and induction of stress granules by ALS mutants. Neurobiology of aging. 32 (12), 
2323.e27–e40.  
GAMAZON, E.R. & STRANGER, B.E. (2014) Genomics of alternative splicing: evolution, development and 
pathophysiology. Human genetics. 133 (6), 679–687.  
GARNCARZ, W., TARIQ, A., HANDL, C., PUSCH, O. & JANTSCH, M.F. (2013) A high-throughput screen 
to identify enhancers of ADAR-mediated RNA-editing. RNA biology. 10 (2), 192–204 
GEARY, R.S., NORRIS, D., YU, R. & BENNETT, C.F. (2015) Pharmacokinetics, biodistribution and cell 
uptake of antisense oligonucleotides. Advanced Drug Delivery Reviews. 87, 46-51 
GEBSKI, B.L., MANN, C.J., FLETCHER, S. & WILTON, S.D. (2003) Morpholino antisense oligonucleotide 
induced dystrophin exon 23 skipping in mdx mouse muscle. Human Molecular Genetics. 12 (15), 1801–
1811.  
GEORGE, C.X., GAN, Z., LIU, Y. & SAMUEL, C.E. (2011) Adenosine deaminases acting on RNA, RNA 
editing, and interferon action. Journal of interferon & cytokine research 31 (1), 99–117.  
GERBER, A., O’CONNELL, M. A & KELLER, W. (1997) Two forms of human double-stranded RNA-specific 
editase 1 (hRED1) generated by the insertion of an Alu cassette. RNA. 3453–463. 
GINN, S.L., ALEXANDER, I.E., EDELSTIEN, M.L., ABEDI, M.R. & WIXON, J. (2013) Gene therapy clinical 
trials worldwide to 2012 - an update. The journal of gene medicine. 15(2):65-77.  
GITAÍ, D.L.G., MARTINELLI, H.N., VALENTE, V., PEREIRA, M.G.A.G., OLIVEIRA, J.A.C., ELIAS, C.F., 
BITTENCOURT, J.C., LEITE, J.P., COSTA-NETO, C.M., GARCIA-CAIRASCO, N. & PACÓ-LARSON, M.L. 
(2010) Increased expression of GluR2-flip in the hippocampus of the wistar audiogenic rat strain after acute 
and kindled seizures. Hippocampus. 20 (1), 125–133.  
GLAUM, S.R., SCHOLZ, W.K. & MILLER, R.J. (1990) Acute- and long-term glutamate-mediated regulation 
of [Ca++]i in rat hippocampal pyramidal neurons in vitro. J Pharmacol Exp Ther. 253 (3), 1293–1302. 
GOEMANS, N.M., TULINIUS, M., VAN DEN AKKER, J.T., BURM, B.E., EKHART, P.F., HEUVELMANS, N., 
HOLLING, T., JANSON, A.A., PLATENBURG, G.J., SIPKENS, J.A., SITSEN, J.M.A., AARTSMA-RUS, A., 
VAN OMMEN, G.-J.B., BUYSE, G., DARIN, N., VERSCHUUREN, J.J., CAMPION, G. V, DE KIMPE, S.J. & 
VAN DEUTEKOM, J.C. (2011) Systemic administration of PRO051 in Duchenne’s muscular dystrophy. The 
New England journal of medicine. 364 (16), 1513–1522 
GOMMANS, W.M., MULLEN, S.P. & MAAS, S. (2010) RNA editing: a driving force for adaptive evolution? 
Bioessays 31 (10), 1137–1145.  
 223 
 
GOMMANS, W.M. (2012) A-to-I editing of microRNAs: regulating the regulators? Seminars in cell & 
developmental biology. 23 (3), 251–257.  
GOREN, A., RAM, O., AMIT, M., KEREN, H., LEV-MAOR, G., VIG, I., PUPKO, T. & AST, G. (2006) 
Comparative Analysis Identifies Exonic Splicing Regulatory Sequences-The Complex Definition of 
Enhancers and Silencers. Molecular Cell. 22 (6), 769–781.  
GOTT, J.M., SOMERLOT, B.H. & GRAY, M.W. (2010) Two forms of RNA editing are required for tRNA 
maturation in Physarum mitochondria. Rna. 16 (3), 482–488. 
GOYENVALLE, A., BABBS, A., VAN OMMEN, G.-J.B., GARCIA, L. & DAVIES, K.E. (2009) Enhanced exon-
skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy. 
Molecular therapy 17 (7), 1234–1240.  
GOYENVALLE, A., GRIFFITH, G., BABBS, A., ANDALOUSSI, S. EL, EZZAT, K., AVRIL, A., DUGOVIC, B., 
CHAUSSENOT, R., FERRY, A., VOIT, T., AMTHOR, H., BÜHR, C., SCHÜRCH, S., WOOD, M.J. A, 
DAVIES, K.E., VAILLEND, C., LEUMANN, C. & GARCIA, L. (2015) Functional correction in mouse models 
of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nature Medicine. (October 2014). 
GRABRUCKER, A., VAIDA, B., BOCKMANN, J. & BOECKERS, T.M. (2009) Synaptogenesis of 
hippocampal neurons in primary cell culture. Cell and Tissue Research. 338 (3), 333–341 
GRAFFMO, K.S., FORSBERG, K., BERGH, J., BIRVE, A., ZETTERSTRÖM, P., ANDERSEN, P.M., 
MARKLUND, S.L. & BRÄNNSTRÖM, T. (2013) Expression of wild-type human superoxide dismutase-1 in 
mice causes amyotrophic lateral sclerosis. Human molecular genetics. 22 (1), 51–60.  
GRAVELEY, B.R. (2000) Sorting out the complexity of SR protein functions. RNA. 6 (9), 1197–1211.  
GRAY, M.W. (2012) Evolutionary origin of RNA editing. Biochemistry. 51 (26), 5235–5242.  
GREENE, L. A & TISCHLER, A S. (1976) Establishment of a noradrenergic clonal line of rat adrenal 
pheochromocytoma cells which respond to nerve growth factor. PNAS  73 (7), 2424–2428. 
GREGER, I.H., KHATRI, L., KONG, X. & ZIFF, E.B. (2003) AMPA Receptor Tetramerization is Mediated by 
Q/R Editing. Neuron. 40, 763–774. 
GREUTER, T., BIEDERMANN, L., ROGLER, G., SAUTER, B. & SEIBOLD, F. (2016) Alicaforsen, an 
antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case 
series. United European gastroenterology journal. 4 (1), 97–104.  
GROOMS, S.Y., NOH, K.-M., REGIS, R., BASSELL, G.J., BRYAN, M.K., CARROLL, R.C. & ZUKIN, R.S. 
(2006) Activity bidirectionally regulates AMPA receptor mRNA abundance in dendrites of hippocampal 
neurons. The Journal of neuroscience 26 (32), 8339–8351.  
GRUART, A., LEAL-CAMPANARIO, R., LÓPEZ-RAMOS, J.C. & DELGADO-GARCÍA, J.M. (2015) 
Functional basis of associative learning and their relationships with long-term potentiation evoked in the 
involved neural circuits: Lessons from studies in behaving mammals. Neurobiology of Learning and Memory. 
124, 3–18.  
GUO, H., LAI, L., BUTCHBACH, M.E.R., STOCKINGER, M.P., SHAN, X., BISHOP, G.A. & LIN, C.G. (2003) 
Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset 
but not the outcome of ALS in mice. Human molecular genetics. 12 (19), 2519–2532.  
 224 
 
GUREVICH, I., TAMIR, H., ARANGO, V., DWORK, A.J., MANN, J.J. & SCHMAUSS, C. (2002) Altered 
editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron. 34 
(3), 349–356. 
GURNEY, M.E. (1997) The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical 
drug studies. Journal of the neurological sciences. 152 Suppl S67–S73. 
GURNEY, M.E., PU, H., CHIU, A.Y., DAL CANTO, M.C., POLCHOW, C.Y., ALEXANDER, D.D., CALIENDO, 
J., HENTATI, A., KWON, Y.W. & DENG, H.X. (1994) Motor neuron degeneration in mice that express a 
human Cu,Zn superoxide dismutase mutation. Science. 264 (5166), 1772–1775. 
HA, J.S., LEE, C.S., MAENG, J.S., KWON, K.S. & PARK, S.S. (2009) Chronic glutamate toxicity in mouse 
cortical neuron culture. Brain Research. 1273, 138–143 
HACHÉ, M., SWOBODA, K.J., SETHNA, N., FARROW-GILLESPIE, A., KHANDJI, A., XIA, S. & BISHOP, 
K.M. (2016) Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial 
Experience. Journal of child neurology. 31 (7), 899–906. 
HANSLICK, J.L., LAU, K., NOGUCHI, K.K., OLNEY, J.W., ZORUMSKI, C.F., MENNERICK, S. & FARBER, 
N.B. (2009) Dimethyl sulfoxide (DMSO) produces widespread apoptosis in the developing central nervous 
system. Neurobiology of disease. 34 (1), 1–10. 
HARMS, M.B., CADY, J., ZAIDMAN, C., COOPER, P., BALI, T., ALLRED, P., CRUCHAGA, C., BAUGHN, 
M., LIBBY, R.T., PESTRONK, A., GOATE, A., RAVITS, J. & BALOH, R.H. (2013) Lack of C9ORF72 coding 
mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. Neurobiology 
of aging. 34 (9), 2234.e13–e19.  
HARRILL, J.A., CHEN, H., STREIFEL, K.M., YANG, D., MUNDY, W.R. & LEIN, P.J. (2015) Ontogeny of 
biochemical, morphological and functional parameters of synaptogenesis in primary cultures of rat 
hippocampal and cortical neurons. Molecular brain. 8, 1–15. 
HARTNER, J.C., SCHMITTWOLF, C., KISPERT, A., MÜLLER, A.M., HIGUCHI, M. & SEEBURG, P.H. 
(2004) Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. 
The Journal of biological chemistry. 279 (6), 4894–4902. 
HARTNER, J.C., WALKLEY, C.R., LU, J. & ORKIN, S.H. (2009) ADAR1 is essential for maintenance of 
hematopoiesis and suppression of interferon signaling. Nature Immunology. 10 (1), 109–115.  
HAYASHI, T., RUMBAUGH, G. & HUGANIR, R.L. (2005) Differential regulation of AMPA receptor subunit 
trafficking by palmitoylation of two distinct sites. Neuron. 47 (5), 709–723.  
HEIMAN-PATTERSON, T.D., SHER, R.B., BLANKENHORN, E.A., ALEXANDER, G., DEITCH, J.S., 
KUNST, C.B., MARAGAKIS, N. & COX, G. (2011) Effect of genetic background on phenotype variability in 
transgenic mouse models of amyotrophic lateral sclerosis: a window of opportunity in the search for genetic 
modifiers. Amyotrophic lateral sclerosis  12 (2), 79–86.  
HERB, A., HIGUCHI, M., SPRENGEL, R. & SEEBURG, P.H. (1996) Q/R site editing in kainate receptor 
GluR5 and GluR6 pre-mRNAs requires distant intronic sequences PNAS. 93 (March), 1875–1880.  
HERBERT, A., ALFKEN, J., KIM, Y.G., MIAN, I.S., NISHIKURA, K. & RICH, A. (1997) A Z-DNA binding 
domain present in the human editing enzyme, double-stranded RNA adenosine deaminase. PNAS. 94 (16), 
8421–8426. 
 225 
 
HEWITT, C., KIRBY, J., HIGHLEY, J.R., HARTLEY, J.A., HIBBERD, R., HOLLINGER, H.C., WILLIAMS, 
T.L., INCE, P.G., MCDERMOTT, C.J. & SHAW, P.J. (2010) Novel FUS/TLS Mutations and Pathology in 
Familial and Sporadic Amyotrophic Lateral Sclerosis. Arch Neurol. 67 (4), 455–461. 
HIDEYAMA, T., YAMASHITA, T., SUZUKI, T., TSUJI, S., HIGUCHI, M., SEEBURG, P.H., TAKAHASHI, R., 
MISAWA, H. & KWAK, S. (2010) Induced loss of ADAR2 engenders slow death of motor neurons from Q/R 
site-unedited GluR2. The Journal of Neuroscience. 30 (36), 11917–11925.  
HIDEYAMA, T. & KWAK, S. (2011) When Does ALS Start? ADAR2-GluA2 Hypothesis for the Etiology of 
Sporadic ALS. Frontiers in molecular neuroscience. 4 (November), 33.  
HIDEYAMA, T., TERAMOTO, S., HACHIGA, K., YAMASHITA, T. & KWAK, S. (2012a) Co-occurrence of 
TDP-43 mislocalization with reduced activity of an RNA editing enzyme, ADAR2, in aged mouse motor 
neurons. PloS one. 7 (8), e43469.  
HIDEYAMA, T., YAMASHITA, T., AIZAWA, H., TSUJI, S., KAKITA, A., TAKAHASHI, H. & KWAK, S. (2012b) 
Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiology of 
disease. 45 (3), 1121–1128.  
HIGASHI, S., TSUCHIYA, Y., ARAKI, T., WADA, K. & KABUTA, T. (2010) TDP-43 physically interacts with 
amyotrophic lateral sclerosis-linked mutant CuZn superoxide dismutase. Neurochemistry. 57 (8), 906–913.  
HIGUCHI, M., SINGLE, F.N., KÖHLER, M., SOMMER, B., SPRENGEL, R. & SEEBURG, P.H. (1993) RNA 
editing of AMPA receptor subunit GluR-B: a base-paired intron-exon structure determines position and 
efficiency. Cell. 75 (7), 1361–1370. 
HIGUCHI, M., MAAS, S., SINGLE, F.N., HARTNER, J., ROZOV, A., BURNASHEV, N., FELDMEYER, D., 
SPRENGEL, R. & SEEBURG, P.H. (2000) Point mutation in an AMPA receptor gene rescues lethality in 
mice deficient in the RNA-editing enzyme ADAR2. Nature. 406 (July), 1998–2001. 
HILGENBERG, L.G.W. & SMITH, M.A. (2007) Preparation of dissociated mouse cortical neuron cultures. 
Journal of visualized experiments : JoVE. (10), 562. 
HOGG, M., PARO, S., KEEGAN, L.P. & O’CONNELL, M. A (2011) RNA editing by mammalian ADARs. 1st 
edition. Elsevier Inc.  
HOLMGREN, M. & ROSENTHAL, J.J.C. (2013) Regulation of Ion Channel and Transporter Function 
Through RNA Editing. In: Stefan Maas (ed.). RNA Editing. Norfolk, Caister Academic Press. pp. 1–16. 
HOOPENGARDNER, B., BHALLA, T., STABER, C. & REENAN, R. (2003) Nervous system targets of RNA 
editing identified by comparative genomics. Science. 301 (5634), 832–836.  
HORSCH, M., SEEBURG, P.H., ADLER, T., AGUILAR-PIMENTEL, J.A., BECKER, L., CALZADA-WACK, 
J., GARRETT, L., GÖTZ, A., HANS, W., HIGUCHI, M., HÖLTER, S.M., NATON, B., PREHN, C., PUK, O., 
RÁCZ, I., RATHKOLB, B., ROZMAN, J., SCHREWE, A., ADAMSKI, J., ET AL. (2011) Requirement of the 
RNA-editing enzyme ADAR2 for normal physiology in mice. The Journal of biological chemistry. 286 (21), 
18614–18622. 
HOWLAND, D.S., LIU, J., SHE, Y., GOAD, B., MARAGAKIS, N.J., KIM, B., ERICKSON, J., KULIK, J., 
DEVITO, L., PSALTIS, G., DEGENNARO, L.J., CLEVELAND, D.W. & ROTHSTEIN, J.D. (2002) Focal loss 
of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral 
sclerosis (ALS). PNAS 99 (3), 1604–1609.  
 226 
 
HUA, Y., VICKERS, T.A., BAKER, B.F., BENNETT, C.F. & KRAINER, A.R. (2007) Enhancement of SMN2 
exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS biology. 5 (4), e73. 
HUANG, H., TAN, B.Z., SHEN, Y., TAO, J., JIANG, F., SUNG, Y.Y., NG, C.K., RAIDA, M., KÖHR, G., 
HIGUCHI, M., FATEMI-SHARIATPANAHI, H., HARDEN, B., YUE, D.T. & SOONG, T.W. (2012) RNA editing 
of the IQ domain in Ca(v)1.3 channels modulates their Ca2+-dependent inactivation. Neuron. 73 (2), 304–
316.  
HUDZIAK, R.M., BAROFSKY, E., BAROFSKY, D.F., WELLER, D.L., HUANG, S.B. & WELLER, D.D. (1996) 
Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense & nucleic 
acid drug development. 6 (4), 267–272 
HUISMAN, M.H.B., SEELEN, M., DE JONG, S.W., DORRESTEIJN, K.R.I.S., VAN DOORMAAL, P.T.C., 
VAN DER KOOI, A.J., DE VISSER, M., SCHELHAAS, H.J., VAN DEN BERG, L.H. & VELDINK, J.H. (2013) 
Lifetime physical activity and the risk of amyotrophic lateral sclerosis. Journal of neurology, neurosurgery, 
and psychiatry. 84 (9), 976–981. 
HUTSON, T.H., VERHAAGEN, J., YANEZ-MUNOZ, R.J. & MOON, L.D. (2012) Corticospinal tract 
transduction: a comparison of seven adeno-associated viral vector serotypes and a non-integrating lentiviral 
vector. Gene Ther. 19 (1), 49–60.  
HUTSON, T.H., FOSTER, E., MOON, L.D.F. & YÁÑEZ-MUÑOZ, R.J. (2014) Lentiviral vector-mediated RNA 
silencing in the central nervous system. Human gene therapy methods. 25 (1), 14–32.  
HWANG, W.Y., FU, Y., REYON, D., MAEDER, M.L., TSAI, S.Q., SANDER, J.D., PETERSON, R.T., YEH, 
J.-R.J. & JOUNG, J.K. (2013) Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature 
biotechnology. 31 (3), 227–229.  
HYRUP, B. & NIELSEN, P.E. (1996) Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential 
Applications. Bioorganic and Medicinal Chemistry. 4 (1), 5–23 
INGRE, C., ROOS, P.M., PIEHL, F., KAMEL, F. & FANG, F. (2015) Risk factors for amyotrophic lateral 
sclerosis. Clinical epidemiology. 7, 181–193.  
JACOBS, M.M., FOGG, R.L., EMESON, R.B. & STANWOOD, G.D. (2009) ADAR1 and ADAR2 expression 
and editing activity during forebrain development. Developmental Neuroscience. 31 (3), 223–237.  
JAIKARAN, D.C.J., COLLINS, C.H. & MACMILLAN, A.M. (2002) Adenosine to inosine editing by ADAR2 
requires formation of a ternary complex on the GluR-B R/G site. The Journal of biological chemistry. 277 
(40), 37624–37629.  
JANSSENS, N. & LESAGE, A.S.J. (2001) Glutamate receptor subunit expression in primary neuronal and 
secondary glial cultures. Journal of Neurochemistry. 77, 1457–1474. 
JARA, J.H., GENÇ, B., COX, G.A., BOHN, M.C., ROOS, R.P., MACKLIS, J.D., ULUPINAR, E. & ÖZDINLER, 
P.H. (2015) Corticospinal Motor Neurons Are Susceptible to Increased ER Stress and Display Profound 
Degeneration in the Absence of UCHL1 Function. Cerebral cortex. 25 (11), 4259–4272 
JEPSON, J.E.C. & REENAN, R. A (2008) RNA editing in regulating gene expression in the brain. Biochimica 
et biophysica acta. 1779 (8), 459–470.  
JIANG, J., ZHU, Q., GENDRON, T.F., RIGO, F., CLEVELAND, D.W., JIANG, J., ZHU, Q., GENDRON, T.F., 
SABERI, S., MCALONIS-DOWNES, M., SEELMAN, A. & CLEVELAND, D.W. (2016) Gain of Toxicity from 
 227 
 
ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting 
GGGGCC-Containing RNAs. Neuron. 1–16. 
JIN, R., BANKE, T.G., MAYER, M.L., TRAYNELIS, S.F. & GOUAUX, E. (2003) Structural basis for partial 
agonist action at ionotropic glutamate receptors. Nat. Neurosci. 6 (8), 803–810.  
JIN, Y., ZHANG, W. & LI, Q. (2009) Origins and evolution of ADAR-mediated RNA editing. IUBMB life. 61 
(6), 572–578.  
KABASHI, E., LIN, L., TRADEWELL, M.L., DION, P. A, BERCIER, V., BOURGOUIN, P., ROCHEFORT, D., 
BEL HADJ, S., DURHAM, H.D., VANDE VELDE, C., ROULEAU, G. A & DRAPEAU, P. (2010) Gain and 
loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Human 
molecular genetics. 19 (4), 671–683.  
KAIN, S.R., ADAMS, M., KONDEPUDI, A., YANG, T.T., WARD, W.W. & KITTS, P. (1995) Green fluorescent 
protein as a reporter of gene expression and protein localization. BioTechniques. 19 (4), 650–655. 
KANDEL, E.R., SCHWARTZ, J.H. & JESSELL, T.M. (2000) Principles of Neural Science. Fourth. Eric R. 
Kandel, James H. Schwartz, & Thomas M. Jessell (eds.). New York, McGraw-Hill, Health and Professions 
Division. 
KARRA, D. & DAHM, R. (2010) Transfection techniques for neuronal cells. The Journal of Neuroscience. 30 
(18), 6171–6177.  
KASK, K., ZAMANILLO, D., ROZOV,  A, BURNASHEV, N., SPRENGEL, R. & SEEBURG, P.H. (1998) The 
AMPA receptor subunit GluR-B in its Q/R site-unedited form is not essential for brain development and 
function. PNAS 95 (23), 13777–13782.  
KASSUBEK, J., MÜLLER, H.-P., DEL TREDICI, K., BRETTSCHNEIDER, J., PINKHARDT, E.H., LULÉ, D., 
BÖHM, S., BRAAK, H. & LUDOLPH, A.C. (2014) Diffusion tensor imaging analysis of sequential spreading 
of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain 137 (Pt 6), 1733–
1740. 
KASTELEIN, J.J.P., WEDEL, M.K., BAKER, B.F., SU, J., BRADLEY, J.D., YU, R.Z., CHUANG, E., 
GRAHAM, M.J. & CROOKE, R.M. (2006) Potent reduction of apolipoprotein B and low-density lipoprotein 
cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 114 (16), 
1729–1735.  
KAUR, S.J., MCKEOWN, S.R. & RASHID, S. (2016) Mutant SOD1 mediated pathogenesis of Amyotrophic 
Lateral Sclerosis. Gene. 577 (2), 109–118.  
KAWAHARA, Y., KWAK, S., SUN, H., ITO, K., HASHIDA, H., AIZAWA, H., JEONG, S.-Y. & KANAZAWA, I. 
(2003) Human spinal motoneurons express low relative abundance of GluR2 mRNA: an implication for 
excitotoxicity in ALS. Journal of Neurochemistry. 85 (3), 680–689.  
KAWAHARA, Y., ITO, K., SUN, H., AIZAWA, H., KANAZAWA, I. & KWAK, S. (2004) RNA editing and death 
of motor neurons. Nature. 427 (February), 801. 
KAWAHARA, Y., ITO, K., ITO, M., TSUJI, S. & KWAK, S. (2005) Novel splice variants of human ADAR2 
mRNA: Skipping of the exon encoding the dsRNA-binding domains, and multiple C-terminal splice sites. 
Gene. 363, 193–201.  
 228 
 
KAWAHARA, Y., SUN, H., ITO, K., HIDEYAMA, T., AOKI, M., SOBUE, G., TSUJI, S. & KWAK, S. (2006) 
Underediting of GluR2 mRNA, a neuronal death inducing molecular change in sporadic ALS, does not occur 
in motor neurons in ALS1 or SBMA. Neuroscience research. 54 (1), 11–14.  
KIRAN, A. & BARANOV, P. V. (2010) DARNED: A DAtabase of RNa editing in humans. Bioinformatics. 26 
(14), 1772–1776.  
KIRBY, J., GOODALL, E.F., SMITH, W., HIGHLEY, J.R., MASANZU, R., HARTLEY, J. A, HIBBERD, R., 
HOLLINGER, H.C., WHARTON, S.B., MORRISON, K.E., INCE, P.G., MCDERMOTT, C.J. & SHAW, P.J. 
(2010) Broad clinical phenotypes associated with TAR-DNA binding protein (TARDBP) mutations in 
amyotrophic lateral sclerosis. Neurogenetics. 11 (2), 217–225.  
KLEBE, R. & RUDDLE, F. (1969) Neuroblastoma: Cell culture analysis of a differentiating stem cell system. 
Journal of Cell Biology. 4369A. 
KÖHLER, M., BURNASHEV, N., SAKMANN, B. & SEEBURG, P.H. (1993) Determinants of Ca2+ 
permeability in both TM1 and TM2 of high affinity kainate receptor channels: diversity by RNA editing. 
Neuron. 10 (3), 491–500. 
KOIKE, M., TSUKADA, S., TSUZUKI, K., KIJIMA, H. & OZAWA, S. (2000) Regulation of kinetic properties 
of GluR2 AMPA receptor channels by alternative splicing. The Journal of neuroscience 20 (6), 2166–2174. 
KOIKE-YUSA, H., LI, Y., TAN, E.-P., VELASCO-HERRERA, M.D.C. & YUSA, K. (2014) Genome-wide 
recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nature 
biotechnology. 32 (3), 267–273.  
KOLE, R., KRAINER, A.R. & ALTMAN, S. (2012) RNA therapeutics: beyond RNA interference and antisense 
oligonucleotides. Nature reviews. Drug discovery. 11 (2), 125–140.  
KONO, M. & AKIYAMA, M. (2013) Dyschromatosis Symmetrica Hereditaria and RNA Editing Enzyme. 
Current Genetics in Dermatology. pp. 105–119. 
KOPPERS, M., BLOKHUIS, A.M., WESTENENG, H.J., TERPSTRA, M.L., ZUNDEL, C.A.C., VIEIRA DE 
S??, R., SCHELLEVIS, R.D., WAITE, A.J., BLAKE, D.J., VELDINK, J.H., VAN DEN BERG, L.H. & 
PASTERKAMP, R.J. (2015) C9orf72 ablation in mice does not cause motor neuron degeneration or motor 
deficits. Annals of Neurology. 78 (3), 426–438.  
KORDASIEWICZ, H.B., STANEK, L.M., WANCEWICZ, E. V, MAZUR, C., MCALONIS, M.M., PYTEL, K.A., 
ARTATES, J.W., WEISS, A., CHENG, S.H., SHIHABUDDIN, L.S., HUNG, G., BENNETT, C.F. & 
CLEVELAND, D.W. (2012) Sustained therapeutic reversal of Huntington’s disease by transient repression 
of huntingtin synthesis. Neuron. 74 (6), 1031–1044.  
KORNBLIHTT, A.R., SCHOR, I.E., ALLÓ, M., DUJARDIN, G., PETRILLO, E. & MUÑOZ, M.J. (2013) 
Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nature reviews. 
Molecular cell biology. 14 (3), 153–165.  
KOVALEVICH, J. & LANGFORD, D. (2013) Considerations for the Use of SH-SY5Y Neuroblastoma cells in 
Neurobiology. In: Shohreh Amini & Martyn K. White (eds.). Neuronal Cell Culture. Methods in Molecular 
Biology. Totowa, NJ, Humana Press. pp. 9–21.  
KRITIS, A. A., STAMOULA, E.G., PANISKAKI, K. A. & VAVILIS, T.D. (2015) Researching glutamate - 
induced cytotoxicity in different cell lines: a comparative/collective analysis/study. Frontiers in Cellular 
Neuroscience. 9 (March), 1–18. 
 229 
 
KUNG, S.S., WU, Y.M. & CHOW, W.Y. (1996) Characterization of two fish glutamate receptor cDNA 
molecules: absence of RNA editing at the Q/R site. Brain research. 35 (1-2), 119–130. 
KUTTAN, A. & BASS, B.L. (2012) Mechanistic insights into editing-site specificity of ADARs. PNAS 109 (48), 
E3295–E3304.  
KWIATKOWSKI, T.J., BOSCO, D.A., LECLERC, A.L., TAMRAZIAN, E., VANDERBURG, C.R., RUSS, C., 
DAVIS, A., GILCHRIST, J., KASARSKIS, E.J., MUNSAT, T., VALDMANIS, P., ROULEAU, G.A., HOSLER, 
B.A., CORTELLI, P., DE JONG, P.J., YOSHINAGA, Y., HAINES, J.L., PERICAK-VANCE, M.A., YAN, J., ET 
AL. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. 
Science. 323 (5918), 1205–1208.  
LACOMBLEZ, L., BENSIMON, G., LEIGH, P.N., GUILLET, P. & MEININGER, V. (1996) Dose-ranging study 
of riluzole in amyotrophic lateral sclerosis. Lancet. 347 (9013), 1425–1431. 
LAGIER-TOURENNE, C., POLYMENIDOU, M., HUTT, K.R., VU, A.Q., BAUGHN, M., HUELGA, S.C., 
CLUTARIO, K.M., LING, S.-C., LIANG, T.Y., MAZUR, C., WANCEWICZ, E., KIM, A.S., WATT, A., FREIER, 
S., HICKS, G.G., DONOHUE, J.P., SHIUE, L., BENNETT, C.F., RAVITS, J., ET AL. (2012) Divergent roles 
of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nature neuroscience. 
15 (11), 1488–1497.  
LAGIER-TOURENNE, C., BAUGHN, M., RIGO, F., SUN, S., LIU, P., LI, H.-R., JIANG, J., WATT, A.T., 
CHUN, S., KATZ, M., QIU, J., SUN, Y., LING, S.-C., ZHU, Q., POLYMENIDOU, M., DRENNER, K., 
ARTATES, J.W., MCALONIS-DOWNES, M., MARKMILLER, S., ET AL. (2013) Targeted degradation of 
sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. PNAS. 110 
(47), E4530–E4539.  
LAI, F., CHEN, C.X., CARTER, K.C. & NISHIKURA, K. (1997) Editing of glutamate receptor B subunit ion 
channel RNAs by four alternatively spliced DRADA2 double-stranded RNA adenosine deaminases. 
Molecular and cellular biology. 17 (5), 2413–2424. 
LANFRANCO, M.F., SEITZ, P.K., MORABITO, M. V., EMESON, R.B., SANDERS-BUSH, E. & 
CUNNINGHAM, K.A. (2009) An innovative real-time PCR method to measure changes in RNA editing of the 
serotonin 2C receptor (5-HT2CR) in brain. Journal of neuroscience methods. 179 (2), 247–257. 
LATTANTE, S., CIURA, S., ROULEAU, G.A. & KABASHI, E. (2015) Defining the genetic connection linking 
amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD). Trends in genetics. 31 (5), 263–
273. 
LEBLEU, B., MOULTON, H.M., ABES, R., IVANOVA, G.D., ABES, S., STEIN, D.A., IVERSEN, P.L., 
ARZUMANOV, A.A. & GAIT, M.J. (2008) Cell penetrating peptide conjugates of steric block oligonucleotides. 
Advanced drug delivery reviews. 60 (4-5), 517–529.  
LEE, S., JOUNG, J.-G., PARK, C., PARK, J. & KIM, J.H. (2015) RCARE: RNA Sequence Comparison and 
Annotation for RNA Editing. BMC Medical Genomics. 8 (Suppl 2), S8 
LEE, Y. & RIO, D.C. (2015) Mechanisms and Regulation of Alternative Pre-mRNA Splicing. Annual review 
of biochemistry. (March), 1–33.  
LEHMANN, K.A. & BASS, B.L. (2000) Double-Stranded RNA Adenosine Deaminases ADAR1 and ADAR2 
Have Overlapping Specificities. Biochemistry. 39 (42), 12875–12884.  
 230 
 
LESUISSE, C. & MARTIN, L.J. (2002) Long-term culture of mouse cortical neurons as a model for neuronal 
development, aging, and death. Journal of Neurobiology. 51 (1), 9–23.  
LEVANON, E.Y., HALLEGGER, M., KINAR, Y., SHEMESH, R., DJINOVIC-CARUGO, K., RECHAVI, G., 
JANTSCH, M.F. & EISENBERG, E. (2005) Evolutionarily conserved human targets of adenosine to inosine 
RNA editing. Nucleic acids research. 33 (4), 1162–1168.  
LEVANON, E.Y. & EISENBERG, E. (2015) Does RNA editing compensate for Alu invasion of the primate 
genome? BioEssays. 37, 175–181.  
LI, J.B., LEVANON, E.Y., YOON, J.-K., AACH, J., XIE, B., LEPROUST, E., ZHANG, K., GAO, Y. & 
CHURCH, G.M. (2009) Genome-wide identification of human RNA editing sites by parallel DNA capturing 
and sequencing. Science. 324 (5931), 1210–1213.  
LI, Q., LEE, J.-A. & BLACK, D.L. (2007) Neuronal regulation of alternative pre-mRNA splicing. Nature 
reviews. Neuroscience. 8 (11), 819–831.  
LIANG, H. & LANDWEBER, L.F. (2007) Hypothesis: RNA editing of microRNA target sites in humans? RNA. 
13 (4), 463–467.  
LIM, L., WEI, Y., LU, Y. & SONG, J. (2016) ALS-Causing Mutations Significantly Perturb the Self-Assembly 
and Interaction with Nucleic Acid of the Intrinsically Disordered Prion-Like Domain of TDP-43 PLOS Biology. 
14 (1), e1002338. LIN, C.-L.G., BRISTOL, L.A., JIN, L., DYKES-HOBERG, M., CRAWFORD, T., 
CLAWSON, L. & ROTHSTEIN, J.D. (1998) Aberrant RNA Processing in a Neurodegenerative Disease: the 
Cause for Absent EAAT2, a Glutamate Transporter, in Amyotrophic Lateral Sclerosis. Neuron. 20 (3), 589–
602.  
LIU, J., LILLO, C., JONSSON, P.A., VANDE VELDE, C., WARD, C.M., MILLER, T.M., SUBRAMANIAM, 
J.R., ROTHSTEIN, J.D., MARKLUND, S., ANDERSEN, P.M., BRÄNNSTRÖM, T., GREDAL, O., WONG, 
P.C., WILLIAMS, D.S. & CLEVELAND, D.W. (2004) Toxicity of familial ALS-linked SOD1 mutants from 
selective recruitment to spinal mitochondria. Neuron. 43 (1), 5–17.  
LIU, S.J. & SAVTCHOUK, I. (2012) Ca(2+) permeable AMPA receptors switch allegiances: mechanisms 
and consequences. The Journal of physiology. 590 (Pt 1), 13–20.  
LIU, Y. & SAMUEL, C.E. (1999) Editing of glutamate receptor subunit B pre-mRNA by splice-site variants of 
interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1. The Journal of biological 
chemistry. 274 (8), 5070–5077. 
LOMELI, H., MOSBACHER, J., MELCHER, T., HÖGER, T., GEIGER, J.R., KUNER, T., MONYER, H., 
HIGUCHI, M., BACH,  A & SEEBURG, P.H. (1994) Control of kinetic properties of AMPA receptor channels 
by nuclear RNA editing. Science. 266 (5191), 1709–1713. 
LOPES, F.M., SCHRÖDER, R., DA FROTA, M.L.C., ZANOTTO-FILHO, A., MÜLLER, C.B., PIRES, A.S., 
MEURER, R.T., COLPO, G.D., GELAIN, D.P., KAPCZINSKI, F., MOREIRA, J.C.F., FERNANDES, M.D.C. 
& KLAMT, F. (2010) Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model 
for Parkinson disease studies. Brain research. 1337, 85–94 
LU, Q.L., MANN, C.J., LOU, F., BOU-GHARIOS, G., MORRIS, G.E., XUE, S., FLETCHER, S., PARTRIDGE, 
T.A. & WILTON, S.D. (2003) Functional amounts of dystrophin produced by skipping the mutated exon in 
the mdx dystrophic mouse. Nature medicine. 9 (8), 1009–1014.  
 231 
 
LU, W. & ROCHE, K.W. (2012) Posttranslational regulation of AMPA receptor trafficking and function. 
Current Opinion in Neurobiology. 22 (3), 470–479.  
LU, W., SHI, Y., JACKSON, A.C., BJORGAN, K., DURING, M.J., SPRENGEL, R., SEEBURG, P.H. & 
NICOLL, R.A. (2009) Subunit Composition of Synaptic AMPA Receptors Revealed by a Single-Cell Genetic 
Approach. Neuron. 62 (2), 254–268.  
LU, Z.J., GLOOR, J.W. & MATHEWS, D.H. (2009) Improved RNA secondary structure prediction by 
maximizing expected pair accuracy. RNA 15 (10), 1805–1813.  
LUSSIER, M.P., NASU-NISHIMURA, Y. & ROCHE, K.W. (2011) Activity-dependent ubiquitination of the 
AMPA receptor subunit GluA2. The Journal of neuroscience 31 (8), 3077–3081.. 
MAAS, S., PATT, S., SCHREY, M. & RICH,  A (2001) Underediting of glutamate receptor GluR-B mRNA in 
malignant gliomas PNAS 98 (25), 14687–14692.  
MAAS, S. & GOMMANS, W.M. (2009a) Identification of a selective nuclear import signal in adenosine 
deaminases acting on RNA. Nucleic acids research. 37 (17), 5822–5829.  
MAAS, S. & GOMMANS, W.M. (2009b) Novel exon of mammalian ADAR2 extends open reading frame. 
PloS one. 4 (1), e4225.  
MACBETH, M.R., SCHUBERT, H.L., VANDEMARK, A.P., LINGAM, A.T., HILL, C.P. & BASS, B.L. (2005) 
Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. Science. 309 (5740), 
1534–1539.  
MACKENZIE, I.R.A., BIGIO, E.H., INCE, P.G., GESER, F., NEUMANN, M., CAIRNS, N.J., KWONG, L.K., 
FORMAN, M.S., RAVITS, J., STEWART, H., EISEN, A., MCCLUSKY, L., KRETZSCHMAR, H.A., 
MONORANU, C.M., HIGHLEY, J.R., KIRBY, J., SIDDIQUE, T., SHAW, P.J., LEE, V.M.-Y., ET AL. (2007) 
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis 
with SOD1 mutations. Annals of neurology. 61 (5), 427–434.  
MACKENZIE, I.R.A., ANSORGE, O., STRONG, M., BILBAO, J., ZINMAN, L., ANG, L.-C., BAKER, M., 
STEWART, H., EISEN, A., RADEMAKERS, R. & NEUMANN, M. (2011) Pathological heterogeneity in 
amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and 
mutation. Acta neuropathologica. 122 (1), 87–98.  
MACKENZIE, I.R., ARZBERGER, T., KREMMER, E., TROOST, D., LORENZL, S., MORI, K., WENG, S.-
M., HAASS, C., KRETZSCHMAR, H.A., EDBAUER, D. & NEUMANN, M. (2013) Dipeptide repeat protein 
pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta neuropathologica. 126 (6), 
859–879.  
MACKENZIE, I.R. A, FRICK, P. & NEUMANN, M. (2014) The neuropathology associated with repeat 
expansions in the C9ORF72 gene. Acta Neuropathologica. 127 (3), 347–357.  
MAHAJAN, S.S., THAI, K.H., CHEN, K. & ZIFF, E. (2011) Exposure of neurons to excitotoxic levels of 
glutamate induces cleavage of the RNA editing enzyme, adenosine deaminase acting on RNA 2, and loss 
of GLUR2 editing. Neuroscience. 189, 305–315.  
MAHARJAN, N., KÜNZLI, C., BUTHEY, K. & SAXENA, S. (2016) C9ORF72 Regulates Stress Granule 
Formation and Its Deficiency Impairs Stress Granule Assembly, Hypersensitizing Cells to Stress. Molecular 
neurobiology [Epub ahead of print] 
 232 
 
MAHENDRAN, R., SPOTTSWOOD, M.S., GHATE, A., LING, M.L., JENG, K. & MILLER, D.L. (1994) Editing 
of the mitochondrial small subunit rRNA in Physarum polycephalum. 
MÄKINEN, P.I., KOPONEN, J.K., KÄRKKÄINEN, A.-M., MALM, T.M., PULKKINEN, K.H., KOISTINAHO, J., 
TURUNEN, M.P. & YLÄ-HERTTUALA, S. (2006) Stable RNA interference: comparison of U6 and H1 
promoters in endothelial cells and in mouse brain. The journal of gene medicine. 8 (4), 433–441.  
MANN, D.A. & FRANKEL, A.D. (1991) Endocytosis and targeting of exogenous HIV-1 Tat protein. The 
EMBO journal. 10 (7), 1733–1739. 
MARC, G., LEAH, R., OFIRA, E., ODED, A., ZOHAR, A. & HANNA, R. (2013) Presymptomatic Treatment 
with Acetylcholinesterase Antisense Oligonucleotides Prolongs Survival in ALS (G93A-SOD1) Mice. BioMed 
research international. 2013, 845345 
MARCUCCI, R., BRINDLE, J., PARO, S., CASADIO, A., HEMPEL, S., MORRICE, N., BISSO, A., KEEGAN, 
L.P., DEL SAL, G. & O’CONNELL, M.A. (2011) Pin1 and WWP2 regulate GluR2 Q/R site RNA editing by 
ADAR2 with opposing effects. The EMBO journal. 30 (20), 4211–4222. 
MARINO, M., PAPA, S., CRIPPA, V., NARDO, G., PEVIANI, M., CHERONI, C., TROLESE, M.C., 
LAURANZANO, E., BONETTO, V., POLETTI, A., DEBIASI, S., FERRAIUOLO, L., SHAW, P.J. & 
BENDOTTI, C. (2015) Differences in protein quality control correlate with phenotype variability in 2 mouse 
models of familial amyotrophic lateral sclerosis. Neurobiology of aging. 36 (1), 492–504.. 
MASLIAH, G., BARRAUD, P. & ALLAIN, F.H.T. (2013) RNA recognition by double-stranded RNA binding 
domains: A matter of shape and sequence. Cellular and Molecular Life Sciences. 70 (11), 1875–1895.  
MASSMAN, P.J., SIMS, J., COOKE, N., HAVERKAMP, L.J., APPEL, V. & APPEL, S.H. (1996) Prevalence 
and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. Journal of neurology, 
neurosurgery, and psychiatry. 61 (5), 450–455. 
MATHEWS, D.H., MOSS, W.N. & TURNER, D.H. (2010) Folding and finding RNA secondary structure. Cold 
Spring Harbor perspectives in biology. 2 (12), 1–15.  
MATHEWS, D.H. (2004) Using an RNA secondary structure partition function to determine confidence in 
base pairs predicted by free energy minimization. RNA. 10, 1178–1190.  
MATTHEWS, M.M., THOMAS, J.M., ZHENG, Y., TRAN, K., PHELPS, K.J., SCOTT, A.I., HAVEL, J., 
FISHER, A.J. & BEAL, P.A. (2016) Structures of human ADAR2 bound to dsRNA reveal base-flipping 
mechanism and basis for site selectivity. Nature Structural & Molecular Biology. (April), 1–10.  
MEAD, A.N. & STEPHENS, D.N. (2003) Involvement of AMPA receptor GluR2 subunits in stimulus-reward 
learning: evidence from glutamate receptor gria2 knock-out mice. The Journal of neuroscience 23 (29), 
9500–9507.  
MEAD, A.N., BROWN, G., LE MERRER, J. & STEPHENS, D.N. (2005) Effects of deletion of gria1 or gria2 
genes encoding glutamatergic AMPA-receptor subunits on place preference conditioning in mice. 
Psychopharmacology. 179 (1), 164–171.  
MEDVEDEV, N.I., RODRÍGUEZ-ARELLANO, J.J., POPOV, V.I., DAVIES, H.A., TIGARET, C.M., 
SCHOEPFER, R. & STEWART, M.G. (2008) The glutamate receptor 2 subunit controls post-synaptic density 
complexity and spine shape in the dentate gyrus. European Journal of Neuroscience. 27 (2), 315–325 
 233 
 
MELCHER, T., MAAS, S., HERB, A., SPRENGEL, R., SEEBERG, P.H. & HIGUCHI, M. (1996) A mammalian 
RNA editing enzyme. Nature. 379 (1), 460–464. 
MENDELL, J.R., GOEMANS, N., LOWES, L.P., ALFANO, L.N., BERRY, K., SHAO, J., KAYE, E.M. & 
MERCURI, E. (2016) Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne 
muscular dystrophy. Annals of Neurology. 79 (2), 257–271.  
MENDELL, J.R., RODINO-KLAPAC, L.R., SAHENK, Z., ROUSH, K., BIRD, L., LOWES, L.P., ALFANO, L., 
GOMEZ, A.M., LEWIS, S., KOTA, J., MALIK, V., SHONTZ, K., WALKER, C.M., FLANIGAN, K.M., 
CORRIDORE, M., KEAN, J.R., ALLEN, H.D., SHILLING, C., MELIA, K.R., ET AL. (2013) Eteplirsen for the 
treatment of Duchenne muscular dystrophy. Annals of neurology. 74 (5), 637–647.  
MENG, Y., ZHANG, Y. & JIA, Z. (2003) Synaptic transmission and plasticity in the absence of AMPA 
glutamate receptor GluR2 and GluR3. Neuron. 39 (1), 163–176.  
MERCADO, P.A., AYALA, Y.M., ROMANO, M., BURATTI, E. & BARALLE, F.E. (2005) Depletion of TDP 43 
overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene. Nucleic acids 
research. 33 (18), 6000–6010.  
MILANESE, M., ZAPPETTINI, S., ONOFRI, F., MUSAZZI, L., TARDITO, D., BONIFACINO, T., MESSA, M., 
RACAGNI, G., USAI, C., BENFENATI, F., POPOLI, M. & BONANNO, G. (2011) Abnormal exocytotic release 
of glutamate in a mouse model of amyotrophic lateral sclerosis. Journal of neurochemistry. 116 (6), 1028–
1042.  
MILLER, T.M., PESTRONK, A., DAVID, W., ROTHSTEIN, J., SIMPSON, E., APPEL, S.H., ANDRES, P.L., 
MAHONEY, K., ALLRED, P., ALEXANDER, K., OSTROW, L.W., SCHOENFELD, D., MACKLIN, E.A., 
NORRIS, D.A., MANOUSAKIS, G., CRISP, M., SMITH, R., BENNETT, C.F., BISHOP, K.M., ET AL. (2013) 
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial 
amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. The Lancet. Neurology. 12 (5), 
435–442. 
MINEFF, E.M. & WEINBERG, R.J. (2000) Differential synaptic distribution of AMPA receptor subunits in the 
ventral posterior and reticular thalamic nuclei of the rat. Neuroscience. 101 (4), 969–982. 
MISAWA, H., NAKATA, K., TODA, K., MATSUURA, J., ODA, Y., INOUE, H., TATENO, M. & TAKAHASHI, 
R. (2003) VAChT-Cre. Fast and VAChT-Cre.Slow: postnatal expression of Cre recombinase in somatomotor 
neurons with different onset. Genesis. 37 (1), 44–50.  
MITCHELL, J.C., MCGOLDRICK, P., VANCE, C., HORTOBAGYI, T., SREEDHARAN, J., ROGELJ, B., 
TUDOR, E.L., SMITH, B.N., KLASEN, C., MILLER, C.C.J., COOPER, J.D., GREENSMITH, L. & SHAW, 
C.E. (2013) Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an 
age- and dose-dependent fashion. Acta Neuropathologica. 125 (2), 273–288.  
MIZIELINSKA, S., LASHLEY, T., NORONA, F.E., CLAYTON, E.L., RIDLER, C.E., FRATTA, P. & ISAACS, 
A.M. (2013) C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and 
antisense RNA foci. Acta neuropathologica. 126 (6), 845–857 
MONYER, H., SEEBURG, P.H. & WISDEN, W. (1991) Glutamate-operated channels: developmentally early 
and mature forms arise by alternative splicing. Neuron. 6 (5), 799–810. 
 234 
 
MORABITO, M. V, ABBAS, A.I., HOOD, J.L., KESTERSON, R.A., JACOBS, M.M., KUMP, D.S., HACHEY, 
D.L., ROTH, B.L. & EMESON, R.B. (2010) Mice with altered serotonin 2C receptor RNA editing display 
characteristics of Prader-Willi syndrome. Neurobiology of disease. 39 (2), 169–180.  
MORCOS, P.A. (2001) Achieving efficient delivery of morpholino oligos in cultured cells. Genesis. 30 (3), 
94–102.  
MORCOS, P., LI, Y. & JIANG, S. (2008) Vivo-Morpholinos: A non-peptide transporter delivers Morpholinos 
into a wide array of mouse tissues. BioTechniques. 45 (6), 613–623.  
MOSBACHER, J., SCHOEPFER, R., MONYER, H., BURNASHEV, N., SEEBURG, P.H. & 
RUPPERSBERG, J.P. (1994) A molecular determinant for submillisecond desensitization in glutamate 
receptors. Science. 266 (5187), 1059–1062. 
MYERS, S.J., PETERS, J., HUANG, Y., COMER, M.B., BARTHEL, F. & DINGLEDINE, R. (1998) 
Transcriptional regulation of the GluR2 gene: neural-specific expression, multiple promoters, and regulatory 
elements. The Journal of neuroscience 18 (17), 6723–6739. 
NAGAI, M., RE, D.B., NAGATA, T., CHALAZONITIS, A., JESSELL, T.M., WICHTERLE, H. & 
PRZEDBORSKI, S. (2007) Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic 
to motor neurons. Nature neuroscience. 10 (5), 615–622.  
NAKAE, A., NAKAI, K., TANAKA, T., TAKASHINA, M., HAGIHIRA, S., SHIBATA, M., UEDA, K. & 
MASHIMO, T. (2008) Serotonin2C receptor mRNA editing in neuropathic pain model. Neuroscience 
research. 60 (2), 228–231.  
NEUMANN, M., SAMPATHU, D.M., KWONG, L.K., TRUAX, A.C., MICSENYI, M.C., CHOU, T.T., BRUCE, 
J., SCHUCK, T., GROSSMAN, M., CLARK, C.M., MCCLUSKEY, L.F., MILLER, B.L., MASLIAH, E., 
MACKENZIE, I.R., FELDMAN, H., FEIDEN, W., KRETZSCHMAR, H.A., TROJANOWSKI, J.Q. & LEE, V.M.-
Y. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. 
Science. 314 (5796), 130–133.  
NEUMANN, M., RADEMAKERS, R., ROEBER, S., BAKER, M., KRETZSCHMAR, H.A. & MACKENZIE, 
I.R.A. (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 132 (Pt 11), 
2922–2931.  
NIAVARANI, A., CURRIE, E., REYAL, Y., ANJOS-AFONSO, F., HORSWELL, S., GRIESSINGER, E., 
SARDINA, J.L. & BONNET, D. (2015) APOBEC3A is implicated in a novel class of G-to-A mRNA editing in 
WT1 transcripts. PLoS ONE. 10 (3), 1–17. 
NISHIKURA, K. (2006) Editor meets silencer: crosstalk between RNA editing and RNA interference. Nature 
reviews. Molecular cell biology. 7 (12), 919–931 
NIZZARDO, M., SIMONE, C., RIZZO, F., ULZI, G., RAMIREZ, A., RIZZUTI, M., BORDONI, A., BUCCHIA, 
M., GATTI, S., BRESOLIN, N., COMI, G.P. & CORTI, S. (2016) Morpholino-mediated SOD1 reduction 
ameliorates an amyotrophic lateral sclerosis disease phenotype. Scientific Reports. 6 (October 2015), 
21301.  
NOH, K.-M., YOKOTA, H., MASHIKO, T., CASTILLO, P.E., ZUKIN, R.S. & BENNETT, M.V.L. (2005) 
Blockade of calcium-permeable AMPA receptors protects hippocampal neurons against global ischemia-
induced death. PNAS. 102 (34), 12230–12235.  
 235 
 
NONAKA, T., MASUDA-SUZUKAKE, M., ARAI, T., HASEGAWA, Y., AKATSU, H., OBI, T., YOSHIDA, M., 
MURAYAMA, S., MANN, D.M.A., AKIYAMA, H. & HASEGAWA, M. (2013) Prion-like properties of 
pathological TDP-43 aggregates from diseased brains. Cell reports. 4 (1), 124–134.  
NOY, A., LUQUE, F.J. & OROZCO, M. (2008) Theoretical analysis of antisense duplexes: determinants of 
the RNase H susceptibility. Journal of the American Chemical Society. 130 (11), 3486–3496.  
O’CONNELL, M. A, GERBER, A. & KELLER, W. (1997) Purification of human double-stranded RNA-specific 
editase 1 (hRED1) involved in editing of brain glutamate receptor B pre-mRNA. The Journal of Biological 
Chemistry. 272 (1), 473–478. 
O’CONNELL, M. A, GERBER, A & KEEGAN, L.P. (1998) Purification of native and recombinant double-
stranded RNA-specific adenosine deaminases. Methods 15 (1), 51–62 
O’ROURKE, J.G., BOGDANIK, L., MUHAMMAD, A.K.M.G., GENDRON, T.F., KIM, K.J., AUSTIN, A., CADY, 
J., LIU, E.Y., ZARROW, J., GRANT, S., HO, R., BELL, S., CARMONA, S., SIMPKINSON, M., LALL, D., WU, 
K., DAUGHRITY, L., DICKSON, D.W., HARMS, M.B., ET AL. (2015) C9orf72 BAC Transgenic Mice Display 
Typical Pathologic Features of ALS/FTD. Neuron. 88 (5), 892–901.  
OHKI, E.C., TILKINS, M.L., CICCARONE, V.C. & PRICE, P.J. (2001) Improving the transfection efficiency 
of post-mitotic neurons. Journal of Neuroscience Methods. 112 (2), 95–99.  
OHLSON, J., PEDERSEN, J.S., HAUSSLER, D. & OHMAN, M. (2007) Editing modifies the GABA(A) 
receptor subunit alpha3. RNA. 13 (5), 698–703.  
OHMAN, M., KÄLLMAN, A.M. & BASS, B.L. (2000) In vitro analysis of the binding of ADAR2 to the pre-
mRNA encoding the GluR-B R/G site. RNA. 6 (5), 687–697. 
OncoGeneX (2016) ONCOGENEX. [Online]. 2016. Available from: 
http://oncogenex.com/physicians/custirsen-ogx-011 [Accessed: 3 May 2016]. 
ORLANDI, C., LA VIA, L., BONINI, D., MORA, C., RUSSO, I., BARBON, A. & BARLATI, S. (2011) AMPA 
receptor regulation at the mRNA and protein level in rat primary cortical cultures. PloS one. 6 (9), e25350.  
OSMAN, E. & MILLER, M. (2014) Morpholino Antisense Oligonucleotides Targeting Intronic Repressor 
Element1 Improve Phenotype in SMA Mouse Models. Human Molecular Genetics 23 (18), 4832-45  
OSMAN, E.Y., YEN, P.-F. & LORSON, C.L. (2012) Bifunctional RNAs targeting the intronic splicing silencer 
N1 increase SMN levels and reduce disease severity in an animal model of spinal muscular atrophy. 
Molecular therapy 20 (1), 119–126.  
PACHERNEGG, S., MÜNSTER, Y., MUTH-KÖHNE, E., FUHRMANN, G. & HOLLMANN, M. (2015) GluA2 
is rapidly edited at the Q/R site during neural differentiation in vitro. Frontiers in Cellular Neuroscience. 9 
(March), 1–14.  
PANDEY, S.P., RAI, R., GAUR, P. & PRASAD, S. (2015) Development- and age-related alterations in the 
expression of AMPA receptor subunit GluR2 and its trafficking proteins in the hippocampus of male mouse 
brain. Biogerontology. 16 (3), 317–328 
PARAKH, S. & ATKIN, J.D. (2016) Protein Folding Alterations in Amyotrophic Lateral Sclerosis. Brain 
Research. 16, 30203–30267.  
 236 
 
PARDO, C.A., XU, Z., BORCHELT, D.R., PRICE, D.L., SISODIA, S.S. & CLEVELAND, D.W. (1995) 
Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and 
in a subset of other neurons. PNAS 92 (4), 954–958 
PASSINI, M.A., BU, J., RICHARDS, A.M., KINNECOM, C., SARDI, S.P., STANEK, L.M., HUA, Y., RIGO, 
F., MATSON, J., HUNG, G., KAYE, E.M., SHIHABUDDIN, L.S., KRAINER, A.R., BENNETT, C.F. & CHENG, 
S.H. (2011) Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal 
muscular atrophy. Science translational medicine. 3 (72) 
PATTERSON, J.B. & SAMUEL, C.E. (1995) Expression and regulation by interferon of a double-stranded-
RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Molecular 
and cellular biology. 15 (10), 5376–5388. 
PAUPARD, M.C., O’CONNELL, M.A., GERBER, A.P. & ZUKIN, R.S. (2000) Patterns of developmental 
expression of the RNA editing enzyme rADAR2. Neuroscience. 95 (3), 869–879. 
PAZ, J.T., BRYANT, A.S., PENG, K., FENNO, L., YIZHAR, O., FRANKEL, W.N., DEISSEROTH, K. & 
HUGUENARD, J.R. (2011) A new mode of corticothalamic transmission revealed in the Gria4(-/-) model of 
absence epilepsy. Nature neuroscience. 14 (9), 1167–1173.  
PAZ, N., LEVANON, E.Y., AMARIGLIO, N., HEIMBERGER, A.B., RAM, Z., CONSTANTINI, S., BARBASH, 
Z.S., ADAMSKY, K., SAFRAN, M., HIRSCHBERG, A., KRUPSKY, M., BEN-DOV, I., CAZACU, S., 
MIKKELSEN, T., BRODIE, C., EISENBERG, E. & RECHAVI, G. (2007) Altered adenosine-to-inosine RNA 
editing in human cancer. Genome research. 17 (11), 1586–1595 
PAZ-YAACOV, N., LEVANON, E.Y., NEVO, E., KINAR, Y., HARMELIN, A., JACOB-HIRSCH, J., 
AMARIGLIO, N., EISENBERG, E. & RECHAVI, G. (2010) Adenosine-to-inosine RNA editing shapes 
transcriptome diversity in primates. PNAS. 107 (27), 12174–12179.  
PELUFFO, H., FOSTER, E., AHMED, S.G., LAGO, N., HUTSON, T.H., MOON, L., YIP, P., WANISCH, K., 
CARABALLO-MIRALLES, V., OLMOS, G., LLADÓ, J., MCMAHON, S.B. & YÁÑEZ-MUÑOZ, R.J. (2012) 
Efficient gene expression from integration-deficient lentiviral vectors in the spinal cord. Gene Therapy. 
(October 2012), 645–657.  
PENG, P.L., ZHONG, X., TU, W., SOUNDARAPANDIAN, M.M., MOLNER, P., ZHU, D., LAU, L., LIU, S., 
LIU, F. & LU, Y. (2006) ADAR2-dependent RNA editing of AMPA receptor subunit GluR2 determines 
vulnerability of neurons in forebrain ischemia. Neuron. 49 (5), 719–733. 
PENN, A.C., BALIK, A. & GREGER, I.H. (2012) Steric antisense inhibition of AMPA receptor Q/R editing 
reveals tight coupling to intronic editing sites and splicing. Nucleic acids research. 41 (2), 1113–1123.  
PENN, A.C., BALIK, A. & GREGER, I.H. (2013) Reciprocal regulation of A-to-I RNA editing and the 
vertebrate nervous system. Frontiers in neuroscience. 7 (April), 61.  
PEREIRA, A.C., GRAY, J.D., KOGAN, J.F., DAVIDSON, R.L., RUBIN, T.G., OKAMOTO, M., MORRISON, 
J.H. & MCEWEN, B.S. (2016) Age and Alzheimer’s disease gene expression profiles reversed by the 
glutamate modulator riluzole. Molecular psychiatry. [Epub ahead of print] 
PETRINI, E.M., LU, J., COGNET, L., LOUNIS, B., EHLERS, M.D. & CHOQUET, D. (2009) Endocytic 
trafficking and recycling maintain a pool of mobile surface AMPA receptors required for synaptic potentiation. 
Neuron. 63 (1), 92–105. 
 237 
 
PHELPS, K.J., TRAN, K., EIFLER, T., ERICKSON, A.I., FISHER, A.J. & BEAL, P. A (2015) Recognition of 
duplex RNA by the deaminase domain of the RNA editing enzyme ADAR2. Nucleic acids research. 1–10.  
PHILIPS, T. & ROTHSTEIN, J.D. (2015) Rodent models of amyotrophic lateral sclerosis. Current Protocols 
in Pharmacology. 2015 (9), 5.67.1–5.67.21 
PICARDI, E., MANZARI, C., MASTROPASQUA, F., AIELLO, I., ERCHIA, A.M.D. & PESOLE, G. (2015) 
Profiling RNA editing in human tissues : towards the inosinome Atlas. Science Reports 5, 14941 
PINTO, Y., COHEN, H.Y. & LEVANON, E.Y. (2014) Mammalian conserved ADAR targets comprise only a 
small fragment of the human editosome. Genome biology. 15 (1), R5.  
PIRHAN, D., YÜKSEL, N., EMRE, E., CENGIZ, A. & KÜRŞAT YILDIZ, D. (2016) Riluzole- and Resveratrol-
Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma. Current eye research. 
41 (1), 59–69.  
PLAITAKIS, A., CONSTANTAKAKIS, E. & SMITH, J. (1988) The neuroexcitotoxic amino acids glutamate 
and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Annals of Neurology. 
24 (3), 446–449. 
PLANT, K., PELKEY, K. A, BORTOLOTTO, Z. A, MORITA, D., TERASHIMA, A., MCBAIN, C.J., 
COLLINGRIDGE, G.L. & ISAAC, J.T.R. (2006) Transient incorporation of native GluR2-lacking AMPA 
receptors during hippocampal long-term potentiation. Nature neuroscience. 9 (5), 602–604.  
POKRISHEVSKY, E., GRAD, L.I. & CASHMAN, N.R. (2016) TDP-43 or FUS-induced misfolded human wild-
type SOD1 can propagate intercellularly in a prion-like fashion. Scientific reports. 622155. 
POLSON, A.G. & BASS, B.L. (1994) Preferential selection of adenosines for modification by double-stranded 
RNA adenosine deaminase. The EMBO journal. 13 (23), 5701–5711. 
POLYMENIDOU, M., LAGIER-TOURENNE, C., HUTT, K.R., HUELGA, S.C., MORAN, J., LIANG, T.Y., 
LING, S.-C., SUN, E., WANCEWICZ, E., MAZUR, C., KORDASIEWICZ, H., SEDAGHAT, Y., DONOHUE, 
J.P., SHIUE, L., BENNETT, C.F., YEO, G.W. & CLEVELAND, D.W. (2011) Long pre-mRNA depletion and 
RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nature neuroscience. 14 (4), 459–
468.  
POPPLEWELL, L.J., TROLLET, C., DICKSON, G. & GRAHAM, I.R. (2009) Design of phosphorodiamidate 
morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Molecular therapy 
17 (3), 554–561 
POPPLEWELL, L.J., ABU-DAYYA, A., KHANA, T., FLINTERMAN, M., ABDUL KHALIQUE, N., RAJU, L., 
ØPSTAD, C.L., SLIWKA, H.-R., PARTALI, V., DICKSON, G. & PUNGENTE, M.D. (2012) Novel cationic 
carotenoid lipids as delivery vectors of antisense oligonucleotides for exon skipping in Duchenne muscular 
dystrophy. Molecules 17 (2), 1138–1148.  
PORATH, H.T., CARMI, S. & LEVANON, E.Y. (2014) A genome-wide map of hyper-edited RNA reveals 
numerous new sites. Nature communications. 5, 4726.  
PORENSKY, P.N., MITRPANT, C., MCGOVERN, V.L., BEVAN, A.K., FOUST, K.D., KASPAR, B.K., 
WILTON, S.D. & BURGHES, A.H.M. (2012) A single administration of morpholino antisense oligomer 
rescues spinal muscular atrophy in mouse. Human Molecular Genetics. 21 (7), 1625–1638.  
 238 
 
PRAMONO, Z.A.D., WEE, K.B., WANG, J.L., CHEN, Y.J., XIONG, Q. BIN, LAI, P.S. & YEE, W.C. (2012) A 
prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD 
gene. Human gene therapy. 23 (7), 781–790.  
RAAL, F.J., SANTOS, R.D., BLOM, D.J., MARAIS, A.D., CHARNG, M.-J., CROMWELL, W.C., LACHMANN, 
R.H., GAUDET, D., TAN, J.L., CHASAN-TABER, S., TRIBBLE, D.L., FLAIM, J.D. & CROOKE, S.T. (2010) 
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in 
patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled 
trial. Lancet 375 (9719), 998–1006.  
RAITSKIN, O., CHO, D.S., SPERLING, J., NISHIKURA, K. & SPERLING, R. (2001) RNA editing activity is 
associated with splicing factors in lnRNP particles: The nuclear pre-mRNA processing machinery. PNAS 98 
(12), 6571–6576.  
RAITSKIN, O., ANGENITZKI, M., SPERLING, J. & SPERLING, R. (2002) Large nuclear RNP particles - The 
nuclear pre-mRNA processing machine. Journal of Structural Biology. 140 (1-3), 123–130.  
RAJEWSKY, N. (2006) microRNA target predictions in animals. Nature Genetics 38, Suppl S8-13 
RAM, O. & AST, G. (2007) SR proteins: a foot on the exon before the transition from intron to exon definition. 
Trends in Genetics. 23 (1), 5–7.  
RAMASWAMI, G., ZHANG, R., PISKOL, R., KEEGAN, L.P., DENG, P., O’CONNELL, M.A. & LI, J.B. (2013) 
Identifying RNA editing sites using RNA sequencing data alone. Nature Methods. 10 (2), 128–132 
RAMASWAMI, G. & LI, J.B. (2014) RADAR: a rigorously annotated database of A-to-I RNA editing. Nucleic 
acids research. 42 (1), D109–D113 
RATTRAY, M. & BENDOTTI, C. (2006) Does excitotoxic cell death of motor neurons in ALS arise from 
glutamate transporter and glutamate receptor abnormalities? Experimental neurology. 201 (1), 15–23. 
RAVITS, J., APPEL, S., BALOH, R.H., BAROHN, R., BROOKS, B.R., ELMAN, L., FLOETER, M.K., 
HENDERSON, C., LOMEN-HOERTH, C., MACKLIS, J.D., MCCLUSKEY, L., MITSUMOTO, H., 
PRZEDBORSKI, S., ROTHSTEIN, J., TROJANOWSKI, J.Q., VAN DEN BERG, L.H. & RINGEL, S. (2013) 
Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about 
pathogenesis. Amyotrophic lateral sclerosis & frontotemporal degeneration. 14 Suppl 15–18. 
REAUME, A.G., ELLIOTT, J.L., HOFFMAN, E.K., KOWALL, N.W., FERRANTE, R.J., SIWEK, D.F., 
WILCOX, H.M., FLOOD, D.G., BEAL, M.F., BROWN, R.H., SCOTT, R.W. & SNIDER, W.D. (1996) Motor 
neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death 
after axonal injury. Nature genetics. 13 (1), 43–47.  
RÉGAL, L., VANOPDENBOSCH, L., TILKIN, P., VAN DEN BOSCH, L., THIJS, V., SCIOT, R. & 
ROBBERECHT, W. (2006) The G93C mutation in superoxide dismutase 1: clinicopathologic phenotype and 
prognosis. Archives of neurology. 63 (2), 262–267.  
REIMERS, J.M., MILOVANOVIC, M. & WOLF, M.E. (2011) Quantitative analysis of AMPA receptor subunit 
composition in addiction-related brain regions. Brain Research. 1367223–233.  
REISEL, D., BANNERMAN, D.M., SCHMITT, W.B., DEACON, R.M.J., FLINT, J., BORCHARDT, T., 
SEEBURG, P.H. & RAWLINS, J.N.P. (2002) Spatial memory dissociations in mice lacking GluR1. Nature 
neuroscience. 5 (9), 868–873.  
 239 
 
RENTON, A.E., MAJOUNIE, E., WAITE, A., SIMÓN-SÁNCHEZ, J., ROLLINSON, S., GIBBS, J.R., 
SCHYMICK, J.C., LAAKSOVIRTA, H., SWIETEN, J.C. VAN, KAGANOVICH, A., SCHOLZ, S.W., 
DUCKWORTH, J., DING, J., TRABZUNI, D., GUERREIRO, R.J., ORRELL, R.W., NEAL, J., MURRAY, A., 
HALLIWELL, N., ET AL. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of 
chromosome 9p21-linked ALS-FTD. Neuron. 72 (2), 257–268.  
RENTON, A.E., CHIÒ, A. & TRAYNOR, B.J. (2014) State of play in amyotrophic lateral sclerosis genetics. 
Nature neuroscience. 17 (1), 17–23.  
REUTER, J.S. & MATHEWS, D.H. (2010) RNAstructure: software for RNA secondary structure prediction 
and analysis. BMC bioinformatics. 11, 129.  
RIEDER, L.E. & REENAN, R. A (2012) The intricate relationship between RNA structure, editing, and 
splicing. Seminars in cell & developmental biology. 23 (3), 281–288.  
RIEDMANN, E.M., SCHOPOFF, S., HARTNER, J.C., RIEDMANN, E.V.A.M. & JANTSCH, M.F. (2008) 
Specificity of ADAR-mediated RNA editing in newly identified targets. RNA. 14, 1110–1118 
RIGO, F., HUA, Y., CHUN, S.J., PRAKASH, T.P., KRAINER, A.R. & BENNETT, C.F. (2012) Synthetic 
oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing. Nature chemical biology. 8 (6), 555–
561. 
RIGO, F., CHUN, S.J., NORRIS, D. A, HUNG, G., LEE, S., MATSON, J., FEY, R. A, GAUS, H., HUA, Y., 
GRUNDY, J.S., KRAINER, A.R., HENRY, S.P. & BENNETT, C.F. (2014) Pharmacology of a central nervous 
system delivered 2’-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and 
non-human primates. The Journal of pharmacology and experimental therapeutics. 350 (1), 46-55 
RINGHOLZ, G.M., APPEL, S.H., BRADSHAW, M., COOKE, N.A., MOSNIK, D.M. & SCHULZ, P.E. (2005) 
Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 65 (4), 586–590.  
RIZZU, P., BLAUWENDRAAT, C., HEETVELD, S., LYNES, E.M., CASTILLO-LIZARDO, M., DHINGRA, A., 
PYZ, E., HOBERT, M., SYNOFZIK, M., SIMÓN-SÁNCHEZ, J., FRANCESCATTO, M. & HEUTINK, P. (2016) 
C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced 
in C9orf72, MAPT and GRN mutation carriers. Acta Neuropathologica Communications. 4 (1), 37.  
ROBBERECHT, W. & PHILIPS, T. (2013) The changing scene of amyotrophic lateral sclerosis. Nature 
reviews. Neuroscience. 14 (4), 248–264.  
ROBBERSON, B.L., COTE, G.J. & BERGET, S.M. (1990) Exon definition may facilitate splice site selection 
in RNAs with multiple exons. Molecular and cellular biology. 10 (1), 84–94.  
ROCA, X., SACHIDANANDAM, R. & KRAINER, A.R. (2005) Determinants of the inherent strength of human 
5′ splice sites. RNA. 11, 683–698.  
ROELZ, R., PILZ, I.H., MUTSCHLER, M. & PAHL, H.L. (2010) Of mice and men: human RNA polymerase 
III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in 
both human and murine progenitor cells. Experimental hematology. 38 (9), 792–797.  
ROHRER, J.D., GUERREIRO, R., VANDROVCOVA, J., UPHILL, J., REIMAN, D., BECK, J., ISAACS, A.M., 
AUTHIER, A., FERRARI, R., FOX, N.C., MACKENZIE, I.R.A., WARREN, J.D., DE SILVA, R., HOLTON, J., 
REVESZ, T., HARDY, J., MEAD, S. & ROSSOR, M.N. (2009) The heritability and genetics of frontotemporal 
lobar degeneration. Neurology. 73 (18), 1451–1456.  
 240 
 
ROSEN, D.R., SIDDIQUE, T., PATTERSON, D., FIGLEWICZ, D.A., SAPP, P., HENTATI, A., DONALDSON, 
D., GOTO, J., O’REGAN, J.P., DENG, H.-X., RAHMANI, Z., KRIZUS, A., MCKENNA-YASEK, D., 
CAYABYAB, A., GASTON, S.M., BERGER, R., TANZI, R.E., HALPERIN, J.J., HERZFELDT, B., ET AL. 
(1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic later 
sclerosis. Nature. 362 (March), 59–62. 
ROSEN, H.J., GORNO-TEMPINI, M.L., GOLDMAN, W.P., PERRY, R.J., SCHUFF, N., WEINER, M., 
FEIWELL, R., KRAMER, J.H. & MILLER, B.L. (2002) Patterns of brain atrophy in frontotemporal dementia 
and semantic dementia. Neurology. 58 (2), 198–208. 
ROSENBERG, B.R., HAMILTON, C.E., MWANGI, M.M., DEWELL, S. & PAPAVASILIOU, F.N. (2011) 
Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3′ UTRs. 
Nature Structural & Molecular Biology. 18 (2), 230–236. 
ROTHSTEIN, J.D., JIN, L., DYKES-HOBERG, M. & KUNCL, R.W. (1993) Chronic inhibition of glutamate 
uptake produces a model of slow neurotoxicity. PNAS. 90 (14), 6591–6595. 
ROTHSTEIN, J.D. (2009) Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. 
Annals of neurology. 65 Suppl 1S3–S9.  
RUETER, S.M., DAWSON, T.R. & EMESON, R.B. (1999) Regulation of alternative splicing by RNA editing. 
Nature. 399 (May), 75–80. 
RULA, E.Y., LAGRANGE, A.H., JACOBS, M.M., HU, N., ROBERT, L. & EMESON, R.B. (2008) 
Developmental Modulation of GABAA Receptor Function by RNA Editing. Journal of Neuroscience. 28 (24), 
6196–6201. 
SAAB, A.S., NEUMEYER, A., JAHN, H.M., CUPIDO, A., SIMEK, A.A.M., BOELE, H.-J., SCHELLER, A., LE 
MEUR, K., GOTZ, M., MONYER, H., SPRENGEL, R., RUBIO, M.E., DEITMER, J.W., DE ZEEUW, C.I. & 
KIRCHOFF, F. (2012) Bergmann Glial AMPA Receptors Are Required for Fine Motor Coordination. Science. 
337, 749–753.  
SALARDINI, E., ZEINODDINI, A., MOHAMMADINEJAD, P., KHODAIE-ARDAKANI, M.-R., ZAHRAEI, N., 
ZEINODDINI, A. & AKHONDZADEH, S. (2016) Riluzole combination therapy for moderate-to-severe major 
depressive disorder: A randomized, double-blind, placebo-controlled trial. Journal of psychiatric research. 
75, 24–30.  
SALTER, J.D., BENNETT, R.P. & SMITH, H.C. (2016) The APOBEC Protein Family: United by Structure, 
Divergent in Function. Trends in Biochemical Sciences. 41 (7), 578–594. 
SAMUEL, C.E. (2012) ADARs: viruses and innate immunity. Current topics in microbiology and immunology. 
353, 163–195.  
SANJANA, N.E., LEVANON, E.Y., HUESKE, E. A, AMBROSE, J.M. & LI, J.B. (2012) Activity-dependent A-
to-I RNA editing in rat cortical neurons. Genetics. 192 (1), 281–287. 
SANJANA, N.E., SHALEM, O. & ZHANG, F. (2014) Improved vectors and genome-wide libraries for CRISPR 
screening. Nature Methods. 11 (8), 783–784. 
SANSAM, C.L., WELLS, K.S. & EMESON, R.B. (2003) Modulation of RNA editing by functional nucleolar 
sequestration of ADAR2. PNAS. 100 (24), 14018–14023.  
 241 
 
SAREEN, D., O’ROURKE, J.G., MEERA, P., MUHAMMAD, A.K.M.G., GRANT, S., SIMPKINSON, M., BELL, 
S., CARMONA, S., ORNELAS, L., SAHABIAN, A., GENDRON, T., PETRUCELLI, L., BAUGHN, M., RAVITS, 
J., HARMS, M.B., RIGO, F., BENNETT, C.F., OTIS, T.S., SVENDSEN, C.N., ET AL. (2013) Targeting RNA 
foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Science 
translational medicine. 5 (208), 208ra149.  
Sarepta (2015) Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne 
Muscular Dystrophy (DMD) Patients. p.clinicaltrials.gov. 
SASAKI, S., YAMASHITA, T., HIDEYAMA, T. & KWAK, S. (2014) Unique nuclear vacuoles in the motor 
neurons of conditional ADAR2-knockout mice. Brain Research. 1550, 36–46.  
SASAKI, S., YAMASHITA, T. & SHIN, K. (2015) Autophagy in spinal motor neurons of conditional ADAR2-
knockout mice: An implication for a role of calcium in increased autophagy flux in ALS. Neuroscience Letters. 
598, 79–84.  
SAVVA, Y.A., RIEDER, L.E. & REENAN, R.A. (2012) The ADAR protein family. Genome biology. 13 (12), 
252 
SAWADA, J., YAMASHITA, T., AIZAWA, H., ABURAKAWA, Y., HASEBE, N. & KWAK, S. (2009) Effects of 
antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line. Neuroscience research. 64 (3), 
251–258.  
SCHIMMER, J. & BREAZZANO, S. (2016) Investor Outlook: Rising from the Ashes; GSK’s European 
Approval of Strimvelis for ADA-SCID. Human Gene Therapy Clinical Development. 27 (2), 57–61.  
SCHNEIDER, C.A., RASBAND, W.S. & ELICEIRI, K.W. (2012) NIH Image to ImageJ: 25 years of image 
analysis. Nature Methods. 9 (7), 671–675.  
SCHOFT, V.K., SCHOPOFF, S. & JANTSCH, M.F. (2007) Regulation of glutamate receptor B pre-mRNA 
splicing by RNA editing. Nucleic acids research. 35 (11), 3723–3732.  
SCHWARZ, L.A., HALL, B.J. & PATRICK, G.N. (2010) Activity-dependent ubiquitination of GluA1 mediates 
a distinct AMPA receptor endocytosis and sorting pathway. The Journal of neuroscience 30 (49), 16718–
16729.  
SEBBAG-SZNAJDER, N., RAITSKIN, O., ANGENITZKI, M., SATO, T.-A., SPERLING, J. & SPERLING, R. 
(2012) Regulation of alternative splicing within the supraspliceosome. Journal of structural biology. 177 (1), 
152–159. 
SHARMA, S., PATNAIK, S.K., TAGGART, R.T., KANNISTO, E.D., ENRIQUEZ, S.M., GOLLNICK, P. & 
BAYSAL, B.E. (2015) APOBEC3A cytidine deaminase induces RNA editing in monocytes and 
macrophages. Nature communications. 66881. 
SHAW, P.J., FORREST, V., INCE, P.G., RICHARDSON, J.P. & WASTELL, H.J. (1995) CSF and Plasma 
Amino Acid Levels in Motor Neuron Disease: Elevation of CSF Glutamate in a Subset of Patients. 
Neurodegeneration. 4 (2), 209–216.  
SHI, S.-H., HAYASHI, Y., ESTEBAN, J. A. & MALINOW, R. (2001) Subunit-Specific Rules Governing AMPA 
Receptor Trafficking to Synapses in Hippocampal Pyramidal Neurons. Cell. 105, 331–343.  
 242 
 
SHIMO, T., TACHIBANA, K., SAITO, K., YOSHIDA, T., TOMITA, E., WAKI, R., YAMAMOTO, T., DOI, T., 
INOUE, T., KAWAKAMI, J. & OBIKA, S. (2014) Design and evaluation of locked nucleic acid-based splice-
switching oligonucleotides in vitro. Nucleic acids research. 1–14. 
SHOSHAN, E., MOBLEY, A.K., BRAEUER, R.R., KAMIYA, T., HUANG, L., VASQUEZ, M.E., SALAMEH, 
A., LEE, H.J., KIM, S.J., IVAN, C., VELAZQUEZ-TORRES, G., NIP, K.M., ZHU, K., BROOKS, D., JONES, 
S.J.M., BIROL, I., MOSQUEDA, M., WEN, Y., ETEROVIC, A.K., ET AL. (2015) Reduced adenosine-to-
inosine miR-455-5p editing promotes melanoma growth and metastasis. Nature Cell Biology. 17, 311-321 
SINGH, S.K. & WENGEL, J. (1998) Universality of LNA-mediated high-affinity nucleic acid recognition. 
1247–1248 
SIVA, K., COVELLO, G. & DENTI, M. a (2014) Exon-skipping antisense oligonucleotides to correct 
missplicing in neurogenetic diseases. Nucleic acid therapeutics. 24 (1), 69–86.  
SLAVOV, D., CLARK, M. & GARDINER, K. (2000) Comparative analysis of the RED1 and RED2 A-to-I RNA 
editing genes from mammals, pufferfish and zebrafish. Gene. 250 (1-2), 41–51. 
SLAVOV, D. & GARDINER, K. (2002) Phylogenetic comparison of the pre-mRNA adenosine deaminase 
ADAR2 genes and transcripts: conservation and diversity in editing site sequence and alternative splicing 
patterns. Gene. 299 (1-2), 83–94. 
SMITH, R.A., MILLER, T.M., YAMANAKA, K., MONIA, B.P., CONDON, T.P., HUNG, G., LOBSIGER, C.S., 
WARD, C.M., MCALONIS-DOWNES, M., WEI, H., WANCEWICZ, E. V, BENNETT, C.F. & CLEVELAND, 
D.W. (2006) Antisense oligonucleotide therapy for neurodegenerative disease. Journal of Clinical 
Investigation. 116 (8), 2290–2296.  
SOBOLEVSKY, A.I. (2015) Structure and gating of tetrameric glutamate receptors. The Journal of 
physiology. 593 (1), 29–38.  
SODHI, M.S., BURNET, P.W.J., MAKOFF, A.J., KERWIN, R.W. & HARRISON, P.J. (2001) RNA editing of 
the 5-HT 2C receptor is reduced in schizophrenia. Molecular psychiatry. 6, 373–379. 
SOLOMON, O., BAZAK, L., LEVANON, E., AMARIGLIO, N., UNGER, R., RECHAVI, G. & EYAL, E. (2014) 
Characterizing of functional human coding RNA editing from evolutionary, structural and dynamic 
perspectives. Proteins. 82 (11), 3117–3131. 
SOMMER, B., KEINÄNEN, K., VERDOORN, T., WISDEN, W., BURNASHEV, N., HERB,  A, KÖHLER, M., 
TAKAGI, T., SAKMANN, B. & SEEBURG, P.H. (1990) Flip and flop: a cell-specific functional switch in 
glutamate-operated channels of the CNS. Science. 249 (4976), 1580–1585. 
SOMMER, B., KOHLER, M., SPRENGEL, F. & SEEBURG, P.H. (1991) RNA Editing in Brain Controls of Ion 
Flow in Glutamate-Gated a Determinant Channels. Cell. 67, 11–19. 
SOO, K.Y., HALLORAN, M., SUNDARAMOORTHY, V., PARAKH, S., TOTH, R.P., SOUTHAM, K.A., 
MCLEAN, C.A., LOCK, P., KING, A., FARG, M.A. & ATKIN, J.D. (2015) Rab1-dependent ER-Golgi transport 
dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS. Acta 
neuropathologica. 130 (5), 679–697. 
STALLINGS, N.R., PUTTAPARTHI, K., LUTHER, C.M., BURNS, D.K. & ELLIOTT, J.L. (2010) Progressive 
motor weakness in transgenic mice expressing human TDP-43. Neurobiology of Disease. 40 (2), 404–414. 
 243 
 
STALMANS, S., BRACKE, N., WYNENDAELE, E., GEVAERT, B., PEREMANS, K., BURVENICH, C., 
POLIS, I. & DE SPIEGELEER, B. (2015) Cell-penetrating peptides selectively cross the blood-brain barrier 
in vivo. PLoS ONE. 10 (10), 1–22.  
STEENLAND, H.W., KIM, S.S. & ZHUO, M. (2008) GluR3 subunit regulates sleep, breathing and seizure 
generation. European Journal of Neuroscience. 27 (5), 1166–1173.  
STEPHENS, B., GUILOFF, R.J., NAVARRETE, R., NEWMAN, P., NIKHAR, N. & LEWIS, P. (2006) 
Widespread loss of neuronal populations in the spinal ventral horn in sporadic motor neuron disease. A 
morphometric study. Journal of the neurological sciences. 244 (1-2), 41–58 
STEPHENS, O.M., YI-BRUNOZZI, H.Y. & BEAL, P.A. (2000) Analysis of the RNA-editing reaction of ADAR2 
with structural and fluorescent analogues of the GluR-B R/G editing site. Biochemistry. 39 (40), 12243–
12251.  
STEPHENS, O.M., HAUDENSCHILD, B.L. & BEAL, P.A. (2004) The Binding Selectivity of ADAR2’s 
dsRBMs Contributes to RNA-Editing Selectivity. Chemistry & Biology. 11, 1239–1250.  
STEPHENSON, M.L. & ZAMECNIK, P.C. (1978) Inhibition of Rous sarcoma viral RNA translation by a 
specific oligodeoxyribonucleotide. PNAS 75 (1), 285–288. 
STRONG, M.J., VOLKENING, K., HAMMOND, R., YANG, W., STRONG, W., LEYSTRA-LANTZ, C. & 
SHOESMITH, C. (2007) TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding 
protein. Molecular and cellular neurosciences. 35 (2), 320–327.  
SUMMERTON, J.E. (2005) Endo-Porter: a novel reagent for safe, effective delivery of substances into cells. 
Annals of the New York Academy of Sciences. 1058, 62–75.  
SUN, H., KAWAHARA, Y., ITO, K., KANAZAWA, I. & KWAK, S. (2006) Slow and selective death of spinal 
motor neurons in vivo by intrathecal infusion of kainic acid: implications for AMPA receptor-mediated 
excitotoxicity in ALS. Journal of neurochemistry. 98 (3), 782–791 
SUN, Y., OLSON, R., HORNING, M., ARMSTRONG, N., MAYER, M. & GOUAUX, E. (2002) Mechanism of 
glutamate receptor desensitization. Nature. 417 (6886), 245–253 
SUN, Y., LI, X., WU, D., PAN, Q., JI, Y., REN, H. & DING, K. (2016) RED: A Java-MySQL Software for 
Identifying and Visualizing RNA Editing Sites Using Rule-Based and Statistical Filters. Plos One. 11 (3), 
e0150465. 
SUN, Z.-W., ZHANG, L., ZHU, S.-J., CHEN, W.-C. & MEI, B. (2010) Excitotoxicity effects of glutamate on 
human neuroblastoma SH-SY5Y cells via oxidative damage. Neuroscience bulletin. 26 (1), 8–16 
SWANSON, G.T., FELDMEYER, D., KANEDA, M. & CULL-CANDY, S.G. (1996) Effect of RNA editing and 
subunit co-assembly single-channel properties of recombinant kainate receptors. The Journal of Physiology. 
492 (1), 129–142.  
SWANSON, G.T., KAMBOJ, S.K. & CULL-CANDY, S.G. (1997) Single-channel properties of recombinant 
AMPA receptors depend on RNA editing, splice variation, and subunit composition. Journal of Neuroscience. 
17 (1), 58–69. 
TAKUMA, H., KWAK, S., YOSHIZAWA, T. & KANAZAWA, I. (1999) Reduction of GluR2 RNA editing, a 
molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray 
of patients with amyotrophic lateral sclerosis. Annals of neurology. 46 (6), 806–815. 
 244 
 
TALBOT, K. (2014) Amyotrophic lateral sclerosis: cell vulnerability or system vulnerability? Journal of 
anatomy. 224 (1), 45–51.  
TARIQ, A. & JANTSCH, M.F. (2012) Transcript diversification in the nervous system: A to I RNA editing in 
CNS function and disease development. Frontiers in neuroscience. 6 (July), 99 
TER BRAKE, O., ’T HOOFT, K., LIU, Y.P., CENTLIVRE, M., VON EIJE, K.J. & BERKHOUT, B. (2008) 
Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Molecular therapy. 16 
(3), 557–564. 
TICOZZI, N., TILOCA, C., MORELLI, C., COLOMBRITA, C., POLETTI, B., DORETTI, A., MADERNA, L., 
MESSINA, S., RATTI, A. & SILANI, V. (2011) Genetics of familial Amyotrophic lateral sclerosis. Archives 
italiennes de biologie. 149 (1), 65–82 
TOOZE, J., HOLLINSHEAD, M., FULLER, S.D., TOOZE, S.A. & HUTTNER, W.B. (1989) Morphological and 
biochemical evidence showing neuronal properties in AtT-20 cells and their growth cones. European journal 
of cell biology. 49 (2), 259–273. 
TOTH, P.P. (2013) Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the 
management of hypercholesterolemia. Journal of clinical lipidology. 7 (3 Suppl), S6–S10 
TRAYNELIS, S.F., WOLLMUTH, L.P., MCBAIN, C.J., MENNITI, F.S., VANCE, K.M., OGDEN, K.K., 
HANSEN, K.B., YUAN, H., MYERS, S.J. & DINGLEDINE, R. (2010) Glutamate Receptor Ion Channels : 
Structure , Regulation , and Function. Pharmacological Reviews. 62 (3), 405–496 
TREMBLAY, R.G., SIKORSKA, M., SANDHU, J.K., LANTHIER, P., RIBECCO-LUTKIEWICZ, M. & BANI-
YAGHOUB, M. (2010) Differentiation of mouse Neuro 2A cells into dopamine neurons. Journal of 
neuroscience methods. 186 (1), 60–67.  
TSUIJI, H., IGUCHI, Y., FURUYA, A., KATAOKA, A., HATSUTA, H., ATSUTA, N., TANAKA, F., 
HASHIZUME, Y., AKATSU, H., MURAYAMA, S., SOBUE, G. & YAMANAKA, K. (2013) Spliceosome 
integrity is defective in the motor neuron diseases ALS and SMA. EMBO molecular medicine. 5 (2), 221–
234 
UDAN-JOHNS, M., BENGOECHEA, R., BELL, S., SHAO, J., DIAMOND, M.I., TRUE, H.L., WEIHL, C.C. & 
BALOH, R.H. (2014) Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 
chaperones. Human molecular genetics. 23 (1), 157–170 
VAN DAMME, P., VAN DEN BOSCH, L., VAN HOUTTE, E., CALLEWAERT, G. & ROBBERECHT, W. 
(2002) GluR2-dependent properties of AMPA receptors determine the selective vulnerability of motor 
neurons to excitotoxicity. Journal of Neurophysiology. 88 (3), 1279–1287. 
VAN DEN BOSCH, L., VANDENBERGHE, W., KLAASSEN, H., VAN HOUTTE, E. & ROBBERECHT, W. 
(2000) Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons. Journal of the 
neurological sciences. 180 (1-2), 29–34. 
VAN DEN HAUTE, C., EGGERMONT, K., NUTTIN, B., DEBYSER, Z. & BAEKELANDT, V. (2003) Lentiviral 
Vector-Mediated Delivery of Short Hairpin RNA Results in Persistent Knockdown of Gene Expression in 
Mouse Brain. Human Gene Therapy. 14 (18), 1799–1807.  
VAN DEVENTER, S.J.H., TAMI, J.A. & WEDEL, M.K. (2004) A randomised, controlled, double blind, 
escalating dose study of alicaforsen enema in active ulcerative colitis. Gut. 53 (11), 1646–1651.  
 245 
 
VASCONCELOS, N.L., GOMES, E.D., OLIVEIRA, E.P., SILVA, C.J., LIMA, R., SOUSA, N., SALGADO, A.J. 
& SILVA, N.A. (2016) Combining neuroprotective agents: effect of riluzole and magnesium in a rat model of 
thoracic spinal cord injury. The spine journal [Epub ahead of print] 
VELDINK, J.H., KALMIJN, S., GROENEVELD, G.J., TITULAER, M.J., WOKKE, J.H.J. & VAN DEN BERG, 
L.H. (2005) Physical activity and the association with sporadic ALS. Neurology. 64 (2), 241–245 
VELTROP, M. & AARTSMA-RUS, A. (2014) Antisense-mediated exon skipping: Taking advantage of a trick 
from Mother Nature to treat rare genetic diseases. Experimental cell research. 325 (1), 50–55. 
VENØ, M.T., BRAMSEN, J.B., BENDIXEN, C., PANITZ, F., HOLM, I.E., ÖHMAN, M. & KJEMS, J. (2012) 
Spatio-temporal regulation of ADAR editing during development in porcine neural tissues. RNA biology. 9 
(8), 1054–1065.  
VERBEECK, C., DENG, Q., DEJESUS-HERNANDEZ, M., TAYLOR, G., CEBALLOS-DIAZ, C., KOCERHA, 
J., GOLDE, T., DAS, P., RADEMAKERS, R., DICKSON, D.W. & KUKAR, T. (2012) Expression of Fused in 
sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight 
into disease pathogenesis. Molecular neurodegeneration. 7, 53 
VERHAART, I.E.C., VAN VLIET-VAN DEN DOOL, L., SIPKENS, J. A, DE KIMPE, S.J., KOLFSCHOTEN, 
I.G.M., VAN DEUTEKOM, J.C.T., LIEFAARD, L., RIDINGS, J.E., HOOD, S.R. & AARTSMA-RUS, A. (2014) 
The Dynamics of Compound, Transcript, and Protein Effects After Treatment With 2OMePS Antisense 
Oligonucleotides in mdx Mice. Molecular therapy. Nucleic acids. 3 (October 2013), e148. 
VIDIGAL, J.A. & VENTURA, A. (2015) Rapid and efficient one-step generation of paired gRNA CRISPR-
Cas9 libraries. Nature communications. 6, 8083.  
VITALI, P., BASYUK, E., LE MEUR, E., BERTRAND, E., MUSCATELLI, F., CAVAILLÉ, J. & 
HUTTENHOFER, A. (2005) ADAR2-mediated editing of RNA substrates in the nucleolus is inhibited by C/D 
small nucleolar RNAs. The Journal of cell biology. 169 (5), 745–753 
VOSS, O.P., MILNE, S., SHARKEY, J., O’NEILL, M.J. & MCCULLOCH, J. (2007) Molecular mechanisms of 
neurite growth with AMPA receptor potentiation. Neuropharmacology. 52 (2), 590–597.  
WAHLESTEDT, C., SALMI, P., GOOD, L., KELA, J., JOHNSSON, T., HO, T., BROBERGER, C., 
PORRECA, F., LAI, J., REN, K., OSSIPOV, M., KOSHKIN, A., JAKOBSEN, N., SKOUV, J., OERUM, H., 
JACOBSEN, M.H. & WENGEL, J. (2000) Potent and nontoxic antisense oligonucleotides containing locked 
nucleic acids. PNAS. 97 (10), 5633–5638 
WAHLSTEDT, H., DANIEL, C., ENSTERO, M. & MARIE, O. (2009) Large-scale mRNA sequencing 
determines global regulation of RNA editing during brain development. Genome Research. 19, 978–986.  
WAINGER, B.J., KISKINIS, E., MELLIN, C., WISKOW, O., HAN, S.S.W., SANDOE, J., PEREZ, N.P., 
WILLIAMS, L.A., LEE, S., BOULTING, G., BERRY, J.D., BROWN, R.H., CUDKOWICZ, M.E., BEAN, B.P., 
EGGAN, K. & WOOLF, C.J. (2014) Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis 
patient-derived motor neurons. Cell reports. 7 (1), 1–11 
WAITE, A.J., BÄUMER, D., EAST, S., NEAL, J., MORRIS, H.R., ANSORGE, O. & BLAKE, D.J. (2014) 
Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal 
degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiology of aging. 35 (7), 
1779.e5–e1779.e13.  
 246 
 
WAN, Y., KERTESZ, M., SPITALE, R.C., SEGAL, E. & CHANG, H. (2013) Understanding the transcriptome 
through RNA structure. Nature Reviews Genetics. 29 (9), 997–1003. 
WANG, A.L., CARROLL, R.C. & NAWY, S. (2014) Down-Regulation of the RNA Editing Enzyme ADAR2 
Contributes to RGC Death in a Mouse Model of Glaucoma PLoS ONE. 9 (3), e91288.  
WANG, E.T., SANDBERG, R., LUO, S., KHREBTUKOVA, I. & ZHANG, L. (2008) Alternative Isoform 
Regulation in Human Tissue Transcriptomes. Nature. 456 (7221), 470–476.  
WANG, H., LIU, H. & ZHANG, Z. (2011) Elimination of redundant synaptic inputs in the absence of synaptic 
strengthening. The Journal of neuroscience 31 (46), 16675–16684.  
WANG, R., PALAVICINI, J.P., WANG, H., MAITI, P., BIANCHI, E., XU, S., LLOYD, B.N., DAWSON-
SCULLY, K., KANG, D.E. & LAKSHMANA, M.K. (2014a) RanBP9 overexpression accelerates loss of 
dendritic spines in a mouse model of Alzheimer’s disease. Neurobiology of disease. 69, 169–179.  
WANG, X., YING, W., DUNLAP, K.A., LIN, G., SATTERFIELD, M.C., BURGHARDT, R.C., WU, G. & BAZER, 
F.W. (2014b) Arginine decarboxylase and agmatinase: an alternative pathway for de novo biosynthesis of 
polyamines for development of mammalian conceptuses. Biology of reproduction. 90 (4), 84. 
WANG, Y., MA, M., XIAO, X. & WANG, Z. (2012) Intronic splicing enhancers, cognate splicing factors and 
context-dependent regulation rules. Nature Structural & Molecular Biology. 19 (10), 1044–1052 
WANG, Z., GERSTEIN, M. & SNYDER, M. (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nature 
reviews. Genetics. 10 (1), 57–63.  
WANG, Z., XIAO, X., VAN NOSTRAND, E. & BURGE, C.B. (2006) General and Specific Functions of Exonic 
Splicing Silencers in Splicing Control. Mol Cell. 23 (1), 61–70. 
WARITA, H., MANABE, Y., MURAKAMI, T., SHIOTE, M., SHIRO, Y., HAYASHI, T., NAGANO, I., SHOJI, 
M. & ABE, K. (2002) Tardive decrease of astrocytic glutamate transporter protein in transgenic mice with 
ALS-linked mutant SOD1. Neurological research. 24 (6), 577–581 
WATANABE, S.Y., ALBSOUL-YOUNES, A.M., KAWANO, T., ITOH, H., KAZIRO, Y., NAKAJIMA, S. & 
NAKAJIMA, Y. (1999) Calcium phosphate-mediated transfection of primary cultured brain neurons using 
GFP expression as a marker: application for single neuron electrophysiology. Neuroscience research. 33 
(1), 71–78. 
WATERSTON, R.H., LINDBLAD-TOH, K., BIRNEY, E., ROGERS, J., ABRIL, J.F., AGARWAL, P., 
AGARWALA, R., AINSCOUGH, R., ALEXANDERSSON, M., AN, P., ANTONARAKIS, S.E., ATTWOOD, J., 
BAERTSCH, R., BAILEY, J., BARLOW, K., BECK, S., BERRY, E., BIRREN, B., BLOOM, T., ET AL. (2002) 
Initial sequencing and comparative analysis of the mouse genome. Nature. 420 (6915), 520–562 
WHEELER, T.M., LEGER, A.J., PANDEY, S.K., MACLEOD,  A R., NAKAMORI, M., CHENG, S.H., 
WENTWORTH, B.M., BENNETT, C.F. & THORNTON, C. A (2012) Targeting nuclear RNA for in vivo 
correction of myotonic dystrophy. Nature. 488 (7409), 111–115. 
WHITNEY, N.P., PENG, H., ERDMANN, N.B., TIAN, C., MONAGHAN, D.T. & ZHENG, J.C. (2008) Calcium-
permeable AMPA receptors containing Q/R-unedited GluR2 direct human neural progenitor cell 
differentiation to neurons. FASEB journal. 22 (8), 2888–2900.  
 247 
 
WICKS, P., ABRAHAMS, S., PAPPS, B., AL-CHALABI, A., SHAW, C.E., LEIGH, P.N. & GOLDSTEIN, L.H. 
(2009) SOD1 and cognitive dysfunction in familial amyotrophic lateral sclerosis. Journal of neurology. 256 
(2), 234–241 
WIEDHOLZ, L.M., OWENS, W.A., HORTON, R.E., FEYDER, M., KARLSSON, R.-M., HEFNER, K., 
SPRENGEL, R., CELIKEL, T., DAWS, L.C. & HOLMES, A. (2008) Mice lacking the AMPA GluR1 receptor 
exhibit striatal hyperdopaminergia and ‘schizophrenia-related’ behaviors. Molecular psychiatry. 13 (6), 631–
640.  
WILLARD, S.S. & KOOCHEKPOUR, S. (2013) Glutamate, glutamate receptors, and downstream signaling 
pathways. International journal of biological sciences. 9 (9), 948–959.  
WONG, K., LYDDON, R. & DRACHEVA, S. (2009) TaqMan-based, real-time quantitative polymerase chain 
reaction method for RNA editing analysis. Analytical biochemistry. 390 (2), 173–180.  
WONG, S.K., SATO, S. & LAZINSKI, D.W. (2001) Substrate recognition by ADAR1 and ADAR2. RNA. 7 (6), 
846–858. 
WRIGHT, A. & VISSEL, B. (2012) The essential role of AMPA receptor GluR2 subunit RNA editing in the 
normal and diseased brain. Frontiers in molecular neuroscience. 5 (April), 34.. 
WU, B., CLOER, C., LU, P., MILAZI, S., SHABAN, M., SHAH, S.N., MARSTON-POE, L., MOULTON, H.M. 
& LU, Q.L. (2014) Exon skipping restores dystrophin expression, but fails to prevent disease progression in 
later stage dystrophic dko mice. Gene therapy. (April), 1–9.  
WUOLIKAINEN, A., MORITZ, T., MARKLUND, S.L., ANTTI, H. & ANDERSEN, P.M. (2011) Disease-related 
changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS. 
PloS one. 6 (4), e17947.  
XIAO, S., SANELLI, T., DIB, S., SHEPS, D., FINDLATER, J., BILBAO, J., KEITH, J., ZINMAN, L., 
ROGAEVA, E. & ROBERTSON, J. (2011) RNA targets of TDP-43 identified by UV-CLIP are deregulated in 
ALS. Molecular and Cellular Neuroscience. 47 (3), 167–180. 
XU, M., WELLS, K.S. & EMESON, R.B. (2006) Substrate-dependent Contribution of Double-stranded RNA-
binding Motifs to ADAR2 Function. Molecular Biology of the Cell. 17 (July), 3211–3220.  
XU, Z., POIDEVIN, M., LI, X., LI, Y., SHU, L., NELSON, D.L., LI, H., HALES, C.M., GEARING, M., WINGO, 
T.S. & JIN, P. (2013) Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and 
frontotemporal dementia causes neurodegeneration PNAS. 110 (19), 7778–7783. 
YAMASHITA, T., HIDEYAMA, T., HACHIGA, K., TERAMOTO, S., TAKANO, J., IWATA, N., SAIDO, T.C. & 
KWAK, S. (2012a) A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis 
pathology. Nature communications. 3, 1307.  
YAMASHITA, T., HIDEYAMA, T., TERAMOTO, S. & KWAK, S. (2012b) The abnormal processing of TDP-
43 is not an upstream event of reduced ADAR2 activity in ALS motor neurons. Neuroscience research. 73 
(2), 153–160. 
YAMASHITA, T., TADAMI, C., NISHIMOTO, Y., HIDEYAMA, T., KIMURA, D., SUZUKI, T. & KWAK, S. 
(2012c) RNA editing of the Q/R site of GluA2 in different cultured cell lines that constitutively express different 
levels of RNA editing enzyme ADAR2. Neuroscience research. 73 (1), 42–48. 
 248 
 
YAMASHITA, T., CHAI, H.L., TERAMOTO, S., TSUJI, S., SHIMAZAKI, K., MURAMATSU, S. & KWAK, S. 
(2013) Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 
delivery to motor neurons. EMBO molecular medicine. 5 (11), 1710–1719.  
YAMASHITA, T. & KWAK, S. (2014) The molecular link between inefficient GluA2 Q/R site-RNA editing and 
TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis patients. Brain research. 1584, 
28–38 
YÁÑEZ-MUÑOZ, R.J., BALAGGAN, K.S., MACNEIL, A., HOWE, S.J., SCHMIDT, M., SMITH, A.J., BUCH, 
P., MACLAREN, R.E., ANDERSON, P.N., BARKER, S.E., DURAN, Y., BARTHOLOMAE, C., VON KALLE, 
C., HECKENLIVELY, J.R., KINNON, C., ALI, R.R. & THRASHER, A.J. (2006) Effective gene therapy with 
nonintegrating lentiviral vectors. Nature medicine. 12 (3), 348–353 
YANG, L., NIU, H., GAO, X., WANG, Q., HAN, G., CAO, L., CAI, C., WEILER, J. & YIN, H. (2013) Effective 
Exon Skipping and Dystrophin Restoration by 2’-O-Methoxyethyl Antisense Oligonucleotide in Dystrophin-
Deficient Mice. PLoS ONE. 8 (4). 
YASUI, M., SUENAGA, E., KOYAMA, N., MASUTANI, C., HANAOKA, F., GRUZ, P., SHIBUTANI, S., 
NOHMI, T., HAYASHI, M. & HONMA, M. (2008) Miscoding Properties of 2′-Deoxyinosine, a Nitric Oxide-
Derived DNA Adduct, during Translesion Synthesis Catalyzed by Human DNA Polymerases. Journal of 
Molecular Biology. 377 (4), 1015–1023 
YE, Z., CHEN, Z., LAN, X., HARA, S., SUNKEL, B., HUANG, T.H.-M., ELNITSKI, L., WANG, Q. & JIN, V.X. 
(2014) Computational analysis reveals a correlation of exon-skipping events with splicing, transcription and 
epigenetic factors. Nucleic acids research. 42 (5), 2856–2869.  
YEO, G. & BURGE, C.B. (2004) Maximum Entropy Modeling of Short Sequence Motifs with Applications to 
RNA Splicing Signals. Journal of Computational Biology. 11 (2-3), 377–394. 
YI-BRUNOZZI, H.Y., STEPHENS, O.M. & BEAL, P. A (2001) Conformational changes that occur during an 
RNA-editing adenosine deamination reaction. The Journal of biological chemistry. 276 (41), 37827–37833.  
YIN, H.Z. & WEISS, J.H. (2012) Marked synergism between mutant SOD1 and glutamate transport inhibition 
in the induction of motor neuronal degeneration in spinal cord slice cultures. Brain research. 1448, 153–162. 
YLÄ-HERTTUALA, S. (2012) Endgame: Glybera Finally Recommended for Approval as the First Gene 
Therapy Drug in the European Union. Molecular Therapy. 20 (10), 1831–1832 
YU, Y., SU, F.-C., CALLAGHAN, B.C., GOUTMAN, S.A., BATTERMAN, S.A. & FELDMAN, E.L. (2014) 
Environmental Risk Factors and Amyotrophic Lateral Sclerosis (ALS): A Case-Control Study of ALS in 
Michigan. PloS one. 9 (6), e101186.  
ZAMECNIK, P.C. & STEPHENSON, M.L. (1978) Inhibition of Rous sarcoma virus replication and cell 
transformation by a specific oligodeoxynucleotide Biochemistry 75 (1), 280–284. 
ZANETTE, G., TAMBURIN, S., MANGANOTTI, P., REFATTI, N., FORGIONE, A. & RIZZUTO, N. (2002) 
Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clinical 
Neurophysiology. 113 (11), 1688–1697. 
ZEITELHOFER, M., VESSEY, J.P., XIE, Y., TÜBING, F., THOMAS, S., KIEBLER, M. & DAHM, R. (2007) 
High-efficiency transfection of mammalian neurons via nucleofection. Nature protocols. 2 (7), 1692–1704. 
 249 
 
ZHANG, K., DONNELLY, C.J., HAEUSLER, A.R., GRIMA, J.C., MACHAMER, J.B., STEINWALD, P., 
DALEY, E.L., MILLER, S.J., CUNNINGHAM, K.M., VIDENSKY, S., GUPTA, S., THOMAS, M. A., HONG, I., 
CHIU, S.-L., HUGANIR, R.L., OSTROW, L.W., MATUNIS, M.J., WANG, J., SATTLER, R., ET AL. (2015) 
The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 525, 56-61 
ZHANG, L., YANG, C.-S., VARELAS, X. & MONTI, S. (2016) Altered RNA editing in 3′ UTR perturbs 
microRNA-mediated regulation of oncogenes and tumor-suppressors. Scientific Reports. 6 (November 
2015), 23226.  
ZHANG, X.H.F. & CHASIN, L.A. (2004) Computational definition of sequence motifs governing constitutive 
exon splicing. Genes and Development. 18 (11), 1241–1250.  
ZHANG, Y., WANG, H., PAN, H., BAO, X., LI, M., JIN, J. & WU, X. (2006) Gene delivery into primary cerebral 
cortical neurons by lentiviral vector. Cell Biology International. 30 (10), 777–783 
ZHOU, H., JANGHRA, N., MITRPANT, C., DICKINSON, R.L., ANTHONY, K., PRICE, L., EPERON, I.C., 
WILTON, S.D., MORGAN, J. & MUNTONI, F. (2013) A novel morpholino oligomer targeting ISS-N1 
improves rescue of severe spinal muscular atrophy transgenic mice. Human gene therapy. 24 (3), 331–342.  
ZHOU, R., HOLMES, A., DU, J., MALKESMAN, O., YUAN, P., WANG, Y., DAMSCHRODER-WILLIAMS, 
P., CHEN, G., GUITART, X. & MANJI, H.K. (2009) Genome-wide gene expression profiling in GluR1 
knockout mice: Key role of the calcium signaling pathway in glutamatergically mediated hippocampal 
transmission. European Journal of Neuroscience. 30 (12), 2318–2326.  
ZOU, L.-L., MA, J.-L., WANG, T., YANG, T.-B. & LIU, C.-B. (2013) Cell-penetrating Peptide-mediated 
therapeutic molecule delivery into the central nervous system. Current neuropharmacology. 11 (2), 197–
208.  
ZUKER, M. (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids 
Research. 31 (13), 3406–3415. 
 250 
 
9 APPENDIX 1 
Multiple sequence alignment by MUSCLE 3.8 (Clustal) between human, rat and mouse. 
Exon 11 of Gria2 is highlighted in grey, followed by intron 11. The edited adenosine is 
highlighted in red. Stars beneath bases indicate perfect alignment across species. 
Dashes indicate a gap in sequence before the alignment continues.  
 
human           AAAGCTGATATTGCAATTGCTCCATTAACTATTACCCTTGTGAGAGAAGAGGTGATTGAC 
rat             AAAGCTGACATTGCAATTGCTCCATTAACTATCACTCTCGTGAGAGAAGAGGTGATTGAC 
mouse           AAAGCTGATATTGCCATTGCTCCATTAACTATCACTCTCGTGAGAGAAGAGGTGATTGAC 
                ******** ***** ***************** ** ** ********************* 
 
human           TTCTCAAAGCCCTTCATGAGCCTCGGGATATCTATCATGATCAAGAAGCCTCAGAAGTCC 
rat             TTCTCCAAGCCCTTCATGAGTCTTGGAATCTCTATCATGATCAAGAAGCCTCAGAAGTCC 
mouse           TTCTCGAAGCCATTCATGAGCCTTGGAATCTCTATCATGATCAAGAAGCCTCAGAAGTCC 
                ***** ***** ******** ** ** ** ****************************** 
 
human           AAACCAGGAGTGTTTTCCTTTCTTGATCCTTTAGCCTATGAGATCTGGATGTGCATTGTT 
rat             AAACCAGGAGTGTTTTCCTTTCTTGATCCTTTAGCCTATGAGATCTGGATGTGCATTGTG 
mouse           AAACCAGGAGTGTTTTCCTTTCTTGATCCTTTAGCCTATGAGATCTGGATGTGCATTGTG 
                ***********************************************************  
 
human           TTTGCCTACATTGGGGTCAGTGTAGTTTTATTCCTGGTCAGCAGATTTAGCCCCTACGAG 
rat             TTTGCCTACATTGGGGTCAGTGTAGTTTTATTCCTGGTCAGCAGATTTAGCCCCTACGAG 
mouse           TTTGCCTACATTGGGGTCAGTGTAGTTTTATTCCTGGTCAGCAGATTTAGCCCCTACGAG 
                ************************************************************ 
 
human           TGGCACACTGAGGAGTTTGAAGATGGAAGAGAAACACAAAGTAGTGAATCAACTAATGAA 
rat             TGGCACACTGAGGAATTTGAAGATGGAAGAGAAACACAAAGTAGTGAATCAACTAATGAA 
mouse           TGGCACACTGAGGAATTTGAAGATGGAAGAGAAACACAAAGTAGTGAATCAACTAATGAA 
                ************** ********************************************* 
 
human           TTTGGGATTTTTAATAGTCTCTGGTTTTCCTTGGGTGCCTTTATGCAGCAAGGATGCGAT 
rat             TTTGGGATTTTTAATAGTCTCTGGTTTTCCTTGGGTGCCTTTATGCAGCAAGGATGCGAT 
mouse           TTTGGGATTTTTAATAGTCTCTGGTTTTCCTTGGGTGCCTTTATGCAGCAAGGATGCGAT 
                ************************************************************ 
 
human           ATTTCGCCAAGGTTGGTTACTCACCTGCTTCAACTTTGTGCATTTCAGGTCTCAAGTGGA 
rat             ATTTCGCCAAGGTTGGTCACTCACCTGCTTCAACTTTGTGCATTTTAGGTCTCAAGTGAA 
mouse           ATTTCGCCAAGGTTGGTCACTCACCTGCTTCAACTTTGTGCATTTTAGGTCTCAAGTGGA 
                ***************** *************************** ************ * 
 
human           CATTCATGGTGTTTATGGATTCACCCTAAAGAAGTTACCAGCTGCCGACTTCCTGTCCAA 
rat             TATTCATGGTGTTTATGAATTCACCATAAAGATGTCACCAGCTGCCAACCATTTGTCCAA 
mouse           TATTCATGGTGTCTATGAATTCACTATAAAGATGTCAGCAGCTGCCGACCATTTGTCCAA 
                 *********** **** ******  ****** ** * ******** **    ******* 
 
human           GC-AGTTTAAGACTCTTGAAGGACATCCTCTTAGCTTCGGCATAAGTCTGTGAAATATTT 
rat             GC-AATTTAAGATGCTTAGAGGGCAAATTTTTACCATCGGCATAAGCCTGTGAATTACCT 
mouse           GCAAATTTAAGATGCTTAGAAGGCAAATTTTTACCGTCGGCGTAAGCCTGTGAAATACCT 
                ** * *******  ***  * * **   * *** * ***** **** ******* **  * 
 
human           GAACAATGTTCTTTGAATGTTGCTCATCTATTTCTCTGGTGAAATTATACACACCATGAA 
rat             GAACAATGTTCCTGGAATGTTGATCAGGTGTTTCCCTGGTGAAATTATAAACACCATGGA 
mouse           GAACAATGTTCCTTGAATGTTGATCATGTGTTTCCCTGGTGAAATCATATACACCATGGA 
                *********** * ******** ***  * **** ********** *** ******** * 
 
human           GAGGCTATAAAATGCATAAGGTTCCTATCATTCCATGCCTTCTTGGAGGGGTACCGTGTT 
rat             GAGGCTATAAAATGCATAAGGTTCCTATCATTCCATGCCTGCTTGGAGGGGTACCGTGTT 
mouse           GAGGCTATAAAATGCAGAAGGTTCCTATCATTCCATGCCTGCTTGGAGGGGTACCGTGTT 
                **************** *********************** ******************* 
 
human           TTTGCTGCATATTCTCATTTTACAGTCATCTGTGTGTTGATCCACAGACCTGTATATGGG 
rat             TTTGCTGCATATTCTCATTTTACAGTTATCTGTGTGTTCATCCACAGACCTGTATATGGG 
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mouse           TTTGCTGCATATTCTCATTTTACAGTTATCTGTGTGTTCATCCACAGACCTGTATATGGG 
                ************************** *********** ********************* 
 
human           AAAATGGGCAACATTATTTATTAACTGCAAAGT-AACACCTTGTTAGATAAAACTTCGTT 
rat             AAAATGGGCGATTTTAGCTTTTTCCTACAGAGTCAACAACTTGTGAGACAACACTTCATT 
mouse           AAAATGGGCGAGGTTAGATTTTTCCTACAGGGTCAACAACTTGTTAGACAACACTTCATT 
                ********* *  ***  * **  ** **  ** **** ***** *** ** ***** ** 
 
human           GGCACACATCTCATCTCTTTTATTTTCCCATCATTAGTTCATGGAAATGGTATGGGAGAG 
rat             T-CACATACCTCATCTT-TTTATTTCCCTAACATCAACTCATGGAAATGGTGTGTGAGCG 
mouse           TGCACATACCTCATCTC-TTTATTTCTCTAACATCAATTCATGGAAATGGTGTGTTTGTG 
                  **** * *******  *******  * * *** *  ************* **   * * 
 
human           ATATTATAAAATTTATTTTTTTTCTAGGTGAGGTTGCTGGATTAATA---TAATAGCATA 
rat             AGATTATTCAA------CTTTTTAAATGTTAGGGTTCTGGATTAAAATGTTGATTATACA 
mouse           AGGTTATTAAA------AGTTTTAAATGTTAGGCTCCTGGAGTAAAAAGTTGATCACACA 
                *  ****  **        ****  * ** *** * ***** *** *   * **   * * 
 
human           TTTTCAACTACCCACAAATGCCTGGAAGGGACTA-ATCATTCATTAAAAA-ACCTGT-CC 
rat             GTTTCAAGTATCTAGAAATACAGACAGAAAAAAAGATGGCTTGCTGAAAATTCCTATGCC 
mouse           --------TATCTAGAAATGCAGACAGAAAAAGA-ATAGCTTGCTGAAAATTCCTGTGCC 
                        ** * * **** *    *    *  * **   *   * ****  *** * ** 
 
human           ATATCGAATGGTAATACACACACACATGGAATAAACTCACCTACCTTTAATCTCATTATG 
rat             ACCTTGAATAGT------------------ACATACTCACACACCTCTCTTCCCATCAGG 
mouse           ACGTTGAAGGAT------------------ACATACTCACACACCTCGATTCACATCAGG 
                *  * ***   *                  * * ******  ****    ** *** * * 
 
human           ATATGTTAAATCCCTGCACTAGAATACCTAATTATAATGAATCTACCACAAAGTACCCAT 
rat             TTATAAT-TATCTCAGGCTTAAAGTACCTAATTATCA-ATATCTGTTGCAAATCACCAAT 
mouse           TTATAAT-TATCTCAGGCTTCAAGTACTTAATTATCA-GTATTTGTCACAAATCACCAAT 
                 ***  *  *** * *   *  * *** ******* *   ** *    ****  *** ** 
 
human           TGATTTTATTCATGTTGCACGTATGAATAAGAATGATAGCCATGTTTGGCTCTTCAGAGG 
rat             TGCTTTTGTTTATGTTAC-------AACATGAATCATAACTATTTGCATCTCTTCAGATA 
mouse           TGCTATTGTTTATGTTAC-------AACATGAATGATAATTACCTGTATCTCTTCGGATA 
                ** * ** ** ***** *       ** * **** ***   *  *    ****** **   
 
human           AATAAATCATGATTTTTCTAGTGTG-----ATTAACATTTTAAGTCAAAATGATTATCAC 
rat             AATGAATCCCACTTTTACTAGTCTATTATCATTAACATTT-AATCCAAGGTG-TTATTTG 
mouse           AATAAATCCCACTTTTGCTAGTGTGTTATCATTAACATTTATAGCCAAGATG-TTATGTG 
                *** ****    **** ***** *      **********  *  ***  ** ****    
 
human           TCTACTGGCACATTTTAATTTGGGCTCTATTACCCTTCTTCGATTTTACAGGATATCTTA 
rat             TCTCTTGGGA-AGTTCAATTTGAGCTCAAATAGCTTCTTTCCATTCCAATAATAATCT-- 
mouse           TCTCTTGGGGAAGTTCAATTTGATCTGGAATAAACACTTTTGATTCCAATAATAATCT-- 
                ***  ***   * ** ******  **  * **      **  ***  *      ****   
 
human           ATAACTAGTGGAGCGGGTGCCTTTCATGATACAATTTTATTATATTGTAAATTTTTAAAA 
rat             -TTGCTAGTTAAGGGAGTGACTTTT-TAATGATAAGTCAATGAAACATTAGTTTTTGGGT 
mouse           -TTACTAGTTAAGGGAGTTAGTTTT-TGATGATAATTCATTGAAATGTTAGTTTTTGTGT 
                 *  *****  ** * **   ***  * **   *  * * *  *   * * *****     
 
human           TCACTTTTGAGAATAACAAGTGATTAATTTAAGAAAACTGTATGAGAAGCTCAAAGATTT 
rat             TC---TTGGAAAATTATAAGCAATTAATTTCTTAATGA-ATATAAGCATCTCAAAAGTGC 
mouse           TC---TTGGAAAATTATAAGCAATTAATTTCATAATGA-ATATAAGCATTTCA------- 
                **   ** ** *** * ***  ********   **     *** ** *  ***        
 
human           GCATCTTTTGCAATCTTTTTAGTATATTTCACTGAGTAAGATAAAGGAAATACATCATGT 
rat             ATAGCTTTC-TAAGTGTCTTAATATCCTTTACTGGCTGAGGATAGGGAAATATATTTTTT 
mouse           --AGCTTTC-TAAGTGTTTTAATATCTTCCACTGGCTGAGAAGAGGGAAATATATCATTT 
                  * ****   **   * *** ***  *  ****  * **   * ******* **  * * 
 
human           AGCCAGAAATTATCAGTAGCTTACTTCTCTGATAGTAGGTAATTATAGTGGGAATGATAA 
rat             AGGCAGAAATTAGTAAACACTTA--TTTCTGATAGCCAGTTGGTATTATGATAATGCATT 
mouse           AGGCAGAGATTATTATATGCTTA--TTTCTGAGAGCCAGTTGCTGTTATGGTACTGCATT 
                ** **** ****  *    ****  * ***** **   **   * *  **  * **     
 
human           AAAAAAATTACAT-----------TTTTATGAATTATACAGATTTT--------AAAAAT 
rat             ATAAAAATCACATAAAAAGAAAAAATAACAGAACTATGTAGCTCCT-AAAAAAGAAAAAT 
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mouse           ACAAAAATCACATATAAAGAAAAATTAACTGAACTATGTAGATCTTTTAAAAAGAAAAAT 
                * ****** ****            *    *** ***  ** *  *        ****** 
 
human           TTCAGTTCCACCAGATTCCCTGTGACTTCCCTGTGGGACTTCAGTGAATTAG--AAATAT 
rat             CTTAGCTCCAT---ATTTACAGTGGAGTCTCTTTATGCCTTGCCTGAATTAG--AAATAT 
mouse           CTTAACTTCAT---ATTCACAGTGGATTCTCTTTATGGCATCCCTGAATTAGAAAAAGAA 
                 * *  * **    ***  * ***   ** ** *  * * *   ********  *** *  
 
human           GCCAATGGAATTTGCACAGCATGACATATGTGTGTATATATATGTGTATATATATATATA 
rat             TCTACATACATTTGTATGACATGA-------ATGAAGGAGTATGTGGTCCTTTATATACA 
mouse           TCTAGTTATATTTGCATGACATGA-------GTGAAGGAGCGTATGGTCCTAAGTAAACA 
                 * *     ***** *   *****        ** *      * **    *   ** * * 
 
human           TATATATATATATATATATATATATATACACACACATTTTTTTTATCTCTGACAA-AATA 
rat             ----------------------------------------ATTAACCACTAACAA-CATG 
mouse           ----------------------------------------GTTAACCACTGACAACAATG 
                                                         ** * * ** ****  **  
 
human           TATAAGATTCATAGTTTTATCATCTCTGTATTTAGTTTATTTGATCTAAGTTAAAGATAT 
rat             TAGAAGGATCT---GCCTCTCATCTCT---CATAG-TTATCTGAATTAGGTTAAATATAT 
mouse           GGGAAGGGTCA---GCCTCTCATCTCT---CATAG-TTACCTTGTTTAGATTAAATATAT 
                   ***  **       * ********     *** ***  *    **  ***** **** 
 
human           ACAGAGAAGTTTCTAATAATTTGGAGGCAAATACTAACCAAATTGGGGTCTCGGAG---- 
rat             GAAGATTAGTTTCTAACAATGAGAAAGAGAAAAGTAGCAAAATTGAGGA-TCAGAG---- 
mouse           GAAGATCAGTTTCTAACAATGAGGAAGAGAAAAATAACAAGATTTGGGG-TCAGAGAGCA 
                  ***  ********* ***  * * *  ** * ** * * ***  **  ** ***     
 
human           AACATTCTGACCCATAAAATGATAAAGAAGTGGTTCTCCCTTTGGTAAGAAGAACAATGA 
rat             AACATCCTATTCCATA-ACTATTAGATTAATAGT--TTACTATGGT---AAGACCTTTGA 
mouse           AACATTCTCTTCCATAGAACACTAAATTGATAGTT-TAGCTTTGGA---AAGACCTCTGA 
                ***** **   ***** *    ** *    * **  *  ** ***    **** *  *** 
 
human           AGTATGTTACCCTAGTTCTGAAATGTAA-------------GGCAATAATATCCTGTGCT 
rat             ATCAGG--------GTTCT-AAGTAAAAGGGAGTTGAGTTTGGCCAGCATACATTACACT 
mouse           GTCAGG--------GTTCT-AAGTAAAA------TGTGCCTGGTCA---------GCACT 
                   * *        ***** ** *  **             **  *            ** 
 
human           ATGTCTTTTGGAT----------------------------------------------- 
rat             CTGTCCTTTGGATTGGATAAGAAGTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 
mouse           CTATCTTTTCTCTC----------TCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 
                 * ** ***   *                                                
 
human           -----------------------AGTAGGGAGAAGTGTATGTGGGTTCATTATGAAGTAG 
rat             CTCTCTCTCTCTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTGGGGTGTAT 
mouse           CTCTCTCTCTCTCTCTCCATATATATATATATATATATATATAT---------------- 
                                         *         * * * *                   
 
human           GATG-TGTCAGCCCAGTCTGGCCTGGGTTCCAGTAGATGCCTGCGCCT------------ 
rat             AATGATGTACACACTGTCCTGCGTTCCTTAGACAAGATCTGGAAGCTTTCCTACATTCTA 
mouse           ------------------------------------------------------------ 
                                                                             
 
human           -GGGCATGATGGCACTGCAGGTAGTTGTTTAGGTATCCAGTGTTTGTCAGGGAGTGGGAA 
rat             CTTACAACACAGCACTGAAGTTACCT-------TAACAAGTGTTTGCTAAGAACTAGATA 
mouse           ------------------------------------------------------------ 
                                                                             
 
human           ACCTATTTGCACACAGGGACTGGAGCACAAGGCATATCAGCAATCTGTATTATCCCAGAG 
rat             ATCTTTTG--CTTTTGTGGCTGTAGTACAAGGCAACTTAT---TCTAGAACATCCTAGAA 
mouse           ------------------------------------------------------------ 
                                                                             
 
human           TCCACCATGACATATAGATGACTTCTCCTTTTCATCAAGGCTGCATCTAAATTAAGATGT 
rat             T-CACTATGGTATTCAGATAATTTCTCATTTT-ATCAAGCTTGCTTCTTACATAGGATAG 
mouse           ---------ATATTCAGACAATTTTTCATTTTTATCAAGCTTGTTTCTTAAGAAGAATAT 
                           **  ***  * ** ** **** ******  **  *** *   *  **   
 
human           TTT-TTCTGTGCTTTTGATTTCATTCATGAGTCATGAC--ACTACAATTTCACATGTAGT 
rat             TTTGTTCTGTGC------TTTCATTCTTGAACCAAGACTAGCTAC-AGTTCACATACAAG 
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mouse           TTTCTTCTGTGC------TTTCATTCTTGAGACAAGGCTTGCTAC-ATTGCACATACAAT 
                *** ********      ******** ***  ** * *   **** * * *****  *   
 
 
human           AACTTTTATTTCCTGGTAGGATAAACAGATTTTTAGATAGCATATTTTTCCTTGTTATTG 
rat             AACATTTAATTCCTAGTAAGAAACACAGGTTTTTAGTTAATGTA-CTTCCCTT--TATTG 
mouse           AACACTTATTTCTTAGAAAGAAACACAGGTTTTTAGTTAAGGTA-TTTTCCTTAATATTG 
                ***  *** *** * * * ** * **** ******* **   **  ** ****  ***** 
 
human           ATTGGTATTTTTTCATTCAGAATGTATTTGATACAAATTTATTTTATTAAAACATTTGAG 
rat             ------ATTTT----ATGGACATGTA---AATAT-AGTACATAACATTAAAA-ATAAAAT 
mouse           ------ATTTTTTTAATTAACATGTA---AATAT-AGTATATACCATTAAAA-ATAAAAT 
                      *****     *    *****    ***  * *  **   ******* **   *  
 
human           GTACATATCTTTC-ACTTATGCTATATATGAATTTTAAAATTCAACATAATACAT----T 
rat             GTATTTTTCTTTCTGCTTATGCTCCATGTGTATTTAAGAACTGTAACTAAAGCATAACAT 
mouse           GTATTTTTCTTTCTGCTTATGCACCATATATATTTAAAAATTATAACTAAAACATGATAT 
                ***  * ******  *******   ** *  **** * ** *  *  ***  ***    * 
 
human           GGAAAAGTTAATGATTTTT----------AATGAACAAAACTATCATTTTTTAAGAATGC 
rat             TGCCAGTTTAATGACCATTTTATGCAAAGAATGAACACAACTATCATGTTT--GGAAGGC 
mouse           TGCCAGTTTAATGACCATTTTAAGAAAAGAATGAACACAACTATCATATTTT-GGAATGC 
                 *  *  *******   **          ******** ********* ***   *** ** 
 
human           AATGATGGTTACCCTAGTTGAGAAGAATACAGTAGCTTATTATCATTTTTAAAAAGCATG 
rat             AGTGATGACCATTGCAGATCAGAGTGGTAGAGTGGGCTACTCTC---TAAAACGAGGTAA 
mouse           AGTAATGACCACTGCAGATCAGAACAGTAGAGTGGGTTAGTCTCTTTTTAAAAGAGCTAA 
                * * ***   *    ** * ***    ** *** *  ** * **   *  **  **     
 
human           ACATCCACAGATCACTTTAGAAATGTCTTTAAATATTAAAAAAATT------ATGAT-TC 
rat             AAATTAACAGACCACTTAGAAATTCCTTTTAAATATTTTTGAAAATATATCCATCATGCT 
mouse           AAATTAACAGACCACTTAGAAACTCCTTTTAATTATTTTTGAAAGTGCAGCAATCAT-CC 
                * **  ***** *****   ** *   ***** ****    *** *      ** **    
 
human           TTTTCCAAGTAAAATATGATATGAAACTATATTATTAATGTTAATAGGACACATTTAAGT 
rat             TTTTTCAAGTAAAATCTACTATGGAACTCCATTAAGAATGTGGAAAGGACATATTTGAAT 
mouse           CTTTTCAAGTAAAGTCTACTATGGACCTCCATTAAGGATGTTGAAAGAACATATTTGAAT 
                 *** ******** * *  **** * **  ****   ****  * ** *** **** * * 
 
human           TGTAATCTAGAGTTATTTATTAAATTAAGTGATTTCTCATTTTTCTGAAATTA------- 
rat             TATAGTCTCAGATCATTTACTGGATTCATTGA-CTATAACTTGTCCAAAATTACAAAAGA 
mouse           TACAGTCTAGGATGATTTAATGAATTCAGTGA-CTATAACTTGTCCAAAATTACAAAAGA 
                *  * ***    * ***** *  *** * ***  * * * ** **  ******        
 
human           ------------------------------------------------------------ 
rat             AGAAAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAA 
mouse           AG--AAGGAGAAGAAGAAGAAGAAAGAAAGAAGAAAGAAGGAGAAGAAGAAGAAGAAGAA 
                                                                             
 
human           ------------------------------------------------------------ 
rat             GAAGAAGAAGAAGAAGAAGAAGAAGAAGGAAGAGGAGGAGGAGGAGGAGGAGGAGAATGT 
mouse           GAAGAAGAAGAAGAAGAAGAAGAAGAAG-------------------------------- 
                                                                             
 
human           ------------------------------------------------------------ 
rat             GGAAAGGACATATTTGAATTATAGTCTCAGATCATTTACTGGATTCATTGACTATAACTT 
mouse           ------------------------------------------------------------ 
                                                                             
 
human           ------------------------------------------------------------ 
rat             GTCCAAAATTACAAAAGAAGAAAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAA 
mouse           ----------------------AAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAA 
                                                                             
 
human           ------------------------------------------------------------ 
rat             GAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGAAGGAAGAGGAGGAGGA 
mouse           AAAGAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAAGAAGAAGAAA----------- 
                                                                             
 
human           ------------------------AGTTTAGAATATCTTATCTATAAGACATGGTCTCAT 
 254 
 
rat             GGAGGAGGAGGAGGTGGTGGTGGTGGCTTGAGGTCTCTTCATAGTAAGATATGTTTT--- 
mouse           ------------------------AGTTTCAGGTCTCTTCATAGTAAGATATGTTTT--- 
                                         * **    * ****     ***** *** * *    
 
 
human           GAAGAATAGAATCACAGAAATTATGAGAGCAATATGCTGTAAAGGTTA---TTTTTATTG 
rat             --------GAA--ATAGAAATTTGGAAAGCAATATGCAATACTGATTAGTTTTTCCTTCA 
mouse           --------GAA--ATAGAAATTAGGAAAG-AATATACCATAGTGA------TTTTCTTCA 
                        ***  * *******  ** ** ***** *  **  *       ***   *   
 
human           TCCTGTTTGCTTCTGGATTGTCCCCAATGACCCTAAAGGAATCAAAT----GAATATAAA 
rat             TCTGGCTTTATTC----------------------AACCAACAACATCTCTCAATAT-AA 
mouse           CCTTGCCTTGTT-------------------------------ATAT-TCACAATAT-AA 
                 *  *  *  **                               * **     ***** ** 
 
human           AACATATATCATTTAAAAA--ATGATTTAGTAGGGATTAAAAAGAAATAAGAGCATATGC 
rat             ATCATAGGCCACTTAAAAATCATTACTTGATGCTTATTAAGAAGAAATGACAGTACTTTT 
mouse           ATCCTAGGCCCCTTAAACATCATTATTTTATGCATATTAAGAAGAAATGACAGTGCTTTT 
                * * **   *  ***** *  ** * **  *    ***** ******* * **    *   
 
human           ACATTTCTTTATTCCTTTAGTGCTGATGCTGATGGGCGAAAGTTTTACTTTTAATTGTAG 
rat             TAATTCATATTATTCAGCATATGTGAT-CTGA--AGTAAAACTTTTGGTTTTAATTAT-- 
mouse           ACATTTATATTCTTCACCATATGTGAT-CTAA--AGTATAACTTTTGATTTTGATTAT-- 
                  ***  * *  * *   *    **** ** *   *   ** ****  **** *** *   
 
human           AAGTAATTTTTGTCTGTCACCATAAAATAATATTGAATTTCCTTCTCTGCATAATTTCTC 
rat             -GGCAACTTT----------CATCAAAATTAAAATAGTTTCCTTCTTAATAAAACTTCAC 
mouse           -GGCAAATTT----------CATCAA------------CCCTCCTTTAATAAAACTTCAC 
                  * ** ***          *** **              *    *    * ** *** * 
 
human           AGGAACTCTTTGAGAAACATGAATTGATACTTTAAAAATACTTAAAAGTAAATAATAAAT 
rat             TAAAACCCCC--AGAAAAATTAATCGTTGCTTTTAAAGCAGTAA-----AAATGATAAAT 
mouse           TAGAACCCCC--AGAAAAATTAATTGTTGCTTTTAAAACAGTTAAAAATAAATGATAAAT 
                   *** *    ***** ** *** * * **** ***  * * *     **** ****** 
 
human           AGTTGAAGTACTTTTCACCTTTGAATTATTTATAAGTCCAATAAAAATTTTTAGATATCA 
rat             TCTAAAACTATTTCTTTATTTTACA------ATTGATGCAATTAAAGT------------ 
mouse           TCTAAAACT-TTTCTATATTTTAGA------GTTAATGCAATTAAAGT------------ 
                  *  ** *  ** *    ***  *       *   * **** *** *             
 
human           TGTACATTTTAAATCAGTTGACATATTAAATCTGA-----TATAAGGACTGGAATAGAGG 
rat             -----------AAT--GTTGAAATATTTAATCTCAATACATTTAAGCATTGGATTAAAAG 
mouse           -----------AAT--ATTGAAATATTTAATCTCAATATTTTTAAACACTGTATTTAAAA 
                           ***   **** ***** ***** *     * ***  * ** * *  *   
 
human           ACAACTTACATCTAACTTTCCTTAATTTTTACAACTGGAATAGAATGACACAAAA--ATG 
rat             AAAACAGGTACTAACTAGTATTTACTTCCT--GTCTAGAATAGAATAACATATAATCATG 
mouse           AAAACAGATATCTACTAGTATTTACTTCCT--GGCTA-AATAGAATAACATATAATCATG 
                * ***    *   *    *  *** **  *    **  ******** *** * **  *** 
 
human           ATTCTTAAACGTGTCATAAATTAATAC-GCAATATGTAGAGTCAAAAGCAATTACCATGT 
rat             ACTCTTGAGCATGCAGGAGATCGGTAC------AGATTCTTTCAAGA-----------AA 
mouse           ATTCTTAATCATGTTGGACATTGGTACAGTGCCAGATTCATTAAAAA-----------AT 
                * **** * * **    * **   ***      *  *    * ** *              
 
human           AATCAGCTTTTGTTTTAAGGGATTTGAGCAGGCAGGTACTGAATCTGCGCTCTTAAATAT 
rat             ATTCTACATCAGTGTTGAGCTGTCCTAGCAGCTGGGCTCTGAGTCTGCCTTCTC-AGTGC 
mouse           ATTCAACATTAGTGTTGAAGGACCCATGCAACTGGGCTCCAAGTCTGCCCTCTT-AGTGC 
                * **  * *  ** ** *         ***    **  *  * *****  ***  * *   
 
human           ATG------ATATGTGTCATATAACTATACTTCCCATTGATATTG----GATAAATAGTG 
rat             AGG------ATATGTGTCCTGTGGTTA----------TGACACTGCAT-GGCAGATAGGA 
mouse           AGGGCACTAAGATGTGTCCTGAAATTA----------TTGTGCTGCATGGGTAGATAGGA 
                * *      * ******* *     **          *     **    *  * ****   
 
human           AACATTTTGAGAGTGATTTTGTCTACATAAGGCATTTTTCAAATGTAAAATATATTTAAT 
rat             TACATTTTGAGGGTGGCTCTGTCCATATCAGG---GTTTTAGAAGTAAAGTTTGTAAAAT 
mouse           TACACCTGGAGTGTGTCTGTGTCAATATCAGG-GTTTTCTAGAAGCAAAGTTTGTAAAAT 
                 ***  * *** ***  * **** * ** ***    **  * * * *** * * *  *** 
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human           ATCCTTTTCAGAATATATGTGAGAAGTGTTTAACTTTTTCCATCCTTTCATATTTATTTT 
rat             ACTCAATTTTGATTCCACACAAGAAATATTTAAACCTTCCATTCTTAATATGTTTATTTT 
mouse           ACTTGATCCTGATCCCACGTGAAAAATATTTAAGCTTTCCATTCCTACTA-------TTT 
                *     *   **    *    * ** * *****   ** *  ** *   *       *** 
 
 
human           -----TTTGTATTTCATACAGACTTTGTGATAAAGTCCCTTAATTATATTCTTTTTGTTA 
rat             AAATATTTACATTTTATCATGACTTTGTCCTGGAGGCTC--AATTATACTCCTTCGGTT- 
mouse           AAATATTTTCATTTTATTGTGACTTTGTTATGGAGGCTC--ACTTATATACTTTCAGTT- 
                     ***  **** **   ********  *  ** * *  * *****  * **  ***  
 
human           TTTCTTGCTATTTTTCTCTCTCTATCTCCTTTATTTT-AGCAACTGATGTTTTTATATCA 
rat             ----------------------------TTTCATTTTAAGCAACAGATATTC-------- 
mouse           --------------------------TTTTTTGTTTTAAGCAACAGATATTC-------- 
                                             **  **** ****** *** **          
 
human           AAAAACTTTTCATTTAAGTTAGCTTCTCTCCTTTCTTAACTGCTTGAGTGGTT--TATTC 
rat             TAAATCTTGAAGTTTTGGGAATTGGCTTTTCCTTTTGTACTGAGTGAGTGGCTTATATTC 
mouse           AAGATATTGTAGTTTGGGGAACAGGAGTTTCCTTTTGTATTGAGTGAGTGGCT--TATTC 
                 * *  **    ***  *  *       * * ** *  * **  ******* *  ***** 
 
human           TACAAATATTTCCCAAGTGTTTGATCTAGAATATGTTTCATCAAAAGATTTATTTCTTAC 
rat             TACCAAAATCACCCACA-ATTTTATCTTGCGTCTAATGTATCAAAGGATACATTGCTTAG 
mouse           TACCAAATT---CCACA-ATTTCATCCTGTGTCTAATGTATCAAAGGATGAACTTCTTAA 
                *** **  *   ***    *** ***  *  * *  *  ****** ***  * * ****  
 
human           TGTTAATTGTCAGAAACTTTA-----GATCACAAATTGCCAA----TCATGATCTAAATT 
rat             TGCTACTTACCAATAAATTTGATTATGCCCACAAGCTGTCCAATTTTCATGTTTTAATAT 
mouse           TGCTAATTGCCAATAAGTTTAATTATGCCCATAAATTGCCCAATTTTCATGTTTTAGTAT 
                ** ** **  **  ** ***      *  ** **  ** * *    ***** * **   * 
 
human           TTTAGAACTATCACTTGTTCACACTAGCAAGTCTAATTGTTAGACATAGTAGAGTTATTG 
rat             TTTAGAAATACTACT--------------------------------------------- 
mouse           TTTAGAAATACTACT--------------------------------------------- 
                ******* **  ***                                              
 
human           ACAACAGAGAAACGGTTAGTTTTATTGGTTTGTCAATATCACTTAAATACTTAGTTACGT 
rat             -----------------------------------------CCAAATTTCTGAAATATAT 
mouse           -----------------------------------------TTGAATTTCTCAAATATAT 
                                                            ** * ** *  **  * 
 
human           GCAGAATCCCATCAAATCTTTCAAAATAATACAGTATATATCTTTTTCTATATCTCTATA 
rat             ACAGAATCCCATAAAATCTTTT-AAGAAATAGACTAGATGCCTGCTGT--TAGCTATATA 
mouse           ACAGAATCCCATAAAATGATTT-AAATAACATGGTAGATGCCTACTGT--TACATATATA 
                 *********** ****  **  **  ** *   ** **  **  *    **  * **** 
 
human           CCTGTAT--------------TCCTCTACTTCAGGTTTTAAAGTAAATTATTGGGTATCT 
rat             GTTGTAT--------------TTATCTCCTTCAATATTTAAAGTAAAATATTAGAAATCT 
mouse           GCTATATTATTATTATTATTATTATCTCCTTCAATATTTAAAGTAAACTATTGGAAATCC 
                  * ***              *  *** *****   *********** **** *  ***  
 
human           ATTAAGCTTTTAAAAACTATTTTATGTAAGAATTTGTAGTCAGAAAAATATTGTTATTTT 
rat             ATTAAGCTTT----------ATTATATAG----TTATAGTCATATACATGCTGCTGTCTT 
mouse           ATTAAGCTTCTAAAGAC---ACAATATATATATTTATAGTCATATAAATGCTGCTGTCTC 
                *********              ** **     ** ****** * * **  ** * * *  
 
human           ATTATACATCAAACTAG-AAATTTATGTCTTCACAAACTTTTAAATGTCTAATTTGTTTT 
rat             ATTAAACTTCACACGAG-GAATTTATACCTTT-TAAACTTTTAAATATCTAATCCGTTTT 
mouse           ATTATAGTTCACATTAGTAAATTTATACCTTTTTAAACTTTAAAACATCTAATCTGTTTT 
                **** *  *** *  **  *******  ***   ******* ***  ******  ***** 
 
human           CTTTGAGTTTTATTTTT-TTTTGAGCAGGACACATAAAGGAACAGGGTCATAGCCATCCA 
rat             CTTTGAGTTTTCTTTTTCTCTTAAGCAGGAAATACAAAGCAGCAGGGTCCGAGCAGTACA 
mouse           CTTTGAGTTTTCTTTTTCTCTTAAGCAGGAAGCACAAAGGAACAGGGTCAGAGCAGTGCA 
                *********** ***** * ** *******   * **** * *******  ***  * ** 
 
human           TACTCTGAAGCCATCTGATTTTTATTCATTAATAGTTATATTTTGTGCGGTATCTTTGCT 
rat             CACCATTAAGGCATTTGATTTATATTCATTAAGAATTATGTTTTA--------------T 
mouse           CACCATTAAAGCATTTGATTTATACTCATTAAGAATTTTGTTTTA--------------T 
                 **  * **  *** ****** ** ******* * ** * ****               * 
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human           TGTAGCATTATTT---TTTCCTCATTTTTCTCTCCTGTACTGTATCTAATACCTATGT-T 
rat             TTTAGTATCATTTCACTTTTTCCA--TTTCTTTCCTGTACTGCATTGAATATCCATGTGT 
mouse           TTTAGTGTCATTTCA-TTTGTCCA--TTTCTTTCCTGTACTGCATCGAATACCCATGTGT 
                * ***  * ****   ***   **  ***** ********** **  **** * **** * 
 
 
human           TTACATACACAAAA---TTAACAAAATTTGAGGCCTTTTTTGTTTTGGAAATTCACTGAT 
rat             TTGCACGCCCAAAA-ACCTACTGGAACTGGGTCTGTTTGTGGGGTTGGG-----GTGGGT 
mouse           TTGCACGCCCAAAAAACCTAATGGAACTGGGTCTATTTGTGGGGTTGGG-----GTGAAC 
                ** **  * *****    **    ** * *     *** * *  ****             
 
human           TGAATTAAAGGGAGGA-TTTCTTTGGTGTTTAAAGTTACATCTGTGGAGTATG-CTTTTT 
rat             TGTGTTAGTGGGAGGATTTTTTTTCATGTTTAAAGCTACATTTATGGTATAAATCATTTC 
mouse           TGTGTTAAAGAGACAG-TTTCTTTCATGTTTAAAGCTACATTTATGATATAAATCATTTC 
                **  ***  * **    *** ***  ********* ***** * **   **   * ***  
 
human           TTAATTTTTGATTTTGTTCATAAATGTTGTTATGAGGTTTGCTGGTGATATTACATTCTC 
rat             TTAATATTTG--------------TTTTGTTATGAACTTTGCTGATATTCTTAGGTTCTC 
mouse           TTAATATTTG--------------TTTTGTT-TGAACTTAGCTAATGTTCTTAGGTTCTC 
                ***** ****              * ***** ***  ** ***  *  * ***  ***** 
 
human           TTGTTTATGTTTACTTACATCATGAGTGGATAAACTTTTATGAGTAT------------T 
rat             TTGTTTGTGATTATTTATGACATGAATAGACGAA-TATTGTGCATATTAGATGAATTACT 
mouse           TTGTTTGTGCATATTTATTACAGGAGTAGACAAAGTATTTTGCATATTAGATCAATTAGT 
                ****** **  ** ***   ** ** * **  ** * ** **  ***            * 
 
human           TGTAAATTTCT----TGAAATTGCTTTCTTATGGGA-TTCATGTCATAAACTATTTGGGC 
rat             TGTATGTGTGTGCACTGAAGTTTCCTTCTTGTGGAATTTTGCACCATCAACTATTTGGAT 
mouse           TGTATGTTTGTACAATGAAGTTTCTTTCTTGTGGAATTTTACACC---AAGTATTTGAGT 
                ****  * * *    **** ** * ***** *** * **     *   ** ******    
 
human           ATTACAATTATGAAAGTATTCCAGAAATCAGAAGTTTTGACCTGTGTGTATGTTATTA-- 
rat             CT----ATTGTGAATGAATCTCAAGAAT--GGAGTTTAGGTCTTTGGGAACATCCTCAGA 
mouse           AC----ATTATGAGAGACTCCCAAGAAT--GGAGTTTAAGTCTTTGGGTACATCCACAGA 
                      *** ***  *  *  **  ***  * *****    ** ** * *  *    *   
 
human           ----AATTTAGCTACTCTGTACTCCTTGCCC--AAAATGTTTAATGATTTCCAGTTTCAT 
rat             TCTCAACCTCATTATTCTGTATTCCTTGCCC-AAAAATAATTAGTAATTTCTAGTTTCAC 
mouse           TCTCAACCTCATTATTCTGTATTCCTTGCCCAAAAAATGAGTAGTAATTTCTAGTTTCAC 
                    **  *   ** ****** *********  *****   ** * ***** *******  
 
human           T-AACTAGTAGATACATTGAAAAATATAAAATTAAATATTCCCCTATAAGTCAATATTTG 
rat             T-AATGAAAAGATATATTGCAGGCTATAAGGT---AAACTCTTCTGTAAGTGGCTATTTG 
mouse           TAAATGAAAAGATATATTGCAAGCTATAAGGT---AAACTCTTCTATAAGTGACTACTTG 
                * **  *  ***** **** *   *****  *   * * **  ** *****   ** *** 
 
human           CATAATACTGCTAACTTGTTTTTTTATTAGGTCATTCATTTCACTTTACAAATCCATTTC 
rat             CATATGAATGTAAACTTG-TTTTATATTAGATCATTCATTTCACTTTACGAATCCATTTC 
mouse           CATATGAGTGTAAACTTC-TTTCATATTAGAGCATTCATTTCGCTTTACGAATCCATTTC 
                ****  * **  *****  ***  ******  ********** ****** ********** 
 
human           ATACTTGTTATTAG 
rat             ATACTTGTTATCAG 
mouse           GTACTTGTTATCAG 
                 ********** ** 
10 APPENDIX 2 – SECONDARY STRUCTURE MODELS: 
MFOLD 
Models shown in increasing order of free energy (Model 1 = MFE structure). Full structure 
shown in bottom left corner of each structure. Area surrounding the Q/R site is enlarged, 
with the Q/R site highlighted by the red arrow.  
10.1 HUMAN SECONDARY STRUCTURE MODELS  
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10.2 RAT SECONDARY STRUCTURE MODELS 
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10.3 MOUSE SECONDARY STRUCTURE MODELS 
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10.4 FREE ENERGIES OF EXON 11 – INTRON 11 SECONDARY 
STRUCTURES (ΔG; KCAL/MOL) 
 
 277 
 
11 APPENDIX 3 – SECONDARY STRUCTURE OF THE B13 
MINIGENE 
11.1 MFOLD PREDICTIONS 
15 predicted models of secondary structure of the B13 minigene from the MFold output. 
Complete minigene is shown, with the area surrounding the Q/R editing site enlarged and the 
edited adenosine highlighted in red. 11 out of the 15 models show the same double-stranded 
pattern followed by internal loops found in the exon 11 – intron 11 models. Free energy (ΔG) 
shown in the top left hand corner of each model (kcal/mol). 
 
  
        
1: ΔG = -237.30 2: ΔG = -236.90 
3: ΔG = -234.00 4: ΔG = -233.90 
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5: ΔG = -233.60 6: ΔG = -233.50 
7: ΔG = -232.90 
8: ΔG = -232.70 
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9: ΔG = -232.20 
10: ΔG = -231.30 
11: ΔG = -230.90 12: ΔG = -230.00 
13: ΔG = -229.60 
14: ΔG = -227.80 
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15: ΔG = -227.00 
